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The presently incurable Human Immunodeficiency Virus 1 (HIV-1) infection is 
a major global health problem which currently can only be chronically managed 
with the expensive and rigid Highly Active Antiretroviral Therapy (HAART). 
To date, there are no effective vaccines available although potential functional 
cure with vaccination is supported by numerous studies where T cell responses 
were reported to control or, plausibly, cure HIV-1 infections. One of the major 
reasons for vaccine failures has been the inability to address extreme viral 
variability with constructs consisting of just a few proteins from a small number 
of strains. Detailed diversity considerations, with human immune relevance, are 
critical for vaccine design but such in-depth characterizations are still currently 
lacking. Thus, an original immunoinformatics strategy, based on reverse 
vaccinology approaches, was proposed in this thesis. A novel methodology was 
developed for the comprehensive dissection of viral nonamer diversity across 
the HIV-1 proteome. Nonamers were chosen as the immune-relevant unit for 
analysis as they represent potential binders of human leukocyte antigen (HLA) 
molecules and T cell receptors (TCRs). The incidences of all defined sequence 
diversity motifs, including the most common “index” sequence and its variants, 
of a large HIV-1 quasispecies population were quantified. Except for two 
completely conserved sites observed in the Polymerase (Pol) protein, all other 
positions contained, up to 98% in proportion, variants and regions of extreme 
diversity were numerous (~14% of proteome). Nevertheless, the entire viral 
proteome is not totally diverse, there are still a limited number of 253 clade B 
nonamers (~9% of proteome), concatenated into 42 contiguous sequences, that 
remained evolutionarily highly conserved and of which 25% of them are 
conserved pan-clade (clades A, B, C and D). Such highly conserved sequences 
are favourable vaccine targets which would likely remain conserved as 
supported by prospective correspondences to a separate futuristic sequence 
dataset. Beyond, additional functional, structural and immunological 
characterizations were performed and key diversity features defining potential 
HIV-1 vaccine targets were identified. In general, they were (i) frequently 
localized in regions of primary functional importance and are not within 
ix 
 
“redundant” domains which are observed to possess enhanced level of sequence 
variability, (ii) potentially immunogenic as correlated with reported 
experimental epitopes, and (iii) unlikely to induce cross-reactive immune 
responses against human proteins by molecular mimicry analysis. However, 
further assessment revealed only 11 potential candidates (out of the 42 
sequences) which are suitable for pre-clinical non-human primate (NHP) 
studies. In summary, this thesis has defined and laid the foundation for a generic 
novel immunoinformatics pipeline for elucidation of HIV-1 vaccine targets 
through comprehensive nonamer sequence, functional, structural and 
immunological characterization of HIV-1 sequences. Equally applicable to 
other human RNA pathogen, preliminarily tested on a number of human RNA 
pathogen of varying degrees of diversity ranging from the conserved West Nile 
virus (WNV) to the highly diverse Hepatitis C virus (HCV), this pipeline is 
believed to be useful for the study of other viral pathogens and individual 
quasispecies for the design of personalized vaccines in the advent of the 
personalized genomics era. 
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Chapter 1  Introduction 
 
Ranked sixth amongst the top 10 causes of death worldwide (WHO, 2013), 
Human Immunodeficiency virus (HIV) type 1 (HIV-1) infection is one of the 
deadliest diseases ever experienced by mankind. In 2011 alone, about 1.7 
million individuals died of HIV-1 infections, 2.5 million people were newly 
infected and a total of more than 34 million individuals were reported to be 
living with HIV-1 infections worldwide (UNAIDS, 2012). Currently from a 
public health perspective, there are no cost-effective drugs or vaccines against 
HIV-1 infections. Consequently, individuals infected with HIV-1 will almost 
always die of the disease over a period of approximately 22 years (Harrison et 
al., 2010; Rambaut et al., 2004). Available highly active antiretroviral therapy 
(HAART) is costly, requires long term adherence (Duggan et al., 2009) and 
harbours potential side effects like diabetes, cardiovascular disease and 
fractures (Carr et al., 2000; Mondy et al., 2003; Thiebaut et al., 2000). In 
addition, acquired HAART drug resistance, observed in about 6% of patients, 
dictates the need for a change to a more expensive second-line treatment which 
will inevitably increase the financial burden of patients in disease management 
(Audelin et al., 2009; Dolling et al., 2012; Gill et al., 2010; Long et al., 2010). 
Most importantly, HAART does not cure HIV-1 infections but only helps to 
delay the disease progression to acquired immunodeficiency syndrome (AIDS) 
and the eventually death. Thus, there is an urgent need for a therapeutic or 
preventive/prophylactic vaccine that can offer economical life-long protection 
or a lasting cure from HIV-1 infections (Gamble and Matthews, 2010; Graham, 
2002; Ho and Huang, 2002; Korber et al., 2009; Levitz et al., 2012; Munier et 
al., 2011). To date, no vaccine has been successfully developed for HIV-1 
although the development of a low cost, nontoxic and effective vaccine is still 
enticing. A HIV-1 vaccine is , perhaps, still possible as supported by the recent 
RV144 clinical trial and numerous animal trials with Simian Immunodeficiency 
Virus (SIV) proteins-expressing rhesus cytomegalovirus (RhCMV) vectors 
where promising results of vaccine-induced viral protection, control and even 
progressive viral clearance were demonstrated (Bonsignori et al., 2012; de 
Souza et al., 2012; Hansen et al., 2011; Hansen et al., 2013; Haynes et al., 2012; 
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Karasavvas et al., 2012; Rerks-Ngarm et al., 2009). Nevertheless, the design of 
an effective HIV-1 vaccine is largely impeded by the extreme viral diversity 
among different viral populations circulating worldwide. Vaccinology efforts 
need to deviate from traditional vaccine development approaches which 
typically include one or few proteins from one or several viral strains within 
vaccine constructs. For effective vaccine development, the extraordinary 
sequence diversity of the vast population of viruses needs to be systematically 
and comprehensively addressed in relation to the immunologically 
heterogeneous human population worldwide  (Barouch, 2008; Gamble and 
Matthews, 2010; Kawalekar et al., 2010; Saunders et al., 2012; Tieu et al., 
2013).  
Viral sequence diversity is introduced into the HIV-1 genome by mutations and 
recombination events. The high rate of mutations, >0.2 to two, and 
recombination, two to three recombination events, per genome per replication 
cycle coupled with the relatively short viral generation time of about 2.5 days 
(Basavapathruni and Anderson, 2007; Drake, 1993; Mansky and Temin, 1995; 
Perelson et al., 1996; Preston et al., 1988; Ramirez et al., 2008; Ricchetti and 
Buc, 1990; Roberts et al., 1988; Tebit et al., 2007) rapidly generates a complex 
set of quasispecies within the host (Eigen, 1993a; Eigen, 1993b; Lauring and 
Andino, 2010). As a result, various different phylogenetically distinct groups 
(the major groups are termed as clades) of HIV-1 viruses are reported 
worldwide (Holmes, 2009; Rambaut et al., 2004). Currently, there are more than 
10 clades, 50 circulating recombinant forms (CRFs) (see 
http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html) and copious 
number of  unique recombinant forms (URFs) where intra-subtype and inter-
subtype sequence diversity can reach up to 20% and 35% respectively (Gaschen 
et al., 2002; Walker and Korber, 2001). Each viral variant within the 
heterogeneous viral population can render HAART failure by the acquisition of 
HAART resistant mutations (Clark et al., 2006; Clavel and Hance, 2004; Fun 
et al., 2012; Larder and Kemp, 1989; Tang and Shafer, 2012), and also escape 
immune detection by the accumulation of mutations that result in epitope 
deletion, failure of antigen processing, abrogation of human leukocyte antigen 
(HLA)-peptide binding and T cell receptor (TCR) recognition (Allen et al., 
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2004; Draenert et al., 2004; Kelleher et al., 2001; Leslie et al., 2004; Yokomaku 
et al., 2004). The complexity of high viral sequence diversity adversely affects 
the choice of a single good stock strain for vaccine as a strategy. Efforts in the 
detailed analysis of the enormous pool of available protein sequences by the 
“bottom-up” reverse vaccinology approach can aid in the identification of 
immunogens that can possibly recapitulate the entire viral diversity (Rappuoli, 




Figure 1.1 | A simplified schematic representation of pathogen derived 
peptide presentation at the immunological synapse. The pathogen derived 
peptide (in red) is presented by the Class I or II HLA molecule on the Antigen 
presenting cell (APC), coloured in blue, to the cognate TCR on CD8+ or CD4+ 
T cell in yellow. Pathogen peptides which are able to bind to TCR at the 
immunological synapse can likely elicit downstream T cell responses. (Figure 
adapted and redrawn from 
http://library.thinkquest.org/03oct/01254/images/cd_bind.jpg.) 
 
The study of the extreme viral sequence diversity is further complicated by host 
immune diversity, especially that of cellular immune responses mediated by T 
cells which have been reported to be important in controlling and even clearing 
of HIV-1 infections (Appay et al., 2002; Goonetilleke et al., 2009; Korber et 
al., 2009; Koup et al., 1994). Key events leading to T cell activation are crucial 
to the elicitation of protective T cell responses against HIV-1. Particularly 
crucial is the presentation of viral antigens to the cognate TCRs by the 
heterogeneous pool of HLA molecules, > 9,000 worldwide (accurate as of 
November 2013, http://hla.alleles.org/alleles/index.html), at the immunological 
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synapse (See Figure 1.1). Viral peptides that are able bind to the respective HLA 
molecule and elicit downstream T cell immune responses are known as T cell 
epitopes and they are favourable targets for the inclusion in a HIV-1 peptide 
vaccine. 
T cell epitopes are traditionally mapped by experimental methods that involve 
the generation of synthetic overlapping peptides, spanning the whole length of 
the protein, which are subjected to biochemical binding assays (Sidney et al., 
2013) to one or several HLA molecules. Peptides that are able to bind to HLA 
molecules are thus identified and may be subjected to in vivo and in vitro 
validations (Hatziioannou and Evans, 2012; Simon et al., 2010; Wentworth et 
al., 1995) of immunogenicity. However, such experimental approaches are 
inherently expensive and laborious and generally limit the identification of T 
cell epitopes to one or several HIV-1 protein(s) of a particular viral strain and 
are typically restricted to a small subset of HLA alleles (Kantakamalakul et al., 
2006; Ribeiro et al., 2010; Simon et al., 2010).  
To relieve the bottleneck for experimental validation of potential epitope 
peptides across all virus proteins restricted by different HLA molecules, 
scientists have adopted bioinformatics approaches to identify potential T cell 
epitopes. These methodologies includes (i) epitope prediction algorithms based 
on machine learning approaches like hidden Markov models (HMM) and 
artificial neural networks (ANN) (Brusic et al., 2002), (ii) consensus sequences 
or ancestral sequence reconstruction methods to identify immunogens that are 
most centralized to the analysed viral population (Arenas and Posada, 2010; 
Gaschen et al., 2002; Nickle et al., 2007; Rolland et al., 2007a),and (iii) simple 
amino acid level conservation analyses (Liang et al., 2008; Rolland et al., 
2007c; Srinivasan et al., 2008; Yang, 2009) and nonamer conservation analyses 
(De Groot et al., 2003; De Groot et al., 2005; Finnefrock et al., 2007; Fischer 
et al., 2007) to select antigenic sequences of low variability. Putative vaccine 
targets identified were additionally assessed of their potential immunogenicity 
by correspondences to reported experimental epitopes and/or immunogenicity 
prediction within a simple vaccine discovery pipeline. All methods 
aforementioned relied on the wealth of the sequence information generated from 
genomics and proteomics projects and large-scale screening of pathogen-host 
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and antigen-host interactions, freely available in public databases.  Without 
doubt, such comprehensive computational analyses have enabled the scientific 
community to gain more insights to rational HIV-1 vaccine sequence selection 
in this era of sequence information overflow. However, each computational 
methodology has its limitations. For example, detailed sequence variability 
considerations are lacking in epitope prediction algorithms.  Phylogenetic 
reconstructions methodologies might inadvertently generate artificial sequences 
which dictate exhaustive protein characterization like that of its expression, 
potential immunogenicity and biological activity prior to its usage in vaccine 
formulation (Gaschen et al., 2002). Single amino acid approaches lack immune-
relevant diversity correlations and the complexities of both the viral and human 
immune system diversity need to be systematically addressed in vaccine design. 
Strategies for computational HIV-1 vaccine design need to model how the 
human immune system views viral sequence diversity, which are typically of 
peptide lengths around nine amino acids. Also, there is a need to 
comprehensively and concertedly study the various important factors revolving 
viral and host immune system diversity within a systematic pipeline where 
insights obtain will greatly benefit the rational selection of candidate targets for 
vaccine development. However, to date, none of the current informatics 
methodologies explicitly considers inter- and intra-viral/host factors which 
include: nonamer sequence conservation and variability, functional diversity 
and structural diversity relating to nonamer diversity, host immunological 
diversity (including host molecular mimicry) and suitability of vaccine targets 
for non-human primate (NHP) clinical trials, in an integrated manner which this 
thesis will attempt to address.  
 
1.1 Research Topic 
 
Rational HIV-1 vaccine target selection requires both the in-depth knowledge 
of host immune relevant HIV-1 sequence diversity and the implications of such 
a diversity profile beyond the primary protein sequences and interacting HLA 
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molecules. Equally important are factors like that of the impact functional and 
structural constraints on HIV-1 protein sequence diversity and molecular 
mimicry considerations for vaccine safety and the elicitation of immune 
responses in host. Thus, a novel systematic analysis pipeline is developed and 
described in this thesis to extend the study of HIV-1 nonamer sequence diversity 
(De Groot et al., 2003; De Groot et al., 2005; Finnefrock et al., 2007; Fischer 
et al., 2007) with additional functional, structural and immunological 
considerations which have not been hitherto collectively studied in an 
immunoinformatics context. The study presented in this thesis first starts with 
the systematic collection and pre-processing of large amounts of protein 
sequence data, available in public databases, to obtain a final set of high quality, 
non-redundant (nr) sequences for further quantitative and qualitative analyses. 
The original quantitative analysis methodology, a chief contribution of this 
work, was then applied to these sequences to extensively document the complex 
diversity landscape of the most commonly occurring nonamer, known as the 
index nonamer, and all variants of across all nonamer positions. Before the 
method was applied to HIV-1, immune-relevant diversity was quantified in 
different ribonucleic acid (RNA) viral pathogens of varying level of 
conservation, namely the conserved West Nile Virus (WNV), moderately 
diverse Dengue Virus (DENV) and Influenza A Virus and the highly diverse 
Hepatitis C Virus (HCV). Results obtained from such a cross viral analysis 
elucidated the distinct variant dynamics of the individual viruses which can be 
applied to rational viral vaccine target selection, comparative viral comparison 
and even classification. Also, the outcomes were indicative of the generic 
applicability of the methodology to different viruses, including the highly 
diverse viruses like HIV-1.  
The successful utilization of the novel quantitative methodology to RNA 
pathogens had set the impetus for its application to the hypervariable HIV-1 
viruses. HIV-1 clade B protein sequences were selectively studied as they 
represent members of the most widely studied clade worldwide and results 
obtained from such detailed sequence motifs analysis provided important 
insights on HIV-1 viral nonamer diversity for vaccine design. Moreover, 
additional functional and three dimensional (3D) structural correspondences to 
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the elucidated HIV-1 diversity dynamics revealed plausible mechanisms that 
may impact sequence diversity and potentially affecting the long term stability 
of favourable vaccine targets. Studies of immunological correspondence to 
reported T cell epitopes and that of molecular mimicry were additionally carried 
out to elucidate potentially immunogenic targets that were unlikely to induce 
host cross reactive immune responses as favourable candidates for vaccine 
formulation. Taking together, insights obtained from each step of this novel 
immunoinformatics pipeline provided both a global overview and detailed 
dissection of viral proteome diversity which are integral for the systematic 
characterization of HIV-1 vaccine targets that are evolutionarily highly 
conserved, plausibly immunogenic, lack of structural and functional restrains to 
vary and do not share host protein-like sequences. Potential T cell epitope 
targets selected from this approach are ideal targets for subsequent in vitro 
biochemical and in vivo immunogenicity tests before the selection of 




The key contributions of this thesis include (a) the design of a novel 
methodology for the large-scale quantification of viral pathogen sequence 
variability and conservation, (b) the proof of concept application of the diversity 
analysis on RNA viral pathogens, (c) the application of the quantitative 
methodology for the elucidation of the detailed viral dynamics of HIV-1 
including the most commonly occurring index peptide and its variants, (d) 
functional and structural correlation to the viral diversity motifs for the 
identification of plausible mechanisms revolving sequence diversity of HIV-1, 
and the (e) identification of evolutionarily highly conserved, HIV-1 specific and 
potentially immunogenic HIV-1 vaccine targets, and (f) the development of a 




The thesis contributed to the establishment of a novel integrative analysis 
pipeline which includes the application of nonamer sequence diversity, 
functional, structural, immunological and molecular mimicry considerations for 
the identification of evolutionarily conserved HIV-1 sequences. In total, 42 
evolutionarily conserved, ≥80%, HIV-1 clade B sequences were identified and, 
of which, only seven are pan-clade (Clades A, B, C and D) conserved. All of 
the clade B conserved sequences contained putative T cell epitopes, restricted 
by HLA class I and/or II, by correspondence to reported epitope sequences. 
None of the protein sequences adopted human-like sequences and thus, are 
unlikely to induce cross-reactivity or be non-immunogenic. Functional and 
structural analyses do not demonstrate sole residence of conserved sequences 
within functional sites or adopted any strict spatial localization. However, it is 
interesting to observe the existence of plausible mechanisms involving 
compensatory mutations and functional redundancy which might potentially 
affect sequence diversity as observed by the existence of identical functional 
domains of varying level of conservation within the same Viral protein R (Vpr). 
Conserved sequences were additionally assessed for their suitability in NHP 
studies with peptide sharing studies and immunogenicity correspondences with 
Rhesus macaques (RM) and SIV proteins. 11 conserved sequences, of total 
length of 182 amino acids from three proteins (Pol, Env and Nef), were 
identified and are favourable targets to be included in vaccine formulations. 
In summary, this work provides important insights into antigenic diversity of 
HIV-1, benchmarked with other RNA pathogens such as WNV, DENV, 
Influenza A and HCV. It represents a significant contribution to the fledgling 
field of HIV-1 immunoinformatics (see Chapter 5). The methodology 
developed in this thesis will allow the detailed systematic study of HIV-1 viral 
sequence diversity and also the functional, structural and host immunological 
attributes affecting viral diversity before rationally selecting targets for viral 
vaccine formulation. This process could also be semi-automated for high 
throughput analyses which can be used by pharmaceutical and biotechnology 
companies to accelerate vaccine discovery and development for HIV-1 and 
other RNA viral pathogens at both a population and individual personalized 
vaccine level. The adaptation of the modified reverse vaccinology approach is 
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a departure from traditional approaches where only a single strain or a small 
number of pathogen strains are studied to a large-scale in silico analyses for the 
identification of vaccine targets (Rappuoli and Aderem, 2011). 
 
1.3 Organization of this thesis 
 
There are eight chapters in this thesis. Chapter 1 provides an introduction to the 
research work and Chapter 2 is a detailed literature review, summarizing 
relevant readings about HIV, viral sequence and host immune diversity, 
laboratory experimental and computational identification of targets of immune 
responses and the current status and application of bioinformatics in rational 
HIV-1 vaccine target selection. Chapter 3 primarily describes data pre-
processing employed in this large-scale sequence analysis while chapter 4 
describes the novel quantification methodology that comprehensively studies 
the nonamer sequence conservation and variability landscape of RNA 
pathogens (WNV, DENV, Influenza A virus and HCV). Chapter 5 extends the 
application of the novel diversity quantification methodology to the HIV-1 
clade B proteome where underlying sequence dynamics of HIV-1 sequence 
diversity is elucidated. Insights obtained from such a large-scale sequence 
analysis will aid the identification of targets of low variability for rational HIV-
1 vaccine design (Chapter 7). Chapter 6 describes the mapping of the diversity 
motifs patterns elucidated in Chapter 5 to HIV-1 protein structures and functions 
for the identification of functional and structural restrains driving HIV-1 
diversity. Chapter 7 reports a list of highly conserved targets and summarises 
the sequence, functional, structural and immunological profiles of such 
conserved sequences which can be used for future target selection. Original 
findings of the research undertaken in this thesis are summarized and discussed 
in Chapter 8 and future directions are also proposed. 
Part of the work presented in this thesis has been published in Hu et al. (2013) 
– Dissecting the Dynamics of HIV-1 Protein Sequence Diversity (Chapter 4).  
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Chapter 2  Literature Review 
 
2.1 The Human Immunodeficiency virus (HIV) 
 
Within the recorded history of human civilization, HIV is undeniably one of the 
most severe infectious diseases to have afflicted mankind globally, ranking sixth 
amongst the top ten causes of death worldwide (WHO, 2013).  The infections 
at present are incurable but the administration of HAART helps to reduce short 
term mortality and markedly increases the quality of life of HIV patients by 
decreasing the chances of contracting diseases due to opportunistic infections 
(Hammer, 2002; Palella et al., 1998). Nevertheless, HAART is expensive, 
requires long term drug adherence and most importantly, does not prevent the 
eventual progression to AIDS. Ultimately, HIV infections results in an almost 
100% fatality (Rambaut et al., 2004) with about 1.7 million deaths reported in 
the year 2011 (UNAIDS, 2012). Thus, there is an urgent need for the 
development of a low cost, safe and effective vaccine, therapeutic or 
preventive/prophylactic,  which can confer life-long protection or cure for HIV 
infections (Gamble and Matthews, 2010; Graham, 2002; Ho and Huang, 2002; 
Korber et al., 2009; Levitz et al., 2012; Munier et al., 2011). 
The causative agent of this worldwide epidemic is a member of the genus 
Lentivirus, part of the family of Retroviridae. It is further sub-divided into two 
different types: HIV type 1 (HIV-1) and type 2 (HIV-2). HIV-1 and HIV-2 are 
of phylogenetically divergent ancestry with HIV-1 evolving from a strain of 
SIV, SIVcpz, which infects chimpanzee, typically of the sub-species Pan 
troglodytes troglodytes and Pan troglodytes schweinfurthii, that are endogenous 
to regions of equatorial Western and Central Africa (Gao et al., 1999; Santiago 
et al., 2002), and HIV-2, sharing a nucleotide sequence similarity of about 50% 
with HIV-1, is most phylogenetically related to SIVsm5, which is highly 
prevalent amongst sooty mangabey monkeys (Cercocebus atys) residing in the 
regions of West Africa (Rambaut et al., 2004; Tebit et al., 2007). Although both 
HIV-1 and HIV-2 are commonly transmitted by unprotected sexual intercourse, 
perinatal means and blood-borne exposure (needle-sharing and blood 
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transfusions) (Campbell-Yesufu and Gandhi, 2011; Kanki et al., 1994; Schim 
van der Loeff and Aaby, 1999), HIV-1, in comparison to HIV-2, is highly 
infectious and has a more prevalent global spread beyond West Africa and 
southern/western India. As the chief causative agent for global HIV pandemic, 
the development of therapeutic strategies, in particular vaccines, have been 
focused on HIV-1 over the past few decades.  
 
 
Figure 2.1 | Graphical representation of a HIV-1 viral particle. The legend 
for the various components of the viral particle is included in the figure. 
(Adapted and redrawn from http://www.avert.org/virus.htm ) 
 
The detailed understanding of the underlying viral protein sequence diversity is 
widely recognized to be fundamental to vaccine formulation. Changes in the 
genetic sequence can result in epitope deletion, failure of antigen processing, 
abrogation of HLA-peptide binding and TCR recognition and aids the evasion 
of immune elimination of HIV-1 in humans (Allen et al., 2004; Draenert et al., 
2004; Kelleher et al., 2001; Leslie et al., 2004; Yokomaku et al., 2004).The 
origin of sequence diversity resides within the genome of the 120 nanometre 
HIV-1 viral particle (Figure 2.1) (Gentile et al., 1994). Each viral particle 
contains two single-stranded 9.2 kb RNA molecules, each encoding nine genes: 
gag, pol, vif, vpr, tat, rev, vpu, env and nef (Figure 2.2) (Kuiken et al., 2008; 






Genes Proteins Description of protein encoded GI No a 
gag Gag Gag polyprotein containing proteins matrix 
(MA / p17), capsid (CA / p24), nucleocapsid 
(NC / p7) and p6 protein 
120845 
pol Pol Pol polyprotein containing viral enzymes 
protease (PR / prot), reverse transcriptase (RT 
/ p51), RNase and integrase (p15 and IN) 
77416881 
vif Vif Viral infectivity factor 62291046 
vpr Vpr Viral protein R 62291049 
tat Tat Transactivator of HIV gene expression 6094428 
rev Rev Regulatory factor for HIV expression 132438 
vpu Vpu Viral protein U 139440 
env Env Envelope polyprotein containing gp120 / SU 
and gp41 / TM.  
6015102 
nef Nef Negative factor 288558856 
 
Figure 2.2 | Genomic organization of HIV-1 (with reference to the HXB2 
strain). Information about the proteins encoded by the nine genes is listed in 
the table above. All the nine genes are encoded for in nine different open reading 
frames. a Accession number (GIs) obtained from Los Alamos HIV sequence 
database (http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html). 
 [HIV-1 genome map adapted and redrawn from Kuiken et al., (2008)]  
 
The HIV-1 genome contains three long contiguous open reading frames (ORFs) 
encompassing gag, pol and env, which encodes for the structural and enzymatic 
proteins Gag polyprotein (Gag), Polymerase polyprotein (Pol) and Envelope 
protein (Env). However, unlike other simple retroviruses, the HIV-1 genome 
contains several additional ORFs coding for auxiliary proteins, Viral infectivity 
factor protein (Vif), Viral protein R (Vpr), Viral protein U (Vpu) and Negative 
Factor protein (Nef), and regulatory proteins, Transactivator of HIV gene 
expression protein (Tat) and Regulator of virion gene expression (Rev)  (Kuiken 
et al., 2010). The regulatory proteins are important for virus replication and 
controlling HIV gene expression in host cell while the auxiliary proteins are 
generally not required for viral propagation in tissue cultures but are capable of 
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modulating replication and viral pathogenesis. For example, Vif is important in 
establishing infection (Fisher et al., 1987; Strebel et al., 1987) and Vpr is 
involved in conferring rapid growth rate (Cohen et al., 1990; Ogawa et al., 
1989).  
 
2.2 HIV-1 Diversity and its implications  
2.2.1 Causes for HIV-1 sequence diversity 
 
 
The HIV-1 virus is one of the most hypervariable viruses known to infect man. 
With one of the highest reported mutation rates (see 
http://www.uv.es/rsanjuan/Viral_mutation_rates_snc.htm for list of viruses and 
their mutation rate (Sanjuan et al., 2010)), the sequence diversity level is 
analogous to the global annual population genetic variation of influenza virus 
within a single terminally-infected patient (Korber et al., 2001).Viral diversity 
is first introduced during transmission where one or more HIV-1 variants of one 
infected host is passed on to another (Dickover et al., 2001; Haaland et al., 2009; 
Novitsky et al., 2011; Redd et al., 2012) and this initial infection will ensue the 
subsequent cascades of genetic mutation and recombination events, primarily 
driven by the host immune systems, where pools of highly heterogeneous 
viruses are created within individuals. At a global level, the combined 
differences between individual quasispecies further complicates the already 
complex diversity landscape and present major challenges to the determination 
of HAART regime efficacy, viral virulence, the prediction of the rate of disease 
progression, HIV drug design and the elucidation of immunogens for vaccine 
formulation (Gottlieb et al., 2004; Sagar et al., 2003).  
The main drivers of HIV-1 genome diversification are that of genetic mutations 
and recombination events. Mutations are frequently introduced into the HIV-1 
genome as base substitutions, deletions and insertions by the error-prone RNA 
viral reverse transcriptase (RT). With the absence of an exonuclease domain to 
proof-read the transcription process (Basavapathruni and Anderson, 2007), the 
RT introduces an estimated 0.2 to two errors per genome per replication cycle 
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(Basavapathruni and Anderson, 2007; Drake, 1993; Mansky and Temin, 1995; 
Preston et al., 1988; Ricchetti and Buc, 1990; Roberts et al., 1988) (Step III in 
Figure 2.3). Though rare, mutations can also additionally be introduced into the 
HIV-1 genome by RNA Pol II polymerase during the process of transcribing 
HIV-1 deoxyribonucleic acid (DNA) to RNA to generate infectious viral 
particles post-integration into the host’s genome (Step V in Figure 2.3).  
Equally important in driving HIV-1 sequence diversification is the 
recombination of genetic material between different genetically unique HIV-1 
viral strains. Recombination events occur when host cells are infected with two 
or more different viral strains from the same (within a quasispecies) or different 
phylogenetic clades. During the process, HIV-1 RT switches between two or 
more genetically distinct RNA genomes within an infected cell during negative-
strand DNA synthesis to heterodiploid viruses containing “new” genome 
(Ramirez et al., 2008; Tebit et al., 2007) (See Step III in Figure 2.3 and Figure 
2.4). This generates heterodiploid viruses containing “new” genomes that 
further complicate the diversity landscape of the existing complex quasispecies. 
In fact, as many as two to three recombination events may occur during each 
replication cycle, making it one of the highest recorded (Jetzt et al., 2000; Jung 
et al., 2002). The combination of genetic mutational errors, recombination 
events and the high replication rate of about 1010–1012 new virions each day 





Figure 2.3 | Schematic representation of the life cycle of HIV-1. The typical 
life cycle of a HIV-1 starts with the adsorption of the viral particle to the host 
CD4 receptor by the viral glycoprotein 120 (gp120). The adsorption process is 
aided by co-receptors, CXCR4 and/or CCR5, which are usually found on CD4-
bearing (CD4+) cell (Step I) like the CD4+ T cells, monocytes and dendritic 
cells. After virus adsorption, the membranes of the virus and the host cell will 
fuse together and the viral 'core' will be released into the cytoplasm (Step II). 
The error prone HIV-1 reverse transcriptase (RT) is subsequently activated for 
the synthesis of viral complementary deoxyribonucleic acid (cDNA) (Step III) 
which will be transported to the cell nucleus and integrated into the host genome 
(coloured blue) with the help of HIV integrase (Step IV). In cells which are 
infected with two or more viral strains, recombination events can occur resulting 
in the generation of “new” viral genomes that are distinct from the infected 
viruses (Figure 2.4). Thereafter, viral cDNA will be expressed to produce 
genomic and messenger (spliced) ribonucleic acid (mRNA) molecules which 
are transported to the cell cytoplasm (Step V). HIV mRNAs will be translated 
to HIV-1 proteins (Step VI) which will be subsequently packaged into a new 
virus during viral assembly, prior to viral 'budding' and release from the infected 
cells (Step VII). Newly synthesized viral particles will undergo maturation to 
give rise to a new infectious particle (Step VIII) which is ready to infect other 
host cells. [Adapted and redrawn from Monini et al. (2004)] 
 
The high rate of mutation and recombination generates a large pool of 
genetically related but distinctly diverse sequence variants within host as a 
population of complex quasispecies (intra-host variation) (Eigen, 1993a; Eigen, 
1993b; Lauring and Andino, 2010), and globally as members of various 
different HIV-1 groups and clades (inter-host variation) (Holmes, 2009; 
Rambaut et al., 2004). All circulating HIV-1 strains are phylogenetically 
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classified into three distinct groups: Major (M), Outlier (O) and non-M/non-O 
(N), with inter-group nucleotide sequence variation of more than 30% each 
(Tebit et al., 2007). Group M viruses, causing greater than 90% of HIV-1 
infections worldwide (Gifford et al., 2006; Lau et al., 2007; Takebe et al., 
2008), predominates the HIV-1 pandemic and are targets of intense scientific 
research. Viral sequence variability within group M viruses alone can extend 
beyond 30% in their amino acids (Gaschen et al., 2002) and are genetically 
classified into at least 11 genetically distinct clades, clades A1, A2, B, C, D, F1, 
F2, G, H, J and K. However, HIV-1 sequence variability does not just stop at 
the individual clades level and the extent of the global sequence diversity 
landscape is made more complex by genetic recombination events where 
multiple different CRFs and URFs have emerged.  
HIV-1 recombinant forms, URFs and CRFs, are generated from recombination 
events involving strains of different clades. CRFs typically arise from 
recombination events between HIV-1 viruses from different subtypes/clades of 
group M and exist in epidemic proportions. Viral strains formed from the 
recombination of more than two different subtypes/clades are named as 
complex CRF (CRFcpx). URFs, on the other hand, are diverse forms of HIV-1 
inter-genotype recombinants seen only in a single person or in a few 
epidemiologically linked individuals and are limited in transmissibility within 
the human population (Robertson et al., 2000; Takebe et al., 2008). Currently, 
more than 50 CRFs/CRF-cpx (see 
http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html) and 
numerous URFs have been reported to be circulating worldwide. Each 
recombinant variant, like that of mutational variants within a quasispecies, can 
potentially act as immunological escape mutants which can evade the detection 
of the human immune system at such they can no longer be recognized by 
responding cytotoxic T lymphocytes (CTLs) which are important for 






Figure 2.4 | Schematic representation of recombination events during 
negative strand DNA synthesis by RT. Recombination can occur when 
reverse transcription by RT (in yellow) with the RNA1 (depicted as blue dotted 
line) template is switched to RNA2 (in red dotted line). This change results in 
the degradation of the RNA1 component of the RNA1- DNA hybrid which 
exposes single-stranded portions of the nascent DNA (continuous blue line as 
DNA reverse transcribed from RNA1 and red line from RNA2) that can 
facilitate strand transfer to RNA2 via complementary base pairing. (Adapted 
and redrawn from Smyth et al., 2012). 
 
The final combinatorial result is the generation of a complex heterogeneous 
population of viral quasispecies (Eigen, 1993b; Lauring and Andino, 2010), 
each capable of evading drug targeting, detection and clearance by the human 
immune system (Borrow et al., 1997; Goulder et al., 1997; Price et al., 1997).  
The enormous population of viral strains, within and between quasispecies, 
presents an extremely large pool of distinct antigenic peptides, > 3000 nonamer 
peptides per proteome, possible for the presentation at the immune synapse. 
This causes the immune synapse to be saturated with peptide antigens and the 
overstimulation can lead to T cell anergy and autoimmune diseases, typically 
observed in HIV-1 patients (Bouhdoud et al., 2000; Schwartz, 1996; Schwartz, 
2003; Tsumiyama et al., 2009; Wick, 1999). The complexity of sequence 
diversity needs to be systematically dealt with and a “divide-and-conquer” 
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approach will aid in the detailed study of each viral subpopulation especially 
that of the most widely studied clade B viruses. Insights obtained from such 
analyses are useful in understanding the various factors that are closely linked 
to HIV-1 sequence diversity and can be extended to future studies that include 
HIV-1 viruses of far greater degree of genetic complexities. 
 
2.2.2 Viral diversity and challenges to antiretroviral therapy 
 
Upon the detection of HIV-1 infection, individuals are usually prescribed the 
conventional HAART where it significantly reduces morbidity and mortality 
(Buchacz et al., 2010; Ray et al., 2010) in HIV-1 patients through the partial 
recovery of impaired immunological functions. In 2012, there are about 25 anti-
retroviral (ARV) drugs in six different mechanistic classes approved for usage 
in HIV-1 patients (Thompson et al., 2012). They include nucleoside/nucleotide 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), CCR5 
antagonists, and integrase strand transfer inhibitors (INSTIs). Contemporary 
HIV-1 HAART regimens typically include two NRTIs plus one active drug 
belonging to the class of NNRTIs, PIs (commonly co-dispensed with a ritonavir 
(RTV) boost), INSTI, or a CCR5 antagonist (NIH, 2013). Nevertheless, 
HAART do not cure HIV-1 infections nor do they decrease the latent reservoir 
within infected patients (Archin et al., 2012; Marsden and Zack, 2013) and 
infected individuals will ultimately die of the progression of the infection to 
AIDS. Efficacy of HAART within the heterogeneous population is greatly 
limited by de novo and/or acquired antiretroviral resistance against one or more 
antiretroviral drugs in a typical HIV-1 drug regimen (Goldberg et al., 2012). De 
novo antiretroviral resistance is conferred by infected individuals by the 
inheritance of drug resistant HIV-1 strains (Yerly et al., 1999) through sexual 
intercourse with infected individuals  (Conlon et al., 1994; Conway et al., 1999; 
Erice et al., 1993; Imrie et al., 1997; Imrie et al., 1996; Quigg et al., 1997; Rubio 
et al., 1997), perinatal (Colgrove et al., 1998; Johnson et al., 2001; Kamkamidze 
et al., 2001; Masquelier et al., 2001) and/or via parenteral means (de Ronde et 
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al., 1996; Fitzgibbon et al., 1993; Veenstra et al., 1995). Conversely, acquired 
drug resistance is an induced resistance that occurs after HAART initiation. 
Acquire resistance is a direct result of the inability of current HAART regime 
to block viral replication and it positively drives viral evolution towards the 
generation of a quasispecies with decreased HAART susceptibility (Clark et al., 
2006; Clavel and Hance, 2004; Fun et al., 2012; Larder and Kemp, 1989).  
Resistance, de novo or acquired, to existing HAART dictates a frequent need 
for the change of existing drug regimes, which usually involves a three drug 
combination (NIH, 2013; Thompson et al., 2012). However, with only about 25 
drugs approved (Thompson et al., 2012) and the available drugs are insufficient 
to be used in alternative regimes to overcome the rapid rate of drug resistance 
conferment in HIV-1 positive individuals. Also, the prescription of the ideal 
HAART treatment to effectively avoid drug resistance is extremely challenging 
and requires the identification of all viral variants, drug resistant or non-
resistant. Unfortunately, this area of research is still in its infancy (Beerenwinkel 
and Zagordi, 2011). Alternative therapies are urgently required. The 
development of a HIV-1 vaccine to complement current HAART regime and to 
offer protection, minimization of disease symptoms or potential cure, might be 
a likely way forward in HIV-1 disease management. 
 
2.2.3 Viral diversity and vaccine design 
 
Even as intense research is actively carried out to improve drug efficacy, reduce 
drug toxicity and minimizing the emergence of drug resistance, it must be noted 
that anti-retroviral drugs do not cure HIV-1 infection and is expensive and 
requires long term drug adherence. As the miracle drug for eliminating HIV-1 
infections remained elusive, parallel attention has also been placed by the 
scientific community in the design of an effective HIV-1 vaccine, prophylactic 
or therapeutic, that is able to offer long term immune control or permanent cure 
of the infection. Despite of the decades of intense research, to date, no vaccine 
has been successfully formulated. The ultimate ideal goal is to come up with a 
safe, affordable, well-tolerated vaccine, therapeutic or prophylactic, that elicits 
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effective and long-lasting humoral and cellular immunity against the plethora 
of different HIV-1 strains the target population is likely to respond to (Fauci et 
al., 2008; Haynes and Shattock, 2008; Johnston and Fauci, 2007). 
 
 
2.2.3.1  HIV-1, the immune system and vaccine design 
 
The HIV-1 virus interacts with the human host in complex ways. A prior 
understanding of the interaction of the host immune system and the virus is 
critical to vaccine design. One of the major immunological signatures of HIV-
1 infection is the gradual depletion of CD4-bearing (CD4+) T cells and the 
concomitant increase in viremia. After initial infection, the virus undergoes an 
initial asymptomatic incubation period which usually lasts about 2 weeks 
(Cooper et al., 1985).  This is followed by the subsequent primary infection 
phase, which is linked to the massive increase in viral load before the activation 
of antiviral immune responses decreases the viral load to a lower set-point. 
Thereafter, the infection will progress towards an asymptomatic or chronic 
phase with a gradual increase in viral load from the primary infection set-point 
and a concurrent and gradual irreversible decrease in CD4+ T cell count. This 
process can last between two weeks to more than twenty years. The final stage 
of HIV infection often progresses to AIDS and death is frequently associated 
with the terminal failure of the immune system and disease (Centlivre et al., 
2007). HIV-1 infection is an infection of the immune system and vaccine design 
strategies should include the careful considerations of the role of the immune 
system in HIV-1infections. Collective insights obtained from the study of HIV-
1 immune-relevant diversity, host immune diversity and HIV-1 host molecular 
mimicry induced auto-reactivity and non-immunogenicity (Bjork, 1991; Carter, 
2011; Kanduc, 2008; Kanduc, 2009; Kanduc et al., 2008; Silvestris et al., 1995) 
can aid the rational selection of candidate vaccine targets for the formulation of 
a successful HIV-1 vaccine. 
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2.2.3.2 Vaccines eliciting adaptive immune responses against HIV-
1 infection 
 
The elicitation of a successful immune response post HIV-1 vaccination 
requires the synergy between the innate immune system (Shankar et al., 2012) 
and the adaptive immune system. Particularly important is the participation of 
the human adaptive immune system which allows the recognition of newly 
challenged foreign antigens and the mounting of appropriate and lasting 
immune responses to control or clear the invading HIV-1 viruses. The human 
adaptive immune system contains two different arms: a humoral arm and a 
cellular arm, and an effective vaccine will require the activation of both immune 
pathways to confer long term protection and potential viral clearance. Human 
humoral immunity, involving B cells that secrete antigen-specific antibodies 
(Abs) which bind to pathogens to prevent infection or “neutralize” the antigens, 
has been the major focus in HIV-1 vaccine design, especially that of broadly 
neutralizing Abs (BrNAbs) (Chen et al., 2013; Corti and Lanzavecchia, 2013; 
van Gils and Sanders, 2013) which could potentially confer long term immune 
control against a wide range of viral strains. However, the elicitation of BrNAbs 
via vaccination is greatly impeded by high viral sequence diversity of HIV-1 
(Gaschen et al., 2002; Hemelaar, 2012a; Hemelaar, 2012b; Korber et al., 2001; 
Taylor et al., 2008) and the inaccessibility of relatively conserved domains on 
the external Env protein for BrNAbs binding (Barouch, 2008; Walker and 
Burton, 2008). Also, further immunological concerns surrounding BrNAbs-
induced auto-reactivity with human platelets (Yu et al., 1986), T cells (Ardman 
et al., 1990; Daniel et al., 1989; Ozturk et al., 1987; Silvestris et al., 1994; 
Silvestris et al., 1995) and human host glycan-decorated proteins (Dunlop et al., 
2010; Joyce et al., 2008) needs to be systematically resolved in order to obtain 
a vaccine that induces only sterilizing immunity and does not enhance the rate 




2.2.3.3  HIV-1 vaccine and human cellular immunity  
 
As the search of immunogens which elicit BrNAbs continues, vaccine research 
efforts have advanced to that of the identification of T cell epitopes, mediating 
cellular immunity responses, where a growing body of evidence indicate the 
importance of virus-specific T cell responses in controlling, and potentially 
clearing, HIV infections (Appay et al., 2002; Goonetilleke et al., 2009; Korber 
et al., 2009; Koup et al., 1994). The T cell mediated immune response, or the 
cellular immune response, of the adaptive immune system, comprises both T 
helper lymphocytes (usually CD4-bearing, CD4+) and CTL (usually CD8-
bearing, CD8+). T helper cells are responsible for orchestrating and directing 
an immune response by the secretion of cytokines aiding in the differentiation 
of B cells to antibody-producing plasma cells and maintaining CD8+ memory 
responses while CTLs are the active killer cells that traffic to the sites of 
infection and lyse infected cells. Unlike neutralizing antibodies that targets 
solely the external variable surface Env protein for viral neutralization and 
clearance, T cells are capable for recognizing a wider array of peptides from the 
viral structural and regulatory elements for downstream cellular immune 
responses. Vaccine formulations with enhanced T cell epitope coverage will 
increase the immunological coverage of vaccine against the heterogeneous viral 
population within the human population worldwide. 
 
2.2.3.4  HIV-1 vaccines in clinical trials 
 
Annually, billions of dollars have been spent globally on HIV/AIDS research 
but yet the sobering reality is that at present, there are still no effective vaccines 
against HIV-1 infection (Walker and Burton, 2008). To date, more than 200 
vaccine products have been tested and only four have advanced to phase IIb/III 
clinical trials (IAVI, 2013; Saunders et al., 2012; Tieu et al., 2013). Amongst 
them, two phase IIB clinical trials (Step study and Phambili) using the 
Adenovirus vector serotype 5 HIV-1 Gag/Pol/Nef vaccines (MRKAd5) were 
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aborted due to the inability to confer protection to vaccinated volunteers by 
potentially-biased T cell responses targeted towards less conserved regions 
(Buchbinder et al., 2008; Cohen, 2007; Duerr et al., 2012; Gray et al., 2011; Li 
et al., 2011; McElrath et al., 2008). Additionally, two phase III clinical trials of 
a clade B gp120 envelope glycoprotein vaccine (AIDSVAX B/B) and a clade 
B/E gp120 envelope glycoprotein vaccine (AIDSVAX B/E) have failed due to 
the inability to prevent infection or delayed disease progression, even though 
vaccinated individuals were able to generate antibodies targeting HIV-1 Env 
(Flynn et al., 2005; Pitisuttithum et al., 2006).  
Despite the failure of the predecessors, a recent phase III clinical trial (RV144) 
with a ALVAX and AIDSVAX vaccination regime have reported a slight 
efficacy (~31%) in preventing heterosexual HIV acquisition. The success of the 
trial is believed to be associated with elicitation of the high levels of antibody-
dependent cellular cytotoxicity (ADCC), a modest level of anti-HIV-1 Env 
immunoglobulin A (IgA) antibodies and T cell responses targeted at a variable 
V2 region of the HIV-1 Env protein (Bonsignori et al., 2012; de Souza et al., 
2012; Haynes et al., 2012; Rerks-Ngarm et al., 2009). Viral diversity was 
circumvented by the usage a prime-boost vaccination regime with ALVAC 
vaccines, expressing gp41 of clade CRF01_AE (strain 92TH023) and Gag and 
Protease of clade B (strain LAI), and AIDSVAC B/E vaccines, expressing 
gp120 from clade CRF01_AE (strain A244) and B (strain MN), in the RV144 
trial. This regime sharply contrasts with other vaccines which typically include 
only a few proteins from one or two HIV-1 strains where their limited 
representation within the entire genetically heterogeneous HIV-1 infected 
population have questionable efficacy in the elicitation of immune responses.  
Also, the proportion of epitopes (Li et al., 2011) within vaccine constructs used 
in clinical trials are low and thus compromises the breadth of immune responses 
potentially generated by vaccination. Thus, vaccine design strategies should 
focus on the fundamental dissection and characterization of the immune-
relevant sequence diversity of HIV-1 (Barouch and Korber, 2010) within the 
heterogeneous human population. Insights obtained will undoubtedly aid the 




2.3 Current approaches to study HIV-1 viral diversity for vaccine design 
2.3.1 Experimental approaches to the study of HIV-1 sequence diversity 
 
A successful HIV-1 vaccine must include immunogens that match a large 
number of circulating viral strains and restricted by a wide array of HLA alleles. 
The selection of appropriate immunogens for vaccine design lies in the 
understanding of the diversity of T cell epitopes which is traditionally based on 
experimentation. Conventional “wet” laboratories approaches profoundly rely 
on the initial generation of overlapping peptides of the protein(s) of interest for 
quantitative in vitro binding specificity assays. For example, to experimentally 
identify all nonamer T cell epitopes within the Gag protein (~ 500 amino acids) 
of a particular HIV-1 strain, 492 overlapping nonamers (peptides of nine amino 
acids long) are required to be generated. Typically, nonamer lengths are usually 
adopted as the basic T cell epitope experimental unit as it is the predominant 
length of the binding cores for a majority of peptides recognized by HLA class 
I and II molecules (Rammensee, 1995). In order to comprehensively identify all 
nonamer epitopes and their corresponding interacting HLA allele, all 
overlapping viral peptides generated will be subjected to almost four million in 
vitro binding specificity assays for over 9,946 reported HLAs (accurate as of 
November 2013, http://hla.alleles.org/alleles/index.html ) which needs to be 
cloned, expressed and purified prior to the binding experiments (Figure 2.5A). 
A large proportion of the four million binding assays are expected to yield 
negative results and only a small fraction of the nonamers will be HLA binders 
as the estimated epitope prevalence is about 0.1% to 5% (Brusic and 
Zeleznikow, 1999). Subsequently, HLA binders will additionally be validated 
by further in vivo HLA transgenic mice studies and/or in vitro studies using 
primary immunogenicity cultures like that of the human peripheral blood 
mononuclear cells (PBMC) samples (Bertoni et al., 1997; Sette et al., 2001; 
Wentworth et al., 1995; Wilson et al., 2001). HLA binders that are able to elicit 
T cell responses will be identified as T cell epitopes. The typical steps for the 
traditional experimental identification of T cell epitopes are summarized in 





Figure 2.5 | The experimental pipeline employed for the identification of T 
cell epitopes. Experimental T cell epitopes identification starts with the 
biochemical binding assays of all overlapping nonamers (denoted as Pn, where 
n is the number of overlapping peptides) spanning the entire length of the 
protein (each HLA molecule is designated by Mn, where n is the number of 
HLA molecules) (See Figure 2.5A). Peptides that bind to the HLA molecules 
are known as HLA binders (designated by Bn, where n is the number of HLA 
binding peptides). HLA binders are subsequently tested for immunogenicity in 
transgenic mouse models or human PBMC (See Figure 2.5 B). HLA binders 
which are recognized by the TCR and trigger downstream T cell immune 




Although experimental approaches are the only way to obtain T cell epitope 
information, such experiments are inherently expensive, laborious and time 
consuming and, thus, greatly limits the diversity analysis of T cell epitopes to 
one or several HIV-1 protein(s) of a particular viral strain which are restricted 
by a small set of HLA studied (Kantakamalakul et al., 2006; Ribeiro et al., 2010; 
Simon et al., 2010). Modern technologies, however, have delivered the promise 
to relieve such bottlenecks with state-of-the-art experimental platforms like that 
of microarrays. However, the usage of such technologies is still in its 
rudimentary stage and the high costs involved will likely impede the 
popularization of such T cell epitope identification techniques in recent 
paradigms.  
 
2.3.2 Computational approaches to the study of HIV-1 sequence diversity  
 
The rate at which experimental T cell epitopes are identified is greatly lagging 
behind that of the discovery of new HIV-1 viral strains and HLA alleles. With 
the advent of new next-generation sequencing (NGS) technologies like that of 
ultra-deep sequencing (UDS), sequencing is now cheaper, faster and more 
accurate. More sequencing experiments, particularly that to generate the 
different types of each variant mutant within the complex quasispecies 
(Beerenwinkel and Zagordi, 2011), are carried out and large volumes of 
sequence data are generated daily. We are experiencing an era of data explosion 
and parallel approaches are required to complement and enhance the current rate 
of epitope identification for vaccine design. One of such approaches is that of 
bioinformatics. The use of bioinformatics in the analysis of the huge repository 
of viral sequences generated from large-scale sequencing experiments for the 
identification of a reduced set of potential immunogens which can be validated 
by a smaller number of “wet” laboratories experiments. In addition, the usage 
of such a reverse vaccinology approach will help us gain insight into the hidden 
sequence, functional, structural and immunological patterns of mutational 
changes within the viral population and uncover generic principles for the 
identification of potential epitopes which can be used for vaccine design.  
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Current efforts in the computational identification of T cell epitope vaccine 
targets mainly focuses on analysing HIV-1 group M viral strains which are 
responsible for more than 90% of HIV-1 infections worldwide. Early efforts 
contributing to the in silico identification of putative T cell epitopes in HIV-1 
were primarily based on prediction programs which were built by machine 
learning algorithms like HMM and ANN (Brusic et al., 2002; Larsen et al., 
2007). One of the major limitations of such studies is the lack of detailed 
immune-relevant diversity considerations. The sequence variability of predicted 
epitopes within the viral population remains largely unknown. There is a 
potential risk that such predicted epitopes might reside within regions that are 
highly mutable and, thus, might not be able to mount protective immune 
response against the large population of circulating variants. Also, the long-term 
antigenic relevance for lasting immune protection of variable sequences is in 
question as frequent mutational events can lead to epitope loss (Price et al., 
1997; Price et al., 1998; Yusim et al., 2002).  
Enhanced viral diversity considerations are required and phylogenetic 
reconstructions of consensus sequences or ancestral sequences  can be carried 
out to select vaccine strains that are most relevant and analogous to circulating 
strains of recent paradigm (Gaschen et al., 2002; Nickle et al., 2007). The 
advantage of the aforementioned approach is its ability to identify sequences 
that potentially have the superiority for eliciting cross-clade immune responses 
against the vast number of HIV-1 variants. However, reconstructed consensus 
and/or ancestral sequences are fundamentally not natural sequences observed in 
HIV-1 strains and the careful characterization of the expression, antigenicity, 
and biological activity is necessary prior to the use in vaccine formulations 
(Gaschen et al., 2002). To overcome the issues of artificial sequence 
constructions and high level of viral diversity, alternative methodologies have 
been adopted to identify highly conserved sequences through the study of large 
populations of viral sequences. Conserved sequences are ideal candidates for 
vaccine formulation as they potentially represent the virus’s “Achilles heels” 
which are expected to remain conserved and immunologically relevant, 
probably due to functional and structural constraints, even if the virus 
population continues to mutate and evolve through time (Rolland et al., 2007c). 
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Conserved sequences can be identified by the contiguous concatenation of 
slightly variable amino acids (Liang et al., 2008; Rolland et al., 2007c; 
Srinivasan et al., 2008; Yang, 2009). Nevertheless, such single amino acid 
methods lack correlations to the host immune system as human immune-
relevant diversity is viewed as fragments of roughly nine amino acids long 
(Korber et al., 2009). Several research groups (De Groot et al., 2003; De Groot 
et al., 2005; Finnefrock et al., 2007) have addressed this concern and had 
designed methodologies to include human immune system considerations 
where the diversity of HIV-1 was studied in nonamer units. Conserved 
sequences identified can be further compacted into a few number of native-like 
‘mosaic’ proteins where the immunological coverage of vaccine constructs can 
be enhanced (Barouch et al., 2010; Fischer et al., 2007; Stephenson et al., 2012). 
Ensuing targets identification, computational immunogenicity assessments 
were typically carried out by correspondences to reported epitopes and/or 
epitope prediction. Primary sequence analyses, target sequence /strain 
identifications and immunogenicity correspondences form the important steps 
for most of the published diversity-driven vaccine target discovery pipelines. 
Sequences identified by disparate computational pipeline represent refined sets 
of candidate vaccine targets which can be used for further in vitro or in vivo 
“wet” laboratory experimentation. 
 
2.3.3 Limitations in current computational approaches for vaccine design 
 
Conventional experimental approaches for the identification of T cell epitope 
vaccine targets, though effective in many cases, are extremely tedious, time-
consuming and financially challenging as the number of known variants 
continues to increase with the rapidly mutating HIV-1 virus. The usage of 
bioinformatics is integral in the optimizing the vaccine target selection process 
by enabling scientists to study large number of HIV-1 sequences quickly and 
systematically within the designed analysis pipelines. Beyond the intense focus 
on the study of sequence conservation, there is also a need to comprehensively 
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investigate the variability of HIV-1 (Srinivasan et al., 2008) in order to obtain a 
detailed picture of the diversity landscape of HIV-1 prior to target selection. 
Also, there is a need to analyse other factors that affect the immune-relevant 
diversity and immunogenicity of target sequences beyond its primary sequences 
and this includes protein structural, functional and molecular mimicry 
considerations. Finally, there is a need to revisit the study of HIV-1 sequences 
within group M as an intact entity. Sequence diversity within each individual 
clade can differ more than 35% (Gaschen et al., 2002; Hu et al., 2013; Walker 
and Korber, 2001) and collectively, the combinatorial diversity of all different 
clades within group M will be factorially higher and this will potentially mask 
important sequence variability inherent within different subtypes. Thus, the 
employment of a divide-and-conquer approach will plausibly benefit the 
rational selection of immunogens for HIV-1 vaccine design by unravelling 
hidden insights within individual HIV-1 clades, especially the most widely 
studied clade B, before surmounting the compounded complexity of multiple 
clades. 
 
2.3.4 Going forward in the identification of HIV-1 vaccine targets 
 
Rational HIV-1 vaccine design should begin with the fundamental 
understanding of the HIV-1 viral proteome, in particular that of immune-
relevant sequence diversity which is one of the key considerations in HIV-1 T 
cell vaccine design. Also, additional functional, structural and immunological, 
including molecular mimicry considerations (Kanduc, 2008; Maksyutov et al., 
2004), studies are required to elucidate key features of HIV-1 diversity which 





2.4 A diversity driven immunoinformatics pipeline for rational HIV-1 
vaccine design 
 
The complexity of HIV-1 diversity cannot be effectively addressed by the 
disparate analyses of different factors in isolated studies. There is a need to 
concertedly study sequence diversity with other associated factors within a 
systematic immunoinformatics pipeline for the identification of key factors 
driving or restricting HIV-1 variability. The initial comprehensive 
quantification of HIV-1 nonamer diversity is instrumental for the detailed 
dissection of HIV-1 immune relevant dynamics where further diversity 
correlative studies are based upon. Critical factors that are commonly associated 
with sequence diversity need to be studied in detail thereafter. The analysis of 
factors which are commonly ascribed to limit sequence diversity like that of 
functional, structural (Geyer et al., 2001; Joshi and Xu, 2007; Sangar et al., 
2007; Zolla-Pazner and Cardozo, 2010) and immunological constraints (Carter, 
2011; Kanduc, 2008; Kanduc, 2009; Silvestris et al., 1995) will help elucidate 
key features of HIV-1 immune-relevant sequence variability and conservation 
where generic rules can be established for the selection of plausibly 
immunogenic targets for further experimental validation. It is, thus, the focus of 
this thesis is to adopt a holistic immunoinformatics approach for the 
comprehensive study of HIV-1 sequence diversity and its correlated protein 
function, structure and immunological constraints within an original systematic 
pipeline for the elucidation of key signatures that can, collectively, be used to 
define favourable vaccine targets for vaccine design.  
 
2.4 Objectives of the thesis 
 
Immunoinformatics approaches are essential for the rational selection of 
candidate targets for HIV-1 vaccine design. Insights obtained from the large 
scale analysis of the viral immune-relevant proteomes will aid the 
identification of evolutionarily conserved sequences, which contains structural 
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and functional constraints to vary and are potentially immunogenic. The 
specific objectives of this thesis are 
(i) the development and application of a methodology to analyse the 
immune-relevant diversity of viral proteomes, in particular that of 
HIV-1; 
(ii) corresponding the elucidated immune-relevant diversity landscape 
to reported 3D HIV-1 protein structures and functions for the 
identification of structural and functional constraints which can 
potentially limit viral variability; 
(iii) the identification of potential vaccine targets in HIV-1; 
(iv) the inferred immunogenicity of candidate HIV-1 vaccine targets; 
and  
(v) the definition of a generic pipeline for the analysis of immune-
relevant diversity of viral pathogens for vaccine design. 
 
2.5 Chapter summary 
 
 The combination of the high rates of mutation, recombination and viral 
replication has generated a large pool of HIV-1 variants which act as escape 
mutants which evades the detection of the immune system. These variants 
overwhelm the human immune system, especially that of the cellular 
immunity which is critical in actively killing the viruses and virus-
harbouring cells and the generation of long term immunological memory 
against HIV-1.  
 Traditional experimental approaches to identify T cell epitopes for vaccine 
design are expensive and time consuming thus greatly limits the 
identification to a few HIV-1 proteins, strains and HLA alleles. To relive 
the bottleneck, large-scale bioinformatics analyses, linked together within 
systematic analyses pipelines, are required to aid in the rational selection of 
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candidate T cell epitopes, promiscuous to major HLA class I and II 
supertypes, to prune down the numbers that can be manageable for 
experimental validation.  
 
 Large-scale quantification of nonamer sequence diversity of HIV-1 
sequences coupled with functional, structural and immunological analyses 
within a systematic pipeline will help gain insight to the critical factors 
driving HIV-1 variability and aid the definition of important factors in the 
identification of immunogens for vaccine design. 
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Chapter 3  Collection and manipulation of 
sequence data for the 





The advancement of modern technologies (reviewed in McGinn and Gut, 2013) 
has made sequencing more cost-effective, rapid and accurate. As a result, more 
sequencing experiments are carried out and large volumes of sequence data are 
generated on a daily basis. The enormous numbers of sequence information are 
quintessential for large-scale sequence analyses which insights uncovered are 
critical discoveries for various disciplines of biomedical sciences, including that 
of vaccine design. However, the availability of such a huge repository of 
information is insufficient and, in its raw native form, worthless. Such 
information needs to be pre-processed and enriched with available annotations 
prior to downstream studies. Nevertheless, to date, data curation and annotation 
is greatly lagging behind data generation and large amount of data remained 
unclassified and unannotated (Howe et al., 2008). For example, as of November 
2013, less than 0.1% of the nearly 620,000 HIV-1 protein sequences (from 
National Center for Biotechnology Information (NCBI) protein database) were 
curated and annotated, fully or partially. 
Sequence information needs to be as accurate and well-annotated as possible for 
the study of HIV-1 immune-relevant diversity. Also, it should, ideally, cover the 
entire HIV-1 evolution history for the identification of long standing sequence 
variability and conservation features which can be utilized for rational vaccine 
target selection. Nonetheless, as mentioned previously, the analysis of the entire 
heterogeneous HIV-1 population might mask potential variability signatures 
although this can potentially be rescued by the study of individual clades like 
that of the most widely studied clade B. This divide-and-conquer approach will 
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allow the elucidation of key diversity features where further correspondences to 
other clades or even groups at disparate time points are potentiated. To obtain 
such clade-specific data, sequence pre-processing is essential to classify and 
annotate sequence data as most of the HIV-1 sequences lack annotated clade 
information. Post classification, manual curation and de-duplication is required 
for the generation of a unique, non-redundant and lowly misclassified 
sequences, and subsequent protein alignments, where research efforts can be 
better focused on a smaller refined dataset to accelerate scientific discovery.  
In this chapter, a large number of HIV-1 protein sequences, spanning 30 years 
of HIV-1 evolutionary history (1983-2012), were downloaded from public 
protein databases at two disparate time points, once in 2008 and once in 2012. 
Data pre-processing was carried out to classify clade specific sequences where 
the classified clade B sequences in the 2008 protein sequence dataset were 
aligned and used for the comprehensive dissection of HIV-1 sequence diversity 
(Chapter 5) and the sequences identified as clades A, B, C and D proteins within 
the 2012 dataset was utilized for further correlative studies to demonstrate the 
stability of conserved sequences identified for vaccine formulation (Chapter 7). 
In addition, sequence alignments of RNA pathogens (WNV, DENV, Influenza 
A virus and HCV) were separately obtained from published data or from online 
resources for the proof-of-concept application of the novel quantitative variant 
dynamics methodology prior to its extension to HIV-1 (Chapter 4). All 
sequences, in raw fasta sequence format, and the protein alignments, in fasta, 
fas, aln or taln formats (see Figure S3.1 for the different formats of sequence 
alignment used for the analysis), were stored locally in an in-house database for 
warehousing. Additionally, all HIV-1 sequences and alignments used for the 
analysis were made available online and are accessible from the HIV Resource 






3.2 Materials and methods 
3.2.1 Methodology overview 
 
The methodology employed for the data collection and pre-processing required 
for this thesis is summarized in Figure 3.1. In brief, HIV-1 protein sequences 
were downloaded from NCBI protein database (Wheeler et al., 2005) and 
deduplicated before the classification of protein sequences into respective clades 
and proteins via Basic local alignment search tool (BLAST) (Altschul et al., 
1990; Altschul et al., 1997) (Figure 3.1A and B). Only Clade B protein 
sequences, reported from the year 1983-2008, were aligned (Figure 3.1A). 
Protein sequence alignments of WNV, DENV and Influenza A virus were 
obtained from published data while that of HCV was obtained from the HCV 
database (http://hcv.lanl.gov/content/sequence/NEWALIGN/align.html) 
(Figure 3.1C). All protein sequences and alignments were stored in an in-house 
sequence database. Only HIV-1 protein sequences and alignments are made 





Figure 3.1 | Overview of bioinformatics approaches employed for the 
collection and manipulation of viral sequences. A, B and C represents the 
different data collected for HIV-1 (1983-2012), WNV, DENV, Influenza A and HCV. 
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3.2.2 Collection, pre-processing and alignment of HIV-1 protein 
sequences (1983- 2008) 
3.2.2.1 Data collection, preparation and manipulation to obtain 
non-redundant HIV-1 clade B protein sequence dataset  
 
HIV-1 protein sequence records were obtained from the NCBI Entrez Protein 
Database (Wheeler et al., 2005) in August 2008 by a search of HIV-1 
(Taxonomy ID 11676) on the NCBI taxonomy browser. Only sequences from 
HIV-1 clade B were included in the analysis as clade B is the most commonly 
studied clade. Due to the large number of HIV-1 sequences retrieved, 257,721 
protein sequences in total, the protein sequences were first divided into 10 
smaller and equally sized datasets before clade classification. BLAST (Altschul 
et al., 1990; Altschul et al., 1997) similarity searches, which mimics the 
phylogenetic analysis performed for clade classification, were used to identify 
clade B proteins within each of the 10 datasets using the respective sample query 
HIV-1 clade B protein sequences (Table S3.1) of each of the nine HIV-1 
proteins, Gag, Pol, Vif, Vpr, Tat, Rev, Vpu, Env and Nef, from the HIV database 
(http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html) . Protein 
BLAST (blastp) (version 2.2.18) (Altschul et al., 1990) with the following 
parameters were utilized: low complexity filter off; expect value of 10 or lower; 
descriptions and alignments display capped at 100000 records. Cut-offs for the 
classification of clade B proteins were determined by manual examination of 
each individual BLAST output. Identical sequences (100% sequence identity), 
including sequences that were shorter but 100% identical to another sequence, 
were considered as duplicates and removed to obtain a HIV-1 clade B non-






3.2.2.2  Protein sequence alignment 
 
The alignment of the HIV-1 clade B protein sequences is a challenging task due 
to the absence of alignment software that can accurately align large diverse 
protein sequence datasets. Thus, to optimally align the HIV-1 clade B protein 
sequences, different methods of sequence alignment were explored and are 
described herein. HIV-1 clade B Vif, Vpr and Vpu protein sequences were 
directly aligned using PROMALS3D (Pei et al., 2008) and manual editing was 
performed as required. Larger datasets of HIV-1 Gag, Pol, Tat, Rev, Env and 
Nef protein sequences were divided into smaller subsets (200-500 sequences per 
subset) prior to protein subset alignment using PROMALS3D (Pei et al., 2008) 
or CLUSTAL W (Thompson et al., 1994). Each subset alignment is refined with 
RASCAL (Thompson et al., 2003) before merging into a full protein multiple 
sequence alignment. Manual curation and rectification, if any, was carried out 
to obtain the final multiple sequence alignments. Amino acid positions that are 
highly gapped, containing 95% or more gaps were deemed as insignificant and 
were removed. A proportion (9,661 out of the 29,211 sequences) retrieved for 
Env were aligned and evaluated because of the complexity in aligning the large 
number of highly variable Env sequences.  
 
3.2.3 Data collection and manipulation to obtain non-redundant 2012 
HIV-1 clade A, B, C and D (pan-clade) protein sequence datasets (till 
2012) 
 
An updated set of HIV-1 protein sequence records was retrieved from the NCBI 
Entrez Protein Database (Wheeler et al., 2005) in March 2012 for the study of 
the generic stability of conserved sequences within the HIV-1 sequence 
population at a disparate time point. Duplicate sequences and sequences that 
match to the 2008 dataset were removed from the March 2012 raw HIV-1 
sequence records to obtain a non-redundant HIV-1 2012 (nr2012) dataset. A 
modified BLAST classification approach was used for clade assignment using 
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protein BLAST (blastp) of the BLAST+ package (version 2.2.25) (low 
complexity filter - off; expect - 10; descriptions and alignments - 350000). Each 
of the 108 clade-specific reference sequences (three sample sequences per HIV-
1 protein per clade for clades A, B, C and D), obtained from the HIV sequence 
database 
(http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html#ref) 
(Table S3.2), was used as query sequences to search against a blast database 
constructed with sequences from the nr2012 dataset and 108 clade-specific 
references.  The 108 clade-reference sequences were included in the blast 
database as clade identification anchors to facilitate manual inspection of 
BLAST outputs for clade classification. The final clade status for each sequence 
in the nr2012 dataset, consisting of sequence records from HIV-1 clades A, B, 
C and D, was assigned to the most commonly classified clade obtained from the 
BLAST outputs. Sequences, which had no statuses or the absence of clear clade 
statuses of either clade A, B, C or D, were not classified. Beyond, further data 
cleaning was performed by filtering out errors, discrepancies and irrelevant 
sequences to minimize the propagation of errors in subsequent steps.  The final 
HIV-1 clade specific proteins sequences were extracted, both partial and full 
length, and used in the analyses described in Chapter 7.2.3. 
 
3.2.4 HIV Resource Database 
 
A local data warehouse containing the (i) entire HIV-1 sequence dataset, raw 
and classified, (ii) nr2008-B protein alignments, and (iii) WNV, DENV, 
Influenza A virus and HCV protein alignments was created and maintained. 
Protein sequences were stored as fasta formats while that of the protein 
alignments were stored as fas or taln formats.  
All HIV-1 sequences analysed and alignments generated in this study are 
available for download at the HIV Resource DB 
(http://hivresource.bic.nus.edu.sg/). Briefly, each unique record was assigned a 
database record number and a “Data set” identity which indicated if the sequence 
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was from the nr2008 or nr2012 dataset. Clade information of each record was 
also indicated (refer to 3.2.2.2 and 3.2.3 for the classification scheme). 
Additional information like protein name, Geninfo identifier (GI), accession 
number (with version number) and protein sequences were extracted from the 
corresponding NCBI genpept records. The HIV Resource DB was created using 
MySQL (www.mysql.com) and the user interface was developed using Perl and 
HTML. Also included within this resource is the original diversity analysis (see 
Chapter 4 and 5 for its application) where users can obtain a comprehensive 
nonamer diversity quantification of the protein alignment submitted. 
 
3.2.5 Data alignment collection and preparation for WNV, DENV, 
Influenza A Virus and HCV protein sequence alignments 
 
Protein sequence alignments of WNV, DENV and influenza A were obtained 
directly from authors of previously published articles (Heiny et al., 2007; Khan 
et al., 2008; Koo et al., 2009) while that of the 2008 HCV sequence alignments 
are obtained from the HCV database 
(http://hcv.lanl.gov/content/sequence/NEWALIGN/align.html). Each set of 
protein alignments are manually curated and corrected for errors, if any. 
 
3.3 Results 
3.3.1 HIV-1 non-redundant 2008 (nr2008) sequence dataset 
 
In total, 77,602 clade B sequences, both partial- and full-length, were identified 
with over 1,000 sequences per HIV-1 protein. These sequences were extracted 
to obtain the nr2008-B sequence dataset which were aligned to produce the 
nr2008-B protein alignments. However, only 58,052 protein sequences were 




Table 3.1 | HIV-1 clade B sequences analysed (1983-2008). 
 
Protein Amino acids (aa) a Sequences (No.) b 
Gag 500 6,403 
Pol 947 30,604 
Vif 192 1,147 
Vpr 78  1,041 
Tat 86 1,569 
Rev 116 1,533 
Vpu 81 1,223 
Env 856 9,661 
Nef 206 4,871 
Proteome 3,062 58,052 
a Protein sizes with respect to clade HXB2 reference sequences (Table S5.2). 
The protein size varied to a small degree for some of the sequences. b 
Sequences retrieved from NCBI Entrez Protein Database. These included both 
full-length and partial-length protein sequences, which ranged in size from 17 




Table 3.2 | Breakdown of the number of sequences within each studied 
clade of the HIV-1 nr2012 dataset.  
 
Protein Amino acids 
(aa) a 
Sequences (No.) b  
Clades  
A B C D  
Gag 500 1,476 474 2,381 1,882  
Pol 947 240 1,492 1,061 7  
Vif 192 1,020 479 172 187  
Vpr 78 62 166 986 4  
Tat 86 28 236 678 19  
Rev 116 241 800 246 123  
Vpu 81 819 312 669 112  
Env 856 1,644 5,806 2,987 411  
Nef 206 518 3,235 527 656 Total 
Proteome 3,062 6,048 13,000 9,707 3,401 32,156  
a Protein size with respect to clade HXB2 reference sequence (See table S5.2). 
The protein size varied to a small degree for some of the sequences. b Retrieved 
from NCBI Entrez Protein Database. These included both full-length and a large 







3.3.2 HIV-1 non-redundant 2012 (nr2012) sequence dataset 
 
More than 30,000 sequences, full-length or partial-length, were analysed 
across the nine proteins of four HIV-1 clades (clades A, B, C and D) in the 
nr2012 dataset. None of the previously identified nr2008-B (section 3.3.1) 
sequences were included in the nr2012 dataset. Most of the sequences studied 
in the nr2012 dataset were from HIV-1 clade B, 13,000 sequences (~40%), 




Figure 3.2 | Homepage of the HIV Resource database. The website 
allows users to access all sequences analysed in this study and to perform 
immune-relevant sequence diversity analysis using their own sequences with 





3.3.3  HIV Resource Database 
 
The HIV-1 Resource database is simple web resource created to facilitate 
future immunoinformatics analysis of HIV-1 sequences (Figure 3.2). All 
HIV-1 sequences, > 86,000, and HIV-1 clade B proteins alignments were 
made available online. Each sequence record in the HIV Resource database is 
given a unique identifier in the form of “XXXXX” or “2012YYYYYYYYY” 
where “XXXXX” are records belonging to the nr2008-B dataset with record 
numbers ranging from “1” to “58052” and “YYYYYYYYY” are records 
belonging to the nr2012 dataset with record numbers from “2012000000001” 
to “2012000028921”. In addition to sequence and alignment information, a 
web tool for the comprehensive quantitative dissection of nonamer sequence 
diversity (see Chapter 4 and 5 for more information on the methodology) is 
provided for the public to carry out diversity analysis on pre-aligned protein 
sequences.  
 
Table 3.3 | WNV, DENV, Influenza A and HCV virus sequences 
analysed^. 
 
A WNV  
Protein Amino acids (aa) a Sequences (No.) b 
C 104 264 
prM 497 417 
E 355 927 
NS1 220 164 
NS2a 131 143 
NS2b 619 146 
NS3 145 146 
NS4a 256 142 
NS4b 905 141 
NS5 167 256 











Protein Amino acids (aa) a Sequences (No.) b 
C 110 2,631 
prM 147 2,875 
E 495 5,619 
NS1 352 3,305 
NS2a 218 1,969 
NS2b 130 1,877 
NS3 619 2,033 
NS4a 135 1,782 
NS4b 245 1,862 
NS5 900 2,294 
Total 3,351 26,247 
 
C Influenza A 
Protein Amino acids (aa) a Sequences (No.) b 
PB2 759 3,144 
PB1 757 3,175 
PB1-F2 90 1,989 
PA 716 3,111 
HA 568 7,001 
NP 498 3,763 
NA 469 4,217 
M1 252 3,781 
M2 97 3,153 
NS1 230 3,759 
NS2 121 3,126 
Total 4,557 40,219 
 
D HCV 
Protein Amino acids (aa) a Sequences (No.) c 
Core 191 783 
E1 192 899 
E2 363 627 
NS1/p7 63 700 
NS2 217 672 
NS3 631 918 
NS4a 54 865 
NS4b 261 647 
NS5a 448 673 
NS5b 591 466 
Total 3,011 7,250 
^Breakdown of the number of protein sequences analysed for WNV (Table 
3.2A), DENV (Table 3.2B), Influenza A (Table 3.2C) and HCV (Table 
S3.2D). a Protein size with respect to viral reference sequences (Khan et al., 
2008; Koo et al., 2009; Korber et al., 1998; Kuiken et al., 2006; Kuiken and 
Simmonds, 2009; Tan et al., 2010). The protein size of DENV is taken as 
an average of protein size of DENV1, 2, 3 and 4 reference sequences(Khan 
et al., 2006a). b WNV, DENV and Influenza A virus sequences were 
collected from the NCBI Entrez protein database (Heiny et al., 2007; Khan 
et al., 2006a; Koo et al., 2009). c HCV virus sequences were collected from 




3.3.4 WNV, DENV Influenza A and HCV protein sequences and 
alignments 
 
Available protein sequence alignments from WNV, DENV, Influenza A and 
HCV proteins were used for the preliminary application of the novel 
methodology to quantitate viral immune-relevant sequence diversity. A total 
of over 76,000 sequences (Table 3.3) were analysed across the four different 
viruses. At least 100 sequences were analysed per protein, with the largest 
number of protein sequences studied in Influenza A, totalling more than 
40,000 protein sequences. 
 
3.4 Discussion and conclusion 
 
The advancements in experimental technologies like that of DNA sequencing 
and high throughput analytics have generated voluminous amounts of data such 
as DNA sequences, protein sequences, 3D protein structures and profiles of gene 
expression. Simple one gene(s)/protein(s) analyses were norms of the past. 
Scientists of the current paradigm are required to perform comprehensive large-
scale analyses that involve hundreds, or even thousands, of sequences and 
various other forms of data, including structural and functional information. 
Such analysis will unravel the latent biological dynamics which can offer 
superior scientific insights that were previously impossible (Boyd and 
Crawford, 2012).  
Most of these data, nevertheless, are still in its primitive form. Raw sequence 
data compiled from public databases are prone to errors and discrepancies and 
the direct usage of such sequences may obscure the accuracy of downstream 
analysis. Hence, data pre-processing procedures are critical to cleanse, filter, 
classify and characterize the sequence information prior to large-scale sequence 
analysis in order to minimize the propagation of data induced errors in 
subsequent steps. In this study, data pre-processing was carried out due to the 
paucity of well-annotated HIV-1 protein sequences in public databases. In 
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particular, sequence data was classified into their respective clade in order to 
allow clade-specific analyses to be carried out (Chapters 5 and 7). Clade 
classification via BLAST similarity searches was employed as analogous 
substitutions to that of traditional phylogenetic classifications. Phylogenetic 
classifications were not carried out due to extreme viral sequence heterogeneity, 
involvement of huge datasets in the large-scale sequence-based analysis, and 
limited clade resolution due to probable low statistical significance, as measured 
by bootstrap values. Also, phylogenetic clustering patterns were primarily a 
result of shared sequence similarities and, thus, BLAST similarity searches 
could be used as an ideal replacement for the efficient assignment of HIV-1 
clade status (Cantarel et al., 2006; Theobald, 2011). Erroneous classification of 
non-clade B sequences as clade B was not likely as the dynamics of motif change 
(described later in Chapter 5) with increased mutations were comparable for 
each protein, particularly for Gag, Pol, and Env proteins that form the key 
foundation for phylogenetic classifications (Leitner et al., 2005; Yokoyama and 
Gojobori, 1987). Additional caution was exercised by making manual 
inspections to minimise any plausible misclassifications of protein sequences, if 
any arose. Redundant sequences, full-length or partial, were removed to reduce 
data bias which is a potential consequence from the possible inclusion of protein 
sequences duplicates derived from the same HIV-1 isolates within database 
records. Analogous sequences were not removed as indiscriminate exclusion of 
such sequences would present extra sequence bias. Also, partial sequences were 
incorporated into the alignments as they provide additional information for the 
study of sequence diversity. Finally, the process of selecting one sequence per 
subject was not carried out as HIV-1 viruses exist as complex quasispecies of 
genetically related but distinct sequences in individual subjects as a result of 
high genetic mutation and recombination. The analysis of the comprehensive 
collection of sequences helps study the historical mutations observed in the viral 
population. The selection of one sequence per subject will not give a true 
representation of the viral diversity, and thus was deemed undesirable. Further, 
the arbitrary selection would introduce additional bias. Additionally, the partial 
(~50%) use of the downloaded Env sequences for the analysis was not expected 
to change the sequence dynamics as the proteins were randomly chosen and that 





Figure 3.3 | Example of alignment anchors, consisting of fairly conserved 
amino acids (delimited in red boxes), that aided reliable alignment. A 
shows the protein alignments of Env (alignment position 390-450) and Gag 
(alignment position 86-123)  while B displays the variability between fairly 
conserved amino acids and the variable regions within a sequence logo 
(Crooks et al., 2004). The numbers represent the amino acid positions of the 
protein alignment [Adapted and reconstructed from Hu et al., 2013]. 
 
Protein alignment of the nr2008-B sequence dataset was immensely challenging 
due to the extreme diversity of HIV-1 proteins. Different techniques were 
deployed in the alignment of protein sequences. In general, protein sequence 
alignments can be carried in a more direct manner using with available sequence 
alignment software and minimal manual sequence editing if the proteins are of 
shorter protein sequence length and of a smaller sequence number. Highly or 
relatively conserved regions (Figure 3.3) can serve as alignment anchors and 
greatly facilitate the reliable alignment of highly diverse protein sequences.  
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For protein sequences that are lowly diverse, e.g. Pol, the presence of a large 
proportion of highly conserved regions anchors have greatly enhanced the speed 
and the accuracy of protein alignment. Though conserved anchors still exist in 
more diverse proteins like that of Env and Nef, such anchors are inherently rare 
and the alignment of highly diverse protein regions are still challenging, 
especially at highly gapped regions where the alignment of amino acids were 
highly subjective. Till more sophisticated software is made available, the 
participation of human curation and manual inspection are still vital for the 
classification of protein sequences and for protein alignments, including for 
available alignments from published data and reliable web resources.  
The experience obtained from the classification of HIV-1 clade B sequences of 
the 2008 dataset had set the impetus for the adoption of a modified clade 
classification schema for the nr2012 dataset. The methodology was a 
modification of that performed for the nr2008-B dataset and it is designed to 
recapitulate more closely the cladistics classification approach with quick 
BLAST similarity searches. Protein sequences from nr2012 dataset were used 
for the correspondence of long term conservational relevance and cross-clade 
relevance of highly conserved sequences elucidated from the study of the 
detailed sequence, structural, functional and immunological dynamics of 
nr2008-B (Chapter 7). Protein alignments were not carried out for the nr2012 
sequence datasets in this study due to the consistency of the variant dynamics 
elucidated for nr2008-B, the historical HXB2 strain (Ratner et al., 1985) and the 
recent circulating C1P strain (Sahu et al., 2010) (Chapter 5). For the ease of 
future sequence analyses, all protein sequences and alignments were archived in 








3.5 Chapter summary 
 
Background: The immunoinformatics approach for the elucidation of candidate 
HIV-1 vaccine targets relies heavily on the availability of a large number of 
highly annotated HIV-1 clade B protein sequences. The explosion of sequences 
in public databases, due to the advances in sequencing technologies, has left 
large number of sequences ill annotated. Thus, it is of critical importance to 
classify and align the available sequences to obtain a refined and curated set of 
sequences for downstream analysis.  
Results:  HIV-1 sequences of the past 30 years (1983-2012) were downloaded 
from the NCBI protein database. About 90,000 non-redundant sequences of 
HIV-1 clade A, B, C and D proteins were classified and extracted. Only 58,052 
HIV-1 sequences (nr2008-B dataset) were aligned and used for HIV-1 
quantitative variant dynamics elucidation based on a novel method tested in 
WNV, DENV, Influenza A virus and HCV ( > 76,000 sequences). The rest of 
the HIV-1 sequences (nr2012) were used for extrapolative studies the stability 
and relevance of conserved sequences within a different dataset of a disparate 
time point (Chapter 7). All analysed HIV-1 sequences and alignments are 
available online at the HIV Resource DB (http://hivresource.bic.nus.edu.sg/).  
Conclusions: The heart of sequence-based analysis starts with the pre-
processing of sequence information. In this chapter, the detailed computational 
pre-processing process was documented and explicitly discussed. The intense 
participation of manual inspection in data pre-processing greatly limits the rate 
of scientific discovery. Nevertheless, it is hopeful that in the future, with 
combined efforts placed by the scientific community, more annotated HIV-1 
sequences and advanced computation tools will be made available to enhance 









Chapter 4  Methodology for immune-relevant 
kinedynamics analysis of human viral 




The combination of the high mutation rates, ~10−4 to 10−6 errors per nucleotide 
(Sanjuan et al., 2010), high recombination rates (Simon-Loriere and Holmes, 
2011) and relatively low viral generation time (Holland et al., 1982), allowed 
RNA viruses to quickly replicate within the hosts to produce complex viral 
populations, known as quasispecies.  The generation of such a heterogeneous 
population of genetically distinct, yet related, progeny viruses allowed the rapid 
adaptation viruses to prevailing changes within the host microenvironment. 
Undoubtedly, RNA viruses are prominent pathogens of emerging or re-
emerging diseases in recent paradigm (Lauring and Andino, 2010; Nichol et al., 
2000). However, there is a general scarcity of effective anti-viral therapeutics 
due to the ability of RNA viruses to quickly produce mutant progeny viruses 
which can confer drug resistance or evade “pre-primed” immune responses 
generated by vaccination. Thus, the in-depth understanding of the quantitative 
viral sequence diversity of the individual viruses might hold the key to enhance 
current therapeutic design strategies, especially that of vaccine design where 
vaccination is known to be able to provide offer long term protection or viral 
clearance (Hellstrom and Hellstrom, 2003). Insights obtained from the detailed 
dissection of viral immune-relevant dynamics can aid the identification of viral 
diversity “Achilles heels” where candidate targets can be selected for vaccine 
formulation. 
The detailed understanding of the immune-relevant diversity of different RNA 
viral pathogens were primarily absent due to the lack of a centralised 
methodology to systematically unravel the sequence dynamics, which still 
remained obscured within the enormous repository of viral pathogens sequences. 
Therefore, in this chapter, a novel methodology for the study of viral proteomes 
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is described.  Large-scale systematic analyses of the immune-relevant sequence 
dynamics were carried out on human viral pathogens with RNA genomes, 
namely West Nile virus (WNV), Dengue Virus (DENV), Influenza A virus and 
Hepatitis C virus (HCV). Nonamers were selected as the basic unit of analysis 
as they represent potential viral HLA binding core (Rammensee, 1995) and TCR 
ligand (Wucherpfennig et al., 2009). Overlapping nonamers of all viral nonamer 
positions were extracted from the respective WNV, DENV, Influenza A and 
HCV protein alignments (see Chapter 3) and the incidence of all diversity motifs, 
including the most common nonamer index nonamer and all variants, were 
noted. Results obtained revealed the unique distributions of the different 
diversity motifs with increasing degree of mutational change. The total 
variability space was largely limited by the conservancy of the virus, with the 
conserved WNV displaying the least variability and the hypervariable HCV 
displaying the widest range of variability where the complex viral variant 
dynamic interplay is potentiated. Insights obtained serve to characterize the 
differential patterns of diversity motifs distribution, ranging from the most 
conserved WNV to the hypervariable HCV, and allow cross-viral dynamics 
comparison and pathogen classification to be carried out. Also, further 
extrapolation of the results could be made for the identification of key regions 
where vaccine targets could be rationally selected. Ultimately, the methodology 
is generic in nature and can be applied to the study of various different viruses, 
including the highly diverse viruses like HIV-1. 
 
4.2 Materials and methods 
4.2.1 Methodology overview 
 
The bioinformatics approach adopted in for the analysis is summarized in Figure 
4.1. These steps include the creation a sequence alignment database and the 
detailed analysis of nonamer entropy and incidences of the viral index and 





Figure 4.1 | Overview of bioinformatics approaches employed for the viral 
pathogen diversity motif analyses. 
 
4.2.2 Data collection and preparation for WNV, DENV, Influenza A Virus 
and HCV protein sequence alignments 
 
The methodology used was previously described in Chapter 3.2.5. 
 
4.2.3 Nonamer Sequence Analysis Approach 
 
Nonamer sequence diversity is studied via a sliding window approach of length 
nine amino acids, overlapping each by eight (positions 1-9, 2-10, 3-11 etc.), was 
carried out to comprehensively capture the entire repertoire of nonamers across 
the proteomes of WNV, DENV, influenza A and HCV (Khan et al., 2006a; Khan 
et al., 2006b), respectively. The nonamer approach was adopted in order to 
model sequence diversity with human cellular immunity considerations where 
peptides of length nine represent the potential binding core of HLA and that of 
the typical TCR binders at the immunological synapse. Further, each nonamer 
could be a likely T cell epitope as the prevalence of HLA binding peptides are 
estimated to be about 0.1-5% (Brusic and Zeleznikow, 1999) . The nonamer 
approach demonstrates the potential impact of mutations where a single 
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mutation will affect 17 amino acids, nine nonamer positions, except mutations 
arising within the first and last eight amino acids of the protein termini (Figure 
S4.1). On the contrary, such mutations will not be captured in a single amino 
acid approach and the diversity, as measured by information entropy, will be 
minuscule, down from 39 (log2209) (nonamer approach) to 4.3 (log220)  (single 
amino acid approach). 
 
4.2.4 Nonamer Entropy analysis 
 
A modified form of Shannon’s entropy for immunological applications, named 
nonamer peptide entropy (Miotto et al., 2008; Shannon, 1948), was carried out 
to measure viral protein sequence diversity. The analysis was carried out as 
described in Khan et al. (Khan et al., 2008) and Miotto et al. (Miotto et al., 
2008). 
The typical nonamer length of the core of immunologically relevant T cell 
epitopes (Rammensee, 1995) was used as the base unit of variability measure. 
The entropy values take into account the number of different variant nonamers 
at a particular position and the incidences of each of these variants. Entropy 
values were calculated for overlapping peptides of window size nine (nonamer) 
across the entire length of each viral protein alignment. For a particular nonamer 
position x in the protein alignment, nonamer entropy H(x) was calculated using 











where pi,x is the likelihood of the occurrence of nonamer i with its centre 
nonamer position at x, and n(x) is the total number of nonamer sequences 
observed at that position. As entropy values were calculated for each nonamer 
window based on its centre position x by convention, four amino acids at the 
beginning and end of the alignments will not have any entropy values. For each 
position x, all nonamers except those containing gaps (-) or any one of the 
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unresolved characters, including B (asparagine or aspartic acid), J (leucine or 
Isoleucine), X (unspecified or unknown amino acid) and Z (glutamine or 
glutamic acid), were analysed. A position with a high level of sequence 
variability would have high entropy value, up to a maximum value of 39 
(log2209). Conversely, if the position is completely conserved, consisting of only 
a single type of nonamer peptide, the entropy will be zero, i.e. no sequence 
variation with zero variants.  
Since such entropy calculations are sensitive to the number of peptides analysed, 
sequence size bias correction via a statistical sub-sampling method (Khan et al., 
2008) was carried out on all entropy calculations to allow entropy to be 
compared across different proteins with varying number nonamer positions 
studied. In accordance to the bias correction proposed by Paninski (2003), the 
alignment size bias is inversely proportionate to the sample size (Paninski, 2003) 
and statistical extrapolation of entropy values to an infinitely large number of 
peptides at a particular nonamer position with similar peptide composition will 
minimize alignment size bias (See Figure S4.2). The estimate is achieved by 
repetitive random sampling of the protein alignment to obtain smaller 
alignments of varying size where entropy is calculated for each sample. The 
entropy of these subset alignments (size N) were plotted against its inverse (1/N) 
where the entropy as N tends towards infinity (N ∞ or 1/N  0) is calculated 
using linear regression at each nonamer position. The goodness-of-fit of the 
estimate is subsequently determined by the regression coefficient (r2). The 
entropy of all overlapping nonamer sites across the protein alignment was 
measured and plotted by use of the ggplot2 suite (Wickham, 2009) of the R 
programming language and environment (R_Development_Core_Team, 2008). 
 
4.2.5 Quantitative analyses of variant forms/motifs 
 
The original definition of the sequence diversity motifs is described below. All 
sequences of each of the nonamer sites in the protein alignments were extracted 
and quantified for the incidence of the index (most prevalent) nonamer peptide 
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and its total number of variants, each having a different amino acid sequence 
from the index nonamer (Figure 4.2). The individual sequence incidences of 
each position were ordinal ranked, with random sorting for equal incidences, to 
define the index nonamer peptide and its variant motifs. The first and second 
ranked sequences were defined as the index and the major variant, respectively, 
while the remaining ranked sequences were defined as part of (i) minor variants 
which included the total number of nonamer variant sequences each with an 
incidence lower or occasionally equal to the major variant, or (ii) unique variants 
which included singly occurring isolates. Nonamers that contained gaps (-) or 
any one of the unresolved characters, including B (asparagine or aspartic acid), 
J (leucine or Isoleucine), X (unspecified or unknown amino acid) and Z 
(glutamine or glutamic acid) were excluded from the analysis. Incidences of the 
occurrence of each motif (index, major variant, minor variants and unique 
variants) were taken as a percentage of all nonamers analysed. In addition, the 
incidence of individual variant nonamer sequence types at each given nonamer 
position, termed nonatypes, was also calculated as a percentage of the total 
number of nonamers observed at a nonamer position x. In this study, the 
“breadth” of sequence diversity was quantified by the incidences of various 
sequence motifs and the “depth” was defined as the number of different variant 
sequences (nonatypes). All analyses were done with nonamer positions that had 
100 sequences or greater.  Data for positions less than 100 sequences are shown 
in some figures and tables (indicated when done so) for the sake of completeness, 
but are not considered for any of the proteome or protein quantitative analyses. 
The incidences of all variant motifs and nonatypes across all analysed nonamer 
positions were plotted against increasing by use of the ggplot2 suite (Wickham, 
2009) of the R programming language and environment 
(R_Development_Core_Team, 2008). Also, the relative proteomic incidence 
distributions of the index, major variant, minor variants, unique variants and 
nonatypes, as estimated by a one dimensional statistical smoothing Gaussian 
kernel function (smoothing bandwidth with nrd0, unweighted, adjust factor of 1 
and 512 equally spaced points for density estimation), for each human pathogen 
is demonstrated using violin plots (Hintze and Nelson, 1998). The quantitative 
dissection methodology had been converted into an online tool and is available 





Figure 4.2 | A sample protein alignment depicting the different diversity 
motifs. The definition of the index nonamer, major variant, minor variants, 
unique variants and nonatypes are illustrated in this example. At each amino 
acid position, residues that are identical to the index sequence are represented 
by “.” while those that differ have their one letter amino acid code displayed. In 
this example, the most common “index” nonamer sequence is present in 40% 
(8/20) of the isolates. The most prevalent variant to the index nonamer, also 
known as the “Major” variant, is present in 5 out of the 20 isolates. “Minor” 
variants are many recurring sequences, each with a proportion lower than or 
occasionally equal to that of the major variant.  “Unique” variants are those 
exclusive to a solitary viral isolate. “Nonatypes” (boxed) is the total number of 
different variant sequences at a given position; in this example one major, two 
minor, and three unique [Redrawn from Hu et al., 2013]. 
 
4.3 Results 
4.3.1 Scope of WNV, DENV, Influenza A and HCV protein sequences 
analysed 
 
The preliminary application of the novel methodology to systematically dissect 
the quantitative immune-relevant sequence diversity was carried out for RNA 
viruses, namely the highly conserved WNV, moderately conserved DENV and 
Influenza A and the hypervariable HCV. In total, more than 76,000 sequences 
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and 13,000 nonamer positions (Table 3.2 and S4.1) across the four proteins were 
analysed. Variability of viruses can fundamentally be correlated to their distinct 
entropy values ranging from a maximum of ~2 in WNV (Koo et al., 2009), ~4 
in DENV (Khan et al., 2008), ~6 in Influenza A (Tan et al., 2010) and > 9 for 
the hypervariable HCV (Figure 4.3). Total variants incidence, inversely 
correlated to that of the fraction of index nonamer, displayed lowered incidences 
in more conserved viruses like the WNV, < 6% average, and extreme values of 
above 98% in the highly variable HCV (Figures 4.3 and Figures S4.3 – S4.6).  
Nonamer entropy values are usually indicative of the corresponding level of 
nonamer sequence diversity where a low entropy value suggests low variability 
and high level of conservation and a high entropy value is usually correlative to 
high variability and low level of conservation. This is generally true for 
proteomic regions that have a low proportion of variants (< 20%) and that total 
variants incidence and entropy share an apparently linear relationship (red linear 
regression lines in Figure 4.3). Except for DENV, where nonamer entropy across 
all positions adopted a seemingly linear relationship with increasing total 
variants incidence, and WNV, where less than 3% of the proteome has total 
variants incidences of larger than 20%, the aberration of the observed linear rise 
of entropy values was observed at positions with total variants beyond 20% (blue 
arrows at 40% and 60% total variants incidence in Figure 4.3C and 4.3D). Such 
observations were mainly attributed to the complex interactions of enhanced 
sequence diversity and the increase in the incidences of the different variant 




Figure 4.3 | Entropies of WNV (A), DENV (B), Influenza A (C) and HCV 
(D) with increasing mutations. The relationship between entropy and 
increasing variants incidence across the proteomes of WNV, DENV, Influenza 
A and HCV. The red line depicts the linear regression of Total variants incidence 
onto nonamer entropy. Dotted sections of the red line denote the extrapolation 
of the linear regression relationship. The entropy range at 20%, 40%, 60% and 
80% total variants incidence are denoted by blue arrows. Since total variants in 
WNV do not exceed 50%, zero entropy range at 60% and 80% total variants 
incidences are represented with a horizontal blue line.  
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4.3.2 Distribution of conserved and variant nonamer positions in WNV, 
DENV, Influenza A and HCV proteins 
 
In this thesis, sequence nonamers are divided into three different categories: 
highly conserved, mixed-variable and highly diverse. Unless otherwise 
mentioned, highly conserved nonamers are defined as nonamers with an index 
incidence of 90% or higher, mixed-variable nonamers are defined as nonamers 
with an index incidence between 20% and 90% and highly diverse nonamers 
have index incidences of 20% or lower. In general, the level of viral diversity is 
closely related to the proportion of highly conserved positions and the number 
of totally conserved positions (100% index incidence). The most number of 
completely conserved positions was observed the conserved WNV (465 
nonamer positions). However, this trend was not consistently observed as 
moderately conserved virus like DENV (one position) and Influenza A (no 
positions) contains fewer totally conserved positions than the hypervariable 
HCV (7 positions) (data not shown).  
Highly conserved positions were most abundant in WNV (~81%) and were the 
least prevalent in DENV where only about 8% of the proteome contained index 
sequences in 90% or more of the aligned viruses. The most diverse HCV had 
about 9% of their proteome being highly conserved. Mixed variable positions, 
containing variants that have on average 2-3 of amino acids mismatch to the 
index sequences (data not shown), were present in all pathogens and ranged 
from 19% in WNV to above 90% in DENV. Highly variable positions were only 
observed, in larger proportion, within the diverse HCV, 14% and 5% 
respectively (Figure 4.4).  Moderately conserved DENV and Influenza A have 
only 1% of their proteome being highly variable and none was highly diverse 
for the conserved WNV. The detailed breakdown of the diversity regions for 
each protein within the respective viral proteome of WNV, DENV, Influenza A 




Figure 4.4 | Distribution of conservation level of nonamer positions of 
WNV, DENV, Influenza A and HCV. The nonamer positions of the proteomes 
of each virus were defined as highly conserved (blue, index incidence ≥ 90%), 
mixed-variable (white, index incidence <90% & >20%), and highly diverse 
(yellow, index incidence ≤ 20%). Highly conserved positions range from only 
8% in DENV to more than 80% in WNV. Mixed-variable positions on average 




4.3.3 Complexity of WNV, DENV, Influenza A HIV and HCV sequence 
diversity 
 
Each viral pathogen displayed an unexpectedly similar general diversity 
landscape with increased mutations (Figures S4.2 to S4.5).  In this thesis, 
variants were defined as nonamers that have one or more amino acid different 
from the index nonamer sequence. The variants of the index (Figure 4.2) were 
organized as three variant forms or motifs: (1) the “major” variant, the single 
most common variant of the index; (2) “minor” variants as numerous disparate 
sequences that each observed twice or more within the aligned viral sequences 
and having incidences that are lower than or equal, rarely, to that of the major 
variant; and (3) “unique” variants as multiple different sequences occurring only 
once within the aligned viral sequences. “Nonatypes” was the proportion of the 
types of individual variant sequences observed at a particular nonamer position.  
The inverse relationship of the index nonamer incidence and total variants 
incidence remained across all viruses due to their defined inverse relationship. 
Violin plots (Figure 4.5) (Hintze and Nelson, 1998) were used to demonstrate 
the incidence range and relative proteomic incidence distributions of each 
sequence motifs for each human pathogen. Each viral pathogen displayed a 
characteristic index nonamer incidences range with the smallest range of about 
50% (index nonamer incidence of >51% to 100%) observed in the most 
conserved WNV and an extreme range of nearly 99% (nonamer incidence of < 
2% to 100%) observed in the highly diverse HCV. 
The observed nonamer entropy and index nonamer incidences seemed to support 
that index nonamer incidence alone is correlative to the level of sequence 
diversity of the pathogen studied. However, each viral pathogen exhibited 
interesting underlying variant motifs dynamics with increased mutations. For 
example, the average index nonamer incidence of DENV is about 47% which is 
very similar to that of highly variable viruses like HCV (~53%). Detailed 
dissection of the variants (major variant, minor variants, unique variants and 
nonatypes) elucidate differential depth of variability of DENV contrary to that 
represented by the index nonamer incidence alone. For example, DENV has a 
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substantially lower number, almost eight folds lower (Table 4.1), of variant 
nonatypes (< 1% on average) as compared to HCV (~7.4%) and HIV-1 (~8%). 
This level is comparable to other lowly to moderately variable virus like that of 
WNV (~1.5%) and Influenza A (~1.3%) (Figure 4.5) though the index nonamer 
incidence of WNV and Influenza A have a significantly higher average, 95% 
and 69% respectively. 
Major variants distribution adopted the distinctive pyramidal distributional 
pattern (Figures S4.2-4.5) due to its definition where the major variant has a 
lower representation than the index sequence and the corresponding reduction 
of both the index sequence and major variant incidences, at nonamer positions 
with > 50% total variants, was a result of this. Low mutational rates are generally 
observed in the major variants of each pathogen, usually 1 amino acid different 
from the index, but such mutations significantly increased for the other variant 
motifs where, for example, a large proportion of positions, > 60%, in HCV 
contain minor and unique variants with 4 or more amino acids different from the 
index (data not shown).  
 










variants b Nonatypes b 
WNVa ~95% ~4% <1% <1% ~2% 
DENV - +++ ++++ -- - 
Influenza 
A - ++ - - - 
HCV - +++ ++ +++ + 
a Values of the incidence were given as numerical values for WNV as a 
reference.  b Fold change reflected as a proportion of that of WNV. “x” indicates 
a fold change of incidence between 0 to 2.5, “xx” indicates a fold change of 
incidence between 2.5 and 5, “xxx” indicates a fold change of incidence between 
5 and 10, “xxxx” indicates a fold change of incidence greater than 10, where “x” 
can be a plus symbol “+” indicates a positive fold change in incidence and minus 




Minor variants dominated a large proportion of the positions, especially at 
positions of with more than 80% variant sequences for each virus except for 
WNV which highly diverse regions are absent. Hypervariable viruses like HCV 
might likely exploit the generation of multiple singly occurring unique variants, 
especially beyond 60% total variants, to enhance viral depth. The moderately 
conserved influenza A virus exhibited a similar pattern though is limited in 
scope due to the relatively higher prevalence of the index, major and minor 
variants. Nevertheless, at regions of hypervariability, the influenza A virus 
displayed the increase representation of unique variants where it represents up 
to 16% of the entire viral population studied.  
Nonatypes, the proportion of distinct variant nonamer sequences, is generally 
indicative of the increased level of sequence diversity depth due to the increase 
in unique variants at highly variable positions. However, a counterintuitive 
observation is observed in DENV where the nonatypes incidence never exceeds 
4%, even as total variants reach more than 80%. This might be indicative of 







Figure 4.5 | Comparative comparison on the distribution of index nonamer 
and the variant motifs incidences in different viral pathogens. Index 
sequence, major variant, minor variants, unique variants, and nonatypes 
incidences for WNV, DENV, Influenza A and HCV are depicted. 
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4.4 Discussion and conclusion 
 
This chapter herein defined the novel methodology for the quantitative 
dissection of the immune-relevant diversity of viral pathogens with RNA 
genomes and this method was applied to the analysis of several clinically 
important viral pathogens, namely WNV, DENV, Influenza A and HCV. 
Analysis was carried out with a heterogeneous pool of viral sequences derived 
from varied sources, including the geographical localization and stage of 
infection, and thus results obtained were able to provide landscape overviews of 
the possible ranges of sequence variability that have been historically selected 
for viral fitness under various diverse conditions. Also, extrapolations from such 
findings can be made for the inference of any generic global viral 
microevolutionary processes (Biek and Real, 2010) that drives sequence 
diversity.  
The study performed is able to replicate the proteomic viral conservation of 
published results of WNV, DENV and Influenza A viruses where the diversity 
of Influenza A is greater than that of DENV and the lowest being that of WNV 
(Heiny et al., 2007; Khan et al., 2008; Koo et al., 2009). However, what is 
additionally achieved from the novel analysis was the elucidation of the 
strikingly divergent variant dynamics for each viral pathogen of different 
variability. In fact, the manifestation of sequence variability, at over 80% total 
variants incidence, is often observed as an enigmatic increase in the number of 
singly occurring variants (unique variants) with a non-linear increase in the 
observed entropy values. This is possibly an outcome of viral evolution which 
favours the positive selection of a complex viral population that promotes host 
immune evasion.  Undoubtedly, such an observation cannot be achieved by 
simple conservational studies which focus mainly on the most commonly 
occurring peptide. This, thus, demonstrates that sequence diversity needs to be 
additionally quantified and that computational vaccine design strategies needs 
to systematically incorporate the study of different viral variants, including 
major variant, minor variants, unique variants and variant nonatypes, for the 
rational selection of sites with minimized incidences of immune escape variants. 
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Nevertheless, the current methodology needs to be applied in coordination with 
additional studies to obtain a more holistic and generic, if any, structure of viral 
pathogen sequence diversity with increased mutations. For example, the 
sequence diversity elucidated could not be sufficiently used to explain the 
lowered average unique variants incidence in DENV, >2.5 times, as compared 
with the relatively more conserved WNV. Although the lack of unique variants 
could be explained by the large number of lethal mutations incurred by DENV 
(Holmes, 2003), the potential explanation behind such observations might be 
closely related to vector-dependent viral lineage extinction where singly 
occurring variants cannot accumulate (Myat Thu et al., 2005). Such stochastic 
events occurring in DENV are contrastingly different from that of the orthodox 
quasispecies model, observed in HIV and HCV, where the high level of 
sequence plasticity and the high incidences of unique variants with increased 
mutations are thought to be an adaptive evolutionary tool to facilitate the 
survival of hypervariable viruses and their progenies (Eigen, 1993b; Eigen and 
Schuster, 1977; Hu et al., 2013). 
The major application of the diversity motif quantification methodology is to 
aid in the rational selection of T cell epitopes in computational vaccine design 
by first understanding the immune relevant dynamics of the virus, between and 
within individuals. Insights obtained from the detailed analysis of the underlying 
population sequence variants architecture will aid the identification of slightly 
variable sites, if any, for vaccine design. Vaccine development efforts could be 
better focused on a set of selected targets, comprising only of highly conserved 
sequences, which has greatly reduced changes of mutational changes and a 
lowered pool of mutants which could function as altered peptide ligands, 







4.5 Chapter summary 
 
Background: The understanding of the sequence dynamics of viruses is 
essential for the rational selection of targets for therapeutics design. However, 
there is a lack of centralized methodology to document the detailed dynamics of 
viruses with increasing mutation. Thus, the novel methodology for sequence 
diversity quantification was defined in this chapter and applied to disease-
causing RNA viruses of varying levels of conservation, namely the conserved 
WNV, the moderately conserved DENV and Influenza A virus and the 
hypervariable HCV. 
Results: This study is the first to elucidate the distinct variant dynamics profiles 
of the various viruses in addition to its ability to replicate the reported 
conservational patterns across different viral proteomes. Nonamer sequence 
variability is restricted by the index nonamer incidence and is especially eminent 
in conserved viruses like the WNV. Increased sequences variability is typically 
attributed by the enhanced proportion of different types of variant sequence 
nonatypes, especially singly occurring unique variants, resulting in enhanced 
variability depth. Nevertheless, despite of the varying degree of diversity, all of 
the viruses, even the hypervariable HCV, contained highly conserved positions, 
ranging from as low as 8% in DENV to more than 80% in WNV. 
Conclusions: The application of the defined novel sequence diversity 
quantification methodology had elucidated the distinct interplay of different 
viral sequence motifs with increasing mutation in WNV, DENV, Influenza A 
and HCV respectively. Sequence variability was generally greatly limited by the 
index nonamer sequence incidence but the detailed dynamics, especially at 
highly diverse regions, were unique to each virus studied. Insights obtain can 
aid the identification of highly conserved and slightly variable targets for 
vaccine design. The generic nature of the methodology, as demonstrated by its 
application to different viruses of variable diversity dynamics, makes it 
applicable for the application to a wide range of human pathogens, including the 




Chapter 5 Immune-relevant kinedynamics of 




HIV-1 is one of the most highly mutable RNA pathogen (Wain-Hobson, 1993) 
with an astonishing rate of genetic mutation (Holland et al., 1982) and 
recombination (Jetzt et al., 2000). The result of such is the rapid generation of a 
complex pool of genetically related but distinct viruses, each capable of escaping 
the host immune detection, known as a quasispecies from the infection of a 
single founder virus (Abram et al., 2010; Boutwell et al., 2010; Liu et al., 2011; 
McMichael et al., 2010; Troyer et al., 2009). The enormous number of escape 
mutant genotypes complicates the diversity landscape and places intense 
immunological pressure on the host immune system where the genetic diversity 
in an infected individual near the end-stages of the disease is analogous to that 
of the annual genetic variation of the influenza virus worldwide (Korber et al., 
2001). Such huge diversity is one of the major causes for the slow progress in 
HIV-1 vaccine development (Barouch and Korber, 2010; McBurney and Ross, 
2008; Taylor et al., 2008; Walker and Burton, 2008). One favourable solution is 
to understand the extent of HIV-1 mutational changes where it holds the key not 
only to understand the quantitative constitution of individual sequence variants 
of the viral proteome virus, but to aid in the development of effective approaches 
to overcome HIV-1 sequence diversity in vaccine design. 
Using the novel quantitative methodology established for RNA pathogens like 
WNV, DENV, Influenza A virus and HCV in Chapter 4, a large-scale systematic 
sequence diversity analysis of over 58,000 HIV-1 sequences, spanning over 26 
years of HIV-1 evolution, was carried out. 2874 overlapping clade B nonamers, 
each representing a potential viral HLA binder and TCR ligand, were extracted 
from the protein alignments (see Chapter 3) and the proportions of all variants 
documented. Clade B was selectively chosen for analysis as it is the most widely 
studied clade worldwide. A rugged global landscape of varying variants 
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incidences across the proteome was observed but interestingly, the pattern of 
mutational change with increasing sequence diversity is strikingly similar for 
the nine different proteins regardless of their structure and function. This large-
scale analysis of the changes in HIV-1 mutational nonamer sequence profile 
provides a model to study the sequence conservation and diversity of HIV-1 
progeny proteins that has important applications to the design of vaccines and 
therapeutics by the selection of unique sequences that remained highly 
conserved. 
 
5.2 Materials and methods 
5.2.1 Methodology overview 
 
The methodology employed in this chapter is summarized in Figure 5.1 for the 
~58,000 sequences of the nr2008 dataset. Briefly, the protein alignments were 
first separated into their entire nonamer repertoire via a sliding window 
approach. All nonamers were subjected to entropy analysis for a global 
summarized view on HIV-1 nonamer sequence diversity. Subsequently, the 
detailed dynamics of HIV-1 sequence diversity was comprehensively elucidated 
by quantitatively studying all nonamer variant motifs across the proteome.  
 
5.2.2 Nonamer Sequence Analysis Approach 
 
The HIV-1 proteomic nonamer sequence diversity was studied by the approach 





Figure 5.1 | Overview of the different analyses involved in the study of 
HIV-1 nonamer diversity. 
 
5.2.3 Nonamer Entropy analysis 
 
The HIV-1 nonamer entropy calculations were carried out, as described in 
Chapter 4.2.4, for each individual HIV-1 proteins across the virus proteome.  
 
5.2.4 Quantitative analyses of variant forms/motifs 
 
The proteomic quantitative analysis of variant forms/motifs for HIV-1 was 
performed as described in Chapter 4.2.5. A further correspondence of the index 
sequences to that of the first clade B isolate and prototype, HXB2 (Korber et al., 
1998; Ratner et al., 1985), and a randomly selected recent strain, C1P (Sahu et 
al., 2010) was evaluated. All analyses were done with experimentally defined 






5.3.1 Sequence diversity landscape of HIV-1 clade B proteome  
 
Nonamer peptide entropy (Khan et al., 2008; Miotto et al., 2008; Shannon, 1948) 
was used to quantify the overall sequence diversity across all nonamer positions 
in the HIV-1 clade B proteome (Figure 5.2A). The general entropy landscape is 
an uneven one with a large proportion of positions with high entropy values (>28% 
with entropy values larger than 4), including the most conserved Gag (>12% 
with entropy > 4) and Pol (>6% with entropy > 4). The maximum evolutionary 
entropy (~9.2) of HIV-1 nonamer sequences greatly surpassed that of ~ 6 for 
influenza A (Heiny et al., 2007), ~4 for DENV (Khan et al., 2008), and only ~2 
for WNV (Koo et al., 2009), making it one of the most hypervariable virus ever 
documented with the nonamer entropy methodology (Figure 5.3). The patterns 
of entropy distribution is analogous to that reported by Yang (2003) and Frahm 
et al. (2004). However, direct quantitative comparison could not be made as the 
entropy measured in the above mentioned studies was differentially defined as 
averages of single amino acids where entropy of single amino acids cannot 
exceed 4.3 ( log220). In fact, most of the reported entropy values were that of 
single amino acid and this greatly reduces the magnitude of immune-relevant 
diversity of HIV-1 from a maximum of 39 to just 4 (Altfeld et al., 2003; Frahm 
et al., 2004; Gaschen et al., 2002; Korber et al., 1994; Yusim et al., 2002).  
Variants are defined as sequences with one or more amino acid different from 
the most commonly occurring index peptide. Total variants incidence is a 
representation of the proportion of all variants at particular nonamer position x. 
Except for two sites that are completely conserved in Pol (Pol 956–964, 957–
965), all HIV-1 proteins contain nonamer positions with variants and extreme 
variability demonstrated in nonamer positions (5 positions in Env) with more 
than 98% of the sequences being variants to the index nonamer sequence. This 
variability was roughly twice that of the conserved WNV (maximum total 
variants incidence at <50%) and analogous to the hypervariable HCV 




Figure 5.2 | Entropy of HIV-1 clade B proteome. A. Nonamer entropy (in black) 
and incidence of the total variants of the index (in purple) was quantitated for each aligned 
nonamer (nine amino acids) position (1-9, 2-10, etc.) of the proteins. Nonamer entropy 
value is a measure of overall diversity at each nonamer position. An entropy value of zero 
represents completely conserved sites (0% total variants incidence) while that of extremely 
variable sites can reach a maximum entropy of about 9 (~ 98% total variants incidence). 
Nonamer positions with less than 100 sequences analysed have their entropy values 
depicted in grey. B. The relationship between entropy and increasing variants incidence 
across 2874 nonamer positions of the HIV-1 proteome. The red line depicts the linear 
regression of total variants incidence onto nonamer entropy and dotted regions denote 
extrapolated regression values. The entropy ranges at 20%, 40%, 60% and 80% total 




Figure 5.3 | Entropy distributions of WNV (A), DENV (B), Influenza A (C), 
HCV (D) and HIV (E) proteomes. The red line depicts the linear regression of 
total variants incidence onto nonamer entropy and dotted regions denote 
extrapolated regression values. The entropy ranges at 20%, 40%, 60% and 80% 
total variants incidence are denoted by blue arrows. Values of the estimated 




In addition, there is an overall lack of strict correspondence between entropy and 
total variants incidence across all nonamer positions (Figure 5.2B). The general 
rule of thumb dictates that high entropy values are usually indicative of high 
levels of nonamer sequence diversity. However, there are many positions of 
comparatively lower entropy that contained a high proportion of variants, which 
can be analogous to those with extreme entropy. There is a seemingly linear 
association between entropy and total variants incidence of less than 20% (red 
linear regression line in Figure 5.2B). However, as total variants incidence 
increases beyond 20%, a deviation from the linear rise of the entropy values, 
encompassing a large value range (denoted by arrows i, ii, iii and iv in Figure 
5.2B and value range reported in Table 5.1), is observed. This is especially 
evident at positions with variants accounting for 80% or higher (arrow iv in 
Figure 5.2B and Table 5.1) where the enhanced entropy spread can be ascribed 
to the diversity and incidence of the different variant motifs that consists 
numerous disparate sequences which is reported in section 5.3.4 (Figure 5.5A). 
In general, the enhanced sequence variability is usually accompanied by the 
increase in entropy range. This observation is true until a maximum entropy 
range is reached and thereafter, the entropy range decreases with increased level 
of sequence variability (Figure 5.3 and Table 5.1). Displayed in WNV, DENV, 
Influenza virus, HCV and HIV, such characteristic patterns could be used to 
create a classification index, like that of the “Hu index” showed in Table 5.1, for 
different viral pathogens. The “Hu index” is defined in this study as the ratio of 
the entropy ranges at 20%, 40%, 60% and 80% total variants incidence. 
However, prior to the generic deployment of the “Hu index” for viral 
classification, there is a need to further develop the classification scheme. This 
will require the study of a larger number of protein sequences, increasingly 
available from large scale genomic sequencing experiments in current paradigm, 
where the unique signature ranges of entropy at 20%, 40%, 60% and 80% total 
variants incidence, if any, can be used to represent each viral pathogen. Well-
conserved viruses are expected to have a restricted value range as observed in 
WNV where entropy ranges cannot be reported for total variants exceeding 50% 
(Table 5.1 and Figure 5.3A). On the other hand, more complex viruses like 
Influenza A, HCV and HIV display enhanced sequence variability where the 
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entropy ranges continues to increase beyond 80% and only decrease at extreme 
level of variability, ~90% in HIV (results not shown) which is the highest 
observed amongst all human pathogens studied in this thesis.  
 
Table 5.1 | Entropy range for WNV, DENV, Influenza A, HCV and HIV 
proteomes at different total variants incidence. 
 
Protein 
Entropy Range (bits) a 









WNV 1.26 0.42 0.00 0.00 1.26: 0.42: 0.00: 0.00 
DENV 0.55 0.94 1.03 0.69 0.55: 0.94: 1.03: 0.69 
Influenza A 0.84 1.95 2.79 1.66 0.84: 1.95: 2.79: 1.66 
HCV 0.95 1.92 2.28 1.58 0.95: 1.92: 2.28: 1.58 
HIV 0.73 1.69 2.72 3.52 0.73: 1.69: 2.72: 3.52 
a Estimated entropy range at different total variants incidences. b The Hu Index 
depicts the characteristic entropy range values at 20%, 40%, 60% and 80% total 
variants incidence of different viral pathogen. 
 
5.3.2 Scope of the HIV-1 sequence diversity 
 
The novel quantification methodology, defined in Chapter 4, is applied to the 
study of HIV-1 immune-relevant diversity. This work is the first to define the 
various different diversity motifs (index nonamer, major variant, minor variants, 
unique variants and nonatypes) of HIV-1 which is published in Hu et al. (2013) . 
The data for each of the 2874 nonamer positions included the number of aligned 
sequences of the viruses represented in the dataset, entropy of the sequences at 
each nonamer position, the amino acid sequence and prevalence of the most 
common, “index”, sequence, and the incidences (% occurrence) of the variant 
forms of the index sequence (Please refer to Supplementary Table S3 from Hu 
et al., 2013 for full diversity information). The entropy (Khan et al., 2008; 
Miotto et al., 2008; Shannon, 1948) of each nonamer position was used as a 
measure of the global proteome conservation and diversity. The index sequence, 
the nonamer with the greatest representation at a given position, had an 
incidence range from 100% to about 2% of the sequences at the position. The 
variants of the index were organized as the pre-defined major variant, minor 
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variants and unique variants (Figure 4.3). Nonatypes at each nonamer position 
represents the different types of individual variant sequences observed. Further, 
correlation of the evolutionary stability of the index sequences was carried out 
with that of the first clade B isolate, HXB2 (Ratner et al., 1985), and the newly 
isolated infectious C1P strain (Sahu et al., 2010) (record identities of each 
protein in the HXB2 and C1P strains are listed in Table S5.2). 
An example of the complete data of the 2874 positions of the total proteome 
(please refer to Supplementary Table S3 in Hu et al., 2013) is demonstrated with 
24 overlapping positions of Env 116-147 (Table 5.2) which included regions of 
relatively high level of index sequence incidence ( ≥80%) and regions of 
extreme sequence variability (total variants incidence of ~98%). All of the 24 
positions contained more than 100, about 1000 to >3900, at each aligned 
sequences. The initial three positions of Env 116-122 to 118-126 were fairly 
conserved with entropies of about 1.0 and index incidences between 85 to 89%. 
At these positions, the index sequences were identical to that of the HXB2 and 
C1P nonamers. The remaining 11 to 15% sequences of these three Env position 
were variants of the index, almost equally distributed between the major and 
minor motifs, plus about 1% of the unique, with 2% of the sequences as different 
nonatypes. Beginning at Env 119-127, the positions had increased diversity, 
some with entropy as high as 9.2, index of 2%, major variant of 1%, combined 
minor and unique variants of 97%, and about 30% of the sequences as different 
nonatypes. The high variability at these positions was also evident with the 
consensus HXB2 and the recent C1P isolates; the highly mutated HXB2 
nonamers corresponded to variants of negligible fractions of the reported 
population (~ 1% or less), while those of C1P were novel variant nonamer 
sequences not observed in the dataset. 
 
5.3.3 Nonamer conservation and variability of HIV-1 nonamer positions  
 
There were only two completely conserved nonamer positions, as 10 
consecutive amino acids of Pol (Pol 956–964, 957–965), in the entire proteome, 
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and only 9% were highly conserved with index sequences incidences of 90% or 
more, especially in Pol, Gag, and Env (Figure 5.4). The proportion of the highly 
conserved regions in HIV-1 was one of the lowest reported amongst the RNA 
viruses studied (Figure 4.3).  The remaining 10% or less of the sequences were 
variants with generally one amino acid mismatch to the index (median; data not 
shown). About 14% of the proteome were highly diverse positions, with 
incidences of 80% or more total variants, and these positions were chiefly found 






Figure 5.4 | Distribution of variant sequences at highly conserved, mixed-
variable and highly conserved regions of the HIV-1 clade B proteome. 
Fractions of the nonamer positions of the proteome and individual proteins that 
are highly conserved (blue, index incidence ≥ 90%), mixed-variable (white, 
index incidence < 90% & > 20%), and highly diverse (yellow, index incidence 
≤ 20%). [Adapted and redrawn from Hu et al., 2013] 
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Table 5.2 | Sample excerpt of the quantitative dissection of HIV-1 clade B Env protein diversity. ^ 
Aligned nonamers H(x)c Index d Variants e HXB2j C1Pk 
Position a No. b Sequence No / [%] 
Total Major f Minor g Unique h Nonatypes i
No / [%] Sequence No / [%] Sequence No / [%] 
& 116-124 1066 1.1 KPCVKLTPL 904/85 162/15 60/6 86/8 16/2 30/3 ......... 904/85 ......... 904/85 
& 117-125 1517 0.8 PCVKLTPLC 1357/89 160/11 59/4 84/6 17/1 30/2 ......... 1357/89 ......... 1357/89 
& 118-126 1568 0.8 CVKLTPLCV 1397/89 171/11 83/5 71/5 17/1 30/2 ......... 1397/89 ......... 1397/89 
& 119-127 1594 1.1 VKLTPLCVT 1374/86 220/14 83/5 118/7 19/1 34/2 ........S 22/1 ......... 1374/86 
& 120-128 2665 1.0 KLTPLCVTL 2341/88 324/12 101/4 193/7 30/1 51/2 .......S. 32/1 ......... 2341/88 
& 121-129 2670 1.7 LTPLCVTLN 2037/76 633/24 142/5 457/17 34/1 64/2 ......S.K 10/<1 ......... 2037/76 
& 122-130 3112 1.9 TPLCVTLNC 2313/74 799/26 151/5 610/20 38/1 74/2 .....S.K. 22/1 ......... 2313/74 
& 123-131 3326 2.6 PLCVTLNCT 2195/66 1131/34 146/4 925/28 60/2 121/4 ....S.K.. 23/1 ........I 76/2 
& 124-132 3368 4.1 LCVTLNCTD 1488/44 1880/56 425/13 1355/40 100/3 201/6 ...S.K... 25/1 .......I. 40/1 
+ 125-133 3673 6.2 CVTLNCTDN 455/12 3218/88 353/10 2661/72 204/6 389/11 ..S.K...L 25/1 ......I.V 24/<1 
+ 126-134 3675 7.4 VTLNCTDNW 353/10 3322/90 116/3 2920/79 286/8 556/15 .S.K...LK 19/1 .....I.VN 20/<1 
+ 127-135 3677 7.8 TLNCTDNWN 348/9 3329/91 108/3 2878/78 343/9 698/19 S.K...LK. 19/1 ....I.VNI 0/0 
+ 128-136 3719 8.3 LNCTDNWNN 227/6 3492/94 78/2 3006/81 408/11 814/22 .K...LK.D 19/1 ...I.VNIT 0/0 
+ 129-137 3725 8.3 NCTDNWNNT 227/6 3498/94 78/2 2956/79 464/12 901/24 K...LK.D. 18/<1 ..I.VNITN 0/0 
+ 130-138 3912 8.6 CTDNWNNTG 216/6 3696/94 79/2 3110/79 507/13 982/25 ...LK.D.N 21/1 .I.VNITNT 0/0 
+ 131-139 3917 8.7 TDNWNNTGN 210/5 3707/95 79/2 3077/79 551/14 1052/27 ..LK.D.NT 21/1 I.VNITNT. 0/0 
+ 132-140 3911 8.9 DNWNNTGNV 199/5 3712/95 78/2 3066/78 568/15 1099/28 .LK.D.NTN 18/<1 .VNITNT.S 0/0 
+ 133-141 3863 8.8 NWNNTGNVS 196/5 3667/95 78/2 2990/77 599/16 1134/29 LK.D.NTN. 19/<1 VNITNT.ST 0/0 
+ 134-142 3838 9.0 WNNTGNVSD 175/5 3663/95 78/2 2967/77 618/16 1157/30 K.D.NTN.S 19/<1 NITNT.STN 0/0 
+ 135-143 3807 9.0 NNTGNVSDS 173/5 3634/95 85/2 2906/76 643/17 1167/31 .D.NTN.S. 21/1 ITNT.STNP 0/0 
+ 136-144 3747 9.0 NTGNVSDSS 169/5 3578/95 87/2 2833/76 658/18 1195/32 D.NTN.S.G 19/1 TNT.STNPT 0/0 
+ 137-145 3701 9.1 TGNVSDSSW 179/5 3522/95 89/2 2781/75 652/18 1192/32 .NTN.S.GR 19/1 NT.STNPTS 0/0 
+ 138-146 3473 8.9 GNVSDSSWK 144/4 3329/96 42/1 2643/76 644/19 1167/34 NTN.S.GRM 20/1 T.STNPTSS 0/0 
+ 139-147 3090 9.2 TSVNSNSSG 49/2 3041/98 42/1 2408/78 591/19 1071/35 .NSS.GRMI 20/1 N.T.PT..W 0/0 
^ Table adapted from Hu et al., 2013.  a Start and end amino acid positions (Hu et al., 2013). b Total number of nonamers analysed; differences in number at was due to the inclusion of both partial and full-length 
sequences in the alignments. c Nonamer peptide entropy denoted by H(x). d The most ubiquitous nonamer sequence, Index, at the given nonamer position. e Variants differ by one or more amino acids from the index 
sequence. f The major variant is the most prevalent variant sequence at that position. g Minor variants are multiple different sequences, each occurring more than once but with an incidences less than or equal to the 
major variant. h Unique variants are different sequences that occur only once. i Nonatypes was the proportion of distinct sequences of all variants. j,k HXB2 and C1P nonamer sequence and its incidence at the given 
nonamer position; amino acids identical to the index are denoted as "." C1P nonamers not found at the aligned nonamer position are indicated with no nonamers observed and 0% incidence (i.e. 0/0).   
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5.3.4 Kinetics of sequence motifs dynamics in HIV-1 diversity 
 
HIV-1 diversity is a major challenge to vaccine design. To date, there is a lack 
of the detailed documentation of the immune-relevant diversity of HIV-1. The 
novel application of the defined sequence motifs helps to unravel the interplay 
of the index sequence and variants with increasing mutations within the 
proteome. Insights obtain from such an analysis will aid the identification of 
key regions that are highly conserved with a low sequence diversity breadth and 
depth. The unique dynamics of each diversity variant motif in relation to 
increased total mutations is depicted in Figure 5.5A.  A near complete range for 
index nonamer incidence, and inversely for total variants, was observed. The 
proteomic range of index incidence covers a range of more than 98% (100% to 
less < 2%) across 2874 nonamer positions examined (see Figure 5.5A). 
Breaking down the components of total variants into the major, minor and 
unique variants for each of the positions allowed the more detailed dissection of 
various variant motifs present in the heterogeneous variants pool. Each variant 
motif displayed distinctive dynamics of incidence variation with increased 
variability. The primary major variant adopted a seemingly triangular 
distributional incidence pattern with a majority of positions with incidences 
below 15%, and a few rising above 30%. The underlying reason for the observed 
triangular distribution was previously described in Chapter 4.3.3. Numerous 
positions, <0.1%, with almost equivalent incidences of index and major variants 
were present though the average incidence of the major variant was only about 
10%. This highlights the presence of positions of high level of diversity where 
the index nonamer might not possess quantitative supremacy over the major 
variant and possibly other variants like the minor and unique variants, as 
immune targets. Minor variants, each with incidences lower than or sometimes 
equal to that of the major variant, were jointly the primary variant motif for a 
large number of positions, particularly at highly diverse positions. Unique, 
singularly occurring, variants are ubiquitous and had uniquely low incidences, 
~3% on average, which sharply increases to a maximum > 60% at highly diverse 
positions. The variability depth of different variant sequences (Figure 5.5A) was 
quantified by the nonatypes incidence where up to 68% nonatypes incidence, 
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consisting of mainly the different minor and unique variants, at positions of 80% 
total variants incidences or higher.  
Additionally, violin plots (Figure 5.5B) (Hintze and Nelson, 1998) were used to 
demonstrate the incidence range and relative proteomic incidence distributions 
of each sequence motifs with increasing variability. The index nonamer was the 
chief motif with an average incidence of only about 52%, analogous to the 
hypervariable HCV (See Chapter 4.3.2). Following, the minor variant motif was 
ranked second in average motif prevalence and shares an inverse relationship 
with the index sequence distribution. Most nonamer positions have low 
incidences of the major and unique variants, as also shown in Figure 5.5A, 
which is accompanied with a fraction of high incidence unique variants, 
particularly at positions of highly diverse positions. The “nonatypes”, consists 
of different type of sequences (see Figure 4.2 for definition), were primarily of 
low occurrence except for the large increase observed at hyper-variable 
positions due to increase in the number of singly occurring unique variants. This 
enhanced breadth in the number of nonatypes at highly diverse positions 
represents the extreme repertoire of potential immune escape variants within a 
quasispecies population. 
The patterns of the change in variant motif dynamics were repeated for each of 
the individual proteins, especially for proteins with a larger number of nonamer 
positions like that of Gag, Pol, Env and Nef (Figure 5.6). More conserved 
proteins like that of Gag and Pol had lowered incidences of variants (Gag and 
Pol) than the more variable Env and Nef (Figure 5.7). Despite the differences in 
their fundamental protein structures and functions, the motifs and incidences of 
the variants of the index sequences were basically similar for each protein, with 






Figure 5.5 | Diversity motifs of HIV-1 proteome. A. Incidence of each of the 
diversity motifs in relation to total variants incidence: (i) the most common 
index sequence (orange); (ii) all variant sequences as total variants (black); (iii) 
the most common variant sequence as major variant (red); (iv) multiple variants, 
observed more than once and having an incidence lower than the major variant, 
as minor variants (blue), singly occurring variants as unique variants (green), 
and different variant sequence types as nonatypes (purple). B. Violin plot 
(Hintze and Nelson, 1998) of the incidence distribution of specified sequence 
motifs. The width of the plot (x-axis) represents the frequency distribution of a 
given incidence of the indicated motif. “x” represents the arithmetic mean 





Figure 5.6 | Diversity motifs of HIV-1 proteins. The colour key for each 
sequence motif is described in Figure 5.5 and N represents the total number of 





Figure 5.7 | Violin plot of the frequency distribution of diversity motif 
incidence of Gag, Pol, Env and Nef. The width of the plot (x-axis) represents 
the frequency distribution of the index (A), the major variant (B), minor variants 
(C), unique variants (D) and nonatypes (E). “x” represents the arithmetic mean 
incidence value. [Adapted and redrawn from Hu et al., 2013 , please refer to 
publication for full figure.] 
 
5.3.5 Correlation of Index Sequences with HXB2 and C1P Proteins 
 
Similarity analyses to HXB2 and C1P viruses, respectively, were carried out for 
all index sequences which are concatenated as full-length proteins. The 
concatenation was carried out to obtain a sequence that represents all amino 
acids that are most commonly observed in the sequence records. 
Correspondence of Nef is showed in Figure 5.8 while the full comparison of all 
nine HIV-1 proteins with HXB2 and C1P can be located in Figure S5.1. In 
general, high single amino acid identity (>82%) is observed between the clade 
B index sequences and that of C1P and HXB2 (Table S5.3), with variations that 
comprised of a small fraction of indels (insertions/deletions) and mutations 
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(Figures 5.8 and S5.1). Nonamer sequence identities were comparatively lower, 
with only 61% of the HXB2 and 49% of the C1P nonamers identical to the index 
sequences (Table S5.3B). Such matches between the index and the individual 
HXB2 and C1P sequences are mainly observed at positions with high index 
sequence incidence, i.e. highly conserved nonamer positions, and virtually 
absent at the highly diverse positions (please refer to Supplementary Table S3 
in Hu et al., 2013), demonstrating the uniformity of sequence variations within 
the viral population. At such, it is estimated that roughly half of the nonamer 
positions of a particular HIV-1 strain is expected to be different from the index 




Figure 5.8 | Shared sequence identity and differences of HIV-1 clade B Nef 
concatenated index sequence with the HXB2 and C1P sequences. The 
numbers before and after the concatenated index sequence represent amino acid 
positions of the comparison. Amino acids that are identical of the index amino 
acids with those of HXB2 (blue) and/or C1P (green) are represented by “.”; 
those that differ are shown by the respective amino acid. Mutations within the 
aligned viruses that did not follow the concatenation of the index are shown in 
orange with the corresponding amino acids of HXB2 and C1P sequences 
displayed. Blue dashes represent amino acid deletions in HXB2. [Adapted and 





5.3.6 Index swap and reversion 
 
One interesting finding from this study is that of the index sequence swap and 
reversion. Index swap and reversion is a phenomena observed when the ranking 
of a particular variant nonatype is changed to that of the index, alternative to the 
anticipated index sequence based on the previous position. The mechanism of 
the observed index swap and reversion is illustrated in Figure 5.9B where the 
intended index sequence (KALTEVVPL) at position 442-450 of the Gag protein 
alignment is “swapped” to an alternate sequence KALTEVIPL instead of the 
expected KALTEVVPL. Another index swap event is observed two nonamer 
positions towards away at 444-452 where the expected index LTEVVPLTE is 
reverted. Positions with observed index swap and reversion were identifiable by 
amino acid mutations within the observed index sequences which does not 
ensue the expected successive concatenation of the index sequences, as shown 
by the orange labelled residues in Figure 5.8 and Figure S5.1. This is usually 
observed, at mixed-variable and highly diverse positions only, where the index 
sequences and major variants have highly similar occurrences, average 12% and 
8% respectively. Such mechanisms could possibly aid the enhancement of viral 
fitness by the introduction of one or more amino acid mutations in a significant 
number of positions along the HIV-1 clade B proteome. Index swap and 
reversion may be a prevalent phenomenon involving multiple variant motifs, 
e.g. major with minor variant motifs, and likely be inherent within a 
quasispecies population, where the members of the diversity motifs (index 
nonamer, major variants, minor variants and unique variants) switch ranking as 
mutation increases. This generates dynamic quasispecies of altered peptide 
ligands that can circumvent immune detection, especially at highly diverse 








Figure 5.9 | Index swapping and reversion. A. Pol protein alignment region of amino 
acid (aa) positions 440 to 456 is shown for the first and last five sequences of the aligned viruses. 
The aa position 448 (coloured) is involved in index switching and includes two aa, the prevalent V 
observed in 54% of the sequences, with its variant I in 46%. B. The nine aligned overlapping nonamer 
positions (from 440–448 to 448-456) represent the sliding windows of the alignment region in A. 
Each nonamer position is shown with the index sequence, two of the variant nonatype sequences and 
the total number of remaining variant nonatypes of incidence equal or below 10%. The first nonamer 
position, 440 to 448, is shown with the index sequence (26%) containing aa V at the 9th position. The 
major variant (24%) contains the variable aa I at the corresponding position. A minor variant (14%) 
has a mutation at aa position 2 relative to the index. A total of 80 nonatypes had individual incidences 
less or equal to 10%. The dominance of aa V in the index is maintained for the next nonamer position. 
At position 442 to 450, index switching is observed, where the sequence with aa I is now the index 
(35%) and the one with V is the major variant (33%). This relationship continued at position 443-
451, with reversal of sequence ranks to the original state at position 444-452, where the sequence 
with aa V is the index. At an index switching position, the index is alternative to that expected, 
relative to the preceding position. C. Overlapping index sequences of the nine nonamer positions are 
linked together to form the “Concatenated Index”. At position 448 (coloured), the aa I, which did not 
follow the concatenation of the index is shown below the sequence. [Adapted and reconstructed from 
Hu et al., 2013] 
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5.4 Discussion and conclusion 
 
The application of the novel quantitative nonamer variant diversity 
methodology to HIV-1 elucidated the detailed variants sequence organization 
and distribution with increased mutation of HIV-1 virus proteome sequences. 
The analysis started with the collection of protein sequences from over 26 
(1983-2008, based on records with available isolation date) years where they 
consisted of sequences of diverse sources including mode of HIV transmission, 
stage of infection, treatment, and possible co-infection (please refer to Chapter 
3 for the pre-processing carried out for the prior to analysis in this chapter). 
These sequences thus provided a general overview of the potential range of 
different variants that have been historically selected for viral fitness under 
various diverse conditions, and represent a model of the collective evolution of 
the underlying sequence complexity of numerous HIV-1 viral populations as 
quantified by the sequence records of the past 26 years.  
All but two nonamer positions of the clade B proteome possessed multiple 
different variants of the index sequence, demonstrating that virtually all 
nonamer positions are capable of generating fit variants of the founder virus. 
The analysis is interested to quantitate the immune-relevant diversity of the 
HIV-1 proteome with increasing mutations and this cannot be achieved with 
traditional phylogenetic analyses. In addition, the high diversity of HIV-1 
proteome will generate phylogenetic trees with a high bootstrap value and thus 
rendering the interpretation of the tree topology highly subjective. Also, the 
involvement of the large number of sequences will complicate the phylogenetic 
process making the final interpretation almost impossible. Extreme sequence 
plasticity was demonstrated by the highest Hu Index values, the large 
distribution range of total variants incidence from 0% to 98% and with, on 
average, about 50% of the nonamer sequences of all proteome positions were 
mutants of the corresponding index sequences. Remarkably, however, the 
incidence patterns of the different variant forms, major, minor and unique 
variants, with increased mutation were similar for each viral protein.  
The observed changes of the diversity motifs might represent the inherent 
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patterns of HIV-1 viral sequence organization that might aid in HIV-1 fitness 
selection and adaptation, possibly directed by the protein structural and/or 
functional requirements of the mutant viruses which are interesting parameters 
that was subsequently explored (see Chapters 6 and 7). The sequence plasticity 
of the highly diverse positions, resulting from the complex mixture of various 
different unique and minor variants sequences, may provide for a spectrum of 
virus subtypes that allow a quasispecies population to exploit different 
responses to punctuated changes in selection pressure (Wilke et al., 2001). 
Highly diverse positions were numerous and are located in all proteins even in 
the more conserved Gag and Pol. Though so, such highly variable regions were 
primarily more abundant in Rev, Vpu, Env, and Nef, where about a quarter of 
the aligned nonamer positions contained 80% or more variants to the index 
sequences. Unique variants, albeit generally having low incidences, were 
present at nearly all positions and displayed a large incidence increase at the 
positions that are hyper-variable (i.e. ≥80% total variants incidence). The 
enhanced sequence complexity variability depth is demonstrated by the great 
increase in the incidence of nonatypes at highly diverse positions where it can 
reach, for example, about 70% in Nef. This is speculated to be integral in 
maintaining the fitness of the underlying quasispecies (Eigen, 1993b) by the 
exploration of different viral protein sequences. This pattern of mutation is 
hypothesized to have evolved in the micro-evolutionary history of HIV as a 
combination of defined mode of Darwinian selective fitness, preferentially 
selecting the index over the variants, and non-Darwinian mechanism of directed 
HIV-1 mutation, selecting multiple variant motifs that are as fit as the index at 
the highly diverse positions (Mas et al., 2010). That this combination of 
evolutionary modes may facilitate the continuation of evolutionary stability and 
versatility was further reinforced by the consistency of the results obtained from 
the analysis of sequence data of the past 26 years with that of HXB2 and C1P 
viruses. 
The extreme repertoire of possible variants in the virus population represents 
the culmination of the multitude of mechanisms responsible for the 
overwhelming host immune control of the virus. Within a day, 1010 – 1012 of 
viruses can be produced and each virus is a potential new viral variant, exploring 
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novel sequence combinations that enhance viral fitness. Such variants are able 
to escape immune detection by individual cytotoxic T cells by changing the 
sequence of targeted antigen epitopes and induce the abolition of early 
immunity against the virus by altered peptide ligand inhibition of T cell 
responses and T cell exhaustion (Bouhdoud et al., 2000; Kirksey et al., 1999; 
Klenerman et al., 1995; Klenerman and Zinkernagel, 1998; Moschella et al., 
2003; Purbhoo et al., 1998; Reid et al., 1996; Sauce et al., 2011; Sewell et al., 
1997; Streeck et al., 2008). The quasispecies population has a multitude of 
different variant sequences, with relatively equal availability for HLA and T cell 
ligand binding, and as possible altered peptide ligands. For example, the highly 
diverse positions that represented about 14% of the proteome had little 
difference in the incidences of the index sequence (average 11%), major variant 
(average 8%), and individual minor and unique variants (< 8%). The diversity 
landscape is further complicated by various mechanisms of fitness enhancement 
including that of index swapping and reversion. The mutational changes 
reported demonstrate the high incidence, complexity, and diverse spectrum of 
variants of the virus and will continue to be a challenge for the design of a 
vaccine with a lasting immunity. Strategies of vaccines containing any of the 
full-length proteins or selected variant sequences may be considered futile given 
the great spectrum of different variant sequences. The current paradigm of 
vaccine needs to focus on dealing with HIV-1 diversity and novel vaccination 
strategies that systematically addresses this issue, including peptide-based 
vaccines comprising of highly conserved sequences (present with high 
incidence in the representative virus population), many of which are 
immunogenic as observed by matches to reported T cell epitopes (Chapter 7), 
is urgently required. Vaccination, coupled with drug-based therapeutic 
interventions (e.g. HAART), and continued surveillance of viral variants for the 
possible selection of variants of even the highly conserved sequences, is perhaps 





5.5 Chapter summary 
 
Background: The extreme diversity of the HIV-1 proteome is widely 
recognized as one of the largest challenge in the design of an effective HIV-1 
vaccine. This chapter sets forth to quantitatively uncover the detailed immune-
relevant sequence dynamics of HIV-1 clade B diversity using a novel nonamer 
diversity methodology. The results from the comprehensive analysis of over 
58,000 protein sequences for 26 years will reveal the hidden dynamics of 
mutational changes that is integral for HIV-1 vaccine design.  
Results: The quantification analysis of the 2874 nonamer positions revealed the 
extreme rugged landscape of HIV-1 nonamer sequence diversity with entropy 
values ranging from 0, completely conserved, to more than 9, extremely diverse. 
Only two nonamer positions, 10 amino acids, in Pol were completely conserved 
and all the other positions contained some form of variants (major, minor and/or 
unique).  Positions exceeding 50% total variants contained reduced incidences 
of index sequences and major variants with an increase in the proportion of 
minor and unique variants. Highly diverse positions, representing ~14% of the 
proteome, with up to 98% variant nonamer sequences, were present in every 
protein, including 5% of the conserved Gag, and 27% of the diverse Env. The 
enormous pool of different variant nonamer sequences, each having one or more 
amino acids different from the index, represents the extreme repertoire of 
different sequences which reaches to nearly 70% at highly diverse position 
where immune escape and index swap and reversion of the intended index can 
occur. The elucidated dynamics of variant distribution with increased mutations 
were in accordance with that historical HXB2 strain and a recently circulating 
C1P strain and, thus, can potentially be applicable to quantitate all HIV-1 viral 
strains. 
Conclusions: The described methodology has elucidated the detailed dynamics 
of HIV-1 clade B nonamer sequence diversity where the comprehensive 
characterization of the changes in nonamer mutational landscape will aid in the 
rational selection of vaccine targets, focusing on a limited set of highly 
conserved sequences.  
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Chapter 6 Functional and structural 





It has been widely acknowledged that sequence conservation is associated with 
protein structures and functions preservation. A corresponding change in one 
amino acid can induce a probable structural change, potential protein functions 
abolishment, and affect the immunogenicity of up to 17 amino acids (9 nonamer 
positions) (Figure S4.1). Paradoxically, such casual correlative relationships of 
sequence conservations are not fully observed in the hypervariable HIV-1 and 
proteins are ironically able to maintain their critical functions, and thus survival 
fitness, despite their extreme sequence diversity (up to 98% total variants). The 
survival of HIV-1 progeny virus relies heavily on the ability to generate and 
presumably maintain sequence variations that aid the evasion of viral immune 
detection whilst preserving critical protein functions and structural orientations. 
Thus variability patterns that are absent within HIV-1 viruses potentially 
represent structurally and functionally impermissible variations where such 
variations, if adopted, will likely attenuate or destroy viral functions which 
might lead to extinction of that mutant within the quasispecies. Thus, it is 
postulated that vaccine development efforts should be focused on the selection 
of targets within structurally and functionally permissive regions in order to 
prime the immune system to detect the “fit” viral variants for clearance. 
Nevertheless, to date, such regions have not been well documented. 
One of the crucial factors contributing to the lack of categorization of the 
allowed and prohibited structural and functional sequence variations is the lack 
of in-depth sequence diversity characterization. However, with the detailed 
immune-relevant sequence diversity landscape elucidated in Chapter 5, the 
mapping of protein functions and structures to HIV-1 nonamer conservation and 
variability can be carried out. This chapter aims to gain deeper understanding 
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of HIV-1 protein functional, structural and immune-relevant sequence diversity, 
including (i) the association of sequence variation profiles with individual 
protein functional domains, (ii) the 3D localization of functional domains and 
their corresponding nonamer diversity , i.e. does externally exposed residues 
have a higher level of conservation than residues residing within the protein 
core to evade antibody targeting, (iii) correlation of diversity profiles between 
different domains, especially multiple similar domains within a single protein 
like the type 1 and 2 CCHC Zn2+ finger domains in NC. Insights obtain will 
allow casual connections of sequence diversity, protein function and 3D 
localization to be established and further refines the selection criteria for rational 
vaccine development.  
 
6.2 Materials and methods 
6.2.1 Methodology overview 
 
 
Figure 6.1 | Overview of bioinformatics approaches employed for the HIV-
1 protein diversity, functional and structural analyses. 
 
The methodology employed in this analysis is summarized in Figure 6.1. In 
brief, the level of conservation of the index, most commonly occurring, 
sequence is mapped to the 3D location of the structures with reported protein 




6.2.2 Functional domain and 3D structural data collection 
 
Protein functional domain information was obtained in two ways. First, a 
comprehensive literature search was conducted to obtain data on any reported 
and putative functional domains residing within the HIV-1 proteins. Relevant 
publications were read and localisation of the domains and their corresponding 
sequences were extracted. Second, a keyword search of “Human 
immunodeficiency virus type 1” was carried out against the Swiss-Prot database 
(UniProt_Consortium, 2012), via the Uniprot search interface 
(http://www.uniprot.org).  Only reviewed clade B records were downloaded 
from the Swiss-prot database. Both experimental and putative functional 
information were extracted from the database records for subsequent 
manipulation.  
3D structures of HIV-1 proteins were obtained from the Protein Data Bank 
(PDB) (Berman et al., 2000). 3D X-ray crystallography structures that cover the 
entire length of each viral protein were preferentially obtained. However, if such 
structures were not available, one or more partial protein structures, elucidated 
from either nuclear magnetic resonance (NMR) or X-ray crystallography and 
covering the largest proportion of the protein, were downloaded and used for 
subsequent analysis. 
 
6.2.3 Mapping of nonamer sequence diversity and HIV-1 protein 
functions on 3D protein structures 
 
The spatial localization of the distribution of the HIV-1 clade B immune-
relevant diversity (elucidated in Chapter 5) and protein functional domains were 
visualized by the mapping of the protein domains and corresponding index 
nonamer conservation on the 3D protein structure. This was carried out in a two 
steps process where in step one, sequence matches were carried out between the 
3D protein structures and the protein functional domains. However, due to the 
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heterogeneity of HIV-1 proteins, the protein domain sequences might not match 
exactly to the 3D protein sequences. Thus, anchor residues were identified and 
used to align the functional domain sequences with that of the HIV-1 3D 
structural sequences (Figure S6.1).  Next in step two, the distribution of the 
index nonamer conservation was mapped to the 3D protein structures. Reliable 
alignment between the HIV-1 clade B index nonamers and the 3D structures 
was performed with the help of anchor residues as shown in Figure S6.1. 
Diversity, as quantified by index nonamer incidence, assignment was 
subsequently carried out.  
Each amino acid matched in the 3D structure was considered as the centre of 
the nonamer x, encompassing residues from alignment positions x-4 to x+4, 
matched in the clade B protein alignment and was assigned with the index 
nonamer incidence of the nonamer (x-4) - (x+4) by convention. Thus, four 
amino acids matching to beginning, i.e. amino acid alignment position one to 
four, of the alignment of the HIV-1 clade B alignment were assigned with index 
nonamer incidence of the first nonamer position (Figure S6.2B). Similarly, 
sequence match between the 3D protein structures and the HIV-1 clade B 
protein sequences that included the last four amino acids of the protein sequence 
alignments were assigned with the index nonamer incidence of the last nonamer 
position (Figure S6.2A). Also, amino acids that were not corresponded between 
the 3D structures and the HIV-1 clade B protein alignments were not given any 
values, i.e. 0% index nonamer incidence. 
Index incidences were encoded by a colour scale created using the R colour 
brewer package (http://www.colorbrewer.org) of the R programming language 
and environment. By definition, positions with high index incidences will be 
coloured in a warm colour tone with red representing positions with 100% index 
incidences. Conversely, cold colour tones were assigned to positions with low 
index nonamer incidences where white indicates 0% incidence. Structural 
visualization of the 3D structures, functional regions and diversity distribution 
were carried out in Pymol (Schrodinger, 2010). All molecules of the 3D 
structures were displayed in the “Spheres” mode and that regions that 
corresponded to reported HIV-1 protein functions were displayed in the 




6.3.1 HIV-1 protein structures 
 










Gag MA/p17 2H3F 131 Saad et al. (2006b) 
Gag CA/p24 1E6J 210 Monaco-Malbet et al. (2000)
Gag NC/p7 2EXF 44 Bourbigot et al. (2008) 
Pol Protease 1OHR 99 Kaldor et al. (1997) 
Pol RT/RNaseH 3T19 563 Gomez et al. (2011) 
Pol Int 1EX4 239 Chen et al. (2000) 
Vif Vif 3DCG 39 Stanley et al. (2008) 
Vpr Vpr 1M8L 96 Morellet et al. (2003) 
Tat Tat 3MIA 86 Tahirov et al. (2010) 
Rev Rev 3LPH 72 Daugherty et al. (2010b) 
Vpu Vpu 1PI7 36 Park et al. (2003) 
Env gp120 1G9M 321 Kwong et al. (2000) 
Env gp41 3P30 96 Frey et al. (2010) 
Nef Nef 2XI1 208 Singh et al. (2011) 
a PDB records downloaded from PDB  
(http://www.rcsb.org/pdb/home/home.do) (Berman et al., 2000) on Jan 
2013. b Amino acid length of full length protein or protein fragment.  
 
In total, 14 PDB structures were obtained from the PDB. The PDB identification 
number, the proteins, the amino acid length and associated publication are listed 
in Table 6.1. One structure out of the 1337 structures available, when searched 
with keyword “Human Immunodeficiency Virus 1”, was selected for each 
protein (Vif, Vpr, Tat, Rev, Vpu and Nef) and individual protein products of the 
HIV-1 polyproteins (Gag, Pol and Env) based on their quality (resolution of 3D 
structures) and completeness, unless otherwise mentioned.  
 
6.3.2 Gag Protein 
 
The HIV-1 Gag proteins, consisting of mainly the matrix (MA/p17), capsid 
(CA/ p24) and the nucleocapsid (NC/p7), form major structural components of 
the core of the virus.  
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6.3.2.1 Matrix (MA/p17) 
 
HIV-1 MA protein is one of the major protein involved in viral assembly 
(Morikawa et al., 1998). Multiple protein domains, including the nuclear 
localization signal (NLS), nuclear export signal (NES) and the trimerization 
domain, resides within the simple compact structure consisting of six helices 
and three β sheet strands (Hill et al., 1996; Massiah et al., 1994; Saad et al., 
2007; Saad et al., 2006a; Tang et al., 2004). In comparison to non-functional 
sites, functional domains have a slightly higher average conservation of about 
~47%, 7% higher than the non-functional sites. Also, the sequence conservation 
levels of disparate functional domains were not analogous. For example, the 
NES domain (Figure 6.2A) has a higher conservation level (~ 68% average) 
than NLS (NLS-1 at ~33% and NLS-2 at ~51% average) which could be closely 
related to its primary viral assembly. Functionally similar domains like the N-
terminal NLS-1 and C-terminal NLS-2 were not equally conserved with NLS-1 
having a lower level of conservation than NLS-2.  
HIV-1 MA oligomerization into hexamers are usually required for functional 
activations and viral assembly (Alfadhli et al., 2009a; Alfadhli et al., 2007; 
Alfadhli et al., 2009b; Frankel and Young, 1998). The formation in MA 
hexamers is facilitated through the interaction of the trimerization domains, 
which adopts a helix-turn-helix structure (see Figure 6.2B and 6.3). Sequence 
conservation across the entire trimerization domain is not uniformly high and 
that regions of higher conservation, residue 42-46, are separated by a random 
coil region to an adjoining high variability region, residues 56-77, in a helix-
turn-helix region. However, it is observed that the multimer formation between 
monomers required the interaction between the more conserved trimerization 
domain region of one monomer, average ~70% nonamer incidence, to the less 






Figure 6.2 | Conservation across 3D MA structure. The NES (A), NLS-1 (A), 
NLS-2 (B) and the trimerization domain (B) are depicted in “ribbon” 
representation while the rest of the molecule is in a space filling “sphere” 
representation. The colour scale for the represented index nonamer incidence is 








Figure 6.3 | Interaction of MA monomers in a hexamer complex. The 
trimerization domains, annotated with “Trimerization”, in each monomer (I to 
VI) are depicted in “ribbon” representation while the rest of the molecule is in 
space-filling representation. The region enclosed by the white dotted box 
includes the interaction of monomer II, II and IV through their trimerization 
domain. The colour scale for the represented index nonamer incidence is 
included in the bottom right. 
 
6.3.2.2 Capsid (CA/p24) 
 
The HIV-1 CA is another structural protein which forms a conical core that 
surrounding the viral genomic RNA-nucleocapsid complex. The protein 
contains two disparate domains (Figure 6.4) which are (i) the N terminal core 
domain (residues 1-150) that aids viral core formation and binds cyclophilin A 
for nuclear import, viral integration targeting and enhanced replication efficacy 
(Schaller et al., 2011) and, (ii) the C terminal dimerization domain (residues 
151-200) required for capsid dimerization, Gag oligomerization and virion 
formation (Franke et al., 1994; Gamble et al., 1997; Gitti et al., 1996; von 
Poblotzki et al., 1993; Yoo et al., 1997). In general, the average incidences of 
the N terminal core domain and the C terminal dimerization are roughly 
analogous, 75% and 78% respectively. However, there is an unevenness of the 
distribution of sequence conservation along the N terminal core domain where 
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stretches of high conservation (e.g. residues 19-24) are interspersed with regions 
of relatively lowered incidences (e.g. residues 11-18) (results not shown). Also, 
most of the variable regions are exposed surface on the surface of the N terminal 




Figure 6.4 | Conservation across 3D CA structure. The MHR is depicted in 
“ribbon” representation while the rest of the molecule is in space-filling 
“sphere” representation. The N terminal core domain is boxed up in the left and 
that of the C terminal dimerization domain is on the right. The colour scale for 
the represented index nonamer incidence is included in the bottom right. 
 
In comparison, the C terminal dimerization domain does not contain such 
distribution patterns. Instead, the region adjoining the N terminal core domain 
is of low incidence, < 50%, which can potentially be an adaptive structural 
mechanism to enhance protein flexibility (Gagne et al., 2012) . In addition, the 
remainder of the C terminal domain has generally high incidences of above 70% 
and residues that are fairly conserved within other retroviruses, positions Glu-
155, Gly-156, Glu-159 and Arg-167, are observed to remain highly invariant in 
HIV-1as well (Mammano et al., 1994). Also, residing within the C terminal 
dimerization domain is the highly conserved, ~85% average, helical major 
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homology region (MHR), which plays a critical role in protein folding and 




Figure 6.5 | N terminal Core domain of CA. Diverse residues are found on 
the as a strip on the surface of the CA N terminal core domain surrounding the 
conserved residues. A region (residues 11-24) depicting the linkage of the 
conserved and diverse amino acids is boxed up in white. The colour scale for 
the represented index nonamer incidence is included in the bottom right. 
 
6.3.2.3 Nucleocapsid (NC/p7) 
 
The HIV-1 NC protein is a small, basic nuclei acid-binding protein that possess 
a primarily chaperone role including the protection of single-stranded RNA 
from degradation and aiding negative strand transfers during viral RNA reverse 
transcription (Arfi et al., 2009; Auxilien et al., 1999; Darlix et al., 2011; Darlix 
et al., 1995; Levin et al., 2005; Levin et al., 2010; Rein et al., 1998; Thomas 
and Gorelick, 2008; Tsuchihashi and Brown, 1994). Nucleic acid binding 
capability is conferred by the presence of protein zinc finger domains within the 
NC protein. Such Zinc finger domains are also known as CCHC domains due 
to the highly conserved “Cys-X-X-Cys-X-X-X-X-His-X-X-X-X-Cys” (where X 
can be any amino acid) sequence motif. Within HIV-1 NC protein, there are two 
CCHC domains known as the CCHC-type 1 and CCHC-type 2 domains 
respectively (Figure 6.6). The CCHC-type 1 domain has a more N terminal 
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localization while that of CCHC-type 2 domain is located nearer to the C 
terminal of the NC protein. However, the localization of the two domains is 
spatially adjacent to each other, indicating potential cooperative roles in binding 
nucleic acids. 
The CCHC-type 2 domain, separated by a region of hydrophobic residues from 
type I domain, is observed to be relatively more well conserved (average 70% 
incidence in type II domain and average ~50% nonamer incidence in type I 
domain). However, critical Cysteine and Histidine residues, required to bind to 
the zinc atoms, were nearly invariant which is indicative of the functional 




Figure 6.6 | Conservation across 3D NC structure. The Zinc finger CCHC 
type I and II domains are depicted in “ribbon” representation while the rest of 
the molecule is in “sphere” representation. The bright green sphere represents 
the Zinc atom. The colour scale for the represented index nonamer incidence 
is included in the bottom right. 
 
6.3.3 Pol Protein 
 
The HIV-1 Pol polyprotein contains three important protein products, the 
Protease (PR/prot), Reverse transcriptase (RT/p51) with RNase H (p15) 
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function and Integrase (IN/p31). These proteins provide the essential enzymatic 
functions ranging from the DNA/RNA processing functions to the post 
translation polyprotein processing into respective mature protein products. 
 
6.3.3.1 Protease (PR/prot) 
 
The HIV-1 PR is an extremely important aspartyl protease that is responsible 
for cleaving the immature viral polyprotein chains into mature functional 
proteins like MA, CA, NC from Gag and PR, RT and IN proteins from Pol. PR 
monomers have 3D structures consisting of primarily β-sheets and random coils 
and the formation of active PR requires PR homodimers (I and II in Figure 6.7) 
to be formed. Active site formation at the dimer interface (enclosed in white 
circle in Figure 6.7) is achieved through monomer dimerization process where 
the catalytic triad residues, Aspartic acid, Threonine and Glycine, of each 
monomer, are brought to close proximity. The residues within the active site are 
extremely conserved (> 90%) and are targets of various HIV-1 therapeutics 
including Viracept, a Nelfinavir Mesylate protease inhibitor (Kaldor et al., 
1997) (yellow in Figure 6.7). Viracept drug resistance mutations (Figure 6.8) 
are usually observed at an allosteric site away from the catalytic active site and 
they are Asp-30, Met-46, Ile-47, Gly-48, Ile-54, Val-82, Ile-84, Asn-88. These 
amino acids are in close spatial contact with Viracept and are moderately 
conserved (index incidence >70%). Away from the inner catalytic core of the 
PR dimers are exposed residues which are generally lowly conserved with 





Figure 6.7 | Conservation across 3D PR dimer structure. The peptidase 
domain is depicted in “cartoon” representation with the conserved catalytic triad in 
space-filling “spheres” (enclosed in white circle). The rest of the PR molecules are 
illustrated in “cartoon” representation. ‘I’ and ‘II’ denotes monomer I and II of the 
PR dimer structure. The yellow spheres represent the atoms in Viracept, a PR 
inhibitor. The colour scale for the represented index nonamer incidence is included 
in the bottom right. The internal core containing the active site is highly conserved 




Figure 6.8 | Viracept resistant mutations in PR. Both Viracept (yellow) and 
associated drug resistant mutations are depicted in space-filling “sphere” 
representation while the rest of the PR molecule is illustrated in “cartoon” 
representation. The white circle enclosed the catalytic triad within the peptidase 
domain. The colour scale for the represented index nonamer incidence is included 
in the bottom right. 
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6.3.3.2 Reverse transcriptase (RT/p51/p66) and RNaseH (p15)  
 
HIV-1 RT catalyses both the RNA-dependent and DNA-dependent DNA 
polymerization reactions and the removal of the RNA portion of RNA-DNA 
hybrids. The active RT is made up of two sequentially similar monomers, the 
p66 and p51 monomers where the p66 monomer has an extra RNase H domain. 
The structure of the p66 monomer is depicted in Figure 6.9. Three important 
domains are illustrated: the RT domain, the RNase H domain and the tryptophan 
repeat region. Within the RT domain resides the active site which consist of the 
highly conserved, >90%, catalytic triad (Asp-110, Asp-185 and Asp-186). 
Equally important is the tryptophan repeat which is essential for the association 
of the p51/p66 RT heterodimer for protein activation (Restle et al., 1990; Restle 
et al., 1992; Tachedjian et al., 2003; Tachedjian et al., 2005).  However, not all 
of the tryptophan residues within the tryptophan domain are highly conserved 
and the level of conservation can range from ~49% to >90%. This might be 
associated with their varying degree of functional importance as demonstrated 
by multiple studies where the mutation of some tryptophan residues, including 
Trp-398, Trp-401, Trp-402, Trp-405, Trp-406 and Trp-414, have a more 
profound role in the abrogation of dimerization which had severe effects on the 
subsequent activity of RT (Restle et al., 1990; Restle et al., 1992; Tachedjian et 
al., 2003; Wapling et al., 2005). Nevertheless, such casual correlation between 
the functional importance of different residues within the tryptophan domain 
and their respective sequence conservation were not universal as most of these 
functionally important tryptophan residues have a generally low index 
incidence (< 60%). Interestingly, the interaction interface is formed between the 
highly conserved tryptophan region (residues 410 and 412) of p66 and the lowly 
conserved region (residues 401 and 405) of the p51’s tryptophan repeat (Figure 






Figure 6.9 | Conservation across 3D RT monomer structure. The default 
mode of structure representation is in space filling “spheres” mode except for the 
tryptophan repeat region, the RT domain and the RNaseH domain which are 
depicted in “cartoon” representation. Additionally, the conserved catalytic triad, 
consisting of Asp-110, Asp-185 and Asp-186, is depicted as space filling “spheres” 
representation within the RT domain. The colour scale for the represented index 




Figure 6.10 | Conservation across 3D RT structure. The conserved tryptophan 
region and the catalytic triad are depicted in “spheres” representation while the rest of 
the molecule is in “cartoon” representation. I and II represents the RT monomer p66 
and p51 respectively. The highly conserved segment of the tryptophan repeat region of 
subunit I and that of a relatively lowly conserved region of subunit II are in close 
proximity within the heterodimer complex. The colour scale for the represented index 
nonamer incidence is included in the bottom right. 
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6.3.3.3 Integrase (IN/p31) 
 
Functional HIV-1 IN protein is indispensable for the integration of viral DNA 
into the host’s genome, essential for HIV-1 replication and pathogenesis. A fully 
functional IN protein contains a N-terminal region, a catalytic domain and a C-
terminal SH3-like DNA binding domain (Bushman et al., 1993; Chiu and 
Davies, 2004; Eijkelenboom et al., 1995). However, to date, the full 3D 
structure of HIV-1 IN has yet to been fully elucidated and the most complete 
and high quality IN structure (PDB accession: 1EX4), containing both the 
catalytic domain and C-terminal SH3-like DNA binding domain, was used for 
the analysis.  
The catalytic domain contains both α-helices and β-sheets while that of the C 
terminal SH3-like domain contains only β-sheets (Figure 6.11). Conservation 
levels of both domains are fairly high (> 75% average) though the overall 
conservation of the catalytic domain is slightly lower, ~6% lower in average 
index nonamer incidence, than the C terminal SH3-like domain. In addition, the 
catalytic triad within the catalytic domain, consisting of Asp-64, Asp-116 and 
Glu-152 (Figure 6.11), is not as conserved with a nonamer incidence ranging 
from ~30-78%, average ~52%. This is about two times lower than the catalytic 
triads of other HIV-1 enzymatic proteins like that in PR and RT which have 
average incidences of ~94% and ~75% respectively. The more highly conserved 
C terminal SH3-like DNA binding domain has a relatively higher incidence of 
~81% and this might be closely linked to the necessity to preserve positively 
charged Lysine residues integral for DNA binding (Chen et al., 2000; Jenkins 















Figure 6.11 | Conservation across 3D IN structure. The catalytic domain and 
C terminal SH3-like DNA binding domain are depicted in “ribbon” 
representation while catalytic triad and the rest of the molecule is in space filling 
“sphere” representation. The colour scale for the represented index nonamer 




Figure 6.12| Int dimers. Monomer I and monomer II of IN are separated by a 
dotted white line. Catalytic triad I and II, KRK (I) and KRK (II) represent the 
catalytic residues (Asp-64, Asp-116 and Glu-152) and the conserved residues 
critical for dimerization (Lys-186, Arg-187 and Lys-188), respectively, in 
monomer I and II of the integrase dimer. The dimerization interface are on either 
side of the white dotted line and consists of two alpha helices, one conserved 
and one moderately conserved from each monomer subunit. The colour scale 




Similar to HIV-1 MA and RT, active IN exists as dimers where two alpha 
helices (Figure 6.12), one highly conserved and one relatively diverse, within 
the catalytic domain of each subunit were brought into close proximity. 
Important residues required for dimerization, namely Lys-186, Arg-187 and 
Lys-188 residues (KRK), remained fairly highly conserved, >80% conservation 
(Berthoux et al., 2007; Bushman et al., 1993; Tsurutani et al., 2000; Wang et 
al., 2001).  
 
6.3.4  Vif Protein 
 
Vif proteins, together with Vpu, Vpr and Nef, are auxiliary proteins that are not 
essential for viral propagation but modulate viral replication and pathogenesis. 
Vif is mainly involved in the degradation of cytidine deaminases, like 
apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G 
(APOBEC3G) by tethering it to cellular E3 ligase for the promotion of HIV-1 
reverse transcription efficacy (Harris et al., 2003; Mangeat et al., 2003; Suspene 
et al., 2004; Yu et al., 2004; Zhang et al., 2003). For the E3 ligase to gain 
specificity for APOBEC3G, the binding of Vif, by its BC box domain, to the E3 
ligase is required (Malim and Emerman, 2008; Sheehy et al., 2002; Yu et al., 
2003). The BC box comprised mainly of hydrophobic amino acids (e.g. Leu-
148, Ala-149 and Ile-154) which forms extensive hydrophobic interactions with 
ElonginC (part of cellular E3 ligase) (Stanley et al., 2008). However, the 
domain is poorly conserved with an average incidence of less than 50% (Figure 
6.13). This might be closely related to the intrinsic disordered nature of the BC 
box domain which allows Vif to possess structural flexibility interaction with 
the E3 ligase components (Figure 6.14) (Bergeron et al., 2010; Reingewertz et 
al., 2010; Romero et al., 2001). Only a small segment of the domain is highly 
conserved, >80% index nonamer incidence, and this corresponded structurally 






Figure 6.13 | Conservation across 3D Vif structure. The BC box domain is 
depicted in “ribbon” representation while the rest of the molecule is in space-
filling “sphere” representation. The colour scale for the represented index 
nonamer incidence is included in the bottom right. 
 
 
Figure 6.14 | Interaction of Vif BC box with ElonginC. The interaction 
interface between Vif’s BC box (boxed in white) and the ElonginC protein (in 
green) is boxed in white. The colour scale for the represented index nonamer 
incidence of Vif is included in the bottom right. 
 
6.3.5 Vpr Protein 
 
The auxiliary Vpr protein has been reported to facilitate the efficient 
translocation of the pre-integration complex (PIC) into the nucleus and aids the 
subsequent infection of primary monocytes/macrophages and other non-
dividing cells (Connor et al., 1995; Subbramanian et al., 1998). Vpr adopts a 
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simple structure consisting of three helices and contains three important 
functional domains: the oligomerization domain, N-terminal NLS and C-
terminal NLS (Morellet et al., 2003) (See Figure 6.15).  The N-terminal NLS is 
embedded within the oligomerization domain and it contains relatively 
conserved, >70%, negatively charged residues like Leu-20, Glu-21, Leu-22, 
Leu-23 (Figure 6.15). The C terminal NLS, parallel to the N terminal NLS, has 




Figure 6.15 | Conservation across 3D Vpr structure. The alpha-helical C 
terminal and N terminal NLS and oligomerization domain is depicted in 
“ribbon” representation while the rest of the molecule is in “sphere” 
representation. The colour scale for the represented index nonamer incidence is 
included in the bottom right. 
 
6.3.6 Tat Protein 
 
HIV-1 Tat protein is well-known for its regulatory role in triggering HIV-1 gene 
expression and the synthesis of stable full length viral transcripts (Romani et 
al., 2010). These functions are fulfilled by the transactivation domain (Figure 
6.16) and an arginine-rich domain for binding transactivation responsive 
element (TAR) RNA. The transactivation domain aids gene expression by 
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binding to cyclic adenosine monophosphate (cAMP) response element-binding 
protein (CREB) binding protein (CREBBP), various other chromatin modifying 
complexes and histone modifying enzymes which acetylates nucleosomes 
(Deng et al., 2001; Pumfery et al., 2003). Positive Transcription-Elongation 
Factor b (P-TEFb), consisting of CycT1 and Cdk9, will be subsequently 
recruited and this complex formation will aid the production of stable full length 
transcripts (Williams et al., 2006; Zhou et al., 2003). Though functionally 
important, the entire transactivation domain is not uniformly conserved though 
key residues in close proximity to CycT1 and Cdk9 (Figure 6.17) are more 





Figure 6.16 | Conservation across 3D Tat structure. The 3D structure depicts 
the entire transactivation domain. The CREBBP binding domain is depicted in 
“ribbon” representation while the rest of the molecule is in space-filling 
“sphere” representation. The colour scale for the represented index nonamer 





Figure 6.17 | Interaction of transactivation domain of Tat with Cyclin T1 
and Cdk 9 (components of P-TEFb). Cyclin-T1 and Cdk9 are represented as 
space-filling yellow and green spheres respectively. Only the Tat protein is 
coloured according to their index incidence and the colour scale for the 
represented index nonamer incidence is included in the bottom right. The two 
white circles enclosed highly conserved residues in close proximity to Cyclin-
T1 and Cdk9. 
 
6.3.7 Rev Protein 
 
Predominantly located in the nucleus and nucleolus (Cochrane et al., 1990; 
Malim et al., 1989; Suhasini and Reddy, 2009), HIV-1 Rev proteins plays a 
significant role in regulating the transition between early and late phases of viral 
gene expression (Cullen, 1998; Cullen, 2003; Hope, 1999; Nekhai and Jeang, 
2006; Pollard and Malim, 1998; Strebel, 2003; Suhasini and Reddy, 2009). The 
interaction of Rev and RNA molecules for the formation of a Rev Response 
Element (RRE) Ribonucleoprotein (RNP) complex is important for the export 
of RNA into the cytoplasm for gene expression. The domain responsible for 
such a function is the highly conserved, >90%, arginine rich RRE/nuclear 
localization domain (Figure 6.18). The homo-oligomerization domain (Figure 
6.19) is conversely less conserved with nonamer index incidence of ~19% to 
44%. Such low incidences might be indicative of its secondary functional 
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importance where complex formation is reported only to enhance the binding 




Figure 6.18 | Conservation across 3D Rev structure. The NLS and RRE 
binding domain and the homomultimerization domain are depicted in “ribbon” 
representation while the rest of the molecule is in space-filling “sphere” 
representation. The colour scale for the represented index nonamer incidence is 
included in the bottom right. 
 
 
Figure 6.19 | Rev tetramers. The four Rev monomers (I, II, III and IV), 
depicted in “ribbon” representation, are arranged perpendicular to each other 
with the homomultimerization domain indicated. The colour scale for the 
represented index nonamer incidence is included in the bottom right. 
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6.3.8 Vpu Protein 
 
HIV-1 Vpu protein is a phosphorylated integral membrane protein that is 
involved in the control of viral particle release (Klimkait et al., 1990) and the 
degradation of CD4 molecules in the endoplasmic reticulum (Bour et al., 1995; 
Willey et al., 1992) . The detailed characterization of sequence conservation and 
3D Vpu structure is impossible due to the absence of structures that covers the 
entire length of Vpu. However, with available NMR structural information, 
correlation of the transmembrane anchor domain with sequence conservation 
can be made. The Vpu transmembrane domain have been reported to enhance 
viral particle release (Schubert et al., 1996) but the conservation of within this 
region is relatively low, highest at 40% (Figure 6.20). Nevertheless, such 
observations are inconclusive and the mapping of sequence conservation across 
all Vpu domains will definitely aid the correspondence of sequence 




Figure 6.20 | Conservation across 3D Vpu transmembrane domain 
structure. The molecule is in “sphere” representation. The colour scale for the 






6.3.9 Env Protein 
 
HIV-1 particles are decorated with the surface Env proteins, consisting of the 
surface SU) glycoprotein (gp) 120 (proteins and the transmembrane (TM) gp41 
proteins. Env proteins have been central to HIV-1 vaccine design, especially 
that of vaccine developments that could elicit antibodies that bind the viral Env 
and block initial infection of target cells and provide sterilizing immunity or 
long term controlled infection. 
  
6.3.9.1 gp120 (SU) 
 
The first contact between the host cell and the HIV-1 viral particle is that of the 
viral surface gp120 protein with its cognate cell surface receptor (CD4) and co-
receptor (CCR5 and/or CXCR4).  The CD4 binding loop adopts a helical 
structure with a relatively low level of conservation (~41 % average) which 
might be indicative of the peptide flexibility required for CD4 binding (Figure 
6.21). Also critical are the binding sites of gp120 with gp41 but such residues 
are mainly hydrophobic or neutral amino acids, e.g. Asn-85, Ala-219 and Val-
489, and were lowly conserved (ranging from 6% to 56%) (Helseth et al., 1991; 
Leavitt et al., 2003; Pancera et al., 2010; Sen et al., 2008; Thali et al., 1992; 
Wang et al., 2008; Yang et al., 2003). This conservational pattern is highly 
similar to that observed in MA and Rev where it might be indicative of the 
probable structural complementarity, without sequence conservation, required 





Figure 6.21 | Conservation across 3D gp120 structure. The CD4 binding (A) 
is depicted in “ribbon” representation while the rest of the molecule is in 
“sphere” representation. A close up view of the interaction of gp120 and CD4 
(in green) is displayed in B. The colour scale for the represented index nonamer 
incidence is included in the bottom right. 
 
6.3.9.2 gp41 (TM) 
 
The complete fusion of viral with host cell membrane post CD4-gp120 binding 
requires major refolding events within the non-covalently linked 
transmembrane gp41 (Frey et al., 2010; Harrison, 2005; Harrison, 2008). 
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Though the exact role of different regions of gp41 for viral and host cell fusion 
remains to be elucidated, the participation of the membrane proximal external 
region (MPER) is required. The MPER region adopts a primarily right handed 
helical structure (see Figure 6.22) with a fairly low conservation level (~40%). 
In comparison, the immunosuppression domain (Figure 6.22) is relatively more 
conserved (>70%) and possibly harbour important interaction sites, 




Figure 6.22 | Conservation across 3D gp41 structure. The 
immunosuppression region and the MPER region are depicted in “ribbon” 
representation while the rest of the molecule is in space-filling “sphere” 
representation. The colour scale for the represented index nonamer incidence is 
included in the bottom right. 
 
6.3.10 Nef Protein 
 
HIV-1 Nef  is an auxiliary protein that is involved in a multitude of cellular 
functions, ranging from the induction of cellular activation for viral replication 
in resting cells (Fackler et al., 1999; Saksela et al., 1995) to the down-regulation 
of CD4 receptors on infected host cells (Geyer et al., 2001; Lu et al., 1998). 
However, due to the dynamic nature of the N-terminal protein region, structures 
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of the full protein cannot be experimentally obtained (Arold and Baur, 2001). 
To date, structures of Nef that have been elucidated contained mainly the 
PxxPxR SH3 binding domain, the dimerization domain and part of (Romero et 
al., 2001) the catalytic subunit H of the vacuolar ATPase (ATPV1H) binding 




Figure 6.23 | Conservation across 3D Nef structure. The SH3 binding 
domain, dimerization domain (enclosed in white circle) and ATPaseV1H 
binding domain are depicted in “ribbon” representation while the rest of the 
molecule is in space-filling “sphere” representation. The colour scale for the 
represented index nonamer incidence is included in the bottom right. 
 
Amongst the three domains, the most highly conserved domain is that of the 
SH3 binding domain which has a maximum conservation level of over 90%. 
Such high levels of conservation might be highly correlated to the requirement 
of an intact SH3 domain to down-regulate class I major histocompatibility 
complex (MHC) (also known as HLA in humans) (Greenberg et al., 1998). The 
second most conserved Nef domain is the dimerization domain. It adopts a 
helical conformation and has an average incidence of about 53%. Its structural 
conformation, mainly alpha helical, and conservation is analogous to the 
dimerization/oligomerization domains reported in HIV-1 MA and Rev proteins. 
The least conserved Nef domain is the ATPV1H binding domain which is less 
than 30% conserved. This low level of conservation might be important in 
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maintaining the flexible disordered C-terminal region (Arold and Baur, 2001; 
Tompa, 2005) .  
 
6.4 Discussion and conclusion 
 
In this chapter, viral diversity and HIV-1 viral protein functions have been 
mapped onto available 3D structures. This correspondence allowed the 
visualization of the spatial localization of nonamer diversity across the different 
HIV-1 proteins, essential and auxiliary, and the permissive sequence variation 
within functional domains. In general, amino acids residing within the core of 
proteins are deemed to be more conserved than the exposed residues (Biswas et 
al., 2009; Guharoy and Chakrabarti, 2005) and that protein residues that are 
functionally important, like that required for protein-protein interactions, are 
usually more conserved than the rest of the surface residues (Bordner and 
Abagyan, 2005; Caffrey et al., 2004; Elcock and McCammon, 2001; Guharoy 
and Chakrabarti, 2010; Valdar and Thornton, 2001). However, there are no 
observable differences in the localization of highly diverse nonamers on the 
surface of HIV-1 proteins, demonstrated by CA and IN proteins. Also, not all 
functional domains are highly conserved as observed within the dimerization 
domains of MA, Rev and Nef. Although the generic correlations of sequence 
conservation with functional and structural correspondence cannot be made 
with HIV-1 proteins, this analysis have elucidated some important insights 
pertaining to the possible mechanisms adopted by HIV-1 proteins to maintain 
protein functionality despite their high level of sequence diversity. Such 
observations highlight the patterns of the permissive sequence variation profiles 
within HIV-1 which can be used to enhance the criteria for candidate vaccine 
target selection with the inclusion of functional and structural constraints.  
Functional preservation with continued sequence variation could be achieved 
with the possession of several identical domains within the same protein. The 
multiplicity of identical domains within the same protein suggests that each 
domain can potentially adopt a differential level of mutability and allows 
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essential viral protein functions to be resuscitated in case of deleterious 
mutations occur in any one of the domains. The cooperative nature of such 
“domain multiplicity” is observed in HIV-1 MA and NC proteins where both 
the proteins contain two nearly identical functional domains, the NLS and 
CCHC zinc finger domains respectively. In HIV-1 MA proteins, the 
abolishment of viral nuclear import can only be achieved by the inactivation of 
both the NLS and the protein function can be salvaged with just one functional 
NLS (Haffar et al., 2000). Also, the presence of two CCHC zinc finger domains 
within the NC proteins works in an coordinated manner to destabilize nucleic 
acids for optimal chaperone functionality during the reverse transcription 
process (Chaurasiya et al., 2012; Williams et al., 2002) where one domain is 
allowed to vary more than the other but still be able to maintain an overall 
function. Extending such synergistic conservation and variability beyond a 
single protein, such cooperativity is also observed at a multimer level where one 
monomer is relatively more conserved than the other. One example is that of 
HIV-1 RT heterodimers where the p66 tryptophan-rich dimerization domain is 
more conserved than the cognate interacting domain on p51. In fact, such a 
mechanism has also been reported in Group O proteins (Tebit et al., 2010) and 
the cooperative functionality between similar functional domains along the 
same protein or between monomers of multimer proteins could represent a 
generic mechanism for HIV-1 proteins for ensuring functional preservation as 
protein sequences continues to vary to escape immune detection.  
Sequence plasticity could be closely related to the importance of the particular 
functional domain within proteins. As observed across all the different proteins 
within the HIV-1 proteome, the level of index nonamer incidence are not 
analogous. A bias in sequence conservation is observed within domains of 
primary importance like that of the NES within the MA protein which have a 
fundamental importance for enhanced virus assembly efficacy (Alfadhli et al., 
2011; Alfadhli et al., 2009b; Cai et al., 2010; Chang et al., 2008; Chukkapalli 
et al., 2010; Cimarelli and Luban, 1999; Datta et al., 2011; Hearps et al., 2008; 
Lochrie et al., 1997; Ott et al., 2005; Purohit et al., 2001). This is also observed 
in the highly conserved catalytic triad residues of RT and PR where the 
conservation of critical residues are required for chemical reactions involved in 
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reverse transcription and proteolytic cleavage of immature viral proteins 
respectively. Conversely, if the particular protein domain does not encode for 
an essential function for the protein, the conservation of such a domain might 
not be vital. For example, the oligomerization domain of Rev is relatively more 
diverse than the Rev RRE. This might be attributed to the fundamental 
importance of the RRE to facilitate the export of RNA into the cytoplasm while 
mutations within the oligomerization domain do not abolish Rev function 
though oligomerization is compromised with a lowered RNA binding affinity 
(Daugherty et al., 2010a; Daugherty et al., 2008). However, sequence 
conservation do not necessary correlate to structural conservation (Flores et al., 
1993) and structural conformations required for protein-protein interaction 
might be preserved even when the observed variability at that domain is high. 
The combination of domain redundancy and differential domain importance is 
possible and was observed in the Vpr protein with two NLS.  The N terminal 
NLS, though not resembling a canonical NLS like the C terminal NLS, is more 
highly conserved. The general higher level of conservation can be generally 
attributed to the multitude of important functions performed by the N terminal 
NLS, including that of a NES (Sherman et al., 2001) and an oligomerization site 
(Venkatachari et al., 2010). The results were indicative of complex evolutionary 
adaptations where viruses are not only able to maintain their protein functions 
whilst varying their sequence to evade immune detection, but they are also able 
to enhance the economy of their small genomic space by housing multiple 
functional domains within redundant domains. 
The comprehensive correspondence of functional and sequence diversity to 3D 
structures of all full-length HIV-1 proteins will undoubtedly aid the 
identification of any functional and structural restraints driving sequence 
diversity. However, the major limitation for a comprehensive functional and 
structural diversity study is the inability to obtain full length 3D structures for 
all HIV-1 proteins from public structural databases like PDB. Often only 
structures from part of the protein, for example Vif and Nef, are elucidated. 
Though so, with the limited number of protein structures available, this study 
has elucidated, as comprehensive as possible, the sequence, functional and 
structural diversity landscape of HIV-1 proteins. Findings of this study set the 
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impetus for the exploration of such landscapes in other human pathogens like 
the Influenza A virus and DENV, where general sequence diversity, functional 
and structural correlative patterns, if any, can tremendously aid in rational 
therapeutic design.  
 
6.5 Chapter summary 
 
Background: The amazing ability of HIV-1 proteins to vary vastly in their 
protein sequences whilst maintain their protein function has left many baffled. 
This study aims to unravel the possible underlying mechanisms, functional and 
structural, that drives HIV-1 sequence diversity. 
Results:  There are no definitive correlation patterns observed between 
sequence conservation with protein functional regions and spatial localization. 
However, plausible mechanisms including that of (i) domain redundancy, where 
one domain is observed to vary more than the other functionally equivalent 
domain, (ii) enhanced mutation in domains that does not encode for the proteins’ 
primary functions, and (iii) sequence diversity with structural preservation for 
the maintenance of structural conformations required for protein interactions, 
are utilised by HIV-1 to preserve important protein functions despite of its high 
level of sequence variability. 
Conclusions: This study elucidated some of the plausible mechanisms adopted 
by HIV-1 to preserve protein functions while diversifying their protein 
sequences. Insights obtain are critical for vaccine design where candidate 
vaccine targets identified should be preferably focused on highly conserved 
sequences that are residing within critically important and/or primary functional 









The extreme sequence diversity of HIV-1 is one of the greatest challenges 
limiting the successful design of an effective vaccine (Barouch and Korber, 
2010; McBurney and Ross, 2008; Taylor et al., 2008; Walker and Burton, 
2008). However, the entire viral proteome is not totally hypervariable and there 
are still conserved sites (Chapter 5) which can be chosen as potential vaccine 
targets. Prior to downstream experimental validation, further computational 
characterization of the sequences are required to enhance the process of 
candidate target selection. Insights obtained from additional functional, 
structural and immunological analyses will undeniably complement existing 
diversity analysis to provide a better and more in-depth understanding of the 
interplay of different HIV-1 diversity determining factors, critical for vaccine 
design. For instance, the comprehensive study of viral protein sequence 
diversity, functions and structures reported in Chapter 6 have aided the 
identification of key association features beyond the simplistic correlation of 
protein structures and functions preservation with sequence conservation. In 
addition to being slightly variable, candidate vaccine targets should not reside 
within “redundant” domains and regions of secondary functional importance as 
such regions were typically associated with increased level of sequence 
variability.  
Since this thesis is concerned with the identification of potential immunogens 
for vaccine formulation, the immunogenicity of potential targets needs to be 
corresponded. Immunogenicity correlation was carried out by mapping reported 
HIV-1 human T cell epitopes, nonamer length or longer, onto selected highly 
conserved vaccine targets. In addition to inferred immunogenicity, likely non-
immunogenicity of targets was assessed by human molecular mimicry analyses 
where a refined list of sequences with low variability was matched to all 
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reported human proteins. Shared peptide identity of HIV-1 conserved sequences 
and human proteins was considered in this novel vaccine discovery pipeline in 
order to computationally eliminate potential target non-immunogenicity due to 
the potential lack of cognate TCR on immune-competent T cells which are 
clonally deleted during T cell maturation (Burnet, 1976). Also, vaccine safety 
can be enhanced by the exclusion of targets that can potentially induce of auto-
immune diseases in humans due to likely cross reactive immune reactions 
generated against host’s proteins by identical viral peptides (Kanduc, 2008; 
Kanduc, 2009). Finally, continued relevance of the highly conserved sequences 
as vaccine targets were studied by its correspondence to a disparate updated 
dataset (nr2012).  
Herein, the scope of HIV-1 sequence diversity for vaccine design is defined and 
criteria revolving HIV-1 protein structures, functions and immunogenicity were 
tabulated. Highly conserved HIV-1 sequences were identified and its 
immunogenicity, risk of inducing potential host cross-reactivity and long term 
sequence stability were correlated. Ultimately, this study have established an 
analysis pipeline which is generic for the application in the identification of 
candidate vaccine targets through the comprehensive study of viral sequence, 
structure, function and immunological diversity.  
 
7.2 Materials and methods 
 
7.2.1 Methodology overview 
 
The methodology employed in this study is summarized in Figure 7.1. Highly 
conserved 2008 HIV-1 sequences, with nonamer index conservation of 90% and 
higher, were identified. Correspondence of the slightly variable sequences was 
carried out with the updated nr2012 and a set of highly conserved 2012 
sequences, at 80% conservation or higher, was reported. Further 
characterizations were carried out for the identification of key functional, 
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immunological and structural profiles which are potentially useful for future 
target selection.  
 
 
Figure 7.1 | Flowchart for the conserved sequence identification pipeline 
employed in this chapter.  
 
7.2.2 Identification of highly conserved 2008 HIV-1 clade B sequences  
 
Highly conserved HIV-1 clade B sequences were selected based on the detailed 
nonamer sequence dynamics elucidated from the protein sequences reported 
between the year 1983 and the year 2008 (Chapter 5). Nonamer positions which 
have index incidences of 90% or more with more than 100 sequences analysed 






7.2.3 Identification of highly conserved 2012 HIV-1 clade B and pan-
clade sequences  
 
The identification of highly conserved 2012 HIV-1 clade B and pan-clade 
sequences were carried out on a separate sequence dataset which included 
protein sequences deposited into the NCBI protein database till March 2012 
(nr2012). Protein sequences previously analysed in Chapter 5 were removed 
and not included in this analysis. The detailed methodology for data pre-
processing for the nr2012 dataset has been described in Chapter 3.2.3.  
The identification of highly conserved 2012 HIV-1 sequences was carried out 
using BLAST searches. In brief, each of the conserved 2008 nonamer was 
searched against databases constructed from the nr2012-A, nr2012-B, nr2012-
C and nr2012-D datasets, respectively, using the blastp program of the BLAST+ 
package (version 2.2.25) (low complexity filter - off; expect - 1000; descriptions 
and alignments – 5000000, word size - 2). All nonamer matches (identical 
nonamer match and similar nonamer matches with more than one amino acid 
mismatch to the conserved 2008 nonamer) were extracted and the incidences 
calculated. Nonamers with an incidence of 80% or more in the nr2012-B dataset 
were termed as highly conserved 2012 HIV-1 clade B nonamers while nonamers 
which have incidences of 80% or more in each of the clades A, B, C and D were 
termed as highly conserved pan-clade nonamers. Only nonamer positions with 
more than 100 sequences analysed were tabulated and adjacent nonamers were 






7.2.4 Functional and immunological characterization of highly conserved 
2012 clade B sequences 
7.2.4.1 Functional domains and Epitope data collection and 
preparation 
 
Functional information of HIV-1 proteins collection was carried out as 
described in 6.2.2. HLA class I and II epitope information was collected from 
the HIV-1 immunology database 
(http://www.hiv.lanl.gov/content/immunology/) as of December 2012. Manual 
epitope data curation was carried out to remove any records that do not contain 
allele, supertype or supermotif information. Only human and macaques epitope 
records were extracted and used for immunogenicity correspondence. 
 
7.2.4.2 Computational functional and immunogenicity correlation 
to reported HIV-1 epitopes 
 
Epitopes and functional regions that matched, nine amino acids or more, to 
highly conserved 2008 clade B, 2012 clade B and 2012 pan-clade sequences 
were extracted and tabulated.  
 
7.2.5 Immune-relevant protein molecular mimicry of HIV-1 clade B 
nonamers to Human, Rhesus macaques (RM) and Simian 
Immunodeficiency Virus (SIV) proteins  
7.2.5.1  Data collection and preparation 
 
Human, RM and SIV protein sequences and nucleotide records were retrieved 
from the NCBI Entrez Protein Database (Wheeler et al., 2005) in May 2012 by 
searching the NCBI taxonomy browser for Homo sapiens (Taxonomy ID 9606), 
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RM Macaca mulatta (Taxonomy ID 9544) and SIV (Taxonomy ID 11723) 
respectively. Redundant sequences, defined as identical sequences (100% 
sequence identity) and sequences that were shorter but 100% identical to 
another sequence, were removed prior to analysis to obtain non-redundant 
Human, RM and SIV protein and nucleotide datasets.  
 
7.2.5.2 Identification of nonamer matches to Human, RM and SIV 
proteins  
 
Molecular mimicry analyses were carried out by matching the highly conserved 
2012 HIV-1 clade B nonamer sequences to human, RM and SIV proteins and 
to the human translated genomes respectively. All human, RM and SIV proteins 
in the non-redundant protein datasets were split into overlapping nonamers prior 
to the analysis. A comprehensive comparative study was carried out to identify 
Human, RM and SIV protein nonamers that matched to each highly conserved 
2012 clade B nonamer. Further, shared peptide identity of conserved sequences 
to translated human genomes was carried out by translated BLAST (tblastn) 
(version 2.2.25) (low complexity filter - off; expect - 10; descriptions and 
alignments - 350000) searches with the conserved nonamers queries and the 
translated human genome database. Exact nonamer matches of the highly 
conserved nonamers to the translated genomic records were identified and were 
considered to share peptide identity with the translated human genome. The 
total number of conserved nonamers matched was tabulated and the identities 








7.3.1 Highly conserved 2008 HIV-1 Clade B sequences 
Table 7.1 | Highly conserved 2008 HIV-1 clade B sequences. 
Protein Position a Sequence b 
Gag 35-45 VWASRELERFA 
 154-164 SPRTLNAWVKV 
 166-178 EEKAFSPEVIPMF 
 180-208 ALSEGATPQDLNTMLNTVGGHQAAMQMLK 
 210-220 TINEEAAEWDR 
 235-247 REPRGSDIAGTTS 
 275-285 GLNKIVRMYSP 
 293-306 QGPKEPFRDYVDRF 
 349-362 LEEMMTACQGVGGP 
 439-447 NFLGKIWPS 
Pol 57-65 PQITLWQRP 
 77-88 EALLDTGADDTV 
 150-174 GCTLNFPISPIETVPVKLKPGMDGP 
 176-189 VKQWPLTEEKIKAL 
 204-214 KIGPENPYNTP 
 239-254 TQDFWEVQLGIPHPAG 
 260-272 SVTVLDVGDAYFS 
 279-289 FRKYTAFTIPS 
 298-316 RYQYNVLPQGWKGSPAIFQ 
 384-399 WMGYELHPDKWTVQPI 
 406-426 SWTVNDIQKLVGKLNWASQIY 
 453-465 EAELELAENREIL 
 766-786 HGQVDCSPGIWQLDCTHLEGK 
 790-815 VAVHVASGYIEAEVIPAETGQETAYF 
 817-825 LKLAGRWPV 
 852-867 QEFGIPYNPQSQGVVE 
 879-887 QVRDQAEHLKTAVQMAVFIHNFKRKGGIG 
 950-969 WKGPAKLLWKGEGAVVIQDN 
 981-997 KIIRDYGKQMAGDDCVA 
Vif 1-18 MENRWQVMIVWQVDRMRI 
 142-150 VGSLQYLAL 
Rev 33-46 GTRQARRNRRRRWR 
Vpu 49-57 RAEDSGNES 
Env 34-45 WVTVYYGVPVWK 
 47-58 ATTTLFCASDAK 
 66-76 NVWATHACVPT 
 264-273 VSTVQCTHGI 
 275-289 PVVSTQLLLNGSLAE 
 505-517 DNWRSELYKYKVV 
 555-563 AGSTMGAAS 
 595-608 LQLTVWGIKQLQAR 
Nef 80-88 PQVPLRPMT 
a Start and end position in the protein alignment. b Highly conserved sequences of 9 or 
more amino acids, each with nonamer index sequence incidence of 90% or more. This 
analysis was done for all nonamer positions with more than 100 sequences. 
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Approximately 9 % (253 nonamers) of all the nonamers analysed for the 2008 
HIV-1 clade B dataset were highly conserved (Table 7.1). The concatenated 
sequences have peptide lengths ranging from nine amino acids to 29 amino 
acids. The number of highly conserved peptides was generally closely 
correlated to the conservancy of the proteins with the largest number of 
conserved sequences observed in Pol. Env, though variable with maximum 
nonamer entropy of  more than nine (Figure 5.2 and Table 5.2) , contains eight 
conserved peptides of amino acid length nine to 15. 
 
7.3.2 Highly conserved 2012 HIV-1 Clade B sequences and pan-clade 
sequences 
7.3.2.1 Highly conserved 2012 HIV-1 Clade B sequences 
 
More than 30,000 sequences were analysed in the 2012 dataset (Table 3.3). 
Greater than 40% of the total analysed sequences were from HIV-1 clade B, 
followed by clade C (~30%), A (~19%) and D (~11%). Potential long term 
relevance of the highly conserved 2008 HIV-1 nonamers within a disparate 
dataset was demonstrated by their maintained high level of conservation within 
the nr2012 dataset. The result obtained was in line with earlier observations 
where the HIV-1 clade B conservation dynamics were correlative between the 
historical HXB2 and the recent circulating C1P strain (Chapter 5). A large 
proportion, ~90%, of the highly conserved 2008 HIV-1 nonamers remained 
highly conserved (≥90% index incidence) in the 2012 dataset. However, a 
modified cut off of 80% or higher was used for the identification of highly 
conserved 2012 HIV-1 clade B and pan-clade sequences to include a larger 
number of nonamers and a list of corresponding concatenated peptides with 
longer amino acid length. With the new cut-off, more than 98% of the highly 
conserved 2008 clade B nonamers sequences, accounting to about 20% of the 
HIV-1 proteome, remained conserved till the year 2012. All nonamers were 




7.3.2.2 Highly conserved 2012 HIV-1 pan-clade sequences 
Table 7.2 | Highly conserved 2012 HIV-1 clade B sequences. 
 
Protein Position a Sequence b 
Gag 35-45 VWASRELERFA 
 154-164 SPRTLNAWVKV 
 166-178 EEKAFSPEVIPMF 
 180-208 ALSEGATPQDLNTMLNTVGGHQAAMQMLK 
 210-220 TINEEAAEWDR 
 237-247 PRGSDIAGTTS 
 275-285 GLNKIVRMYSP 
 293-306 QGPKEPFRDYVDRF 
 349-362 LEEMMTACQGVGGP 
 439-447 NFLGKIWPS 
Pol 57-65 PQITLWQRP 
 77-88 EALLDTGADDTV 
 150-174 GCTLNFPISPIETVPVKLKPGMDGP 
 176-189 VKQWPLTEEKIKAL 
 204-214 KIGPENPYNTP 
 239-254 TQDFWEVQLGIPHPAG 
 260-272 SVTVLDVGDAYFS 
 279-289 FRKYTAFTIPS 
 298-316 RYQYNVLPQGWKGSPAIFQ 
 384-399 WMGYELHPDKWTVQPI 
 406-426 SWTVNDIQKLVGKLNWASQIY 
 453-465 EAELELAENREIL 
 766-786 HGQVDCSPGIWQLDCTHLEGK 
 790-815 VAVHVASGYIEAEVIPAETGQETAYF 
 817-825 LKLAGRWPV 
 852-867 QEFGIPYNPQSQGVVE 
 879-907 QVRDQAEHLKTAVQMAVFIHNFKRKGGIG 
 950-969 WKGPAKLLWKGEGAVVIQDN 
 981-997 KIIRDYGKQMAGDDCVA 
Vif 1-18 MENRWQVMIVWQVDRMRI 
 142-150 VGSLQYLAL 
Rev 33-46 GTRQARRNRRRRWR 
Vpu 49-57 RAEDSGNES 
Env 34-45 WVTVYYGVPVWK 
 49-58 TTLFCASDAK 
 66-76 NVWATHACVPT 
 264-273 VSTVQCTHGI 
 275-289 PVVSTQLLLNGSLAE 
 505-517 DNWRSELYKYKVV 
 555-563 AGSTMGAAS 
 595-608 LQLTVWGIKQLQAR 
Nef 80-88 PQVPLRPMT 
a Start and end position of the 2008 clade B protein alignment (Hu et al., 2013). b Highly 
conserved 2012 sequences of nine or more amino acids, each with nonamer index 
sequence incidence of 80% or more. This analysis was done for all nonamer positions 





Highly conserved 2008 HIV-1 clade B sequences were additionally 
corresponded to clades A, B, C and D of the 2012 protein sequence datasets. 
Nonamers which manifested a high level of conservation, ≥80%, in clades A, 
B, C and D were termed as highly conserved pan-clade nonamers. Most of the 
nonamers remained conserved in clades A (~71%), B (~96%), C (~75%) and D 
(~40%) and such an observation is indicative of the presence of cross-clade 
sequence signatures that display long term sequence conservation and are 
favourable targets for a HIV-1 pan-clade vaccine.  
However, the insufficient number of sequences available for some proteins of 
certain clades, especially that of clade D Pol protein, greatly limits the 
significant quantitative correlation of conservancy of nonamers. Thus, only a 
very limited set of seven highly conserved 2012 HIV-1 pan-clade sequences 
were identified. These sequences were found solely in the Gag and Env proteins 
and they are mainly short, with maximum length of 15 amino acids (Table 7.3).  
 
Table 7.3 | Highly conserved 2012 HIV-1 pan-clade sequences. 
 
Protein Position a Conserved sequence b Length (aa) 
Gag 180-191 ALSEGATPQDLN 12 
 197-208 VGGHQAAMQMLK 12 
 237-247 PRGSDIAGTTS 11 
 293-306 QGPKEPFRDYVDRF 14 
  349-362 LEEMMTACQGVGGP 14 
Env 275-289 PVVSTQLLLNGSLAE 15 
  505-517 DNWRSELYKYKVV 13 
a Start and end position in the 2008 protein alignment (Hu et al., 2013). b Highly 
conserved pan-clade sequences of concatenated nonamer sequences, of length 12 or 
longer, each conserved in 80% or more in Clades A, B, C and D of all nonamer 
positions with more than 100 sequences. 
 
7.3.3 Functional and immunological profile of the conserved peptides 
 
The correspondence of the highly conserved HIV-1 sequences (2008 clade B, 
2012 clade B and pan-clade) with reported epitopes was low (Figure 7.2, Figure 
S7.1 and Table S7.1). Only 15 out of the 42 highly conserved 2008 HIV-1 clade 
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B sequences matched to reported human HIV-1 HLA class I and/or II epitopes. 
Conserved proteins like HIV-1 Gag displayed a comparatively higher level of 
epitope promiscuity, with a larger number of highly conserved sequences 
corresponding to reported epitopes restricted by HLA class I and II alleles. 
Conversely, for more diverse proteins like HIV-1 Env, there are only three 
conserved sequences matched to reported epitopes, each with a dedicated class 
I or II correlation (Table S7.1).  
 
Figure 7.2 | Functional and immunological maps of the highly conserved 
HIV-1 Gag and Env sequences. Sequences of the highly conserved 2008 HIV-
1 clade B sequences, highly conserved HIV-1 2012 clade B sequences 
(underlined) and highly conserved 2012 pan-clade sequences (in bold-faced) are 
shown.  Sequences corresponding to class I and/or class II HLA epitopes were 
indicated by black and green arrows respectively. The identity of individual 
proteins within the Gag and Env polyproteins are labelled. Domains were 
enclosed in coloured rectangles. For example, the trimerization domain within 
the Gag 35-45 (sequence: ERFA) is enclosed in a yellow rectangle. The legend 
for the colouring scheme and symbols is included at the bottom of the figure.
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7.3.4 Shared peptide identity with reported human protein sequences 
 
Shared sequence identity, or human protein mimicry, between highly conserved 
HIV-1 sequences and human protein sequences were identified by matching 
highly conserved HIV-1 nonamers to reported human proteins. None of the 
highly conserved HIV-1 protein nonamers matched to reported human proteins. 
The scope of the analysis was enhanced to include all possible translated protein 
products by sequence identity searches against translated human genomes. 
Similar to the protein searches, there no nonamer peptide identity was observed 
between conserved sequences and translated human genomes. Nevertheless, it 
was observed that a single mutation within the conserved nonamer will render 
sequences human-like and mimic sequences identical to parts of human 
Copines, Dixins and DNA associated proteins (Table 7.4). Except for two 
human-like mimics observed within the analysed HIV-1 variant sequences, one 
each in Gag and Env, most of the variant mutant sequences were absent in 
natural HIV-1 proteomes (results not shown).  
 
7.3.5 Systematic pipeline for rational vaccine target selection 
 
The systematic immunoinformatics-driven vaccine discovery pipeline 
employed combines the insights obtained from the quantitative protein 
sequence, functional, structural and immunological diversity analyses of the 
HIV-1 viruses. The combination of the multitude of analyses allowed the 
elucidation of important factors that characterize sequence conservation and are 
summarized in Table S7.2.  In general, not all highly conserved sequences 
belong to functionally important domains. Only 45% (19 out of 42) of the highly 
conserved 2012 clade B sequences have a corresponding function. 
Corresponded reported functions are closely related to the critical protein 
functions and interactions like the Aspartic acid residue, part of RT catalytic 
triad, which resides within Pol 260-272 (SVTVLDVGDAYFS) and the key 
functional SH3-like binding domain within Nef 80-88 (Saksela, 2011). Of 
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which, 11, mainly from Pol, sequences contained matches to reported HLA 
class I and/or II epitopes and displayed no sequence identity with human 
proteins. Though no distinct structural localization is observed, structural 
proteins (Env and Nef) have the conserved sequences exposed externally while 
enzymatic proteins (Pol) have most of theirs buried (Table 7.5).  
 
7.3.6 Implications of conserved sequences for non-human primates 
(NHP) clinical trials 
 
Highly conserved sequences were additionally characterized for their suitability 
in pre-clinical non-human primate studies by computational molecular mimicry 
analyses with SIV proteins and RM proteins and correspondence to reported 
RM epitopes. Ideally, candidate vaccine targets should share sequence 
similarity with SIV, a naturally primate infecting virus, and be distinct in their 
amino acid sequence from NHP, e.g. RM, proteins to prevent cross reactivity 
and non-immunogenicity. The complete functional, immunogenicity and 
structural profiles of HIV-1 highly conserved sequences are summarized in 
table S7.2. However, only 11 highly conserved sequences are reported to be 
devoid of RM-like protein sequences and are SIV-like (Table 7.5). This refined 
list of peptide sequences with low variability represents potentially useful 
targets which can be included in vaccine formulations suitable for both 
preclinical NHP and clinical human trials.  
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Table 7.4 | List of human proteins that contain exactly one amino acid different from the highly conserved HIV-1 2012 clade B 
sequences. 
 
Protein Position a Conserved Sequence b Human proteins Accession GI c 
Gag 293-306 QGPKEPFRDYVDRF   
   
   V........ 
    ........T 
Copine 5 
 
13626179, 25141323, 31753190, 119624316, 
119624317, 119624318, 119624319, 119624320 
  
   V........ 
    ........S 
Copine 9 120660186, 300669696, 88703066 
Pol 260-272 SVTVLDVGDAYFS   
   
.......N. Cadherin EGF LAG seven-
pass G-type receptor 2 
9828190, 13325064, 21929188, 22095550, 
55959329, 119576776 





Nuclear mitotic apparatus 
protein 
35119, 35121, 743447, 13278786, 68533069, 
71361682, 74355465, 116283736, 119595227, 
119595228, 119595229, 119595230, 119595231, 
119595232, 119595233, 119595234, 119595235, 
119595236, 119595237, 145559510 
   
   .K.....Q. Centrosomal protein of 89 
kDa 
50083293, 223460818, 296439414 
Env 275-289 PVVSTQLLLNGSLAE   
       .......P. Dixin 39930479, 83816971, 147641721 
        .......P. DIX domain containing 1 34190572, 109138673, 119587576, 119587577 
a  Start and end position of 2008 protein alignments. (Hu et al., 2013) b Concatenated HIV-1 2012 clade B nonamer sequences, each conserved in 80% or 
more of all nonamer positions with more than 100 sequences. Underlined amino acids corresponding to 1 mismatch to reported human proteins at nonamer 




Table 7.5 | Functional, immunological and structural profiles of candidate vaccine targets. 
 
Protein Position a Sequence b Functional region c HLA d Mimicry e Structure f
Pol 239-254 TQDFWEVQLGIPHPAG RT Domain I H-, SIV+, RM- B 
 260-272 SVTVLDVGDAYFS RT Domain - Catalytic Triad "D" 
residue 
I H-, SIV+, RM- B 
 279-289 FRKYTAFTIPS RT Domain II H-, SIV+, RM- B 
 298-316 RYQYNVLPQGWKGSPAIFQ RT Domain I H-, SIV+, RM- B 
 790-815 VAVHVASGYIEAEVIPAETGQETAYF Integrase Catalytic domain I & II H-, SIV+, RM- N.D. 
 817-825 LKLAGRWPV Integrase Catalytic domain I H-, SIV+, RM- N.D. 
 852-867 QEFGIPYNPQSQGVVE Integrase DNA binding domain - 
Conserved Acidic residues 
interacting with DNA 
I H-, SIV+, RM- N.D. 
 879-907 QVRDQAEHLKTAVQMAVFIHNFKRKG
GIG 
Integrase DNA binding domain - 
Conserved Acidic residues 
interacting with DNA 
I & II H-, SIV+, RM- N.D. 
 950-969 WKGPAKLLWKGEGAVVIQDN Integrase DNA binding domain - 
Conserved Lysine residues 
I H-, SIV+, RM- N.D. 
Env 595-608 LQLTVWGIKQLQAR Immuno-suppression II H-, SIV+, RM- E 
Nef 80-88 PQVPLRPMT SH3-like binding domain I & II H-, SIV+, RM- E 
a Start and end position of 2008 protein alignments. (Hu et al., 2013). b Concatenated 2012 clade B nonamer sequences, each conserved in 80% or more of all nonamer positions 
with more than 100 sequences. c Correspondence of highly conserved sequences, nonamer or longer, to their reported protein functions. d Correspondence of highly conserved 
sequences, nonamer or longer, to reported HLA class I and/or II epitopes. e Correspondence of highly conserved sequences, nonamer or longer, to human (H), SIV (SIV) and 
Rhesus macaques (RM) sequences. The combination of “+” or “-” symbol next to the alphabet denotes the presence or absence, respectively, of highly conserved sequences in 
Humans, SIV and RM respectively. For example, the order of “H-,SIV+,RM-“ denoted that the highly conserved sequence is absent in human protein sequences, present in SIV 
protein sequences and absent in Rhesus macaques protein sequences. f Correspondence of highly conserved sequences, nonamer or longer, to protein structures (see Chapter 6). 
“B” denotes the sequences are buried within the 3D structure, “E” denotes sequences that are exposed on the 3D surface of the protein and “N.D.” is not 
determined as the full structure of the protein is not available.
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7.4 Discussion and Conclusions 
 
The novel systematic analysis pipeline for the study of HIV-1 diversity has been 
reported. The originality of the work lies in its deviation from traditional 
sequence-based approaches to include the study of other factors that affects 
HIV-1 proteomic diversity. In particular, this study is the first to include 
molecular mimicry analyses as a secondary consideration for inferred 
immunogenicity beyond the fundamental correspondence to reported 
experimental epitopes.  In total, 11 conserved sequences, spanning a total length 
of 182 amino acids, were identified as potential vaccine targets for further 
experimental validations. The results obtain represent the collective immune-
relevant sequence, functional, structural and immunological insights obtain 
from the study of a large number of HIV-1 populations and quasispecies for at 
least 30 years (1983 to 2012, based on records with available isolation date). 
Not only are the candidate vaccine targets highly conserved, they are potentially 
immunogenic, non-host cross-reactive and present distinct functional and 
structural profiles which are potentially restricting further sequence variation.  
The extreme proteomic diversity of HIV-1 is apparent (Chapter 5) and the 
random selection of any sequence, especially the highly diverse ones, within the 
complex HIV-1 population will likely have limited efficacy as vaccine targets. 
Nevertheless, the HIV-1 proteome is no totally diverse and there are regions of 
low variability within the viral proteome which vaccine target can be selected. 
Such relatively conserved targets plausibly represent critical sequence 
signatures that were historically preserved for viral survival and propagation 
(Rolland et al., 2007c) and, thus, are unlikely to vary and be relevant 
immunogens for vaccine formulation in the current paradigm and the future. In 
addition, the inclusion of highly conserved sequences within vaccine constructs 
is believed to have immunological importance in preventing immune mis-
targeting towards less conserved regions of the protein (Li et al., 2011). 
Conserved sequences were typically identified by retrospective sequence 
analyses and that the prospective stability of such sequences beyond the 
analysed time period and within other disparate HIV-1 sequence datasets were 
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not extensively studied. Thus, this novel vaccine discovery pipeline included 
predictive studies to estimate the plausible sequence stability of the highly 
conserved HIV-1 sequences in another disparate dataset obtained at a futuristic 
time point. The correlation of highly conserved 2008 HIV-1 nonamers to the 
updated 2012 dataset served as an extended reference time point, similar to the 
C1P strain analysed in Chapter 5, where the forecast of the sequence relevance 
in the future and within disparate sequence datasets could be made.  
It is generally assumed that structural and functional restraints play integral but 
unknown roles in determining HIV-1 sequence diversity. Potential complex 
mechanisms driving sequence diversification have already been reported and 
discussed in Chapter 6. However, it is important to re-emphasize that 
functionally important regions are not always conserved (see Chapter 6) and, 
often, they do not adopt rigid spatial localizations, i.e. exposed on the surface 
or buried within the protein core. Moreover, such functional sites have a poor 
correlation to reported epitopes and this might be the cumulative outcome result 
of years of viral evolution where the progeny viruses adopts unique viral 
functional domain sequences to constantly evade host immune detection. 
Nevertheless, it is intriguing that majority of the conserved sequences have 
correlated immunogenicity and only four out of the 42 highly conserved HIV-1 
sequences contained corresponded epitopes solely within their variants and not 
within the index nonamer (results not shown). It is possible that future vaccine 
formulations could consider the addition of viral variants for enhanced breadth 
and depth of immune responses (Barouch et al., 2010).  
Corresponded immunogenicity, as well as, the potential non-immunogenicity 
and immune toxicity need to be considered for rational vaccine target selection. 
The presence of human/host-like sequences in HIV-1 proteome has two 
important implications in vaccine design. First, such human-like sequences 
might not be able to generate immune response in host due to clonal deletion of 
immune molecules during human development process to prevent auto-
immunity against self-proteins (Burnet, 1976). Second, immune cross reactivity 
might be elicited against both the host and HIV-1 proteins, as defined by the 
low similarity hypothesis (Kanduc, 2008; Rolland et al., 2007b), and collateral 
immunological damages to both the human host and the HIV-1 virus will be 
139 
 
inflicted. This phenomenon is classically exemplified by HIV-1 BrNAbs 
induced human cardiolipin polyspecific autoreactivities (Haynes et al., 2005; 
Vcelar et al., 2007). The impact of molecular mimicry, or shared peptide 
identity, can potentially lead to low or no therapeutic outcomes and potential 
autoimmunity and thus, HIV-1 conserved sequences that contain such human 
sequence signatures should be excluded. Fortunately, such highly conserved 
sequences are rare in human proteins (Rolland et al., 2007b) and that the highly 
conserved targets identified in this study do not share a significant, nonamer 
length or longer, identity with any reported or translated human proteins. 
Additionally, the application of the host molecular mimicry concept was 
extended to the characterization of sequences for pre-clinical NHP, e.g. RM, 
studies where vaccine targets selected for NHP studies should have any RM-
like protein sequences removed to prevent non-immunogenicity or cross 
reactivity within pre-clinical hosts. Nevertheless, it is important to note that a 
change in only one amino acid will render a HIV-1 sequence human-like (Table 
7.4). This can be circumvented by the inclusion of only totally conserved 
sequences but is impractical for the highly diverse HIV-1 where only 10 amino 
acids were discovered to be invariant. Thus, strategies could be focused on the 
selection of highly conserved sequences to minimize immune targeting or 
escape of candidate sequences resulting in vaccine failure.  
In summary, this thesis has identified a set of potential HIV-1 vaccine targets 
through the comprehensive analyses immune-relevant sequence, functional, 
structural and immunological diversity of HIV-1. Conserved targets identified 
represent a refined set of targets which can be used for further experimental 
validations prior to the inclusion into vaccine constructs. Established for the 
application of a selected population of HIV-1 virus, it is believed that the 
flexibility of the defined pipeline can also be generically applied to study the 
complexity within each patient viral quasispecies. Such individualized 
conserved sequences identified could be used for personalized vaccine 
formulations and complement currently available personalized immunotherapy 
where immune responses could be directed to least variable protein regions 
specific to the viruses circulating within the particular host (Jenabian et al., 
2013; Routy et al., 2010; Routy and Nicolette, 2010).  
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7.5 Chapter summary 
 
Background: The comprehensive understanding of HIV-1 sequence diversity 
is essential for the identification of vaccine targets for vaccine design. The 
enhanced characterization, beyond primary sequence diversity, is required to 
identify key restrains or patterns, if any, that governs the evolutionary 
conservation of such peptides. In this chapter, insights obtained from HIV-1 
nonamer sequence diversity, functional, structural and immunological analysis 
were combined to obtain a more comprehensive view on rational HIV-1 vaccine 
design. 
Results: The collective outcomes obtained from the comprehensive analyses 
revealed important sequence, functional, structural and immunological 
characteristics of the 11 potential vaccine targets. In general, such sequences 
should (i) be highly conserved, (ii) be preferably localized within functionally 
important regions and not within redundant domains, (iii) contain promiscuous 
epitopes restricted by a wide array of HLA alleles, (iv) have no sequence 
identity with human proteins and (v) display long-term conservation.  
Conclusions:  The pipeline for the identification of HIV-1 vaccine targets has 
been constructed and key sequence, function, structure and immunological 
features of candidate vaccine targets were elucidated. The successful 
application of the analysis pipeline to the general population of HIV-1 viruses 
is expected to be generically applicable to the large-scale analyses of different 
viral pathogens and also to individual complex viral quasispecies for 






Chapter 8 General Discussion, Conclusions and 
Future Work 
 
8.1 General Discussions 
 
HIV-1 is a hypervariable virus with an astonishing rate of mutation and 
recombination where immune escape mutants can be rapidly generated to evade 
host detection and elimination. Traditional vaccine development approaches 
which comprises of inactivated or live attenuated viruses or recombinant 
proteins from a single or several viral strains are insufficient to recapitulate the 
diversity of the entire repertoire of HIV-1 mutants and, thus, cannot be effective 
against the enormous number of viral strains within and between individuals. 
New strategies are urgently required for HIV-1 vaccine design, especially one 
that addresses the different aspects of the viral immune-relevant diversity. Thus, 
this thesis attempts to address the problem with an original systematic pipeline 
for the elucidation of HIV-1 vaccine targets through the detailed dissection of 
HIV-1 nonamer sequence conservation and variability (Figure 8.1). The work 
described is a step forward in the field of HIV-1 reverse vaccinology, where 
large amount of HIV-1 sequence, structural, functional and immunological 
information were concertedly studied by a number of bioinformatics algorithms 
and methodologies for the identification of putative targets for successful 
vaccine formulations. Targets obtained from such immunoinformatics-based 
analyses dictates that the need to perform large number of experiments on all 
overlapping peptides within the different viral proteomes is no longer required. 
Instead, efforts can be focused on a smaller number of key experiments, both in 
vitro and in vivo, on a refined list of vaccine candidates. Further, the feasibility 
of such reverse vaccinology approaches has been successfully demonstrated by 
the successful development of a number of vaccines including the universal 
vaccines against group B Streptococcus (Maione et al., 2005) and the vaccine 
against Neisseria meningitides (Pizza et al., 2000), among others (Rappuoli and 
Covacci, 2003). The power of such “bottom-up” methodology lies in its ability 
to carry out large-scale sequence analysis that could potentially mirror the 
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immune-relevant diversity of the target pathogen population and the diversity 
of the hosts’ immune system at the immunological synapse. However, the 
successful application of such a method lies in the design of a suitable analysis 
pipeline that can comprehensively study the immune-relevant sequence 
diversity, and rationally screen pathogen data to select candidate vaccine targets 
that considers both the host immune system and viral sequence diversity. 
Distinct from other computational HIV-1 vaccine discovery methodologies 
(Brusic and Zeleznikow, 1999; De Groot et al., 2004; De Groot et al., 2005; 
Finnefrock et al., 2007; Gaschen et al., 2002; Korber et al., 2009; Liang et al., 
2010; Liu et al., 2006; Nickle et al., 2007; Rolland et al., 2007a; Rolland et al., 
2007c; Srinivasan et al., 2008; Yang, 2009), this work is the first to elucidate 
the detailed dynamics of HIV-1 immune-relevant sequence diversity of 26 years 
(>58,000 sequences) prior to subsequent candidate target vaccine selection with 
the comprehensive structural, functional and immunological characterization. 
Also, conserved sequence stability for vaccine target relevance within another 
disparate dataset was performed by the correspondence of vaccine targets to an 
updated 2012 dataset (>30,000 sequences). These analyses form a unique 
systematic pipeline where key features relating sequence conservation, protein 
functions, protein structures and immunogenicity were elucidated. In total, 11 
highly conserved sequences were identified as favourable vaccine targets that 
corresponded to reported human epitopes, contained potential functional 
restraints to vary and were unique from human proteins to prevent non-
immunogenicity and host cross-reactivity. 
The advent of technologies have brought about a tremendous increase in the 
availability of a multitude data, including sequence information, protein 
functional information, protein interaction data and 3D structural data. In 
addition to viral population data, information can now be derived from 
individual viral quasispecies which is a significant step forward in personalized 
vaccines development. This data explosion has significantly enriched the 
current scientific research landscape as more insights can be drawn from the 
analysis of the larger sequence datasets which otherwise could not have been 
possible previously. However, one of the biggest challenges to such large-scale 
sequence analysis is that of the sequences itself. Quality of the sequences from 
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the database is unproven and most of the sequence records are poorly annotated 
with incomplete information on the source of the virus, origin of the infection, 
treatment information, or details of cultivation. As such, data pre-processing 
becomes mandatory and a large amount of precious man hours will be required 
for manual curation which greatly limits the rate of contemporary sequence-
based analysis. Also, the subsequent alignment of the large number of protein 
sequences has also been proven to be a daunting one, especially the alignment 
of highly diverse proteins like that of HIV-1 Env. Though various multiple 
sequence algorithms have been developed to address the issue of sequence 
diversity in protein alignments, the complexity of diverse protein alignments 
cannot be solved by any single algorithm and manual editing and human 
curation of the automated protein alignments were almost essential. As the main 
focus of this thesis is not to design and develop a protein alignment algorithm 
for aligning highly diverse proteins, distinct strategies were employed in the 
alignment of HIV-1 protein sequences using available algorithms (See Chapter 
3). Nevertheless, the participation of manual curation was necessary and such 
intense requirement of manual curation is one of the major limiting factors for 
the scalability of the analyses to larger sets of protein sequences.   
One of the key contributions of this work is the design and application of the 
novel quantitative variant dynamics dissection methodology which allowed the 
detailed distribution of various sequence motifs across all overlapping nonamer 
units of the entire pathogen proteome to be revealed. Protein sequences were 
preferentially studied as this thesis is interested in mimicking the diversity 
relevant to the host immune system, especially events leading to potential 
immunogenicity at the immunological synapse. Further, mutations introduced 
into the viral genome will not necessarily be reflected as a corresponding change 
in the protein sequence due to the degeneracy of the viral codon. Nevertheless, 
the diversity observed at the protein nonamer level is significantly lower than 
that of corresponded nucleotide diversity which can be measured in units of 27 
nucleotides (nine amino acids). Thus, it might be of interest to conduct future 
works to elucidate the complete proteomic and genomic sequence variability 
spectrum of any viral pathogen, including HIV-1, though the translation of such 





Figure 8.1 | Systematic pipeline applied for the identification of highly 
conserved HIV-1 sequences for vaccine design.  
 
In this study, the global view of viral immune-relevant sequence diversity was 
obtained through the comprehensive proteomic nonamer entropy analysis. 
However, it was the comprehensive quantitative dissection of viral proteome 
diversity that elucidated the distinct dynamics of the depth (types of different 
sequences) and breadth (incidences of different sequences) of variants incidence 
where the extent immunological challenges at the immunological synapse by 
altered peptide ligands, especially at highly variable positions, can be 
appreciated. The aforementioned quantitative methodology was not only useful 
for the analysis of the highly diverse HIV-1 virus, but also useful in dissecting 
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the immune relevant sequence dynamics of a wide array of human RNA viral 
pathogens like the WNV, DENV, Influenza A virus and HCV which is reported 
in Chapter 4 . The results obtained from such quantitative analysis allowed the 
unique diversity landscape to be revealed and vaccine targets could be identified 
for further structural, functional and immunological studies. Moreover, the 
distinctive combinatorial profiles of the index nonamers, major variants, minor 
variants and unique variants across all nonamer positions could be used to 
construct a classification scheme, analogous to the “Hu Index” reported in 
Chapter 5, for pathogen diversity categorization. 
In general, sequence preservation is often closely related to structural and 
sequence conservation. However, it is intriguing how the hypervariable HIV-1 
is able to maintain its protein functions despite of its high sequence variability. 
Thus, a comprehensive structural, functional and sequence diversity analysis 
was carried out in this study to reveal plausible mechanisms relating protein 
sequence, structures and functions. Outcomes from the analysis indicate the 
general lack of strict correlation between sequence variability within protein 
functional regions and its structural localization but sites integral for protein 
function, like protein catalytic sites, were less likely to vary. Also, sequence 
variability could be potentiated by the presence of “redundant domains” where 
one domain was usually more conserved than the cognate domain within the 
same protein. Hence, insights obtained are likely to be important in determining 
the long term sequence stability of selected targets and can be used as selection 
criteria for vaccine design. In addition, future studies can be enhanced with 
protein dynamics considerations as it have been recently reported that protein 
dynamics play important roles in functional determination (Hensen et al., 2012).   
The combined sequence diversity, structural, functional and immunological 
analyses aided the identification of the 11 highly conserved HIV-1 sequences 
for vaccine formulation. Such sequences are assumed to be unlikely to vary in 
the future and will continue to be useful in vaccine formulations against a broad 
spectrum of pathogen variants, including existing and those yet to emerge as 
indicated by the (i) low peptide entropy they exhibited, (ii) structural and 
functional relevance to HIV-1 proteins and (iii) extensive conservation to the 
historical HXB2 sequences, the recent circulating C1P sequence and the 
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updated 2012 sequence dataset. The inclusion of fragments of highly conserved 
proteins in subunit vaccine formulations is a deviation of traditional HIV-1 
vaccine design approaches which mainly focused on the usage of one or more 
intact proteins of one or several HIV-1 strains (Buchbinder et al., 2008; 
Pitisuttithum et al., 2006; Rerks-Ngarm et al., 2009). This will allow enhanced 
immunological responses to be elicited against the wide repertoire of circulating 
virus and prevents erroneous targeting of primed immune response against less 
conserved regions, as seen in the Step and Phambili study (Buchbinder et al., 
2008; Cohen, 2007; Duerr et al., 2012; Gray et al., 2011; Li et al., 2011; 
McElrath et al., 2008). The generic nature of the pipeline makes it suitable for 
the large-scale study of a wide range of human pathogens for global pathogen 
vaccines and, also, for the detailed analysis of the complex host quasispecies 




The main contribution and findings of this thesis include: 
 
8.2.1 Novel methodology for the comprehensive dissection and 
quantification of RNA viral pathogen proteome diversity 
 
One of the key contributions of this work is the construction of the novel 
diversity analysis methodology that extensively studies the quantitative 
occurrences of different sequence motifs, including the most common index and 
its variants (Major variant, minor variants and unique variants). Also, the 
diversity depth, as analysed by the proportion of sequence nonatypes, was 
concertedly determined. Its use was not restricted only to the hypervariable 
HIV-1 but was demonstrated to be equally applicable for various viral 
pathogens like the conserved WNV, the moderately diverse DENV, Influenza 
A virus and the highly diverse HCV. The applicability to the various viruses 
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demonstrated the feasibility of the methodology to be used as a generic 
approach to study viral diversity prior to rational vaccine target selection in 
human RNA pathogens. Insights obtained from the distinct sequence dynamics 
elucidated from each pathogen allowed the quantification and identification of 
nonamer sites with low variability, if any, within viral proteomes. Such 
sequences could be further characterized for their corresponding functions, 
structural localization and immunogenicity prior to their inclusion in vaccine 
formulations.  
 
8.2.2 Dissection of the quantitative HIV-1 nonamer sequence diversity 
landscape 
 
The application of the novel quantitative methodology aided the elucidation of 
the immune-relevant diversity dynamics of the HIV-1 clade B proteome prior 
to vaccine target selection. The extreme range of HIV-1 variability, total 
variants incidence of 0% to more than 98%, demonstrates the complex interplay 
of different variants, namely the major, minor and unique variants with 
increasing mutations. Fortunately, the analysis provided information on the 
unevenness of the diversity landscape where about 9% of the proteome is highly 
conserved and can be targeted for further characterization before the rationally 





8.2.3 Pipeline for elucidation of vaccine targets in HIV-1 
 
An original systematic pipeline for the identification of HIV-1 vaccine targets 
was established. Beyond the application of the novel quantitative methodology 
to elucidate the detailed quantitative sequence dynamics HIV-1, this study is the 
first to comprehensively characterize protein functional, structural and 
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immunological signatures of HIV-1 immune-relevant sequence diversity. 
Insights obtained from such a comprehensive study had aided the construction 
of key selection criteria for candidate vaccine target selection. In general, 
vaccine targets are assumed to be (i) highly conserved and of low variants 
representation, (ii) immunogenic, (iii) contain functional and structural 
restraints to vary, (iv) non-cross reactive and unlikely to be non-immunogenic 
due to the lack of shared peptide identity with reported human proteins and, (v) 
evolutionarily stable for long term vaccine relevance. Generic suitability for 
application to human pathogens has been demonstrated, in part, in a number of 
human RNA pathogens and is expected to be useful to other human pathogens 
and within complex viral quasispecies.  
 
8.3 Future work 
 
This thesis has provided the foundation for some of future work listed below. 
 
8.3.1 Nonamer sequence, structural, functional and immunological 
dynamics of HIV-1 variants 
 
The work carried out in the thesis have elucidated the nonamer sequence, 
structural, functional and immunological dynamics of the HIV-1 clade B 
proteome, in particular the highly conserved regions.  An extension of the 
application of the current analysis to the mixed-variable and highly diverse 
regions could aid in the identification of distinguishing features and constrains, 
if any, that differentiates the highly conserved regions from the rest of the 
proteome of varying diversity. The identification of such discriminating criteria 
could provide new insights into the HIV-1 proteomes and further refine the set 
of criteria critical for candidate vaccine targets selection. 
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In addition, a complete structural, functional and immunological profiling of the 
heterogeneous pool of variants, one or more amino acid different from the index 
nonamer sequence, could be carried out and insights obtain will enrich the 
current understanding of the detailed HIV-1 sequence variants dynamics. 
 
8.3.2 Additional considerations for antigen presentation at the immune 
synapse 
 
This thesis focuses on the rational selection of vaccine targets by considering 
both the HIV-1 immune-relevant diversity and the host immune diversity. Viral 
diversity was mapped by overlapping nonamers throughout a large number of 
sequences covering the entire HIV-1 proteome while that of human immune 
diversity was focused primarily at that of the different HLA presentation 
molecules at the immune synapse. However, events leading to adaptive immune 
responses at the immunological synapses include the participation of the 
cognate TCR and future immunological analyses could be extended and 
strengthened with structural analysis between TCR and conserved sequence-
HLA complexes (Huang et al., 2010; Stewart-Jones et al., 2012). Also, the 
relationships between protein sequence, structure, protein dynamics and protein 
function can be additionally be qualified for conserved sequence for estimation 
of long term stability and conservation of sequence targets. 
 
8.3.3 Peptide sharing of HIV-1 index sequences and its variants 
 
Peptide sharing or molecular mimicry was briefly explored in Chapter 7 as 
criteria for the selection highly conserved peptides that were not identical to 
host proteins for the elimination of possible non-immunogenicity due to clonal 
deletion of immune cells that recognizes self-proteins and to prevent potential 
immunological cross reactivity of HIV-1 proteins and host proteins. Insights 
obtained from the preliminary analysis displayed a preview of the entire 
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possible peptide sharing repertoire, limited to exact nonamer matches of the 
highly conserved HIV-1 sequences and the human proteome. In order to obtain 
a comprehensive view on the overlap of the human proteome with that of HIV-
1, variants included, it is suggested an extension to include the comparisons with 
all possible host protein sequences, including those translated from the human 
genome. Such detailed analysis will elucidate potential casual relationships, if 
any, revolving around host peptide sharing patterns and potential T cell epitopes 
derived from HIV-1 index nonamer sequences and all of its variants. The 
mechanism of immunogenicity maintenance in totally different or lowly similar 
viral peptides, as exemplified by B-cell epitopes (Kanduc, 2009), needs to be 
validated for the generic applicability in T cell epitopes. Insights obtain from 
such large-scale studies will not only allow the establishment of simple 
correlations between viral peptides and immunogenicity, but also reveal more 
complex evolutionary relationships which potentially negates the Prigoginian 
model of evolution (Doolittle, 2005; Kanduc et al., 2008) and favours the 
Darwinian evolution where each organism adopts unique sequence architectures 
that are essential for survival in their milieu.  
 
8.3.4 Evolutionary dynamics predictability of future viruses 
 
The computational analysis of the large set of HIV-1 clade B protein sequences, 
from 1983 till 2008, the correspondence to historical HXB2 (Ratner et al., 1985) 
strain, a recent circulating C1P (Sahu et al., 2010) virus and that of the updated  
2012 sequence dataset have demonstrated the stability of the highly conserved 
peptides through the reported history of HIV-1 viruses. The preliminary pipeline 
established in this work is extensible for future HIV-1 analyses and, once 
sufficiently comprehensive and accurate, patterns of diversity obtained could be 
used as a model to predict the viral dynamics of progeny viruses and the long 
term evolutionary stability of candidate vaccine targets.  This will also aid in 
the continual development of the “Hu index” which could be better used to 




8.3.5 Computational characterization of targets for experimental and 
pre-clinical trials  
 
Immunogenicity correlation and molecular mimicry analyses to human, SIV 
and RM were carried out for the correspondence of possible immunogenicity 
and non-immunogenicity of candidate vaccine targets. The goal for such an 
analysis is to characterize targets that will favourable vaccine targets as they 
systematically avoid non-immunogenicity and cross reactivity with the human 
host and model organism proteins. Since most NHP models utilize SIV-infected 
macaques as a model, it is crucial to ensure that the sequences included in the 
vaccine constructs are SIV-like.  Finally, an extension to the current 
methodology to selectively include variant sequences within a mosaic vaccine 
(see Fischer et al., 2007 for the mosaic approach) could greatly enhance the 
breadth of the immunogenicity of a HIV-1 vaccine. 
 
8.3.6 Platform for automated analysis of RNA viruses, including 
sequence updates  
 
Long term stability of conserved sequences requires the study of immune-
relevant protein viral dynamics over extended period of time. In order to achieve 
that, it is proposed that future work could be focused on analysis automation. 
Regular updates from the sequence database could be automatically obtained 
from public databases at regular time intervals and semi-automated data 
filtering, clade classifications, conserved sequence incidences elucidation could 
also be incorporated. However, the elucidation of the quantitative viral 
dynamics at a disparate time point will still require the generation of protein 
alignments which at the moment still requires a large amount of manual editing 
and curation. A preliminary web resource has been built and is accessible online 
at http://hivresource.bic.nus.edu.sg/. Sequences analysed and the immune 
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relevant quantitative diversity analysis developed in this study are made 
available for public access. Continual development of this web resource is 
suggested to include more updated and curated HIV-1 sequences and also the 
inclusion of extra sequence analysis tools like Clustal W (Thompson et al., 
1994) for sequence alignment. 
 
8.4 Concluding Summary 
 
The success of the recent RV144 phase III clinical trial and numerous animal 
studies have injected hope to the development of a HIV-1 vaccine to prevent, 
control and even clear HIV-1 infections (Barouch et al., 2010; Hansen et al., 
2011; Hansen et al., 2013; Hansen et al., 2009; Rerks-Ngarm et al., 2009; Santra 
et al., 2008; Seaman et al., 2005). However, major limiting factors, namely the 
high viral sequence and host immune system diversity, needs to be 
systematically addressed prior to vaccine design. This thesis presents a novel 
methodological pipeline which deviates from the traditional reverse 
vaccinology approaches (Maione et al., 2005; Pizza et al., 2000; Rappuoli, 
2000; Rappuoli, 2001a; Rappuoli, 2001b; Rappuoli and Covacci, 2003; Sette 
and Rappuoli, 2010; Vernikos, 2008) as it adopts a novel immunoinformatics 
approach which begins with the fundamental quantitative analysis of the 
comprehensive HIV-1 nonamer diversity landscape. Viral sequence diversity 
with host immune relevance was examined in detail and the dissection of the 
HIV-1 sequence variability revealed punctures within the extreme diversity 
landscape as limited potential vaccine targets for the vaccine formulation. In-
depth characterization of additional functional, structural and immunological, 
including molecular mimicry analyses, constrains were carried out in this study 
for the rational identification of 11 highly conserved HIV-1 clade B sequences 
for future experimental validation. This quantitative methodology, together with 
the developed pipeline, is extensible for the application in other viral pathogens 
and could potentially serve as a novel platform for the comparison on the 
sequence diversity across different of viral pathogens.  Equally applicable is the 
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study of complex quasispecies within individual patients which is a huge step 
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Table S3.2 | Accession numbers of reference clade A, B, C and D protein sequences. 
 
Protein 
HIV-1 Clade Reference Accession GI numbers a 
Clade A Clade B Clade C Clade D 
Gag 112497801 114431075 114431155 37677884 37725248 29119256 1353861 2194184 55139337 2570308 326678 38491812
Pol 112497802 114431076 114431156 37677885 29119257 37725256 1353862 2194185 55139339 326679 38491811 2570314 
Vif 112497803 114431077 114431157 29119258 37677886 37725249 1353863 2194189 55139331 2570311 326680 38491813
Vpr 112497804 114431078 114431158 29119259 37677887 37725250 1353864 2194190 55139332 2570312 326681 38491814
Tat 112497805 114431079 114431159 29119263 37677888 37725251 1353865 2194191 55139333 2570316 326676 38491815
Rev 112497806 114431080 114431160 29119264 37677889 37725252 1353866 2194192 55139334 2570310 326677 38491816
Vpu 112497807 114431081 114431161 29119260 37677890 37725253 1353867 2194188 55139335 2570315 326682 38491817
Env 112497808 114431082 114431162 29119261 37677891 37725254 1353868 2194186 55139338 2570309 326683 38491818
Nef 112497809 114431083 114431163 29119262 37677892 37725255 1353869 2194187 55139336 2570313 326684 38491819






Figure S3.1 | Different formats of protein sequence alignments used in this 
study. Excerpts of different protein alignment formats used in this study, 
including the fas formatted HIV-1 protein sequence alignments (A), aln 
formatted Dengue Virus (DENV) protein alignments (B), afa formatted 
Influenza A protein sequence alignments (C), taln formatted West Nile Virus 
(WNV) protein sequence alignments and fasta formatted Hepatitis C Virus 

















Table S4.1 | Nonamer positions analysed in WNV, DENV, Influenza A 
and HCV virus ^. 
 
A WNV  
Protein Amino acids a Nonamer 
C 104 115
prM 497 493 
E 355 344 
NS1 220 223 
NS2a 131 123 
NS2b 619 611 
NS3 145 141 
NS4a 256 239 
NS4b 905 897 
NS5 167 159 
Total 3399 3345 
 
B DENV 
Protein Amino acids a Nonamer 
positions b 
C 110 106
prM 147 158 
E 495 487 
NS1 352 344 
NS2a 218 211 
NS2b 130 122 
NS3 619 603 
NS4a 135 142 
NS4b 245 241 
NS5 900 877 
Total 3351 3291 
 
C Influenza A 
Protein Amino acids a Nonamer 
positions b 
PB2 759 751
PB1 757 749 
PB1-F2 90 82 
PA 716 692 
HA 568 500 
NP 498 482 
NA 469 458 
M1 252 244 
M2 97 89 
NS1 230 229 
NS2 121 113 
Total 4557 4389





Protein Amino acids a Nonamer 
positions b 
Core 191 167
E1 192 176 
E2 363 300 
NS1/p7 63 55 
NS2 217 209 
NS3 631 599 
NS4a 54 46 
NS4b 261 245 
NS5a 448 368 
NS5b 591 568 
Total 3011 2733 
^Breakdown of the number of nonamer positions analysed for WNV (Table 
3.2A), DENV (Table 3.2B), Influenza A (Table 3.2C) and HCV (Table S3.2D). 
a Protein size with respect to viral reference sequences (Khan et al., 2008; Koo 
et al., 2009; Korber et al., 1998; Kuiken et al., 2006; Kuiken and Simmonds, 
2009; Ratner et al., 1987; Tan et al., 2010). The protein size of DENV is taken 
as an average of protein size of DENV1, 2, 3 and 4 reference sequences. b 
Number of nonamer positions analysed, each with more than 100 sequences. 
Difference between expected number nonamer positions, derived from the 
expected protein size, and nonamer positions analysed are due to the different 
lengths of the proteins, alignment gaps, and the removal of positions with low 





Figure S4.1 | Effect of mutation on overlapping nonamer sequences. A. The 
numbers represent amino acids of overlapping nonamer sequences. B. A change 
in one amino acid, for example from Q to H at position 9, will affect nine 










Figure S4.2 | Estimation of normalized entropy with Paninski’s bias 
correction. A sample protein alignment at nonamer position x is showed on the 
left. Repetitive random sampling of the protein alignment was carried out to 
obtain smaller alignments of varying size n. Peptides with the same sequence 
are coloured with the same colour. The entropy was calculated for each sample 
(from 1 to X) and plotted against the inverse of sample size extrapolation. Linear 
regression was carried out (purple dotted line) for the extrapolation of entropy 
values to an infinitely large number of peptides (i.e. 1/n  0) where the 










Figure S4.3 | Distribution of diversity motifs in the WNV proteome. A. 
Incidence of each of the motifs in relation to total variants incidence: index 
sequence (orange), total variants (black), major variant (red), minor variants 
(blue), unique variants (green), and nonatypes (purple). B. Violin plot of the 
frequency distribution of the indicated proteome sequence motifs. The width of 
the plot (x-axis) represents the frequency distribution of a given incidence of 





Figure S4.4 | Distribution of diversity motifs in the DENV proteome. A. 
Incidence of each of the motifs in relation to total variants incidence: index 
sequence (orange), total variants (black), major variant (red), minor variants 
(blue), unique variants (green), and nonatypes (purple). B. Violin plot of the 
frequency distribution of the indicated proteome sequence motifs. The width of 
the plot (x-axis) represents the frequency distribution of a given incidence of 






Figure S4.5 | Distribution of diversity motifs in the Influenza A virus 
proteome. A. Incidence of each of the motifs in relation to total variants 
incidence: index sequence (orange), total variants (black), major variant (blue), 
minor variants (blue), unique variants (green), and nonatypes (purple). B. Violin 
plot of the frequency distribution of the indicated proteome sequence motifs. 
The width of the plot (x-axis) represents the frequency distribution of a given 






Figure S4.6 | Distribution of diversity motifs in the HCV proteome. A. 
Incidence of each of the motifs in relation to total variants incidence: index 
sequence (orange), total variants (black), major variant (red), minor variants 
(blue), unique variants (green), and nonatypes (purple). B. Violin plot of the 
frequency distribution of the indicated proteome sequence motifs. The width of 
the plot (x-axis) represents the frequency distribution of a given incidence of 





Figure S4.7 | Predominance of WNV variant sequences. Fractions of the 
nonamer positions of the proteome and individual proteins that are highly 
conserved (blue, index incidence ≥ 90%), mixed-variable (white, index 
incidence < 90% & > 20%), and highly diverse (yellow, index incidence ≤ 
20%). Highly conserved positions accounts for more than 80% of total proteome 
nonamer positions, ranging from 59% for NS2a, to 92% for E. Mixed variable 






Figure S4.8 | Predominance of DENV variant sequences. Fractions of the 
nonamer positions of the proteome and individual proteins that are highly 
conserved (blue, index incidence ≥ 90%), mixed-variable (white, index 
incidence < 90% & > 20%), and highly diverse (yellow, index incidence ≤ 
20%). Highly conserved positions accounts for more than 80% of total proteome 
nonamer positions, ranging from 0% for C and prM, to 15% for E. Mixed 






Figure S4.9 | Predominance of Influenza A virus variant sequences. 
Fractions of the nonamer positions of the proteome and individual proteins that 
are highly conserved (blue, index incidence ≥ 90%), mixed-variable (white, 
index incidence < 90% & > 20%), and highly diverse (yellow, index incidence 
≤ 20%). Highly conserved positions accounts for more than 80% of total 
proteome nonamer positions, ranging from 0% for NS1, to 59% for PB1. Mixed 






Figure S4.10 | Predominance of HCV variant sequences. Fractions of the 
nonamer positions of the proteome and individual proteins that are highly 
conserved (blue, index incidence ≥ 90%), mixed-variable (white, index 
incidence < 90% & > 20%), and highly diverse (yellow, index incidence ≤ 
20%). Highly conserved positions accounts for less than 10% of total proteome 
nonamer positions, ranging from 0% for ns4a, to 35% for Core. Mixed variable 




















Table S5.1 | HIV-1 clade B sequences analysed. 
 
Protein Amino acids a Nonamer positions b Sequences (No.) c 
Gag 500 492 6,403 
Pol 947 762 30,604 
Vif 192 184 1,147 
Vpr 78  88 1,041 
Tat 86 93 1,569 
Rev 116 108 1,533 
Vpu 81 65 1,223 
Env 856 876 9,661 
Nef 206 206 4,871 
Proteome 3,062 2,874 58,052 
a Protein size with respect to clade HXB2 reference sequence (see Table S5.2).  
b Number of nonamer positions analysed, each with more than 100 sequences. Some 
proteins had more nonamer positions than the expected from the HXB2 protein size 
because of different lengths of the proteins and alignment gaps. Several of the proteins 
had fewer nonamer positions than expected from the HXB2 reference sequence. This 
is particularly true of Pol and is the result of removal of positions with low support 
(less than 100 sequences). 
c Retrieved from NCBI Entrez Protein Database. These included both full-length and 
a large number of partial sequences, which ranged in size from 17 to 912 amino acids. 
 
 
Table S5.2 | Accession numbers of consensus HXB2 and C1P sequences 
protein sequences.  
 
Protein HXB2 a C1P a 
Gag 120845 293573191 
Pol 77416881 293573192 
Vif 62291046 293573193 
Vpr 62291049 293573194 
Tat 6094428 293573195 
Rev 132438 293573196 
Vpu 139440 293573197 
Env 6015102 293573198 
Nef 288558856 293573199 




Table S5.3 | Correspondence of concatenated index with HXB2 and C1P sequences ^*. A. Amino acid (aa) level comparisons. B. 
Nonamer level comparisons.  
 
A 
 Protein # HXB2 & Index aa 
identical 
# C1P & Index aa 
Identical 
# HXB2 & C1P aa 
Identical 
# HXB2, C1P & Index aa 
Identical 
[%] 
Gag 91 88 91 87 
Pol 98 94 72 92 
Vif 93 89 72 85 
Vpr 73 91 75 70 
Tat 80 89 86 77 
Rev 89 84 71 73 
Vpu 84 86 87 81 
Env 82 79 80 74 
Nef 82 85 81 77 















Protein # HXB2 & Index 
Nonamers identical 
# C1P & Index 
Nonamers Identical 
# HXB2 & C1P 
Nonamers Identical 
# HXB2, C1P & Index Nonamers 
Identical 
[%] 
Gag 77 62 58 55 
Pol 85 60 56 56 
Vif 58 34 25 25 
Vpr 52 58 35 35 
Tat 48 48 37 30 
Rev 56 36 31 24 
Vpu 28 43 11 11 
Env 47 37 31 27 
Nef 17 42 21 15 
Proteome 61 49 41 38 
^ All comparisons in these analyses contained more than 100 sequences. 



























Figure S5.1 | Proteome-wide comparison of concatenated index sequences 
of each HIV-1 clade B proteins with the corresponding HXB2 (blue) and 
C1P (green) sequences. The numbers before and after the concatenated index 
sequence represent amino acid positions of the comparison; the comparison is 
shown in blocks of 60 amino acids. Identical amino acids between the 
comparisons are represented by “.”; those that differ are shown by the respective 
amino acids. Amino acid mutations of the aligned viruses that did not follow 
the concatenation of the index are shown in orange. The corresponding amino 
acids of HXB2 and C1P sequences are also shown at these positions, but without 
representing identical amino acids by “.”. The blue and green dashes represent 

























Figure S6.1 | Example of alignment anchors that aided reliable alignment 
of the functional domain sequence with the 3D structure sequence. The 
sequence region depicts the domain within HIV-1 Nef protein that interacts with 
the V-type proton ATPase subunit H. Residues that are identical are showed in 
red and are used as anchors for aligning the domain (obtained from Swiss-Prot 





Figure S6.2 | Comparison of HIV-1 clade B Vpr concatenated index 
nonamer with PDB 3D structure sequence (accession number: 1M8L). A. 
The first four (1 to 4) and last four (93 to 96) amino acids of 1M8L matching to 
the index sequences (boxed in red) were assigned the incidence of the index 
nonamer position 1-9, centred at position 5(underlined and bold), and the index 
nonamer of position 88 to 96, centred at position 92 (underlined and bold), 
respectively.  B. An example to illustrate the convention of assignment of 
incidence on 3D structure. Each amino acid matched in the 3D structure was 
considered as the centre of the nonamer x, alignment positions x-4 to x+4, 
matched in the clade B protein alignment and was assigned with the index 
nonamer incidence of the nonamer x by convention. Thus, amino acid 
5(underlined and bold) in 1M8L is assigned with index incidence of nonamer 1 
to 9 (enclosed in purple box) in the concatenated index, amino acid 6 in 1M8L 
is assigned with index incidence of nonamer 2 to 10 in the concatenated index 
and amino acid 7 in 1M8L is assigned with index incidence of nonamer 3 to 11 
in the clade B protein alignment. “… … …” denotes the truncation of the full 









Figure S7.1 | Functional and immunological maps of the highly conserved 
HIV-1 sequences. Highly conserved 2008 HIV-1clade B sequences, highly 
conserved HIV-1 2012 clade B sequences (underlined) and highly conserved 
2012 pan-clade sequences (in bold-faced) were labelled.  Sequences that were 
matched to class I and/or class II HLA epitopes were indicated by black and 
green arrows respectively. Individual proteins within the Gag, Pol and Env 
polyproteins were stated. Domains were enclosed in coloured rectangles. For 
example, the trimerization domain within the Gag 35-45 conserved sequence 




















Table S7.1 | Epitope matched to highly conserved HIV-1 sequences.  
Protein Position a Sequence b Epitopes c 
HIVDB record number d 
CTL Thelper 
Gag 35-45 VWASRELERFA A*0205 ,A*3001 ,A*3002 ,A*6801 ,B*3501 
,B*4201 ,B*5301 ,B*5701 ,B*570301 ,Cw*0401 
,Cw*0602 ,Cw*1701 ,Cw*1801 ,DQB1*0301 
,DQB1*0601 ,DRB*0101 ,DRB1*0401 
,DRB1*0405 ,DRB1*0701 ,DRB1*1302 
,DRB1*1303 ,DRB1*1501,DRB1*1502 
,DRB3*0101 ,DRB5*0102  
56678 ,53056 
,53958 ,57478 
,55, 1200 ,57868 
201066 ,201065 
,201008 
 154-164 SPRTLNAWVKV B*0702 147  
 166-178 EEKAFSPEVIPMF A*0201 ,A*0205 ,A*2601 ,A*300101 ,A*3002 
,A*3402 ,A*680101 ,A*7401 ,A*8001,B*0705 
,B*0801 ,B*080101 ,B*4415 ,B*4501 ,B*4801 
,B*5701 ,B*5703 ,B*5801 ,B*5802 ,Cw*0302 
,Cw*0701 ,Cw*0702 ,Cw*1601 ,DRB1*0101 
,DRB1*0401 ,DRB1*0405 ,DRB1*0701 





,162 ,163 ,52082 
,52086 ,52760 






















A*2902 ,A*3001 ,A*3303 ,A*3402 ,A*6801 
,A*7401 ,B*0702 ,B*0801 ,B*1402 
,B*1510,B*3901 ,B*3910 ,B*4001 ,B*4201 
,B*4403 ,B*5301 ,B*5802 ,B*8101 ,Cw*0401 
,Cw*0802 ,DRB*0101 ,DRB1*0401 ,DRB1*1302 
,DRB1*1503  
178 ,53232 ,180 



















 210-220 TINEEAAEWDR A*0201 ,A*2501 ,A*3002 ,A*6801 ,B*0702 
,B*1801,B*1801 ,B*5101 ,B*5301 ,Cw*0102 
,Cw*1203 ,DRB1*0101 ,DRB1*0405 
53969 ,209 ,210 







,DRB1*0701 ,DRB1*1302 ,DRB1*1501 
,DRB1*1503 
 235-247 REPRGSDIAGTTS DQB1*0301 ,DQB1*0601 ,DRB1*0301 
,DRB1*0401 ,DRB1*1303 ,DRB1*1502 
,DRB3*0101 ,DRB5*0102 
 201121 ,201068 
 275-285 GLNKIVRMYSP A*0201 ,A*0205 ,A*1103 ,A*2402 ,A*3001 
,A*6801 ,B*1402 ,B*1501 ,B*4201,B*4201 
,B*5301 ,B*5701 ,B*5802 ,B7 supertype 
,Cw*0401 ,Cw*0602 ,Cw*0802 ,Cw*1701 
,Cw*1801 ,DPA1*0201 ,DPB1*0101 ,DPB1*1301 
,DQB1*0301 ,DQB1*0601 ,DQB1*0602 
,DQB1*0604 ,DR supermotif ,DRB*0101 
,DRB1*0101 ,DRB1*0301 ,DRB1*0401 
,DRB1*0405 ,DRB1*0503 ,DRB1*0701 
,DRB1*1101 ,DRB1*1301 ,DRB1*1302 
,DRB1*1303 ,DRB1*1501 ,DRB1*1502 
,DRB1*1601,DRB3*0101 ,DRB3*0301 
,DRB5*0101,DRB5*0101 ,DRB5*0102  














 293-306 QGPKEPFRDYVDRF B*440301 ,DPA1*0103 ,DPA1*0201 
,DPB1*0101 ,DPB1*1301 ,DRB1*0101 
,DRB1*0301 ,DRB1*0401,DRB1*0405 
,DRB1*0701,DRB1*0701 ,DRB1*1301 







 349-362 LEEMMTACQGVGGP    





Pol 57-65 PQITLWQRP    
 77-88 EALLDTGADDTV    
 150-174 GCTLNFPISPIETV
PVKLKPGMDGP 
A*0201 ,A*0206 ,A*4301 ,A2 supertype ,B*3910 







 176-189 VKQWPLTEEKIKAL B*4202 53991  
 204-214 KIGPENPYNTP    
 239-254 TQDFWEVQLGIPHP
AG 
A*6801 53993  
 260-272 SVTVLDVGDAYFS A*0201 ,A*0201 ,A*0201 ,A*0301 ,A*2402 
,B*0702 ,B*3501 ,B*3503 ,Cw*0303 






 279-289 FRKYTAFTIPS DR supermotif  400 ,200937 
 298-316 RYQYNVLPQGWKGS
PAIFQ 
A*1101 ,B*1501 ,B*3910 ,B*4403 ,B*5101 






   
 406-426 SWTVNDIQKLVGKL
NWASQIY 
A*0205 ,A*0201 ,A2 supertype ,B*1501 ,A*3002 54006 ,56187 
,56508 ,1598 
,491 ,1196 ,1762 
,53329 ,54007 
 
 453-465 EAELELAENREIL B*3503 ,Cw*0401 ,Cw*0702 ,Cw*0202 53424 ,54009  
 766-786 HGQVDCSPGIWQLD
CTHLEGK 





A*0207 ,A*3101 ,B*4002 ,B*4601 ,A*6802 
,Cw*0102 ,Cw*0304 ,B*4403 ,DRB1*0101 
,DRB1*0401 ,DRB1*0405 ,DRB1*0701 





 817-825 LKLAGRWPV A*0301 53941  
 852-867 QEFGIPYNPQSQGV
VE 
A*0202 ,A*1101 ,A*2403 ,A*2901 ,A*6801 
,B*0702 ,B*1503 ,B*1518 ,B*3503 ,B*3801 
,B*5301 ,B*5801 ,B7 supertype, Cw*0210 








A*0201 ,A*0205 ,A*0301,A*2402 ,A*2601 ,A3 
supertype ,B*0705 ,B*1402 ,B*3901 ,B*5701 
,B*5801 ,B*5801 ,Cw*0701 ,Cw*0702 ,Cw*0802 

















   
Vif 1-18 MENRWQVMIVWQVD
RMRI 
DRB*0101  201235 
 142-150 VGSLQYLAL    
Rev 33-46 GTRQARRNRRRRWR - -  
Vpu 49-57 RAEDSGNES A*2301 ,A*2902 ,B*4101 ,B*4201 ,Cw*1701 56262  
Env 34-45 WVTVYYGVPVWK A*0101 ,A*0201 ,A*0301 ,A*2902 ,A*3001 
,A*3201 ,A*4301 ,A*6601 ,A*6801 ,A*6802 







a Start and end position in the 2008 protein alignment (Hu et al., 2013). b Highly conserved 2008 sequences of 9 or more amino acids, each with nonamer 
index sequence incidence of 90% or more. Amino acids that are underlined are highly  conserved in 2012 clade B protein sequences and that in bold is 
conserved in 2012 clades A, B, C and D. c Allele information extracted for epitope records downloaded from the HIV Molecular Immunology Database 
(http://www.hiv.lanl.gov/content/immunology/). Records with no detailed allele, supertype and supermotif information were excluded. d CTL and Thelper 
record number from the HIV Molecular Immunology Database (http://www.hiv.lanl.gov/content/immunology/). 
 
 
,B*1801 ,B*3501 ,B*3503 ,B*4201 ,B*4504 
,B*4901 ,B*5301 ,B*5703 ,B*5801 ,B*8101 
,Cw*0202 ,Cw*0304 ,Cw*0401 ,Cw*0701 
,Cw*0702 ,Cw*1203 ,Cw*1601 ,Cw*1701 
,Cw*1801  
,58516 ,53812 
,56581 ,631 ,633 











 66-76 NVWATHACVPT    
 264-273 VSTVQCTHGI    
 275-289 PVVSTQLLLNGSLA
E 
   
 505-517 DNWRSELYKYKVV    
 555-563 AGSTMGAAS DRB*0101  201242 
 595-608 LQLTVWGIKQLQAR    
Nef 80-88 PQVPLRPMT A*0201 ,B*1503 ,B*3501 ,B*3501 ,B7 supertype 
,DRB*0101 







Table S7.2 | Functional, immunological and structural profiles highly conserved HIV-1 sequences. 
 
Protein Position a Sequence b Functional region c HLA d 
Molecular 
Mimicry e Structure f 
Gag 35-45 VWASRELERFA - I & II H-,SIV+,RM- E 
 154-164 SPRTLNAWVKV - I H-,SIV+,RM- E 
 166-178 EEKAFSPEVIPMF - I & II H-,SIV+,RM- E 
 180-208 ALSEGATPQDLNTMLNTVGGHQAAMQMLK - I & II H-,SIV+,RM- E 
 210-220 TINEEAAEWDR - I & II H-,SIV+,RM- E 
 237-247 PRGSDIAGTTS - II H-,SIV+,RM- E 
 275-285 GLNKIVRMYSP - I & II H-,SIV+,RM- E 
 293-306 QGPKEPFRDYVDRF Major Homology domain I & II H-,SIV+,RM+ E 
 349-362 LEEMMTACQGVGGP - - H-,SIV+,RM- E 
 439-447 NFLGKIWPS - II H-,SIV-,RM- N.D. 
Pol 57-65 PQITLWQRP - - H-,SIV+,RM- E 
 77-88 EALLDTGADDTV Peptidase Catalytic Triad - H-,SIV+,RM- B 
 150-174 GCTLNFPISPIETVPVKLKPGMDGP Peptidase and RT Domain I H-,SIV+,RM- E 
 176-189 VKQWPLTEEKIKAL RT Domain I H-,SIV+,RM- B+E 
 204-214 KIGPENPYNTP RT Domain - H-,SIV+,RM- B 
 239-254 TQDFWEVQLGIPHPAG RT Domain I H-,SIV+,RM- B 
 260-272 SVTVLDVGDAYFS RT Domain - Catalytic Triad "D" residue 
I H-,SIV+,RM- B 
 279-289 FRKYTAFTIPS RT Domain II H-,SIV+,RM- B 
 298-316 RYQYNVLPQGWKGSPAIFQ RT Domain I H-,SIV+,RM- B 
 384-399 WMGYELHPDKWTVQPI - - H-,SIV+,RM- B+E 
 406-426 SWTVNDIQKLVGKLNWASQIY - I H-,SIV+,RM- B+E 
 453-465 EAELELAENREIL - I H-,SIV+,RM+ E 
 766-786 HGQVDCSPGIWQLDCTHLEGK Integrase Catalytic domain - H-,SIV+,RM- N.D. 
 790-815 VAVHVASGYIEAEVIPAETGQETAYF Integrase Catalytic domain I & II H-,SIV+,RM- N.D. 
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 817-825 LKLAGRWPV Integrase Catalytic domain I H-,SIV+,RM- N.D. 
 852-867 QEFGIPYNPQSQGVVE 
Integrase DNA binding domain 
- Conserved Acidic residues 
interacting with DNA 
I 
H-,SIV+,RM- N.D. 
 879-907 QVRDQAEHLKTAVQMAVFIHNFKRKGGIG 
Integrase DNA binding domain 
- Conserved Acidic residues 
interacting with DNA 
I & II 
H-,SIV+,RM- N.D. 
 950-969 WKGPAKLLWKGEGAVVIQDN Integrase DNA binding domain - Conserved Lysine residues 
I H-,SIV+,RM- N.D. 
 981-997 KIIRDYGKQMAGDDCVA Integrase DNA binding domain - Conserved Lysine residues 
- H-,SIV+,RM- N.D. 
Vif 1-18 MENRWQVMIVWQVDRMRI - I H-,SIV-,RM-  
 142-150 VGSLQYLAL BC-Box like motif - H-,SIV+,RM- N.D. 
Rev 33-46 GTRQARRNRRRRWR Nuclear localization and RRE binding 
- H-,SIV-,RM- E 
Vpu 49-57 RAEDSGNES - I H-,SIV+,RM- N.D. 
Env 34-45 WVTVYYGVPVWK - I H-,SIV+,RM- N.D. 
 49-58 TTLFCASDAK - I H-,SIV+,RM- N.D. 
 66-76 NVWATHACVPT - - H-,SIV+,RM- N.D. 
 264-273 VSTVQCTHGI - - H-,SIV-,RM- E 
 275-289 PVVSTQLLLNGSLAE - - H-,SIV+,RM- B 
 505-517 DNWRSELYKYKVV - - H-,SIV+,RM- B 
 555-563 AGSTMGAAS - - H-,SIV+,RM- N.D. 
 595-608 LQLTVWGIKQLQAR Part of Immunosuppression II H-,SIV+,RM- E 
Nef 80-88 PQVPLRPMT SH3-like binding domain I & II H-,SIV+,RM- E 
a  Start and end position of 2008 protein alignments. (Hu et al., 2013)  
b Concatenated 2012 clade B nonamer sequences, each conserved in 80% or more of all nonamer positions with more than 100 sequences. 
c Correspondence of highly conserved sequences, nonamer or longer, to their reported protein functions. 
d Correspondence of highly conserved sequences, nonamer or longer, to reported HLA class I and/or II epitopes. 
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e Correspondence of highly conserved sequences, nonamer or longer, to human (H), SIV (SIV) and Rhesus macaques (RM) sequences. The combination 
of “+” or “-” symbol next to the alphabet denotes the presence or absence, respectively, of highly conserved sequences in Humans, SIV and RM 
respectively. For example, the order of “H-,SIV+,RM-“ denoted that the highly conserved sequence is absent in human protein sequences, present in SIV 
protein sequences and absent in Rhesus macaques protein sequences.  
f Correspondence of highly conserved sequences, nonamer or longer, to protein structures ( see Chapter 6). “B” denotes the sequences are buried within 
the 3D structure, “E” denotes sequences that are exposed on the 3D surface of the protein, “B+E” denotes the sequences being partially buried or being 
buried in a multimer complex and “N.D.” is not determined as the full structure of the protein is not available.
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The rapid mutation of human immunodeficiency virus-type 1 (HIV-1) and the limited characterization of the composition
and incidence of the variant population are major obstacles to the development of an effective HIV-1 vaccine. This issue was
addressed by a comprehensive analysis of over 58,000 clade B HIV-1 protein sequences reported over at least 26 years. The
sequences were aligned and the 2,874 overlapping nonamer amino acid positions of the viral proteome, each a possible
core binding domain for human leukocyte antigen molecules and T-cell receptors, were quantitatively analyzed for four
patterns of sequence motifs: (1) ‘‘index’’, the most prevalent sequence; (2) ‘‘major’’ variant, the most common variant
sequence; (3) ‘‘minor’’ variants, multiple different sequences, each with an incidence less than that of the major variant; and
(4) ‘‘unique’’ variants, each observed only once in the alignment. The collective incidence of the major, minor, and unique
variants at each nonamer position represented the total variant population for the position. Positions with more than 50%
total variants contained correspondingly reduced incidences of index and major variant sequences and increased minor and
unique variants. Highly diverse positions, with 80 to 98% variant nonamer sequences, were present in each protein,
including 5% of Gag, and 27% of Env and Nef, each. The multitude of different variant nonamer sequences (i.e. nonatypes;
up to 68%) at the highly diverse positions, represented by the major, multiple minor, and multiple unique variants likely
supported variants function both in immune escape and as altered peptide ligands with deleterious T-cell responses. The
patterns of mutational change were consistent with the sequences of individual HXB2 and C1P viruses and can be
considered applicable to all HIV-1 viruses. This characterization of HIV-1 protein mutation provides a foundation for the
design of peptide-based vaccines and therapeutics.
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Introduction
The quasispecies replication of RNA viruses has been recog-
nized for over 30 years following the initial observation of the high
proportion of mutants in a growing population of bacteriophage
Qb [1]. HIV-1 is now a classic example of this model of rapid
genome evolution [2–6]. As a result of high rates of genetic
mutation [7] and recombination [8], cell infection by HIV-1 is
followed by immune escape of viruses with related and highly
diverse genotypes [9,10]. Even a single founder virus, when
introduced into cells, is quickly transformed into a quasispecies
assortment of progeny viruses [11–13]. Given the vast array of
different genotypes generated in every replication cycle, the
challenge of designing a vaccine that would prevent the immune
escape of the mutant progeny of infected cells is widely recognized
[14–17]. A continuing goal is a greater understanding of HIV-1
diversity and an effective strategy to overcome this diversity.
Towards this end, there is a need for more detailed and
quantitative analysis of the extent of HIV-1 mutational changes,
including the composition and incidence of the different variants
of the viral proteome.
Herein, we describe a large-scale analysis of the diversity of
HIV-1 sequences reported over at least 26 years. Clade B was
selected for the developmental studies as it had the largest number
of recorded HIV-1 sequences. Over 58,000 clade B sequences,
both partial- and full-length and distributed among the nine
proteins, were aligned, with over 1,000 sequences at most
nonamer positions (Table S1). As the immune-relevance of the
sequences was a primary focus of the study, the analysis was
conducted with 2,874 nonamer positions, overlapping eight
residues (1–9, 2–10, etc.), where each nonamer at the positions is
a potential viral human leukocyte antigen (HLA) binding core [18]
and T-cell receptor (TCR) ligand [19]. As expected, there were
major differences in the fractions of variant nonamer sequences of
the proteins, with more conserved positions in Gag and Pol, and
greater diversity in Env and Nef. However, despite the differences
in the structure and function of the proteins, or the extent of their
genomic diversity, the viral proteins shared characteristic patterns
of change in the incidence of index, major, minor, and unique
nonamer motifs with increased mutation. This quantitative
characterization of the mutational changes of the clade B
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proteome provides data that are applicable to the design of
vaccines and therapeutics that are least impacted by the diversity
of the viral proteins. HIV-infected individuals, ‘‘elite controllers’’,
who maintain low levels of plasma virus [20–22], as well as animal
model experiments [23–27] suggest that vaccines that generate
CD8+ T cells, even against only a few epitopes, can result in a
long-term control of virus proliferation. We suggest that an
effective immune response to HIV-1 in humans might be possible
with a vaccine comprised solely of the limited set of highly
conserved protein sequences, as described herein, that may
provide memory responses not compromised by immune escape
or the presence of competing altered peptide ligands.
Materials and Methods
Data Preparation, Selection and Alignment of HIV-1
Clade B Proteome
HIV-1 protein sequence records were retrieved from the NCBI
Entrez Protein Database [28] in August 2008 by searching the
NCBI taxonomy browser for HIV-1 (Taxonomy ID 11676). HIV-
1 clade B records were extracted from the collected data by use of
BLAST [29–32] searches (version 2.2.18; parameters: low
complexity filter – off, expect –10, descriptions and alignments –
100,000), using the HIV-1 clade B protein reference sequences
from the Los Alamos HIV sequence database (www.hiv.lanl.gov)
as queries (Table S2). Cutoff for the classification of each clade B
protein was determined by manual inspection of the BLAST
output. Possible misclassification of non-clade B HIV-1 sequences
as clade B was not apparent as the patterns of motif change were
similar for each protein, particularly for Gag, Pol, and Env
proteins that form the major basis of phylogenetic relationships
[33,34]. Additonal phylogenetic study for classification of the
sequences as clade B was not practical given the high viral
diversity, large number of sequences analysed, and the difficulty/
subjectivity in the interpretation of the phylogenetic tree due to
likely low bootstrap values. Duplicate sequences of each protein
were removed to minimize bias that may result from collection of
redundant protein sequences derived from identical HIV-1
isolates. Highly similar sequences were retained because arbitrary
removal of such sequences would introduce additional bias.
Further selection of one sequence per subject was deemed
unnecessary as it would not give a true representation of the
HIV-1 viral diversity as a complex quasispecies of genetically
related but distinct sequences in individual subjects. Thus, all non-
redundant sequences, both full-length and partial, were aligned
and analyzed. Partial sequences were included in the alignment
because they provided additional data for the study of diversity.
Multiple sequence alignment was difficult for some of the proteins
because of the large number of diverse and partial sequences, and
thus different approaches were explored. Sequence alignments of
Vif, Vpr and Vpu were performed with PROMALS3D [35]. The
large sequence datasets of Gag, Pol, Tat, Rev, Env, and Nef were
first split into smaller and more manageable groups (about 200–
500 sequences per group). These smaller groups were aligned by
use of PROMALS3D or CLUSTAL W [35,36] and refined by use
of RASCAL [37]. They were then merged into full protein
multiple sequence alignment, with conserved sites as anchors to
facilitate reliable alignment of the highly diverse positions (Figure
S1). All multiple sequence alignments were manually inspected
and corrected for misalignments. Variation in the number of
collected sequences between adjacent positions of the alignment
resulted from the inclusion of partial sequences. Alignment
positions with high fractions, 95% or more, of gaps (insertions or
deletions) were removed in order to minimize alignment errors.
Because of its great diversity, only 9,661 of the 29,211 extracted
Env protein sequences were successfully aligned and analyzed.
The selection of these Env sequences was semi-selective, however,
the large number of sequences aligned and analyzed help to
reduce sampling bias.
A caveat is the unknown history of the many recorded viral
sequences; for example, the source of the virus, infection history,
possible treatment, or details of cultivation. In addition, the quality
of the sequences from the database is also unproven. Nevertheless,
it is unlikely that analysis of another population of HIV-1 would
differ significantly from the data herein. This assertion is supported
by the sequences of individual infectious clade B viruses, HXB2
[38] and C1P [39], that have nonamer position patterns of
conservation and variability consistent to those of the historically
recorded viruses.
Nonamer Sequence Analysis Approach
HIV-1 clade B sequence alignment diversity was based on a
sliding window approach of size nine, overlapping eight amino
acids (1–9, 2–10, 3–11, etc.) that captured the entire nonamer
repertoire of the proteome [40,41]. Nonamer sequences represent
the possible core HLA and TCR binding domains, and provide a
defined examination of the protein diversity in relation to cellular
immunity. It can be assumed that each nonamer is a potential T-
cell epitope because of the large array of HLAs with different
binding specificities in the human population (HLA Informatics
Group [http://www.anthonynolan.org.uk/HIG]) and given that
an average of 0.1–5% of overlapping nonamers spanning a protein
will bind to a particular HLA molecule [42]. Moreover, in this
context, the potential immune relevance of a mutation is greatly
Figure 1. Definitions of HIV-1 clade B nonamer sequence
motifs. The different sequence motifs of the aligned HIV-1 clade B
isolates were identified as shown with 20 sequences of a model
nonamer position. The ‘‘Index’’ nonamer is the most prevalent
sequence, present in 8 of the 20 isolates. The ‘‘Major’’ variant is the
most common variant of the index (5/20). ‘‘Minor’’ variants are multiple
different repeated sequences, each with incidences less than that or
occasionally equal of the major variant. ‘‘Unique’’ variants are those
represented by a single aligned sequence. ‘‘Nonatypes’’ (boxed) are the
distinct variant sequences at a given nonamer position; in this example
one of major, two of minor, and three of unique.
doi:10.1371/journal.pone.0059994.g001
HIV-1 Clade B Variant Population Characterization
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Figure 2. HIV-1 clade B proteome nonamer sequence entropy and total variants. A. Entropy (in black) and incidence of the total variants of
the index (in red) was measured for each aligned nonamer (nine amino acids) position (1–9, 2–10, etc.) of the proteins. The entropy values indicate
the level of variability at the corresponding nonamer positions, with zero representing completely conserved sites (0% total variants incidence), with
a maximum of about 9 at the extremely variant sites (,98% total variants incidence). B. Relationship of entropy and the incidence of total variants for
the proteome nonamer positions.
doi:10.1371/journal.pone.0059994.g002
HIV-1 Clade B Variant Population Characterization
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e59994
expanded whereby a single amino acid substitution affects nine
overlapping nonamers spanning a region of 17 amino acids, except
mutations occurring in the first and last eight amino acids of the
protein termini (Figure S2). These features of immune-relevant
diversity would not be captured by variability analysis of sequence
alignments with a sliding window of size one (single amino acid
approach). Further, mutational entropy is completely different
between these two approaches, with a maximum entropy of 39 for
nonamer approach versus 4.2 for single amino acid approach.
Shannon’s Nonamer Entropy and Quantitative Analyses
of Diversity Motifs
Shannon’s nonamer entropy [31,43,44] was used as a general
measure of HIV-1 protein sequence diversity. Each nonamer
position in the protein alignments was quantitatively analysed for
the incidence (% occurrence) of the different sequences present at
the position, with arbitrary sorting for equal incidences (Figure 1).
The first ranked sequence of each position was defined as the
index, while the remaining ranked sequences with at least one
amino acid difference from the index were defined as variants and
Table 1. A sample of the quantitative analysis of HIV-1 clade B Env protein diversity‘.
Aligned nonamers H(x)c Index
d Variantse Nonatypesi HXB2
j C1Pk
Positiona No.b Sequence [%] Total Majorf Minorg Uniqueh Sequence [%] Sequence [%]
[%]
& 114–122 1032 1.0 SLKPCVKLT 86 14 6 7 1 2 ......... 86 ......... 86
& 115–123 1034 1.0 LKPCVKLTP 86 14 6 7 1 2 ......... 86 ......... 86
& 116–124 1066 1.1 KPCVKLTPL 85 15 6 8 2 3 ......... 85 ......... 85
& 117–125 1517 0.8 PCVKLTPLC 89 11 4 6 1 2 ......... 89 ......... 89
& 118–126 1568 0.8 CVKLTPLCV 89 11 5 5 1 2 ......... 89 ......... 89
& 119–127 1594 1.1 VKLTPLCVT 86 14 5 7 1 2 ........S 1 ......... 86
& 120–128 2665 1.0 KLTPLCVTL 88 12 4 7 1 2 .......S. 1 ......... 88
& 121–129 2670 1.7 LTPLCVTLN 76 24 5 17 1 2 ......S.K ,1 ......... 76
& 122–130 3112 1.9 TPLCVTLNC 74 26 5 20 1 2 .....S.K. 1 ......... 74
& 123–131 3326 2.6 PLCVTLNCT 66 34 4 28 2 4 ....S.K.. 1 ........I 2
& 124–132 3368 4.1 LCVTLNCTD 44 56 13 40 3 6 ...S.K... 1 .......I. 1
+ 125–133 3673 6.2 CVTLNCTDN 12 88 10 72 6 11 ..S.K...L 1 ......I.V ,1
+ 126–134 3675 7.4 VTLNCTDNW 10 90 3 79 8 15 .S.K...LK 1 .....I.VN ,1
+ 127–135 3677 7.8 TLNCTDNWN 9 91 3 78 9 19 S.K...LK. 1 ....I.VNI 0
+ 128–136 3719 8.3 LNCTDNWNN 6 94 2 81 11 22 .K...LK.D 1 ...I.VNIT 0
+ 129–137 3725 8.3 NCTDNWNNT 6 94 2 79 12 24 K...LK.D. ,1 ..I.VNITN 0
+ 130–138 3912 8.6 CTDNWNNTG 6 94 2 79 13 25 ...LK.D.N 1 .I.VNITNT 0
+ 131–139 3917 8.7 TDNWNNTGN 5 95 2 79 14 27 ..LK.D.NT 1 I.VNITNT. 0
+ 132–140 3911 8.9 DNWNNTGNV 5 95 2 78 15 28 .LK.D.NTN ,1 .VNITNT.S 0
+ 133–141 3863 8.8 NWNNTGNVS 5 95 2 77 16 29 LK.D.NTN. ,1 VNITNT.ST 0
+ 134–142 3838 9.0 WNNTGNVSD 5 95 2 77 16 30 K.D.NTN.S ,1 NITNT.STN 0
+ 135–143 3807 9.0 NNTGNVSDS 5 95 2 76 17 31 .D.NTN.S. 1 ITNT.STNP 0
+ 136–144 3747 9.0 NTGNVSDSS 5 95 2 76 18 32 D.NTN.S.G 1 TNT.STNPT 0
+ 137–145 3701 9.1 TGNVSDSSW 5 95 2 75 18 32 .NTN.S.GR 1 NT.STNPTS 0
+ 138–146 3473 8.9 GNVSDSSWK 4 96 1 76 19 34 NTN.S.GRM 1 T.STNPTSS 0
+ 139–147 3090 9.2 TSVNSNSSG 2 98 1 78 19 35 .NSS.GRMI 1 N.T.PT..W 0
‘All percentages are shown to the nearest whole number.
aAmino acid number at the start and end of the nonamer position in the protein alignment. The symbols & and+denote the mixed-variable and highly diverse nonamer
positions, respectively (see Figure 3 for definitions).
bTotal number of protein sequences analysed at the respective nonamer position; the differences between nonamer positions was due to the inclusion of both partial
and full-length sequences in the alignments.
cShannon nonamer entropy (H(x); see Figure 2 for details).
dThe index nonamer is the most prevalent sequence at the given aligned nonamer position.
eVariants differ by one or more amino acids from the index sequence.
fThe major variant is the most common variant sequence at the position.
gMinor variants are multiple different repeated sequences, each occurring more than once and with an incidence less than or occasionally equal to the major.
hUnique variants are those that occur only once in the alignment.
iNonatypes are the distinct sequences among the variants.
jHXB2 nonamer sequence and its incidence at the given nonamer position; amino acids identical to the index are denoted as ‘‘.’’.
kC1P nonamer sequence and its incidence at the given nonamer position; amino acids identical to the index are denoted as ‘‘.’’. HXB2 and C1P nonamers not found at
the aligned nonamer position are indicated with 0% incidence.
doi:10.1371/journal.pone.0059994.t001
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organized as three motifs: (1) ‘‘major’’ variant, the most prevalent
individual variant of the index; (2) ‘‘minor’’ variants, multiple
different sequences, each present in two or more of the aligned
viral sequences, and each with an incidence less than or equal
(occasionally) to that of the major variant; and (3) ‘‘unique’’
variants, each unique to a single viral isolate. The combined
incidence of the major, minor and unique variants at a nonamer
position was inversely related to the corresponding incidence of
the index sequence and represented the total variant population at
the position. The incidence of distinct variant nonamer sequences
at a given nonamer position (nonatypes) was also determined.
Further, the correspondence of the index sequences to the
sequences of the original clade B isolate, HXB2 [38] and an
arbitrarily selected recent strain, C1P [39] was evaluated. HXB2 is
considered the clade B prototype sequence [45], while C1P is an
infectious virus cloned full-length from residual viral RNAs
recovered from the plasma of a HAART-treated patient and
sequenced by modern methodologies.
Variant nonamers that contained gaps (-) or any one of the
unresolved characters, including B (asparagine or aspartic acid), J
(leucine or Isoleucine), X (unspecified or unknown amino acid),
and Z (glutamine or glutamic acid) were excluded from the
quantification. All data analyses were performed with the 2,874
aligned nonamer positions of the proteome that had more than
100 sequences (out of 3,133 total aligned proteome nonamer
positions). However, data for positions with less than 100
sequences are shown in some figures and tables to maintain the
protein sequence structure.
Results
Shannon Entropy Overview of HIV-1 Clade B Proteome
Sequence Diversity
Shannon entropy [31,43,44] of the aligned nonamer positions
was used as a measure of overall sequence diversity of the HIV-1
clade B proteome (Figure 2A). The remarkable complexity of the
viral protein sequence structure was evident from the extensive
presence of high entropy nonamer positions, with a large fraction
of variant sequences in each of the HIV-1 proteins, including Gag
and Pol, the most conserved. The maximum evolutionary entropy
(9.2) of HIV-1 nonamer sequences far exceeded that of ,6 for
avian influenza [32], ,4 for dengue [31], and ,2 for West Nile
virus [30]. Each of the HIV-1 proteins was found to contain
positions with greater than 50% variant sequences, and some with
variants as high as 98% of the aligned nonamer sequences. A
severe discordance in the relationship between entropy and the
incidence of variants of the nonamer positions was also evident
(Figure 2B). While high entropy is a general indication of high
diversity, several positions of lower entropy (,2.0) contained high
incidences of variants, some comparable to those of higher entropy
regions (.4.0). In general, only positions with variants incidence of
less than 20% had a relatively linear relationship with entropy. In
contrast, positions with more than 20% variants displayed a wide
range and non-linear rise in entropy that increased greatly at
positions with an incidence of variants $80%. The wide range of
entropy can be attributed to the composition and incidence of the
variant motifs that comprised of many different sequences.
Dissecting HIV-1 Clade B Proteome Sequence Diversity:
Scope of the Analysis
Dissecting protein sequence diversity of HIV-1 clade B included
quantitative analyses of diversity motifs of each of the 2,874
aligned nonamer positions of the proteome (Table S3). An
example of this data is shown with 27 aligned overlapping
nonamer positions of Env 114–148 (Table 1). Each of the 27
aligned nonamer positions contained about 1,000 to 3,900
sequences. The first five positions (Env 114–122 to 118–126)
were relatively conserved with entropies of about 1.0, and index
nonamers with incidences of 85% to 89%. These conserved
sequences were identical to the corresponding sequences of the
HXB2 and C1P. The remaining small fraction (11 to 15%) of the
aligned sequences at these conserved positions were variants of the
index nonamers and represented by about equal fractions of the
major and minor variants (5–7%), and a minimal fraction, ,1 to
,2%, of unique sequences. The incidence of the different variant
nonamer sequenes (nonatypes) at these positions was about 2%,
represented by the single major variant, different minor variants,
and unique variants. In contrast, the remaining nonamer
positions, Env 119–127 to 140–148, included positions of high
diversity, with entropy as high as about 9.2, as few as 2% index
sequences, 98% as variants of the index, and nonatypes as high as
36%, based almost totally on different minor and unique variants.
As an indication of the high variability of these positions in the
HIV-1 population, none of the approximately 2,000 to 4,000
Figure 3. Distribution of conservation level of nonamer
positions. The nonamer positions of the proteome and the individual
proteins were defined as highly conserved (black, index incidence
$90%), mixed-variable (white, index incidence ,90% & .20%), and
highly diverse (grey, index incidence#20%). Highly conserved positions
were only 9% of total proteome nonamer positions, ranging from 0%
for Vpr and Tat, to 19% for Pol. Highly diverse positions comprised 14%
of the proteome, ranging from 1% Pol to 27% Env and Nef, each. Mixed-
variable positions comprised 77% of the proteome, ranging from 69%
Env to 88% Vpr.
doi:10.1371/journal.pone.0059994.g003
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Figure 4. Dynamics of diversity motifs of HIV-1 clade B proteome. A. Motif incidence in relation to total variants incidence: index sequence
(orange), total variants (black), major variant (blue), minor variants (pink), unique variants (green), and nonatypes (yellow). B. Violin plot of the
frequency distribution of the indicated proteome sequence motifs. The width of the plot (x-axis) represents the frequency distribution of a given
incidence of the indicated motif. ‘‘x’’ represents the arithmetic mean incidence value.
doi:10.1371/journal.pone.0059994.g004
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sequences of the aligned population contained nonamers that were
identical to those of C1P, and only a small fraction (1% or less)
corresponded to HXB2 nonamers.
Distribution of Conserved and Variable Nonamer
Positions in HIV-1 Clade B Proteome
Nearly all nonamer positions of the aligned viral proteins
contained variants with one or more mutations. Only two Pol
positions with more than 100 sequences in the alignment (Pol 956–
964, 957–965) were evolutionarily completely conserved among
the recorded sequences that were analyzed in this study. Highly
conserved positions with index sequences in 90% or more of the
aligned viruses represented only 9% of the proteome, mostly in
Pol, Gag, and even Env (Figure 3). The remaining small fraction of
variant nonamers, 10% or less, of these highly conserved positions
generally contained one amino acid mismatch to the index
(median average; data not shown). Highly diverse positions, with
80% or more total variants, represented 14% of the proteome and
23 to 27% of the Env, Nef, Vpu and Rev sequences. The variant
sequences of these highly diverse positions differed greatly from
the index sequences, many with multiple amino acid mismatches
(median average of 3), contributed largely by the unique variants.
Overall, a large fraction (91%) of the proteome nonamer positions
contained more than 10% variants of the index sequence (i.e.
mixed-variable and highly diverse nonamer positions).
Dynamics of Variant Motifs with Increased Mutation
A singular finding was the distinctive dynamics of the individual
variant motifs of the HIV-1 clade B proteome in relation to
increased mutations (Figure 4A). The extreme range in the
conservation decrease represented by incidences of index sequenc-
es, 100% to 2%, was inversely matched by the increase of total
variants incidences, 0% to 98%. Although these inversely related
incidences of the index and total variants appear to be in a
continuum, drawn as a line (Figure 4A), the data depicted were the
actual values of the 2,874 nonamer positions examined. The three
variant motifs, each exhibited a characteristic distribution of
incidence change with increased total variants. The major variant
had a distinctive pyramidal incidence pattern based on the fact
that, by definition, the major variant could not exceed the index
sequence. Thus, at nonamer positions with greater than 50% total
Figure 5. Dynamics of diversity motifs of HIV-1 clade B proteins. The color key for each sequence motif is described in Figure 4.
doi:10.1371/journal.pone.0059994.g005
HIV-1 Clade B Variant Population Characterization
PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e59994
variants, there was a corresponding reduced incidence of both the
index sequence and the major variant. However, although the
mean incidence of the major variant was only about 10%, there
were many positions with over 50% total variants that contained
almost equal incidence of the index and major variant. It is
apparent that index, antigen epitopes of highly diverse proteomic
positions have little quantitative dominance as an immune target
over the major variant. The minor variants, each with individual
incidence less than or occasionally equal to that of the major
variant, were collectively the predominant variant motif for
majority of positions, particularly those with greater than 50%
total variants. It is evident that the minor variants are a highly
dynamic population resulting from fitness selection support in the
continued mutation of the index sequences and major variants.
The multiple different sequences of the minor variants present
additional great variety of potential epitope sequences as immune
escape variants or altered peptide ligands. The remaining
population of variant nonamer sequences comprised of unique
variants, each representing a single viral genotype within the
recorded population. Unique variants were distinctive for their
presence at almost every nonamer position, including the highly
conserved, but with low incidences (average of 3%), despite the
increase of other variant sequences. Notably, at positions of greater
than about 60% total variants, the incidences of unique variants
for some positions were dramatically increased in each of the
proteins, particularly in Nef with a maximum incidence of 53%.
The increased observation of unique sequences represented
positions of hyper-variability, with index incidence of less than
or equal to 10% and the remaining 90% or more variants as
mostly different minor and unique nonamer sequences. The
presence of these unique variants in every protein and at nearly all
nonamer positions (Table S3), even those highly conserved,
indicates that they are not artifacts of sequencing or result of
truncated partial sequences (e.g. due to premature stop codon).
Nonatypes, a measure of distinct variant sequences (Figure 4A),
comprised a large fraction (up to 68%) of the highly diverse
positions, composed largely of different minor and unique variants.
The incidence distributions of the index and variant motifs for
the proteome are depicted by use of violin plots (Figure 4B).
Overall, the index nonamer was the principle motif, but with a
mean incidence of only about 52%. The predominant mutation of
the index was the minor variant motif, with an incidence
distribution inversely related to that of the index. The majority
of the major and unique variants were of low incidence, as also
shown in Figure 4A, but with a fraction of high incidence unique
variants, particularly at positions of $80% total variants
incidences (i.e. highly diverse positions). The nonatypes, composed
of the single major variant, the different minor variants, and each
of the singular unique variants at a nonamer position, were also
chiefly of low incidence, except at highly diverse positions due to
the great increase in unique variants incidences. The increased
incidence of different variants at highly diverse positions provides
an extreme repertoire of possible immune escape variants for a
quasispecies population.
An additional salient finding was that the dynamics in the
changes of the incidence patterns of the variant motifs were
repeated for each of the individual proteins, as most evident with
the large number of nonamer positions of Gag, Pol, Env and Nef
(Figure 5). The only distinct differences between the individual
proteins were the fraction of nonamer positions with low
incidences of variants (Gag and Pol), compared to those with
high incidences of variants (Env and Nef) (Figure 6). Thus, despite
the differences in the structures and functions of the proteins, the
motifs and incidences of the variants of the index sequences were
basically the same for each protein, with similar dynamics in the
patterns of change with increased mutation.
Correspondence of the Index Sequences to those of
HXB2 and C1P Proteins
The correspondence of HIV-1 clade B index nonamer
sequences herein defined, concatenated as full-length proteins,
was compared to Nef (Figure 7) and the other proteins (Figure S3)
of the individual HXB2 and C1P viruses. There was a high single
amino acid identity (.82%) between the historical index and the
individual sequences of these viruses (Table S4A), with differences
that included a small fraction of indels (insertions/deletions),
besides mutations (Figure 7). In contrast, the nonamer sequence
identity was much less than that of single amino acids, with only
61% of the HXB2 and 49% of the C1P nonamers identical to the
index sequences (Table S4B). As expected, the match between the
index and the individual HXB2 and C1P sequences occurred
Figure 6. Frequency distribution violin plots of the diversity
motifs incidences of HIV-1 clade B proteins. The legend for the
violin plot is described in Figure 4.
doi:10.1371/journal.pone.0059994.g006
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mainly at the highly conserved nonamer positions, and almost
none at the highly diverse positions (Table S3), highlighting the
consistency of sequence changes in the viral population. Based on
this, approximately half of the overlapping nonamer sequences of
a given HIV-1 strain can be expected to differ from the historical
index sequences of this study.
Index Switching
Index switching, another relevant finding, results from similar
incidences of the index sequences and major variants at some
mixed-variable and several highly diverse nonamer positions
where the incidences of the major variants (average of 8%) were
almost indistinguishable from the index sequences (average 12%).
Consequently, there were a significant number of nonamer
positions in the proteome where fitness increase of one or more
amino acid mutations were sufficient to change the incidence rank
of a given variant nonatype as the index, alternative to the
expected index sequence based on the preceding position
(Figure 8). Index-switching positions were readily revealed by
amino acid mutations that did not follow the consecutive
concatenation of the index sequences, as shown by the red labeled
residues in Figures 7 and S3. Index switching may also occur with
the other variant motifs and likely represents a subset of a larger
phenomenon, motif switching that may be common in a
quasispecies population, where the members of the motifs
dynamically swap ranking as mutation accumulates. This is likely
particularly so at the hyper-variable nonamer positions where the
difference in the incidences of the different nonatypes is almost
negligible.
Discussion
This study has elucidated the HIV-1 variant nonamer sequence
structure and incidence with increased mutation of the clade B
virus proteome. The virus samples, collected over at least 26 years
(1983 to 2008, based on records with available isolation date),
likely included many differences in mode of HIV transmission,
stage of infection, treatment, co-infection, etc. The results thus
provide a compendium of the possible spectrum of sequence
variants of HIV-1 under many different conditions and a model of
the collective evolution of multiple HIV-1 populations. It was
apparent that virtually all nonamer positions were capable of
generating multiple variants of index sequences for the cooperative
fitness of protein structure; only two Pol positions were completely
conserved. The remarkable plasticity of the virus was demonstrat-
ed both by incidences of the three variant motifs at the different
nonamer positions, and by the presence of numerous variant
nonatypes (distinct sequences), especially at the highly diverse
positions. Such regions of high diversity were present in each
protein, Gag and Pol included, but most commonly in Rev, Vpu,
Env, and Nef, where 23 to 27% of the aligned nonamer positions
contained 80% or more of sequences that were variants of the
index sequence. The incidence of nonatype sequences at the
highly diverse positions was remarkable; for example, about 70%
in Nef. Importantly, the reliability of this collective evolutionary
diversity was supported by the consistency with the individual
patterns of mutational change of HXB2 and C1P viruses.
Despite the many differences in structure and function of the
HIV-1 proteins, the change of incidence of the major, minor and
unique variants with increased sequence change was essentially the
same for each protein, differing only in the relative fractions of
conserved and diverse sequences. An interpretation of these data is
Figure 7. Comparison of HIV-1 clade B Nef concatenated index sequence with the HXB2 and C1P sequences. The numbers before and
after the concatenated index sequence represent amino acid positions of the comparison; the comparison is shown in blocks of 60 amino acids.
Identity of the index amino acids with those of HXB2 (green) and/or C1P (blue) is represented by ‘‘.’’; those that differ are shown by the respective
amino acid. Amino acid mutations of the aligned viruses that did not follow the concatenation of the index are shown in red. The corresponding
amino acids of HXB2 and C1P sequences are also shown at these positions, without representing identical residues by ‘‘.’’. The green dashes represent
amino acid deletions in HXB2.
doi:10.1371/journal.pone.0059994.g007
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that the three variant motifs represent inherent patterns in the
organization of a vast number of variable protein sequences that
facilitate HIV-1 fitness-selection. By definition, as the fraction of
total variants of the nonamer positions increased, the minor
variants became the predominant form, particularly as they
replaced both the index and corresponding major variant at
positions with more than 50% total variants. The large fractions of
nonatypes at highly diverse positions is in keeping with the
quasispecies model, that progeny viruses contain virtually any
sequence change consistent with the cooperative fitness of protein
sequences [2]. This pattern of sequence change was hypothesized
by Eigen [46] to have resulted from a combination of Darwin’s
selective evolution of the dominant replicator and the presence of
a ‘‘clan’’ of variant molecules that also have maximum reproduc-
tive fitness. The extreme sequence plasticity could provide a
spectrum of viral variants that allow the virus population to
efficiently exploit changes in selection pressure and facilitate the
long-term evolutionary stability and versatility of the virus [46].
The intense repertoire of variants in the mixed variable and
highly diverse regions of the virus proteome likely supports a
combination of mechanisms for loss of host immune control of the
virus. In addition to escape from T cell immunity, the multitude of
mutated sequences likely contribute to the general collapse of the
early immunity to the virus by altered peptide ligand inhibition of
T-cell responses and T-cell exhaustion [47–56]. Index switching
may be an important mechanism that facilitates this loss of
immune control. A small incidence increase of a particular amino
acid mutation in the mixed-variable and the highly diverse
positions can result in a variant nonatype replacing the prevalent,
index sequence of a quasispecies population.
Several methodologies for vaccine development that were
designed to overcome HIV-1 sequence diversity have been
reported, the majority as strategies based upon the use of
centralized sequences to limit the differences between viral strains
and the vaccine [15]. The design of these vaccines has generally
been based on phylogenetic relationship or the consensus, most
common sequence, of the viral population [57–61]. However, a
limitation of these approaches as a vaccine strategy is that, as
shown herein, the centralized or consensus sequence is not an
indicator of conservation; the average incidence of the prevalent,
index sequence was about 50%, and at the highly diverse positions
was as low as 2%. A recent modification of the centralized
approach was to prepare sets of ‘mosaic’ proteins, assembled from
fragments of natural sequences that are compressed into a small
number of native-like proteins [62–64]. However, the full-length
mosaic vaccines do not overcome the low incidence (average 12%)
of the index sequences at the highly diverse positions and have the
possibility of unnatural nonamer sequences as epitopes at the
Figure 8. Index switching. A. Gag protein alignment region of amino
acid (aa) positions 310 to 326 is shown for the first and last five
sequences of the aligned viruses. The aa position 318 (coloured) is
involved in index switching and includes two aa, the prevalent E
observed in 59% of the sequences, with its variant D in 41%. B. The nine
aligned overlapping nonamer positions (310–318, 311–319, etc.)
represent the sliding windows of the alignment region in A. Each
nonamer position is shown with the index sequence, two of the variant
nonatype sequences and the total number of remaining variant
nonatypes of incidence equal or below 10%. The first nonamer position,
310 to 318, is shown with the index sequence (41%) containing aa E at
the 9th position. The major variant (38%) contains the variable aa D at
the corresponding position. A minor variant (11%) has a mutation at aa
position 7 relative to the index. A total of 37 nonatypes had individual
incidences less or equal to 10%. The dominance of aa E in the index is
maintained for the next few nonamer positions. At position 314 to 322,
index switching is observed, where the sequence with aa D is now the
index (41%) and the one with E is the major variant (35%). This
relationship continued till position 316–324, with reversal of sequence
ranks to the original state at position 317–325, where the sequence
with aa E is the index. At an index switching position, the index is
alternative to that expected, relative to the preceding position. C.
Concatenated index, formed by linking the overlapping index
sequences of the nine nonamer positions. At position 318 (coloured),
the aa D, which did not follow the concatenation of the index is shown
below the sequence.
doi:10.1371/journal.pone.0059994.g008
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junctions of the mosaic fragment. A reported alternative was the
use of concatenated mosaic sequences selected from the conserved
regions of Gag, Pol and Env [64]; however these also contained
highly diverse sequences, including a sequence of Pol that matched
a minor variant of incidence 3% in our dataset. Further, these
mosaic constructs are also subject to unnatural junctional epitopes.
Given that all nonamer positions are capable of generating
variants, barring the two completely conserved Pol positions, our
rationale for a new vaccine strategy is one based on the selection of
peptide sequences conserved in over 90% of the recorded virus
population as a means for establishing selective T-cell based
immunity. The goal is the selective development of immune
responses that are restricted to highly conserved sequences, with a
greatly reduced incidence of mutations that could function as
altered peptide ligands. These conserved T-cell epitopes would not
be subject to competition in TCR activation by a large or even
greater fraction of variant sequences that could function in
promiscuous HLA binding but act as antagonists to the TCR
receptor. The importance of T-cell responses in the control of
HIV-1 infection has been revealed by the findings of the role of T-
cells in the reduced viremia of elite controllers [20–22]. In
addition, rhesus macaque animal model experiments [23–27]
suggested that CD8+ T cells, even against only a few epitopes,
have the potential of limiting virus replication following virus
infection and result in long-term immune control under conditions
that limit HIV-1 immune escape. The immunity provided by
peptide-based vaccines composed solely of the limited set of highly
conserved index sequences, many of which are immunogenic as
observed by matches to reported T-cell epitopes (data not shown),
may be considered a possible strategy for the development of an
HIV-1 vaccine.
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Figure S1 Sample alignments showing the anchor regions of
relatively conserved amino acids (boxed in red) that facilitated
reliable alignment. The numbers represent the amino acid
positions of the protein alignment.
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Figure S2 The effect of mutation on overlapping nonamer
sequences. A. The numbers represent amino acids of overlapping
nonamer sequences. B. A change in one amino acid, for example
from C to P at position 9, will affect nine nonamers spanning 17
amino acids (boxed in red).
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Figure S3 Comparison of concatenated index sequence of each
HIV-1 clade B protein with the corresponding proteins of HXB2
(green) and C1P (blue) sequences. The numbers before and after
the concatenated index sequence represent amino acid positions of
the comparison; the comparison is shown in blocks of 60 amino
acids. Identical amino acids between the comparisons are
represented by ‘‘.’’; those that differ are shown by the respective
amino acids. Amino acid mutations of the aligned viruses that did
not follow the concatenation of the index are shown in red. The
corresponding amino acids of HXB2 and C1P sequences are also
shown at these positions, but without representing identical amino
acids by ‘‘.’’. The green and blue dashes represent amino acid
deletions in HXB2 and C1P, respectively.
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Table S1 | HIV-1 clade B sequences analysed. 
 
Protein Amino acids a Nonamer positions b Sequences (No.) c 
Gag 500 492 6403 
Pol 1003 762 30604 
Vif 192 184 1147 
Vpr 78  88 1041 
Tat 86 93 1569 
Rev 116 108 1533 
Vpu 81 65 1223 
Env 856 876 9661 
Nef 206 206 4871 
Proteome 3040 2874 58052 
a Protein size with respect to clade HXB2 reference sequence (see Table S2).  
b Number of nonamer positions analysed, each with more than 100 sequences. Some 
proteins had more nonamer positions than the expected from the HXB2 protein size 
because of different lengths of the proteins and alignment gaps. Several of the proteins 
had fewer nonamer positions than expected from the HXB2 reference sequence. This 
is particularly true of Pol and is the result of removal of positions with low support 
(less than 100 sequences). 
c Retrieved from NCBI Entrez Protein Database. These included both full-length and a 






Table S2 | Accession numbers of reference HIV-1 clade B, consensus HXB2 and 
C1P protein sequences.  
 
Protein Reference a HXB2 a C1P a 
Gag 29119256 120845 293573191 
Pol 29119257 77416881 293573192 
Vif 29119258 62291046 293573193 
Vpr 29119259 62291049 293573194 
Tat 29119263 6094428 293573195 
Rev 29119264 132438 293573196 
Vpu 29119260 139440 293573197 
Env 29119261 6015102 293573198 
Nef 29119262 288558856 293573199 




Table S3 | Diversity of HIV-1 clade B proteome. ^
Total Majorf Minorg Uniqueh
Sequence [%] Sequence [%]
Gag & 1-9 1156 1.2 MGARASVLS 82 18 10 7 2 3 ......... 82 ......... 82
& 2-10 1160 1.3 GARASVLSG 81 19 9 7 2 3 ......... 81 ......... 81
& 3-11 1164 1.3 ARASVLSGG 81 19 9 8 2 4 ......... 81 ......... 81
& 4-12 1157 2.8 RASVLSGGE 42 58 24 31 3 5 ......... 42 ......... 42
& 5-13 1157 2.8 ASVLSGGEL 42 58 24 31 3 5 ......... 42 ......... 42
& 6-14 1322 2.8 SVLSGGELD 43 57 25 30 3 5 ......... 43 ......... 43
& 7-15 1320 4.1 VLSGGELDR 28 72 15 54 4 7 ......... 28 ........K 15
& 8-16 1319 3.8 LSGGELDRW 31 69 15 50 3 7 ......... 31 .......K. 15
& 9-17 1322 3.6 SGGELDRWE 34 66 15 48 3 6 ......... 34 ......K.. 15
& 10-18 1324 3.9 GGELDRWEK 33 67 13 51 3 7 ......... 33 .....K..R 2
& 11-19 1453 3.7 GELDRWEKI 39 61 12 47 3 6 ......... 39 ....K..R. 2
& 12-20 1452 3.8 ELDRWEKIR 39 61 12 47 3 7 ......... 39 ...K..R.. 2
& 13-21 1471 2.8 LDRWEKIRL 50 50 19 29 3 5 ......... 50 ..K..R... 4
& 14-22 1477 2.9 DRWEKIRLR 50 50 19 29 3 5 ......... 50 .K..R.... 4
& 15-23 1485 2.8 RWEKIRLRP 50 50 20 28 3 5 ......... 50 K..R..... 4
& 16-24 1551 1.1 WEKIRLRPG 85 15 8 6 1 3 ......... 85 ..R...... 8
& 17-25 1603 1.3 EKIRLRPGG 82 18 8 8 2 3 ......... 82 .R....... 8
& 18-26 1616 2.2 KIRLRPGGK 68 32 8 22 2 4 ......... 68 R........ 7
& 19-27 1630 1.7 IRLRPGGKK 75 25 8 15 2 4 ......... 75 ......... 75
& 20-28 1648 2.7 RLRPGGKKK 60 40 8 30 3 5 ......... 60 ......... 60
& 21-29 1705 2.6 LRPGGKKKY 60 40 8 30 2 4 ......... 60 ......... 60
& 22-30 1723 3.9 RPGGKKKYR 30 70 22 45 4 6 ........K 22 ......... 30
& 23-31 1746 4.1 PGGKKKYRL 29 71 20 47 4 7 .......K. 20 ......... 29
& 24-32 2549 4.1 GGKKKYKLK 27 73 24 46 3 6 ......... 27 ......R.. 24
& 25-33 2602 4.0 GKKKYKLKH 26 74 25 46 3 5 ......... 26 .....R... 25
& 26-34 2624 4.6 KKKYKLKHI 21 79 16 60 4 6 ......... 21 ....R.... 16
& 27-35 2670 4.0 KKYKLKHIV 22 78 20 54 3 5 ......... 22 ...R..... 20
& 28-36 2672 4.0 KYKLKHIVW 23 77 20 54 3 5 ......... 23 ..R...... 20
& 29-37 2717 3.0 YKLKHIVWA 36 64 24 38 2 3 ......... 36 .R....... 24
& 30-38 2720 3.0 KLKHIVWAS 36 64 24 38 2 4 ......... 36 R........ 24
& 31-39 3064 1.8 LKHIVWASR 68 32 19 11 2 3 ......... 68 ......... 68
& 32-40 3146 1.7 KHIVWASRE 68 32 21 9 2 2 ......... 68 ......... 68
& 33-41 3156 1.6 HIVWASREL 68 32 22 9 1 2 ......... 68 ......... 68
& 34-42 3163 1.7 IVWASRELE 68 32 21 9 1 2 ......... 68 ......... 68
# 35-43 3196 0.9 VWASRELER 90 10 2 6 1 2 ......... 90 ......... 90
# 36-44 3269 0.8 WASRELERF 91 9 2 6 <1 2 ......... 91 ......... 91
# 37-45 3316 0.9 ASRELERFA 90 10 2 6 1 2 ......... 90 ......... 90
& 38-46 3311 1.6 SRELERFAV 77 23 10 12 2 3 ......... 77 ......... 77
& 39-47 3325 1.7 RELERFAVN 76 24 10 12 1 3 ......... 76 ......... 76
& 40-48 3506 1.7 ELERFAVNP 77 23 10 12 1 3 ......... 77 ......... 77
& 41-49 3509 1.9 LERFAVNPG 74 26 10 15 1 3 ......... 74 ......... 74
& 42-50 3524 1.8 ERFAVNPGL 74 26 10 15 2 3 ......... 74 ......... 74
& 43-51 3536 1.8 RFAVNPGLL 74 26 10 15 1 3 ......... 74 ......... 74
& 44-52 3641 1.8 FAVNPGLLE 75 25 10 14 1 3 ......... 75 ......... 75
& 45-53 3649 1.9 AVNPGLLET 73 27 10 16 1 2 ......... 73 ......... 73
& 46-54 3650 2.7 VNPGLLETS 60 40 12 27 2 3 ......... 60 ......... 60
& 47-55 3659 2.8 NPGLLETSE 58 42 10 30 2 4 ......... 58 ......... 58
& 48-56 3672 2.7 PGLLETSEG 59 41 10 29 2 3 ......... 59 ......... 59
& 49-57 3677 2.6 GLLETSEGC 60 40 10 28 2 3 ......... 60 ......... 60
& 50-58 3672 3.0 LLETSEGCR 54 46 10 34 2 4 ......... 54 ......... 54
& 51-59 3668 3.2 LETSEGCRQ 52 48 10 36 2 4 ......... 52 ......... 52
& 52-60 3672 3.1 ETSEGCRQI 53 47 10 35 2 4 ......... 53 ......... 53
& 53-61 3666 3.5 TSEGCRQIL 51 49 9 37 3 6 ......... 51 ......... 51
& 54-62 3662 4.7 SEGCRQILG 31 69 11 53 5 8 ......... 31 ......... 31
& 55-63 3664 4.2 EGCRQILGQ 40 60 12 44 4 7 ......... 40 ......... 40
& 56-64 3667 3.4 GCRQILGQL 45 55 19 32 3 5 ......... 45 ......... 45
& 57-65 3660 3.5 CRQILGQLQ 44 56 20 33 3 6 ......... 44 ......... 44
& 58-66 3658 3.7 RQILGQLQP 43 57 19 34 4 6 ......... 43 ......... 43
& 59-67 3648 4.2 QILGQLQPS 30 70 15 51 3 6 ......... 30 ......... 30
& 60-68 3650 4.2 ILGQLQPSL 30 70 15 52 4 7 ......... 30 ......... 30
& 61-69 3640 4.7 LGQLQPSLQ 28 72 13 54 4 8 ......... 28 ......... 28
& 62-70 3648 4.4 GQLQPSLQT 30 70 14 52 3 7 ......... 30 ......... 30
& 63-71 3654 2.9 QLQPSLQTG 51 49 20 27 2 4 ......... 51 ......... 51
& 64-72 3684 3.0 LQPSLQTGS 51 49 20 28 2 4 ......... 51 ......... 51
& 65-73 3687 2.9 QPSLQTGSE 51 49 20 27 2 4 ......... 51 ......... 51
& 66-74 3692 2.8 PSLQTGSEE 53 47 19 26 2 4 ......... 53 ......... 53




& 67-75 3687 3.0 SLQTGSEEL 54 46 17 26 2 4 ......... 54 ......... 54
& 68-76 3695 3.1 LQTGSEELK 37 63 34 27 2 4 ........R 34 ........R 34
& 69-77 3699 2.9 QTGSEELKS 39 61 34 24 2 4 .......R. 34 .......R. 34
& 70-78 3704 2.3 TGSEELKSL 42 58 40 16 2 3 ......R.. 40 ......R.. 40
& 71-79 3696 3.3 GSEELRSLY 26 74 21 51 2 4 ......... 26 ......... 26
& 72-80 3695 3.3 SEELRSLYN 26 74 21 51 2 4 ......... 26 ......... 26
& 73-81 3709 3.5 EELRSLYNT 25 75 20 53 2 4 ......... 25 ......... 25
& 74-82 3700 4.1 ELRSLYNTV 20 80 16 61 3 5 ......... 20 ........I 5
+ 75-83 3693 4.2 LRSLYNTVA 20 80 16 61 3 5 ......... 20 .......I. 4
+ 76-84 3697 4.5 RSLYNTVAT 17 83 15 65 3 5 ......... 17 ......I.. 2
& 77-85 3707 3.6 SLYNTVATL 32 68 22 44 2 4 ......... 32 .....I... 5
& 78-86 3696 3.7 LYNTVATLY 32 68 22 44 3 4 ......... 32 ....I.... 4
& 79-87 3688 3.5 YNTVATLYC 34 66 22 41 3 5 ......... 34 ...I..... 4
& 80-88 3696 2.6 NTVATLYCV 57 43 15 27 2 4 ......... 57 ..I...... 8
& 81-89 3694 2.7 TVATLYCVH 56 44 14 28 2 4 ......... 56 .I....... 8
& 82-90 3653 3.0 VATLYCVHQ 51 49 15 31 2 4 ......... 51 I........ 8
& 83-91 3630 3.8 ATLYCVHQK 26 74 24 48 3 5 ........R 24 ........R 24
& 84-92 3623 3.9 TLYCVHQKI 25 75 24 48 3 5 .......R. 24 .......R. 24
+ 85-93 3615 4.2 LYCVHQRIE 20 80 17 60 3 6 ......... 20 ........D 15
+ 86-94 3611 4.8 YCVHQKIDV 14 86 14 69 4 7 .....R.EI 10 .....R... 14
+ 87-95 3598 5.3 CVHQKIDVK 13 87 13 69 5 9 ....R.EI. 10 ....R.... 13
+ 88-96 3594 5.3 VHQKIDVKD 13 87 13 69 5 9 ...R.EI.. 10 ...R..... 13
+ 89-97 3592 5.3 HQKIDVKDT 13 87 13 69 5 9 ..R.EI... 10 ..R...... 13
+ 90-98 3601 5.5 QKIDVKDTK 12 88 11 72 5 10 .R.EI.... 10 .R....... 11
+ 91-99 3606 5.2 KIDVKDTKE 13 87 11 72 4 8 R.EI..... 10 R........ 11
& 92-100 3625 3.9 IDVKDTKEA 25 75 24 49 3 5 .EI...... 13 ......... 25
& 93-101 3602 3.7 EVKDTKEAL 25 75 25 47 2 4 .I....... 13 D........ 25
& 94-102 3604 3.6 VKDTKEALE 27 73 25 45 2 4 I.......D 8 ......... 27
& 95-103 3600 3.1 KDTKEALEK 35 65 32 31 2 4 .......D. 32 ......... 35
& 96-104 3604 2.7 DTKEALDKI 42 58 34 22 2 4 ......... 42 ......E.. 34
& 97-105 3598 2.8 TKEALDKIE 42 58 33 23 2 4 ......... 42 .....E... 33
& 98-106 3594 2.8 KEALDKIEE 42 58 33 23 2 4 ......... 42 ....E.... 33
& 99-107 3585 2.6 EALDKIEEE 43 57 35 20 2 4 ......... 43 ...E..... 35
& 100-108 3633 2.6 ALDKIEEEQ 43 57 35 20 2 4 ......... 43 ..E...... 35
& 101-109 3614 3.1 LDKIEEEQN 37 63 33 27 3 5 ......... 37 .E....... 33
& 102-110 3601 3.3 DKIEEEQNK 36 64 33 28 3 5 ......... 36 E........ 33
& 103-111 3589 2.8 KIEEEQNKS 65 35 8 24 3 5 ......... 65 ......... 65
& 104-112 3590 2.6 IEEEQNKSK 67 33 8 23 3 5 ......... 67 ......... 67
& 105-113 3565 2.5 EEEQNKSKK 71 29 4 22 3 5 ......... 71 ......... 71
& 106-114 3616 2.8 EEQNKSKKK 67 33 4 25 4 6 ......... 67 ......... 67
& 107-115 3552 3.2 EQNKSKKKA 64 36 3 28 4 7 ......... 64 ......... 64
& 108-116 3546 3.2 QNKSKKKAQ 64 36 4 29 4 7 ......... 64 ......... 64
& 109-117 3538 3.4 NKSKKKAQQ 61 39 3 31 4 8 ......... 61 ......... 61
& 110-118 3536 3.5 KSKKKAQQA 60 40 5 31 5 8 ......... 60 ......... 60
& 111-119 3519 4.0 SKKKAQQAA 50 50 8 37 5 9 ......... 50 ......... 50
& 112-120 3425 3.9 KKKAQQAAA 51 49 8 36 5 9 ......... 51 ......... 51
& 113-121 565 4.9 KKAQQAAAA 32 68 10 44 14 24 ........- 0 ......... 32
& 114-122 420 5.0 KAQQAAAAA 25 75 14 46 14 25 .......-- 0 ......... 25
& 115-123 230 4.8 AQQAQQAAA 25 75 13 44 18 29 ....AA--- 0 ....AA..- 0
& 116-124 228 4.8 QQAQQAAAG 23 77 13 47 18 29 ...AA---D 0 ...AA..-D 0
& 117-125 222 4.9 QAQQAAAGT 23 77 12 42 22 33 ..AA---D. 0 ..AA..-D. 0
& 118-126 222 4.9 AQQAAAGTG 23 77 13 44 21 33 .AA---D.. 0 .AA..-D.. 0
& 119-127 214 4.9 QQAAAGTGN 23 77 7 51 18 31 AA---D..H 0 AA..-D..T 0
& 120-128 215 5.0 QAAAGTGNS 23 77 8 50 19 32 A---D..H. 0 A..-D..TG 0
& 121-129 213 4.8 AAAGTGNSS 24 76 8 49 18 31 ---D..H.N 0 ..-D..TGN 0
122-130 * 7 2.6 QAGAGNSSQ 14 86 14 0 71 86 --DT.H.N. 0 A-DT.TGNN 0
123-131 * 4 1.6 ETAARSAKI 25 75 25 0 50 75 -DTGH.NQ- 0 -DTGTGNNS 0
+ 124-132 215 5.3 DTGNNSQAA 17 83 8 48 27 38 ...HSN.-- 0 ...TGNNS- 0
+ 125-133 216 5.2 TGNNSQAAQ 17 83 8 50 25 36 ..HSN.--- 0 ..TGNNS-K 0
+ 126-134 211 5.4 GNNSQAAQI 10 90 9 55 26 37 .HSN.---V 0 .TGNNS-KV 0
+ 127-135 213 5.4 NNSQAAQIS 10 90 8 55 26 38 HSN.---V. 0 TGNNS-KV. 0
+ 128-136 215 5.5 NSQAAQISQ 11 89 7 54 27 39 SN.---V.. 0 GNNS-KV.. 0
+ 129-137 215 5.3 SQAAQISQN 13 87 9 54 24 35 N.---V... 0 NNS-KV... 0
+ 130-138 217 5.0 QAAQISQNY 13 87 10 58 19 29 .---V.... 0 NS-KV...F 0
+ 131-139 196 4.7 AAQISQNYP 15 85 11 59 15 26 ---V..... 0 S-KV...F. 0
& 132-140 197 4.0 SQVSQNYPI 26 74 11 54 9 18 --....... 0 -K....F.. 0
& 133-141 2950 2.3 QVSQNYPIV 69 31 8 21 2 3 -........ 0 K....F... <1
& 134-142 2961 1.7 VSQNYPIVQ 77 23 8 13 1 3 ......... 77 ....F.... 1
& 135-143 3026 1.0 SQNYPIVQN 89 11 3 8 1 2 ......... 89 ...F..... 2
& 136-144 3008 2.4 QNYPIVQNL 54 46 19 25 2 3 ........I 19 ..F...... <1
& 137-145 3010 2.2 NYPIVQNLQ 57 43 19 22 2 3 .......I. 19 .F....... 1
& 138-146 2951 2.2 YPIVQNLQG 56 44 20 22 2 3 ......I.. 20 F........ 1
& 139-147 3218 2.1 PIVQNLQGQ 58 42 20 21 2 3 .....I... 20 ......... 58
& 140-148 3198 2.1 IVQNLQGQM 58 42 20 21 2 3 ....I.... 20 ......... 58
& 141-149 3190 2.1 VQNLQGQMV 58 42 19 21 2 3 ...I..... 19 ......... 58
& 142-150 3344 2.1 QNLQGQMVH 58 42 19 21 2 3 ..I...... 19 ......... 58
& 143-151 3341 2.0 NLQGQMVHQ 59 41 20 19 2 3 .I....... 20 ......... 59
& 144-152 3328 2.9 LQGQMVHQA 43 57 16 38 2 3 I........ 16 ......... 43
& 145-153 3275 2.3 QGQMVHQAI 56 44 15 28 2 3 ......... 56 ......... 56
& 146-154 3227 2.4 GQMVHQAIS 56 44 14 28 2 3 ......... 56 ......... 56
& 147-155 3165 2.4 QMVHQAISP 56 44 14 28 2 3 ......... 56 ......... 56
& 148-156 3132 2.5 MVHQAISPR 55 45 14 29 2 3 ......... 55 ......... 55
& 149-157 3058 2.4 VHQAISPRT 56 44 14 28 2 3 ......... 56 ......... 56
& 150-158 2757 2.3 HQAISPRTL 57 43 15 26 1 3 ......... 57 ......... 57
& 151-159 2574 2.3 QAISPRTLN 56 44 16 27 1 3 ......... 56 ......... 56
& 152-160 2039 2.3 AISPRTLNA 55 45 16 27 2 3 ......... 55 ......... 55
& 153-161 2049 1.4 ISPRTLNAW 71 29 23 5 1 2 ......... 71 ......... 71
# 154-162 2049 0.5 SPRTLNAWV 95 5 1 3 <1 2 ......... 95 ......... 95
# 155-163 2045 0.4 PRTLNAWVK 97 3 <1 2 <1 2 ......... 97 ......... 97
# 156-164 1976 0.4 RTLNAWVKV 97 3 <1 2 <1 2 ......... 97 ......... 97
& 157-165 1976 1.2 TLNAWVKVV 71 29 25 3 1 2 ......... 71 ......... 71
& 158-166 2001 1.2 LNAWVKVVE 70 30 27 2 <1 2 ......... 70 ......... 70
& 159-167 1985 1.3 NAWVKVVEE 68 32 27 4 1 2 ......... 68 ......... 68
& 160-168 1881 1.3 AWVKVVEEK 68 32 28 3 1 2 ......... 68 ......... 68
& 161-169 1863 1.4 WVKVVEEKA 67 33 28 4 1 2 ......... 67 ......... 67
& 162-170 1854 1.4 VKVVEEKAF 67 33 28 4 1 2 ......... 67 ......... 67
& 163-171 1879 1.4 KVVEEKAFS 66 34 29 3 2 3 ......... 66 ......... 66
& 164-172 1880 1.4 VVEEKAFSP 66 34 29 3 2 3 ......... 66 ......... 66
& 165-173 1880 1.4 VEEKAFSPE 66 34 29 3 2 3 ......... 66 ......... 66
# 166-174 1872 0.6 EEKAFSPEV 94 6 <1 3 2 3 ......... 94 ......... 94
# 167-175 1863 0.6 EKAFSPEVI 94 6 <1 3 2 3 ......... 94 ......... 94
# 168-176 1861 0.6 KAFSPEVIP 95 5 <1 3 2 2 ......... 95 ......... 95
# 169-177 1854 0.5 AFSPEVIPM 95 5 <1 2 2 2 ......... 95 ......... 95
# 170-178 1854 0.4 FSPEVIPMF 96 4 <1 2 1 2 ......... 96 ......... 96
& 171-179 1862 1.3 SPEVIPMFS 76 24 14 8 1 2 ......... 76 ......... 76
& 172-180 1877 1.3 PEVIPMFSA 76 24 15 7 2 2 ......... 76 ......... 76
& 173-181 1869 1.3 EVIPMFSAL 76 24 15 7 1 2 ......... 76 ......... 76
& 174-182 1922 1.5 VIPMFSALS 72 28 15 11 2 2 ......... 72 ......... 72
& 175-183 1925 1.6 IPMFSALSE 72 28 15 12 2 3 ......... 72 ......... 72
& 176-184 1926 1.5 PMFSALSEG 72 28 15 12 1 2 ......... 72 ......... 72
& 177-185 1925 1.5 MFSALSEGA 72 28 15 12 1 2 ......... 72 ......... 72
& 178-186 1924 1.5 FSALSEGAT 72 28 15 12 1 2 ......... 72 ......... 72
& 179-187 1924 1.5 SALSEGATP 72 28 15 12 1 2 ......... 72 ......... 72
# 180-188 1922 0.8 ALSEGATPQ 91 9 3 5 2 2 ......... 91 ......... 91
# 181-189 1923 0.8 LSEGATPQD 91 9 3 5 1 2 ......... 91 ......... 91
# 182-190 1920 0.8 SEGATPQDL 91 9 3 5 1 2 ......... 91 ......... 91
# 183-191 1920 0.6 EGATPQDLN 94 6 1 4 1 2 ......... 94 ......... 94
# 184-192 1919 0.8 GATPQDLNT 92 8 <1 5 2 3 ......... 92 ......... 92
# 185-193 1920 0.8 ATPQDLNTM 92 8 <1 5 2 3 ......... 92 ......... 92
# 186-194 1922 0.8 TPQDLNTML 92 8 <1 5 2 3 ......... 92 ......... 92
# 187-195 1920 0.8 PQDLNTMLN 93 8 <1 5 2 3 ......... 93 ......... 93
# 188-196 1921 0.9 QDLNTMLNT 92 8 <1 5 2 3 ......... 92 ......... 92
# 189-197 1922 0.7 DLNTMLNTV 93 7 <1 4 2 3 ......... 93 ......... 93
# 190-198 1921 0.7 LNTMLNTVG 93 7 <1 4 2 3 ......... 93 ......... 93
# 191-199 1918 0.7 NTMLNTVGG 93 7 1 5 1 3 ......... 93 ......... 93
# 192-200 1922 0.7 TMLNTVGGH 93 7 1 5 1 2 ......... 93 ......... 93
# 193-201 1913 0.6 MLNTVGGHQ 94 6 1 4 1 2 ......... 94 ......... 94
# 194-202 1894 0.5 LNTVGGHQA 94 6 1 3 1 2 ......... 94 ......... 94
# 195-203 1870 0.5 NTVGGHQAA 94 6 1 3 1 2 ......... 94 ......... 94
# 196-204 1834 0.5 TVGGHQAAM 94 6 1 3 1 2 ......... 94 ......... 94
# 197-205 1824 0.3 VGGHQAAMQ 97 3 <1 1 1 2 ......... 97 ......... 97
# 198-206 1807 0.4 GGHQAAMQM 96 4 2 1 1 2 ......... 96 ......... 96
# 199-207 1798 0.4 GHQAAMQML 96 4 2 1 <1 1 ......... 96 ......... 96
# 200-208 1795 0.4 HQAAMQMLK 96 4 2 1 1 2 ......... 96 ......... 96
& 201-209 1787 1.0 QAAMQMLKE 82 18 15 3 1 2 ......... 82 ......... 82
& 202-210 1780 1.0 AAMQMLKET 81 19 14 3 1 2 ......... 81 ......... 81
& 203-211 1770 1.0 AMQMLKETI 81 19 14 3 1 2 ......... 81 ......... 81
& 204-212 1765 1.1 MQMLKETIN 81 19 14 4 1 2 ......... 81 ......... 81
& 205-213 1655 1.3 QMLKETINE 78 22 15 6 2 3 ......... 78 ......... 78
& 206-214 1654 1.3 MLKETINEE 78 22 15 6 2 3 ......... 78 ......... 78
& 207-215 1652 1.2 LKETINEEA 79 21 15 5 2 2 ......... 79 ......... 79
& 208-216 1653 1.2 KETINEEAA 79 21 15 5 2 3 ......... 79 ......... 79
& 209-217 1644 1.4 ETINEEAAE 77 23 14 7 2 3 ......... 77 ......... 77
# 210-218 1639 0.8 TINEEAAEW 92 8 2 5 1 3 ......... 92 ......... 92
# 211-219 1637 0.7 INEEAAEWD 93 7 2 4 1 2 ......... 93 ......... 93
# 212-220 1638 0.7 NEEAAEWDR 93 7 2 4 2 2 ......... 93 ......... 93
& 213-221 1628 1.8 EEAAEWDRL 69 31 17 12 2 3 ........V 17 ......... 69
& 214-222 1610 1.6 EAAEWDRLH 71 29 18 9 2 3 .......V. 18 ......... 71
& 215-223 1611 1.5 AAEWDRLHP 72 28 18 9 2 3 ......V.. 18 ......... 72
& 216-224 1608 1.8 AEWDRLHPV 69 31 17 11 2 4 .....V... 17 ......... 69
& 217-225 1623 2.0 EWDRLHPVH 66 34 17 15 2 4 ....V.... 17 ......... 66
& 218-226 1623 1.9 WDRLHPVHA 67 33 17 14 2 4 ...V..... 17 ......... 67
& 219-227 1619 2.0 DRLHPVHAG 67 33 17 14 2 4 ..V...... 17 ......... 67
& 220-228 1555 1.9 RLHPVHAGP 68 32 16 13 2 4 .V....... 16 ......... 68
& 221-229 1547 3.0 LHPVHAGPI 50 50 12 35 3 6 V........ 12 ......... 50
& 222-230 1554 2.5 HPVHAGPIA 58 42 18 22 3 5 ......... 58 ......... 58
& 223-231 1552 2.5 PVHAGPIAP 58 42 18 21 3 5 ......... 58 ......... 58
& 224-232 1552 2.5 VHAGPIAPG 58 42 18 21 3 5 ......... 58 ......... 58
& 225-233 1553 2.3 HAGPIAPGQ 59 41 18 21 2 4 ......... 59 ......... 59
& 226-234 1558 2.5 AGPIAPGQM 58 42 17 22 3 4 ......... 58 ......... 58
& 227-235 1556 2.5 GPIAPGQMR 58 42 17 22 3 4 ......... 58 ......... 58
& 228-236 1555 2.7 PIAPGQMRE 56 44 16 24 3 5 ......... 56 ......... 56
& 229-237 1555 2.6 IAPGQMREP 57 43 16 24 3 5 ......... 57 ......... 57
& 230-238 1566 1.5 APGQMREPR 78 22 7 13 2 3 ......... 78 ......... 78
& 231-239 1566 1.0 PGQMREPRG 86 14 5 7 2 3 ......... 86 ......... 86
& 232-240 1541 1.1 GQMREPRGS 85 15 5 8 2 3 ......... 85 ......... 85
& 233-241 1541 1.1 QMREPRGSD 85 15 5 8 2 3 ......... 85 ......... 85
& 234-242 1529 1.2 MREPRGSDI 85 15 5 8 2 3 ......... 85 ......... 85
# 235-243 1532 0.6 REPRGSDIA 93 7 3 3 1 2 ......... 93 ......... 93
# 236-244 1531 0.6 EPRGSDIAG 93 7 3 3 <1 2 ......... 93 ......... 93
# 237-245 1526 0.5 PRGSDIAGT 95 5 <1 3 1 2 ......... 95 ......... 95
# 238-246 1525 0.5 RGSDIAGTT 95 5 <1 3 1 2 ......... 95 ......... 95
# 239-247 1517 0.5 GSDIAGTTS 95 5 <1 3 1 2 ......... 95 ......... 95
& 240-248 1515 1.0 SDIAGTTST 84 16 9 5 1 2 ......... 84 ......... 84
& 241-249 1516 1.0 DIAGTTSTL 84 16 9 5 1 2 ......... 84 ......... 84
& 242-250 1517 1.1 IAGTTSTLQ 84 16 9 5 2 3 ......... 84 ......... 84
& 243-251 1514 1.1 AGTTSTLQE 83 17 9 6 2 3 ......... 83 ......... 83
& 244-252 1511 1.1 GTTSTLQEQ 83 17 9 5 2 3 ......... 83 ......... 83
& 245-253 1510 1.3 TTSTLQEQI 82 18 9 7 2 3 ......... 82 ......... 82
& 246-254 1510 2.2 TSTLQEQIG 66 34 11 21 2 4 ......... 66 ......... 66
& 247-255 1508 2.2 STLQEQIGW 66 34 11 21 2 4 ......... 66 ......... 66
& 248-256 1507 2.2 TLQEQIGWM 66 34 10 22 2 4 ......... 66 ......... 66
& 249-257 1507 1.8 LQEQIGWMT 71 29 14 13 2 4 ......... 71 ......... 71
& 250-258 1494 3.1 QEQIGWMTN 46 54 13 37 3 5 ......... 46 ......... 46
& 251-259 1494 3.0 EQIGWMTNN 46 54 13 38 3 5 ......... 46 ......... 46
& 252-260 1597 3.0 QIGWMTNNP 48 52 13 37 3 5 ......... 48 ......... 48
& 253-261 1598 3.1 IGWMTNNPP 48 52 13 37 3 6 ......... 48 ......... 48
& 254-262 1599 3.2 GWMTNNPPI 48 52 13 36 3 6 ......... 48 ......... 48
& 255-263 1602 2.5 WMTNNPPIP 53 47 16 28 2 4 ......... 53 ......... 53
& 256-264 1603 2.5 MTNNPPIPV 53 47 16 28 2 4 ......... 53 ......... 53
& 257-265 1605 2.5 TNNPPIPVG 53 47 16 28 2 4 ......... 53 ......... 53
& 258-266 1600 2.8 NNPPIPVGE 51 49 15 32 3 5 ......... 51 ......... 51
& 259-267 1607 1.4 NPPIPVGEI 81 19 5 12 2 3 ......... 81 ......... 81
& 260-268 1609 1.4 PPIPVGEIY 81 19 5 12 2 3 ......... 81 ......... 81
& 261-269 1606 1.4 PIPVGEIYK 81 19 5 12 2 3 ......... 81 ......... 81
& 262-270 1606 1.7 IPVGEIYKR 74 26 9 15 2 3 ......... 74 ......... 74
& 263-271 1602 1.4 PVGEIYKRW 79 21 10 10 2 3 ......... 79 ......... 79
& 264-272 1595 1.3 VGEIYKRWI 79 21 10 10 2 3 ......... 79 ......... 79
& 265-273 1480 1.4 GEIYKRWII 79 21 10 9 2 3 ......... 79 ......... 79
& 266-274 1478 2.0 EIYKRWIIL 66 34 10 22 2 4 ......... 66 ......... 66
& 267-275 1480 1.7 IYKRWIILG 70 30 10 18 2 3 ......... 70 ......... 70
& 268-276 1480 1.7 YKRWIILGL 70 30 10 18 1 3 ......... 70 ......... 70
& 269-277 1482 1.7 KRWIILGLN 70 30 10 18 2 3 ......... 70 ......... 70
& 270-278 1486 1.7 RWIILGLNK 70 30 10 18 2 3 ......... 70 ......... 70
& 271-279 1484 1.4 WIILGLNKI 72 28 19 8 1 2 ......... 72 ......... 72
& 272-280 1490 1.4 IILGLNKIV 72 28 19 7 1 2 ......... 72 ......... 72
& 273-281 1498 1.4 ILGLNKIVR 72 28 19 7 1 2 ......... 72 ......... 72
& 274-282 1499 1.3 LGLNKIVRM 73 27 19 7 2 2 ......... 73 ......... 73
# 275-283 1495 0.5 GLNKIVRMY 95 5 1 3 <1 2 ......... 95 ......... 95
# 276-284 1453 0.5 LNKIVRMYS 95 5 1 3 1 2 ......... 95 ......... 95
# 277-285 1458 0.5 NKIVRMYSP 95 5 1 2 1 2 ......... 95 ......... 95
& 278-286 1469 1.7 KIVRMYSPT 59 41 30 10 2 3 ......... 59 ......... 59
& 279-287 1454 1.8 IVRMYSPTS 57 43 29 11 2 3 ......... 57 ........G <1
& 280-288 1453 1.8 VRMYSPTSI 57 43 29 12 2 2 ......... 57 .......G. <1
& 281-289 1449 1.8 RMYSPTSIL 57 43 29 12 2 3 ......... 57 ......G.. <1
& 282-290 1478 1.9 MYSPTSILD 56 44 30 12 2 3 ......... 56 .....G... <1
& 283-291 1481 1.9 YSPTSILDI 56 44 30 12 2 3 ......... 56 ....G.... <1
& 284-292 1479 2.6 SPTSILDIR 38 62 26 33 2 4 ......... 38 ...G..... <1
& 285-293 1478 2.6 PTSILDIRQ 38 62 27 33 2 3 ......... 38 ..G...... <1
& 286-294 1478 2.5 TSILDIRQG 38 62 27 33 2 3 ......... 38 .G....... <1
& 287-295 1481 1.3 SILDIRQGP 72 28 22 4 1 2 ......... 72 G........ <1
& 288-296 1473 1.2 ILDIRQGPK 74 26 22 3 2 3 ......... 74 ......... 74
& 289-297 1468 1.2 LDIRQGPKE 74 26 22 2 2 2 ......... 74 ......... 74
& 290-298 1468 1.3 DIRQGPKEP 72 28 22 4 2 3 ......... 72 ........S 1
& 291-299 1467 1.2 IRQGPKEPF 73 27 22 4 1 2 ......... 73 .......S. 1
& 292-300 1466 1.3 RQGPKEPFR 73 27 22 4 1 2 ......... 73 ......S.. 1
# 293-301 1462 0.5 QGPKEPFRD 95 5 2 2 1 2 ......... 95 .....S... 2
# 294-302 1462 0.5 GPKEPFRDY 95 5 2 2 1 2 ......... 95 ....S.... 2
# 295-303 1461 0.5 PKEPFRDYV 95 5 2 2 1 2 ......... 95 ...S..... 2
# 296-304 1434 0.5 KEPFRDYVD 95 5 2 2 1 2 ......... 95 ..S...... 2
# 297-305 1433 0.5 EPFRDYVDR 95 5 2 2 1 2 ......... 95 .S....... 2
# 298-306 1429 0.5 PFRDYVDRF 95 5 2 2 1 2 ......... 95 S........ 2
& 299-307 1428 0.8 FRDYVDRFY 88 12 9 2 1 2 ......... 88 ......... 88
& 300-308 1374 0.9 RDYVDRFYK 87 13 9 3 1 2 ......... 87 ......... 87
& 301-309 1372 1.1 DYVDRFYKT 85 15 7 6 2 3 ......... 85 ......... 85
& 302-310 1372 1.0 YVDRFYKTL 85 15 7 6 2 3 ......... 85 ......... 85
& 303-311 1313 1.0 VDRFYKTLR 88 12 5 6 1 2 ......... 88 ......... 88
& 304-312 1309 0.9 DRFYKTLRA 88 12 5 6 1 2 ......... 88 ......... 88
& 305-313 1303 0.9 RFYKTLRAE 88 12 5 6 1 2 ......... 88 ......... 88
& 306-314 1289 1.0 FYKTLRAEQ 88 12 5 6 1 2 ......... 88 ......... 88
& 307-315 1283 1.2 YKTLRAEQA 84 16 4 10 2 3 ......... 84 ......... 84
& 308-316 1230 1.5 KTLRAEQAS 77 23 11 10 2 3 ......... 77 ......... 77
& 309-317 1224 1.4 TLRAEQASQ 78 22 12 9 2 3 ......... 78 ......... 78
& 310-318 1205 2.1 LRAEQASQE 41 59 38 18 2 3 ......... 41 ......... 41
& 311-319 1204 2.1 RAEQASQEV 42 58 38 18 2 3 ......... 42 ......... 42
& 312-320 1203 2.0 AEQASQEVK 41 59 39 18 2 3 ......... 41 ......... 41
& 313-321 1119 2.4 EQASQDVKN 41 59 35 22 3 5 .....E... 35 .....E... 35
& 314-322 1118 2.4 QASQDVKNW 41 59 35 22 2 4 ....E.... 35 ....E.... 35
& 315-323 1117 2.4 ASQDVKNWM 40 60 35 22 2 4 ...E..... 35 ...E..... 35
& 316-324 1116 2.2 SQDVKNWMT 41 59 36 21 2 4 ..E...... 36 ..E...... 36
& 317-325 1114 2.0 QEVKNWMTE 47 53 40 10 2 4 ......... 47 ......... 47
& 318-326 1114 2.0 EVKNWMTET 47 53 40 10 3 4 ......... 47 ......... 47
& 319-327 1129 1.0 VKNWMTETL 88 12 4 7 2 3 ......... 88 ......... 88
& 320-328 1129 1.1 KNWMTETLL 87 13 4 7 2 3 ......... 87 ......... 87
& 321-329 1126 1.2 NWMTETLLV 86 14 4 8 2 4 ......... 86 ......... 86
& 322-330 1101 0.9 WMTETLLVQ 88 12 5 5 2 3 ......... 88 ......... 88
& 323-331 1101 0.9 MTETLLVQN 88 12 5 5 2 3 ......... 88 ......... 88
& 324-332 1101 1.2 TETLLVQNA 82 18 6 10 2 3 ......... 82 ......... 82
& 325-333 1101 1.3 ETLLVQNAN 82 18 6 10 2 3 ......... 82 ......... 82
& 326-334 1101 0.9 TLLVQNANP 87 13 6 4 2 3 ......... 87 ......... 87
& 327-335 1102 0.9 LLVQNANPD 88 12 6 4 2 3 ......... 88 ......... 88
& 328-336 1103 0.9 LVQNANPDC 88 12 6 4 2 3 ......... 88 ......... 88
& 329-337 1104 1.2 VQNANPDCK 82 18 6 9 2 3 ......... 82 ......... 82
& 330-338 1105 1.2 QNANPDCKT 82 18 6 10 2 3 ......... 82 ......... 82
& 331-339 1105 1.2 NANPDCKTI 82 18 6 9 2 3 ......... 82 ......... 82
& 332-340 1103 1.2 ANPDCKTIL 82 18 6 9 2 3 ......... 82 ......... 82
& 333-341 1103 1.0 NPDCKTILK 87 13 6 5 2 3 ......... 87 ......... 87
& 334-342 1103 0.9 PDCKTILKA 87 13 6 5 2 3 ......... 87 ......... 87
& 335-343 1106 0.9 DCKTILKAL 87 13 6 5 1 3 ......... 87 ......... 87
& 336-344 1107 1.0 CKTILKALG 87 13 6 5 2 3 ......... 87 ......... 87
& 337-345 1107 1.0 KTILKALGP 87 13 6 6 2 3 ......... 87 ......... 87
& 338-346 1109 1.4 TILKALGPA 78 22 14 6 2 4 ......... 78 ......... 78
& 339-347 1040 1.2 ILKALGPAA 78 22 15 5 2 3 ......... 78 ......... 78
& 340-348 1043 1.4 LKALGPAAT 78 22 14 6 2 4 ......... 78 ......... 78
& 341-349 1036 1.4 KALGPAATL 77 23 15 6 2 4 ......... 77 ......... 77
& 342-350 1033 1.3 ALGPAATLE 77 23 15 6 2 4 ......... 77 ......... 77
& 343-351 1029 1.4 LGPAATLEE 76 24 15 6 3 4 ......... 76 ......... 76
& 344-352 943 1.4 GPAATLEEM 76 24 15 6 3 5 ......... 76 ......... 76
& 345-353 909 1.5 PAATLEEMM 75 25 15 6 3 5 ......... 75 ......... 75
& 346-354 907 1.7 AATLEEMMT 72 28 15 9 3 5 ......... 72 ......... 72
& 347-355 881 1.1 ATLEEMMTA 88 12 2 7 2 4 ......... 88 ......... 88
& 348-356 765 0.9 TLEEMMTAC 89 11 3 6 2 3 ......... 89 ......... 89
# 349-357 722 0.7 LEEMMTACQ 91 9 3 4 2 3 ......... 91 ......... 91
# 350-358 706 0.6 EEMMTACQG 93 7 3 2 2 3 ......... 93 ......... 93
# 351-359 698 0.6 EMMTACQGV 92 8 3 2 2 3 ......... 92 ......... 92
# 352-360 709 0.7 MMTACQGVG 91 9 3 3 2 3 ......... 91 ......... 91
# 353-361 808 0.7 MTACQGVGG 92 8 3 3 2 3 ......... 92 ......... 92
# 354-362 808 0.6 TACQGVGGP 92 8 4 2 2 2 ......... 92 ......... 92
& 355-363 807 1.2 ACQGVGGPG 64 36 33 1 2 3 ......... 64 ......... 64
& 356-364 805 1.3 CQGVGGPGH 64 36 33 1 2 3 ......... 64 ......... 64
& 357-365 794 1.2 QGVGGPGHK 64 36 33 1 2 3 ......... 64 ......... 64
& 358-366 794 1.2 GVGGPGHKA 64 36 32 1 2 3 ......... 64 ......... 64
& 359-367 779 1.4 VGGPGHKAR 63 37 30 5 2 3 ......... 63 ......... 63
& 360-368 819 1.7 GGPGHKARV 62 38 26 11 <1 2 ......... 62 ......... 62
& 361-369 844 1.7 GPGHKARVL 63 37 25 11 <1 2 ......... 63 ......... 63
& 362-370 563 1.7 PGHKARVLA 63 37 23 13 2 3 ......... 63 ......... 63
& 363-371 549 1.8 GHKARVLAE 62 38 23 13 2 3 ......... 62 ......... 62
& 364-372 562 0.9 HKARVLAEA 85 15 8 4 2 3 ......... 85 ......... 85
& 365-373 572 0.9 KARVLAEAM 85 15 8 4 2 3 ......... 85 ......... 85
& 366-374 584 1.1 ARVLAEAMS 82 18 8 7 3 4 ......... 82 ......... 82
& 367-375 586 1.4 RVLAEAMSQ 80 20 8 10 3 4 ......... 80 ........H 1
& 368-376 584 2.4 VLAEAMSQV 57 43 11 28 3 5 ......... 57 .......H. <1
& 369-377 584 3.0 LAEAMSQVT 44 56 16 36 3 7 ......... 44 ......H.. <1
& 370-378 574 3.9 AEAMSQVTN 33 67 16 44 7 13 ......... 33 .....H... <1
& 371-379 133 2.4 EAMSQVSNT 67 33 3 17 14 20 ......T.- 0 ....H.T.- 0
& 372-380 130 2.5 AMSQVSNTA 67 33 2 13 18 24 .....T.-S 0 ...H.T.-P 0
& 373-381 130 2.5 MSQVSNTAA 67 33 2 12 19 25 ....T.-S. 0 ..H.T.-PV 0
& 374-382 128 2.8 SQVSNTAAA 63 38 4 10 23 28 ...T.-S.T 0 .H.T.-PVN 0
& 375-383 128 3.3 QVSNTAAAT 52 48 9 16 23 30 ..T.-S.TI 0 H.T.-PVNI 0
& 376-384 120 2.9 VSNTAAATM 56 44 9 17 18 24 .T.-S.TI. 0 .T.-PVNI. 0
& 377-385 120 2.9 SNTAAATMM 58 43 8 16 19 25 T.-S.TI.. 0 T.-PVNI.. 0
& 378-386 120 2.9 NTAAATMMQ 58 43 8 16 19 25 .-S.TI... 0 .-PVNI... 0
& 379-387 120 2.9 TAAATMMQR 58 43 8 17 18 24 -S.TI.... 0 -PVNI.... 0
+ 380-388 506 5.3 SATIMMQRG 16 84 14 55 15 25 ......... 16 PVN...... <1
& 381-389 562 4.9 ATIMMQRGN 21 79 14 56 10 19 ......... 21 VN......S 0
& 382-390 573 4.4 TIMMQRGNF 24 76 15 53 8 14 ......... 24 N......S. 0
& 383-391 673 3.8 IMMQRGNFR 28 72 18 46 8 12 ......... 28 ......S.. 0
& 384-392 763 3.9 MMQRGNFRN 28 72 19 47 6 11 ......... 28 .....S... 0
& 385-393 803 4.3 MQRGNFRNQ 28 72 16 49 7 13 ......... 28 ....S.... 0
& 386-394 807 4.5 QRGNFRNQR 26 74 12 53 9 15 ......... 26 ...S..... 0
& 387-395 805 4.8 RGNFRNQRK 26 74 12 52 10 17 ......... 26 ..S.....R 0
+ 388-396 806 5.1 GNFRNQRKI 18 82 14 57 12 19 ......... 18 .S.....RM 0
+ 389-397 779 5.2 NFRNQRKIV 16 84 13 58 13 20 ......... 16 S.....RM. 0
+ 390-398 778 5.2 FRNQRKIVK 16 84 13 58 12 19 ......... 16 .....RM.. 0
+ 391-399 777 5.0 RNQRKIVKC 16 84 14 59 11 17 ......... 16 ....RM... 0
+ 392-400 781 4.6 NQRKIVKCF 20 80 17 53 10 15 ......... 20 ...RM.... 0
& 393-401 784 4.0 QRKIVKCFN 28 72 19 47 7 12 ......... 28 ..RM..... 0
& 394-402 783 3.8 RKIVKCFNC 28 72 18 49 5 9 ......... 28 .RM...... 0
& 395-403 767 3.3 KIVKCFNCG 31 69 21 43 4 8 ......... 31 RM....... 0
& 396-404 765 3.2 IVKCFNCGK 28 72 22 45 4 7 ......... 28 M........ 1
& 397-405 766 2.0 VKCFNCGKE 54 46 32 11 3 5 ......... 54 ......... 54
& 398-406 794 1.1 KCFNCGKEG 86 14 4 7 3 4 ......... 86 ......... 86
& 399-407 792 1.1 CFNCGKEGH 87 13 4 7 3 4 ......... 87 ......... 87
& 400-408 927 1.7 FNCGKEGHI 75 25 10 12 3 5 ........T 1 ......... 75
& 401-409 932 1.7 NCGKEGHIA 75 25 10 12 3 5 .......T. 1 ......... 75
& 402-410 935 2.6 CGKEGHIAR 44 56 31 21 4 6 ......T.. 1 ........K 31
& 403-411 923 2.5 GKEGHIARN 45 55 31 21 3 6 .....T... 1 .......K. 31
& 404-412 935 2.6 KEGHIARNC 45 55 30 21 3 6 ....T.... 1 ......K.. 30
& 405-413 942 2.8 EGHIAKNCR 33 67 32 31 4 6 ...T.R... 1 ......... 33
& 406-414 942 2.5 GHIAKNCRA 35 65 34 28 3 5 ..T.R.... 1 ......... 35
& 407-415 938 2.5 HIAKNCRAP 36 64 34 28 3 5 .T.R..... 1 ......... 36
& 408-416 931 2.6 IAKNCRAPR 35 65 34 28 3 5 T.R...... 1 ......... 35
& 409-417 942 2.0 ARNCRAPRK 42 58 38 16 3 4 ......... 42 .K....... 38
& 410-418 1055 2.7 RNCRAPRKK 36 64 30 31 4 5 ......... 36 K........ 30
& 411-419 1031 1.9 NCRAPRKKG 65 35 13 19 3 4 ......... 65 ......... 65
& 412-420 1027 1.8 CRAPRKKGC 65 35 14 18 3 4 ......... 65 ......... 65
& 413-421 965 1.6 RAPRKKGCW 68 32 15 14 2 4 ......... 68 ......... 68
& 414-422 995 1.2 APRKKGCWK 80 20 13 6 2 3 ......... 80 ......... 80
& 415-423 987 1.2 PRKKGCWKC 81 19 12 5 2 3 ......... 81 ......... 81
& 416-424 978 1.2 RKKGCWKCG 80 20 12 5 2 3 ......... 80 ......... 80
& 417-425 926 1.9 KKGCWKCGK 63 37 14 21 2 3 ......... 63 ......... 63
& 418-426 923 1.9 KGCWKCGKE 63 37 14 22 1 3 ......... 63 ......... 63
& 419-427 923 1.5 GCWKCGKEG 74 26 14 10 2 3 ......... 74 ......... 74
& 420-428 907 1.5 CWKCGKEGH 74 26 14 10 2 3 ......... 74 ......... 74
& 421-429 866 1.6 WKCGKEGHQ 74 26 14 11 2 4 ......... 74 ......... 74
& 422-430 865 1.6 KCGKEGHQM 73 27 13 12 2 4 ......... 73 ......... 73
& 423-431 867 1.4 CGKEGHQMK 76 24 13 9 2 3 ......... 76 ......... 76
& 424-432 863 1.9 GKEGHQMKD 63 37 13 22 2 4 ......... 63 ......... 63
& 425-433 859 1.9 KEGHQMKDC 63 37 13 22 2 4 ......... 63 ......... 63
& 426-434 859 1.7 EGHQMKDCT 72 28 14 13 2 4 ......... 72 ........N <1
& 427-435 854 1.8 GHQMKDCTE 71 29 14 13 2 4 ......... 71 .......N. <1
& 428-436 855 1.8 HQMKDCTER 71 29 13 13 3 5 ......... 71 ......N.. <1
& 429-437 857 1.8 QMKDCTERQ 71 29 13 13 2 4 ......... 71 .....N... <1
& 430-438 865 2.4 MKDCTERQA 62 38 10 26 3 5 ......... 62 ....N...V 0
& 431-439 872 2.2 KDCTERQAN 64 36 10 23 3 5 ......... 64 ...N...V. 0
& 432-440 874 2.2 DCTERQANF 64 36 10 24 2 5 ......... 64 ..N...V.. 0
& 433-441 871 1.7 CTERQANFL 73 27 14 11 2 4 ......... 73 .N...V... 0
& 434-442 873 1.7 TERQANFLG 72 28 14 12 2 4 ......... 72 N...V.... 0
& 435-443 877 1.3 ERQANFLGK 77 23 15 6 1 3 ......... 77 ...V..... 15
& 436-444 878 1.4 RQANFLGKI 77 23 14 8 1 3 ......... 77 ..V...... 14
& 437-445 879 1.3 QANFLGKIW 78 22 14 7 1 3 ......... 78 .V....... 14
& 438-446 877 1.3 ANFLGKIWP 78 22 14 6 2 3 ......... 78 V........ 14
# 439-447 875 0.6 NFLGKIWPS 93 7 2 4 1 2 ......... 93 ......... 93
& 440-448 885 2.0 FLGKIWPSH 58 42 24 15 3 4 ........Y 24 ......... 58
& 441-449 883 2.1 LGKIWPSHK 57 43 24 16 4 5 .......Y. 24 ......... 57
& 442-450 882 2.2 GKIWPSHKG 57 43 23 16 4 6 ......Y.. 23 ......... 57
& 443-451 882 2.2 KIWPSHKGR 57 43 23 16 3 6 .....Y... 23 ......... 57
& 444-452 884 2.1 IWPSHKGRP 58 42 24 15 3 5 ....Y.... 24 ......... 58
& 445-453 881 2.0 WPSHKGRPG 59 41 24 14 3 5 ...Y..... 24 ......... 59
& 446-454 880 1.9 PSHKGRPGN 60 40 24 14 3 4 ..Y...... 24 ......... 60
& 447-455 882 1.9 SHKGRPGNF 60 40 24 13 3 4 .Y....... 24 ......... 60
& 448-456 882 2.2 HKGRPGNFL 56 44 23 18 3 5 Y........ 23 ......... 56
& 449-457 885 0.9 KGRPGNFLQ 89 11 3 6 2 3 ......... 89 ......... 89
& 450-458 887 1.7 GRPGNFLQS 63 37 27 8 2 4 ......... 63 ........N 27
& 451-459 887 1.7 RPGNFLQSR 63 37 26 9 2 4 ......... 63 .......N. 26
& 452-460 886 1.8 PGNFLQSRP 63 37 25 10 2 4 ......... 63 ......N.. 25
& 453-461 883 1.9 GNFLQSRPE 62 38 25 11 2 5 ......... 62 .....N... 25
& 454-462 876 1.9 NFLQSRPEP 61 39 25 12 2 4 ......... 61 ....N.... 25
& 455-463 876 2.4 FLQSRPEPT 54 46 24 18 3 6 ......... 54 ...N....S 1
& 456-464 942 2.5 LQSRPEPTA 54 46 23 20 4 6 ......... 54 ..N....S. <1
457-465 * 48 2.2 QSRPEQSRP 38 63 31 19 13 17 .....PTA- 0 .N...P.A- 0
458-466 * 46 2.4 SRPEQSRPE 39 61 30 17 13 20 ....PTA-- 0 N...P.A-- 0
459-467 * 47 2.0 RPEPTAPEP 43 57 38 4 15 19 ......--- 0 ....S.--- 0
460-468 * 46 2.1 PEQSRPEPT 39 61 39 4 17 22 ..PTA---- 0 ..P.A---- 0
461-469 * 46 2.2 EQSRPEPTA 39 61 37 4 20 24 .PTA----- 0 .P.A----- 0
462-470 * 46 2.1 PTAPEPTAP 39 61 39 4 17 22 ...-----. 0 .S.-----. 0
463-471 * 57 2.2 SRPEPTAPP 46 54 32 7 16 21 TA-----.. 0 .A-----.. 0
464-472 * 57 2.4 RPEPTAPPE 47 53 23 12 18 23 A-----... 0 A-----..A 0
465-473 * 57 1.7 PEPTAPPEE 70 30 9 9 12 18 -----.... 0 -----..A. 0
466-474 * 57 1.5 EPTAPPEES 72 28 9 14 5 12 ----..... 0 ----..A.. 0
& 467-475 204 2.4 PPAPPEESF 47 53 25 23 5 9 ---...... 0 ---..A..L 0
& 468-476 204 2.7 PAPPEESFR 45 55 24 25 6 12 --....... 0 --..A..LG 0
& 469-477 204 1.7 APPEESFRF 75 25 7 12 6 9 -.......S 0 -..A..LG. 0
& 470-478 955 2.6 PPEESFRFG 57 43 18 22 3 6 .......S. <1 ..A..LG.. 0
& 471-479 950 2.7 PEESFRFGE 56 44 18 22 4 7 ......S.V <1 .A..LG... 0
& 472-480 945 2.9 EESFRFGEE 53 47 18 24 5 8 .....S.V. <1 A..LG.... 0
& 473-481 903 2.9 ESFRFGEET 51 49 19 26 5 8 ....S.V.. <1 ..LG....A 0
& 474-482 903 3.5 SFRFGEETT 39 61 19 37 6 10 ...S.V... <1 .LG....A. 0
& 475-483 902 3.8 FRFGEETTT 33 67 19 42 7 11 ..S.V.... <1 LG....A.. 0
& 476-484 899 3.7 RFGEETTTP 33 67 19 41 6 10 .S.V..... <1 G....A... 0
& 477-485 889 3.9 FGEETTTPS 27 73 19 47 7 11 S.V.....P <1 ....A...P <1
& 478-486 882 3.7 GEETTTPSQ 30 70 19 45 6 10 .V.....P. <1 ...A...P. <1
& 479-487 888 3.7 EETTTPSQK 30 70 19 45 6 10 V.....P.. <1 ..A...P.. <1
& 480-488 885 3.8 ETTTPSQKQ 30 70 18 46 6 10 .....P... 11 .A...P... <1
& 481-489 884 3.9 TTTPSQKQE 29 71 18 47 6 10 ....P.... 11 A...P.... <1
+ 482-490 907 4.5 AAPSSKQEP 18 82 15 59 8 13 TT.PQ.... 10 TT.PQ...T <1
+ 483-491 881 4.7 APSSKQEPK 18 82 15 57 10 15 T.PQ....I 8 T.PQ...TV 0
& 484-492 875 4.4 PSQKQEPID 24 76 18 50 9 14 .P....... 7 .P....TV. 0
& 485-493 865 4.5 SQKQEPIDK 22 78 18 51 9 14 P........ 8 P....TV.. 0
& 486-494 872 4.4 QKQEPIDKE 26 74 18 49 8 13 ......... 26 ....TV... <1
& 487-495 863 4.9 KQEPIDKEL 21 79 18 52 10 16 ......... 21 ...TV.... <1
& 488-496 862 4.9 QEPIDKELY 21 79 18 52 10 16 ......... 21 ..TV..... <1
& 489-497 862 4.8 EPIDKELYP 21 79 18 52 9 15 ......... 21 .TV...... <1
& 490-498 853 4.8 PIDKELYPL 22 78 17 52 9 15 ......... 22 TV....... <1
& 491-499 837 4.5 IDKELYPLA 28 72 16 46 9 15 ........T 5 V.......T <1
& 492-500 855 4.0 DKELYPLAS 34 66 16 43 7 11 .......T. 6 .......T. 6
& 493-501 540 3.6 KELYPLASL 44 56 11 37 8 13 ......T.. 11 ......T.. 11
& 494-502 518 4.1 ELYPLASLR 26 74 18 48 8 14 .....T... 7 .....T... 7
& 495-503 520 3.7 LYPLASLRS 32 68 19 42 7 11 ....T.... 8 ....T.... 8
& 496-504 526 2.8 YPLASLRSL 44 56 20 30 6 8 ...T..... 12 ...T..... 12
& 497-505 544 2.8 PLASLRSLF 42 58 19 34 4 7 ..T...... 12 ..T...... 12
& 498-506 543 2.8 LASLRSLFG 42 58 20 34 5 7 .T....... 12 .T....... 12
& 499-507 552 3.1 ASLRSLFGN 26 74 18 53 4 6 T........ 14 T.......S <1
& 500-508 556 2.2 SLRSLFGND 40 60 29 28 3 4 ......... 40 .......S. 18
& 501-509 554 2.1 LRSLFGNDP 44 56 29 24 3 4 ......... 44 ......S.. 18
& 502-510 416 2.0 RSLFGNDPS 52 48 28 17 4 5 ......... 52 .....S... <1
& 503-511 414 1.2 SLFGNDPSS 80 20 12 5 4 5 ......... 80 ....S.... 2
& 504-512 410 1.6 LFGNDPSSQ 73 27 12 11 4 6 ......... 73 ...S..... 2
Pol & 1-9 237 2.3 FFRENLAFP 45 55 34 16 5 9 .L..D...L <1 ......... 45
& 2-10 247 2.3 FRENLAFPQ 45 55 33 17 5 9 L..D...L. <1 ......... 45
& 3-11 245 2.5 RENLAFPQG 43 57 31 20 6 11 ..D...L.. 6 ......... 43
& 4-12 247 3.4 ENLAFPQGK 32 68 17 43 8 13 .D...L... 5 ......... 32
& 5-13 262 3.2 NLAFPQGKA 32 68 18 43 6 11 D...L.... 5 ......... 32
& 6-14 269 2.6 LAFPQGKAR 48 52 25 22 4 9 ...L..... 5 ......... 48
& 7-15 267 2.7 AFPQGKARE 46 54 25 23 6 10 ..L...... 5 ......... 46
& 8-16 265 3.2 FPQGKAREF 41 59 20 32 7 12 .L....... 4 ......... 41
& 9-17 267 4.0 PQGKAREFS 24 76 16 51 9 17 L........ 3 ......... 24
& 10-18 265 3.8 QGKAREFSS 26 74 18 46 9 17 ......... 26 ......... 26
& 11-19 267 3.9 GKAREFSSE 24 76 19 48 9 18 ......... 24 ......... 24
& 12-20 471 2.8 KAREFSSEQ 56 44 11 27 6 10 ......... 56 ......... 56
& 13-21 468 2.8 AREFSSEQT 59 41 11 24 6 11 ......... 59 ......... 59
& 14-22 469 2.7 REFSSEQTR 59 41 11 24 6 11 ......... 59 ......... 59
& 15-23 468 2.9 EFSSEQTRA 56 44 11 26 6 11 ......... 56 ......... 56
& 16-24 465 3.5 FSSEQTRAN 40 60 17 37 6 13 ......... 40 ........I 17
& 17-25 465 3.2 SSEQTRANS 44 56 16 35 5 11 ......... 44 .......I. 16
& 18-26 471 2.7 SEQTRANSP 55 45 17 22 6 10 ......... 55 ......I.. 17
& 19-27 474 2.5 EQTRANSPT 57 43 18 19 6 9 ......... 57 .....I... 18
& 20-28 474 2.8 QTRANSPTR 52 48 16 25 7 10 ......... 52 ....I...S 1
& 21-29 467 3.4 TRANSPTRR 32 68 21 40 7 11 ......... 32 ...I...S. 1
& 22-30 475 3.0 RANSPTRRE 36 64 25 33 6 10 ......... 36 ..I...S.. 1
& 23-31 476 3.2 ANSPTRREL 34 66 24 36 7 11 ......... 34 .I...S... 2
& 24-32 494 3.2 NSPTRRELQ 34 66 24 35 7 11 ......... 34 I...S...R 0
& 25-33 434 2.6 SPTRRELQV 45 55 32 17 7 10 ......... 45 ...S...R. <1
& 26-34 433 2.6 PTRRELQVW 45 55 32 17 7 10 ......... 45 ..S...R.. <1
& 27-35 452 2.5 TRRELQVWG 46 54 31 17 6 9 ......... 46 .S...R... <1
& 28-36 448 3.0 RRELQVWGR 33 67 29 32 6 9 ......... 33 S...R...G <1
& 29-37 477 2.9 RELQVWGRD 35 65 28 33 4 9 ......... 35 ...R...GG 0
& 30-38 468 2.6 ELQVWGRDN 55 45 18 21 5 10 ......... 55 ..R...GG. 0
& 31-39 468 3.4 LQVWGRDNN 37 63 18 39 6 12 ......... 37 .R...GG.. 0
& 32-40 485 3.8 QVWGRDNNS 28 72 17 49 5 12 ......... 28 R...GG... 0
& 33-41 484 4.6 VWGRDNNSL 23 77 15 54 9 17 ........P 2 ...GG...P 0
& 34-42 486 4.5 WGRDNNSLS 23 77 15 54 8 17 .......P. 2 ..GG...P. 0
& 35-43 573 4.6 GRDNNSLSE 26 74 13 52 9 17 ......P.. 2 .GG...P.. 0
& 36-44 590 4.9 RDNNSLSEA 24 76 12 55 9 18 .....P... 4 GG...P... 0
& 37-45 618 4.5 DNNSLSEAG 28 72 13 51 8 15 ....P.... 8 G...P.... <1
+ 38-46 622 5.0 NNSLSEAGA 15 85 12 65 9 17 ...P..... 7 ...P....D <1
+ 39-47 671 5.3 NSLSEAGAD 16 84 9 65 10 19 ..P...... 7 ..P....DS 0
+ 40-48 700 5.2 SLSEAGADR 20 80 10 62 9 18 .P....... 10 .P....DS. 0
+ 41-49 699 5.1 LSEAGADRQ 20 80 9 62 9 17 P........ 9 P....DS.. 0
& 42-50 704 4.4 SEAGADRQG 33 67 9 51 6 13 ......... 33 ....DS... 0
& 43-51 730 5.4 EAGADRQGT 24 76 8 59 9 19 ......... 24 ...DS.... 0
& 44-52 733 5.7 AGADRQGTV 22 78 7 60 11 21 ......... 22 ..DS..... 0
& 45-53 735 5.5 GADRQGTVS 23 77 7 60 10 20 ......... 23 .DS...... 0
+ 46-54 732 5.9 ADRQGTVSF 17 83 7 63 14 24 ......... 17 DS....... 0
+ 47-55 743 5.9 DRQGTVSFS 17 83 7 62 14 24 ........N 3 S.......D 0
& 48-56 749 5.4 RQGTVSFSF 26 74 7 55 12 21 .......N. 3 .......DL 0
& 49-57 759 5.2 QGTVSFSFP 27 73 7 56 9 18 ......N.. 3 ......DL. 0
& 50-58 763 4.9 GTVSFSFPQ 29 71 7 55 8 16 .....N... 3 .....DL.. 0
& 51-59 842 5.0 TVSFSFPQI 29 71 7 57 7 14 ....N...V <1 ....DL... 0
& 52-60 865 3.5 VSFSFPQIT 45 55 8 44 3 7 ...N...V. <1 ...DL.... <1
& 53-61 882 2.9 SFSFPQITL 50 50 8 39 2 5 ..N...V.. <1 ..DL..... <1
& 54-62 971 2.8 FSFPQITLW 51 49 8 39 2 4 .N...V... <1 .DL...... <1
& 55-63 976 2.1 SFPQITLWQ 57 43 14 27 1 2 N...V.... <1 DL....... <1
& 56-64 1078 0.8 FPQITLWQR 84 16 14 <1 <1 1 ...V..... <1 L........ 14
# 57-65 7010 0.4 PQITLWQRP 96 4 <1 2 <1 1 ..V...... 1 ......... 96
& 58-66 6829 1.5 QITLWQRPL 70 30 21 9 <1 2 .V....... 1 ......... 70
& 59-67 6894 1.6 ITLWQRPLV 70 30 20 9 <1 2 V........ 1 ......... 70
& 60-68 10152 2.3 TLWQRPLVT 62 38 18 19 1 2 ......... 62 ......... 62
& 61-69 10138 3.0 LWQRPLVTI 53 47 14 31 2 3 ......... 53 ......... 53
& 62-70 10290 3.4 WQRPLVTIK 49 51 13 36 2 4 ......... 49 ......... 49
& 63-71 10240 3.9 QRPLVTIKI 42 58 12 44 2 4 ......... 42 ......... 42
& 64-72 10294 4.2 RPLVTIKIG 41 59 12 45 3 5 ......... 41 ......... 41
& 65-73 10368 4.2 PLVTIKIGG 40 60 11 46 3 5 ......... 40 ......... 40
& 66-74 10472 4.4 LVTIKIGGQ 39 61 11 46 3 5 ......... 39 ......... 39
& 67-75 10642 3.9 VTIKIGGQL 50 50 9 39 3 5 ......... 50 ......... 50
& 68-76 10554 4.2 TIKIGGQLK 48 52 8 41 3 6 ......... 48 ........I <1
& 69-77 10691 3.6 IKIGGQLKE 51 49 9 38 2 4 ......... 51 .......I. <1
& 70-78 10924 3.0 KIGGQLKEA 59 41 8 31 2 3 ......... 59 ......I.. 1
& 71-79 11126 2.6 IGGQLKEAL 65 35 10 24 1 3 ......... 65 .....I... 1
& 72-80 11316 2.1 GGQLKEALL 73 27 6 20 1 2 ......... 73 ....I.... 2
& 73-81 11375 1.8 GQLKEALLD 77 23 6 16 1 2 ......... 77 ...I..... 2
& 74-82 11393 1.7 QLKEALLDT 78 22 6 15 <1 2 ......... 78 ..I...... 2
& 75-83 11460 1.6 LKEALLDTG 79 21 6 14 <1 1 ......... 79 .I....... 2
& 76-84 11671 0.9 KEALLDTGA 89 11 3 8 <1 1 ......... 89 I........ 2
# 77-85 11853 0.5 EALLDTGAD 95 5 3 2 <1 1 ......... 95 ......... 95
# 78-86 12120 0.6 ALLDTGADD 93 7 3 4 <1 1 ......... 93 ......... 93
# 79-87 12133 0.6 LLDTGADDT 93 7 3 4 <1 1 ......... 93 ......... 93
# 80-88 12149 0.6 LDTGADDTV 92 8 3 5 <1 1 ......... 92 ......... 92
& 81-89 12074 0.9 DTGADDTVL 89 11 3 8 <1 1 ......... 89 ......... 89
& 82-90 12069 1.0 TGADDTVLE 88 12 2 9 <1 1 ......... 88 ......... 88
& 83-91 11875 1.7 GADDTVLEE 72 28 16 11 <1 1 ......... 72 ........D 16
& 84-92 11558 2.2 ADDTVLEEM 65 35 13 22 <1 2 ......... 65 .......DI 3
& 85-93 11135 3.8 DDTVLEEMN 46 54 9 43 2 3 ........S 9 ......DID <1
& 86-94 11118 3.8 DTVLEEMNL 46 54 9 43 2 3 .......S. 9 .....DID. <1
& 87-95 11125 3.8 TVLEEMNLP 45 55 9 44 2 3 ......S.. 9 ....DID.. <1
& 88-96 11126 3.9 VLEEMNLPG 45 55 9 44 2 3 .....S... 9 ...DID... <1
& 89-97 10947 4.4 LEEMNLPGR 37 63 9 52 2 4 ....S.... 7 ..DID.... <1
& 90-98 11036 4.1 EEMNLPGRW 39 61 9 50 1 3 ...S..... 7 .DID..... <1
& 91-99 10981 4.2 EMNLPGRWK 39 61 9 51 2 3 ..S...... 7 DID...... <1
& 92-100 11085 3.6 MNLPGRWKP 44 56 9 46 1 2 .S....... 8 ID....... 2
& 93-101 11307 3.1 NLPGRWKPK 49 51 11 39 <1 2 S........ 9 D........ 9
& 94-102 11531 2.2 LPGRWKPKM 62 38 15 22 <1 1 ......... 62 ........I 8
& 95-103 11547 2.2 PGRWKPKMI 62 38 15 22 <1 1 ......... 62 .......I. 7
& 96-104 11593 2.2 GRWKPKMIG 63 37 16 21 <1 1 ......... 63 ......I.. 7
& 97-105 11594 2.2 RWKPKMIGG 63 37 15 21 <1 1 ......... 63 .....I... 7
& 98-106 11885 1.5 WKPKMIGGI 79 21 9 12 <1 1 ......... 79 ....I.... 9
& 99-107 11886 1.5 KPKMIGGIG 79 21 8 12 <1 1 ......... 79 ...I..... 8
& 100-108 11997 1.3 PKMIGGIGG 81 19 9 10 <1 1 ......... 81 ..I...... 9
& 101-109 11925 1.4 KMIGGIGGF 81 19 8 10 <1 1 ......... 81 .I....... 8
& 102-110 11875 1.7 MIGGIGGFI 79 21 6 14 <1 2 ......... 79 I........ 6
& 103-111 12013 1.2 IGGIGGFIK 86 14 5 8 <1 1 ......... 86 ........R <1
& 104-112 12062 1.2 GGIGGFIKV 86 14 6 8 <1 1 ......... 86 .......R. <1
& 105-113 11889 1.5 GIGGFIKVR 79 21 8 13 <1 1 ......... 79 ......R.. <1
& 106-114 11851 1.6 IGGFIKVRQ 78 22 8 14 <1 1 ......... 78 .....R... <1
& 107-115 11844 1.5 GGFIKVRQY 78 22 8 14 <1 1 ......... 78 ....R.... <1
& 108-116 11743 1.9 GFIKVRQYD 73 27 7 19 <1 2 ......... 73 ...R..... <1
& 109-117 11653 2.2 FIKVRQYDQ 71 29 6 22 1 2 ......... 71 ..R.....H 0
& 110-118 11329 3.0 IKVRQYDQI 56 44 15 28 1 3 ......... 56 .R.....HV 0
& 111-119 10856 4.2 KVRQYDQIP 31 69 18 49 2 4 ........L 18 R.....HV. 0
& 112-120 10676 4.9 VRQYDQIPI 27 73 11 59 2 5 .......L. 11 .....HV.. <1
& 113-121 10641 5.1 RQYDQIPIE 26 74 11 60 3 5 ......L.. 11 ....HV... <1
& 114-122 10712 4.8 QYDQIPIEI 29 71 12 56 2 5 .....L... 12 ...HV.... <1
& 115-123 10705 4.8 YDQIPIEIC 29 71 12 56 3 5 ....L.... 12 ..HV..... <1
& 116-124 10708 4.8 DQIPIEICG 29 71 12 56 3 5 ...L..... 12 .HV...... <1
& 117-125 10718 4.8 QIPIEICGH 30 70 11 55 3 5 ..L...... 11 HV......Q 0
& 118-126 10732 4.7 IPIEICGHK 30 70 12 55 3 5 .L....... 12 V......Q. <1
& 119-127 10721 5.0 PIEICGHKA 26 74 12 59 3 5 L........ 12 ......Q.. <1
& 120-128 10982 4.0 IEICGHKAI 42 58 13 42 2 4 ......... 42 .....Q... 1
& 121-129 11210 3.3 EICGHKAIG 58 42 7 33 2 4 ......... 58 ....Q...T 0
& 122-130 11184 3.3 ICGHKAIGT 59 41 6 33 2 4 ......... 59 ...Q...T. 0
& 123-131 11209 3.3 CGHKAIGTV 59 41 7 33 2 4 ......... 59 ..Q...T.. 0
& 124-132 11254 3.2 GHKAIGTVL 59 41 6 33 2 3 ......... 59 .Q...T... 0
& 125-133 10882 4.0 HKAIGTVLV 44 56 15 39 2 4 ......... 44 Q...T...I 0
& 126-134 10933 3.6 KAIGTVLVG 47 53 16 35 2 4 ......... 47 ...T...I. <1
& 127-135 10962 3.5 AIGTVLVGP 49 51 17 33 2 4 ......... 49 ..T...I.. <1
& 128-136 11261 2.7 IGTVLVGPT 55 45 22 22 1 2 ......... 55 .T...I... <1
& 129-137 11602 1.9 GTVLVGPTP 61 39 28 11 <1 1 ......... 61 T...I.... <1
& 130-138 11549 2.3 TVLVGPTPV 55 45 26 18 <1 1 ......... 55 ...I..... 26
& 131-139 11625 2.1 VLVGPTPVN 55 45 27 17 <1 1 ......... 55 ..I...... 27
& 132-140 11581 2.4 LVGPTPVNI 54 46 26 20 <1 1 ......... 54 .I....... 26
& 133-141 11556 2.4 VGPTPVNII 54 46 25 20 <1 2 ......... 54 I........ 25
& 134-142 12019 1.5 GPTPVNIIG 79 21 8 12 <1 1 ......... 79 ......... 79
& 135-143 11997 1.5 PTPVNIIGR 79 21 8 12 <1 1 ......... 79 ......... 79
& 136-144 11891 1.6 TPVNIIGRN 77 23 8 14 <1 1 ......... 77 ......... 77
& 137-145 11820 1.8 PVNIIGRNL 76 24 8 15 <1 1 ......... 76 ......... 76
& 138-146 11653 2.2 VNIIGRNLL 72 28 5 23 <1 2 ......... 72 ........M 5
& 139-147 11745 1.6 NIIGRNLLT 78 22 9 13 <1 1 ......... 78 .......M. 9
& 140-148 11687 1.7 IIGRNLLTQ 77 23 8 14 <1 1 ......... 77 ......M.. 8
& 141-149 11516 2.4 IGRNLLTQI 53 47 25 21 <1 2 ......... 53 .....M... 5
& 142-150 11559 2.3 GRNLLTQIG 53 47 25 21 <1 1 ......... 53 ....M.... 5
& 143-151 11506 2.4 RNLLTQIGC 52 48 25 22 <1 2 ......... 52 ...M..... 5
& 144-152 11615 2.4 NLLTQIGCT 52 48 25 22 <1 2 ......... 52 ..M...... 5
& 145-153 11633 2.2 LLTQIGCTL 53 47 26 20 <1 2 ......... 53 .M....... 5
& 146-154 11728 2.0 LTQIGCTLN 54 46 27 18 <1 1 ......... 54 M........ 5
& 147-155 11594 1.5 TQIGCTLNF 59 41 35 5 <1 1 ......... 59 ......... 59
& 148-156 2933 1.5 QIGCTLNFP 62 38 32 5 1 2 ......... 62 ......... 62
& 149-157 2700 1.3 IGCTLNFPI 64 36 32 2 1 2 ......... 64 ......... 64
# 150-158 2737 0.4 GCTLNFPIS 97 3 <1 2 <1 2 ......... 97 ......... 97
# 151-159 2737 0.4 CTLNFPISP 96 4 <1 3 <1 2 ......... 96 ......... 96
# 152-160 2748 0.5 TLNFPISPI 96 4 <1 3 <1 2 ......... 96 ......... 96
# 153-161 2761 0.8 LNFPISPIE 92 8 2 5 <1 2 ......... 92 ......... 92
# 154-162 2787 0.9 NFPISPIET 91 9 2 6 1 2 ......... 91 ......... 91
# 155-163 2797 0.9 FPISPIETV 91 9 2 6 <1 2 ......... 91 ......... 91
& 156-164 7252 0.9 PISPIETVP 90 10 3 6 <1 1 ......... 90 ......... 90
# 157-165 7351 0.9 ISPIETVPV 90 10 3 6 <1 1 ......... 90 ......... 90
& 158-166 7220 1.0 SPIETVPVK 89 11 3 7 <1 1 ......... 89 ......... 89
& 159-167 7289 0.9 PIETVPVKL 90 10 3 6 <1 1 ......... 90 ......... 90
# 160-168 7091 0.9 IETVPVKLK 90 10 4 6 <1 1 ......... 90 ......... 90
# 161-169 7153 0.8 ETVPVKLKP 90 10 4 5 <1 1 ......... 90 ......... 90
# 162-170 7226 0.5 TVPVKLKPG 95 5 <1 3 <1 1 ......... 95 ......... 95
# 163-171 7228 0.5 VPVKLKPGM 95 5 <1 3 <1 1 ......... 95 ......... 95
# 164-172 7283 0.5 PVKLKPGMD 96 4 <1 3 <1 1 ......... 96 ......... 96
# 165-173 7422 0.5 VKLKPGMDG 96 4 <1 3 <1 1 ......... 96 ......... 96
# 166-174 7480 0.4 KLKPGMDGP 96 4 <1 3 <1 1 ......... 96 ......... 96
& 167-175 7447 0.9 LKPGMDGPK 83 17 14 2 <1 1 ......... 83 ........R 14
& 168-176 7458 1.0 KPGMDGPKV 82 18 14 3 <1 1 ......... 82 .......R. 14
& 169-177 7551 1.0 PGMDGPKVK 82 18 14 4 <1 1 ......... 82 ......R.. 14
& 170-178 7626 1.0 GMDGPKVKQ 82 18 14 4 <1 1 ......... 82 .....R... 14
& 171-179 7679 1.0 MDGPKVKQW 82 18 14 4 <1 1 ......... 82 ....R.... 14
& 172-180 7732 1.0 DGPKVKQWP 82 18 14 3 <1 1 ......... 82 ...R..... 14
& 173-181 8123 0.9 GPKVKQWPL 82 18 14 3 <1 1 ......... 82 ..R...... 14
& 174-182 8301 1.0 PKVKQWPLT 82 18 14 4 <1 1 ......... 82 .R....... 14
& 175-183 8649 1.1 KVKQWPLTE 81 19 13 5 <1 1 ......... 81 R........ 13
# 176-184 8815 0.5 VKQWPLTEE 95 5 1 4 <1 1 ......... 95 ......... 95
# 177-185 8894 0.4 KQWPLTEEK 96 4 <1 3 <1 1 ......... 96 ......... 96
# 178-186 8967 0.4 QWPLTEEKI 96 4 <1 3 <1 1 ......... 96 ......... 96
# 179-187 9435 0.6 WPLTEEKIK 94 6 1 5 <1 1 ......... 94 ......... 94
# 180-188 9651 0.7 PLTEEKIKA 93 7 1 5 <1 1 ......... 93 ......... 93
# 181-189 9839 0.7 LTEEKIKAL 93 7 1 5 <1 1 ......... 93 ......... 93
& 182-190 9589 2.1 TEEKIKALV 66 34 11 22 <1 2 ......... 66 ......... 66
& 183-191 9702 2.2 EEKIKALVE 66 34 9 23 1 2 ......... 66 ......... 66
& 184-192 10053 2.2 EKIKALVEI 67 33 9 23 1 2 ......... 67 ......... 67
& 185-193 10466 2.1 KIKALVEIC 67 33 10 22 <1 2 ......... 67 ......... 67
& 186-194 10377 2.8 IKALVEICT 63 37 8 28 1 3 ......... 63 ......... 63
& 187-195 10460 2.9 KALVEICTE 63 37 8 28 2 3 ......... 63 ......... 63
& 188-196 10506 3.5 ALVEICTEM 48 52 16 35 2 3 ......... 48 ........L 16
& 189-197 10559 3.4 LVEICTEME 48 52 16 35 2 3 ......... 48 .......L. 16
& 190-198 10473 3.8 VEICTEMEK 48 52 11 38 2 4 ......... 48 ......L.. 11
& 191-199 11199 2.9 EICTEMEKE 61 39 11 26 2 3 ......... 61 .....L... 11
& 192-200 11290 2.8 ICTEMEKEG 62 38 11 26 1 2 ......... 62 ....L.... 11
& 193-201 16771 2.7 CTEMEKEGK 64 36 10 25 1 2 ......... 64 ...L..... 10
& 194-202 17052 2.7 TEMEKEGKI 64 36 10 24 1 2 ......... 64 ..L...... 10
& 195-203 17544 2.2 EMEKEGKIS 66 34 13 20 <1 2 ......... 66 .L....... 13
& 196-204 17779 2.4 MEKEGKISK 62 38 13 24 <1 2 ......... 62 L........ 13
& 197-205 19386 1.9 EKEGKISKI 75 25 5 19 <1 1 ......... 75 ......... 75
& 198-206 19448 1.9 KEGKISKIG 75 25 5 19 <1 1 ......... 75 ......... 75
& 199-207 19755 1.4 EGKISKIGP 80 20 5 14 <1 1 ......... 80 ......... 80
& 200-208 19898 1.1 GKISKIGPE 86 14 5 8 <1 1 ......... 86 ......... 86
& 201-209 19919 1.1 KISKIGPEN 86 14 5 8 <1 1 ......... 86 ......... 86
& 202-210 20000 1.0 ISKIGPENP 86 14 5 8 <1 1 ......... 86 ......... 86
& 203-211 19977 1.0 SKIGPENPY 86 14 5 8 <1 1 ......... 86 ......... 86
# 204-212 19970 0.7 KIGPENPYN 90 10 6 4 <1 1 ......... 90 ......... 90
# 205-213 20230 0.4 IGPENPYNT 96 4 1 3 <1 1 ......... 96 ......... 96
# 206-214 20304 0.3 GPENPYNTP 97 3 <1 2 <1 0 ......... 97 ......... 97
& 207-215 19953 0.8 PENPYNTPV 84 16 13 2 <1 1 ......... 84 ......... 84
& 208-216 19954 0.9 ENPYNTPVF 84 16 13 2 <1 1 ......... 84 ......... 84
& 209-217 19951 0.9 NPYNTPVFA 83 17 14 4 <1 1 ......... 83 ........V 2
& 210-218 19936 0.9 PYNTPVFAI 82 18 14 4 <1 1 ......... 82 .......V. 2
& 211-219 19780 1.1 YNTPVFAIK 81 19 13 5 <1 1 ......... 81 ......V.. 2
& 212-220 19748 1.2 NTPVFAIKK 80 20 13 7 <1 1 ......... 80 .....V... 2
& 213-221 19844 1.2 TPVFAIKKK 80 20 13 7 <1 1 ......... 80 ....V.... 2
& 214-222 19523 2.0 PVFAIKKKD 65 35 13 21 <1 1 ......... 65 ...V..... 1
& 215-223 19461 2.3 VFAIKKKDS 62 38 13 24 <1 1 ......... 62 ..V...... <1
& 216-224 19508 2.2 FAIKKKDST 68 32 12 19 <1 2 ......... 68 .V....... <1
& 217-225 19227 2.6 AIKKKDSTK 66 34 6 27 1 2 ......... 66 V........ <1
& 218-226 19331 2.5 IKKKDSTKW 67 33 6 26 <1 2 ......... 67 ......... 67
& 219-227 19310 2.5 KKKDSTKWR 67 33 6 26 <1 2 ......... 67 ......... 67
& 220-228 19454 2.4 KKDSTKWRK 68 32 7 25 <1 2 ......... 68 ......... 68
& 221-229 19249 2.6 KDSTKWRKL 66 34 5 28 1 2 ......... 66 ......... 66
& 222-230 19151 2.8 DSTKWRKLV 66 34 5 28 1 3 ......... 66 ........T <1
& 223-231 19368 2.3 STKWRKLVD 70 30 7 22 <1 2 ......... 70 .......T. <1
& 224-232 19471 2.1 TKWRKLVDF 73 27 7 19 <1 2 ......... 73 ......T.. <1
& 225-233 19751 1.5 KWRKLVDFR 77 23 12 11 <1 1 ......... 77 .....T... <1
& 226-234 20066 0.9 WRKLVDFRE 88 12 4 7 <1 1 ......... 88 ....T.... <1
& 227-235 20053 0.9 RKLVDFREL 88 12 4 7 <1 1 ......... 88 ...T..... <1
& 228-236 20088 0.9 KLVDFRELN 89 11 4 7 <1 1 ......... 89 ..T...... <1
& 229-237 20043 1.0 LVDFRELNK 88 12 4 7 <1 1 ......... 88 .T....... <1
& 230-238 20085 1.2 VDFRELNKR 79 21 14 6 <1 1 ......... 79 T........ <1
& 231-239 20234 0.9 DFRELNKRT 83 17 14 3 <1 1 ......... 83 ......... 83
& 232-240 20313 0.9 FRELNKRTQ 83 17 14 3 <1 1 ......... 83 ......... 83
& 233-241 20302 0.9 RELNKRTQD 83 17 14 2 <1 1 ......... 83 ......... 83
& 234-242 20274 0.9 ELNKRTQDF 83 17 14 2 <1 1 ......... 83 ......... 83
& 235-243 20275 1.0 LNKRTQDFW 82 18 14 3 <1 1 ......... 82 ......... 82
& 236-244 20272 1.0 NKRTQDFWE 82 18 14 3 <1 1 ......... 82 ......... 82
& 237-245 20112 1.1 KRTQDFWEV 80 20 14 6 <1 1 ......... 80 ......... 80
& 238-246 20152 1.1 RTQDFWEVQ 81 19 14 5 <1 1 ......... 81 ......... 81
# 239-247 20402 0.5 TQDFWEVQL 95 5 2 3 <1 0 ......... 95 ......... 95
# 240-248 20415 0.5 QDFWEVQLG 95 5 2 3 <1 0 ......... 95 ......... 95
# 241-249 20408 0.5 DFWEVQLGI 94 6 2 3 <1 0 ......... 94 ......... 94
# 242-250 20454 0.4 FWEVQLGIP 95 5 2 2 <1 0 ......... 95 ......... 95
# 243-251 20430 0.4 WEVQLGIPH 95 5 2 2 <1 0 ......... 95 ......... 95
# 244-252 20484 0.3 EVQLGIPHP 96 4 3 1 <1 0 ......... 96 ......... 96
& 245-253 20263 0.8 VQLGIPHPA 88 12 6 6 <1 0 ......... 88 ........S 6
# 246-254 20407 0.7 QLGIPHPAG 91 9 6 3 <1 0 ......... 91 .......S. 6
& 247-255 20312 0.8 LGIPHPAGL 89 11 6 5 <1 0 ......... 89 ......S.. 6
& 248-256 20018 1.2 GIPHPAGLK 84 16 5 10 <1 1 ......... 84 .....S... 5
& 249-257 19699 1.6 IPHPAGLKK 80 20 5 14 <1 1 ......... 80 ....S.... 5
& 250-258 19288 2.2 PHPAGLKKK 71 29 8 20 <1 1 ......... 71 ...S..... 4
& 251-259 19116 2.4 HPAGLKKKK 69 31 8 22 <1 2 ......... 69 ..S...... 4
& 252-260 19157 2.4 PAGLKKKKS 69 31 8 23 <1 2 ......... 69 .S....... 4
& 253-261 19044 2.6 AGLKKKKSV 67 33 8 25 <1 2 ......... 67 S........ 4
& 254-262 19181 2.1 GLKKKKSVT 72 28 9 19 <1 2 ......... 72 ......... 72
& 255-263 19058 2.2 LKKKKSVTV 71 29 8 20 <1 2 ......... 71 ......... 71
& 256-264 19101 2.2 KKKKSVTVL 71 29 9 18 <1 2 ......... 71 ......... 71
& 257-265 19278 1.8 KKKSVTVLD 74 26 10 15 <1 1 ......... 74 ......... 74
& 258-266 19507 1.6 KKSVTVLDV 77 23 11 12 <1 1 ......... 77 ......... 77
& 259-267 19978 0.9 KSVTVLDVG 90 10 2 8 <1 1 ......... 90 ......... 90
# 260-268 20006 0.7 SVTVLDVGD 92 8 2 6 <1 1 ......... 92 ......... 92
# 261-269 19996 0.7 VTVLDVGDA 92 8 2 5 <1 1 ......... 92 ......... 92
# 262-270 20126 0.6 TVLDVGDAY 94 6 2 4 <1 1 ......... 94 ......... 94
# 263-271 20159 0.6 VLDVGDAYF 93 7 2 4 <1 1 ......... 93 ......... 93
# 264-272 20336 0.5 LDVGDAYFS 95 5 <1 4 <1 1 ......... 95 ......... 95
& 265-273 19978 1.0 DVGDAYFSV 84 16 11 4 <1 1 ......... 84 ......... 84
& 266-274 20009 1.0 VGDAYFSVP 84 16 11 4 <1 1 ......... 84 ......... 84
& 267-275 20010 0.9 GDAYFSVPL 85 15 11 4 <1 1 ......... 85 ......... 85
& 268-276 19885 1.3 DAYFSVPLD 80 20 11 9 <1 1 ......... 80 ......... 80
& 269-277 19322 2.4 AYFSVPLDK 53 47 23 23 <1 1 ........E 23 ......... 53
& 270-278 18934 3.4 YFSVPLDKD 35 65 18 46 <1 2 .......E. 17 ......... 35
& 271-279 18957 3.3 FSVPLDKDF 35 65 18 46 <1 2 ......E.. 17 ......... 35
& 272-280 18929 3.3 SVPLDKDFR 35 65 19 46 <1 1 .....E... 17 ......... 35
& 273-281 18937 3.3 VPLDKDFRK 35 65 19 46 <1 1 ....E.... 17 ......... 35
& 274-282 19242 2.8 PLDKDFRKY 37 63 22 40 <1 1 ...E..... 22 ......... 37
& 275-283 19239 2.8 LDKDFRKYT 37 63 22 40 <1 1 ..E...... 22 ......... 37
& 276-284 19264 2.8 DKDFRKYTA 37 63 22 40 <1 1 .E....... 22 ......... 37
& 277-285 19339 2.5 KDFRKYTAF 37 63 28 35 <1 1 E........ 28 ......... 37
& 278-286 19868 1.3 DFRKYTAFT 69 31 25 6 <1 1 ......... 69 ......... 69
# 279-287 20343 0.2 FRKYTAFTI 99 1 <1 1 <1 <1 ......... 99 ......... 99
# 280-288 20352 0.2 RKYTAFTIP 99 1 <1 1 <1 <1 ......... 99 ......... 99
# 281-289 20183 0.2 KYTAFTIPS 98 2 <1 1 <1 <1 ......... 98 ......... 98
& 282-290 19550 1.8 YTAFTIPSI 58 42 26 16 <1 1 ......... 58 ......... 58
& 283-291 19554 1.8 TAFTIPSIN 58 42 26 16 <1 1 ......... 58 ......... 58
& 284-292 19483 1.8 AFTIPSINN 58 42 26 16 <1 1 ......... 58 ......... 58
& 285-293 19337 2.0 FTIPSINNE 56 44 25 18 <1 1 ......... 56 ......... 56
& 286-294 19221 2.2 TIPSINNET 56 44 24 19 <1 1 ......... 56 ......... 56
& 287-295 19225 2.2 IPSINNETP 56 44 24 19 <1 1 ......... 56 ......... 56
& 288-296 19192 2.2 PSINNETPG 56 44 25 19 <1 1 ......... 56 ......... 56
& 289-297 18793 2.7 SINNETPGI 50 50 22 27 <1 2 ......... 50 ......... 50
& 290-298 18848 2.7 INNETPGIR 50 50 22 27 <1 2 ......... 50 ......... 50
& 291-299 19417 1.1 NNETPGIRY 85 15 7 8 <1 1 ......... 85 ......... 85
& 292-300 19373 1.1 NETPGIRYQ 85 15 7 8 <1 1 ......... 85 ......... 85
& 293-301 19423 1.1 ETPGIRYQY 85 15 7 8 <1 1 ......... 85 ......... 85
& 294-302 19546 0.9 TPGIRYQYN 87 13 7 6 <1 1 ......... 87 ......... 87
& 295-303 19640 0.8 PGIRYQYNV 88 12 7 4 <1 1 ......... 88 ......... 88
& 296-304 19630 0.8 GIRYQYNVL 88 12 7 4 <1 1 ......... 88 ......... 88
& 297-305 19642 0.8 IRYQYNVLP 88 12 7 4 <1 1 ......... 88 ......... 88
# 298-306 20066 0.3 RYQYNVLPQ 96 4 2 1 <1 <1 ......... 96 ......... 96
# 299-307 20112 0.3 YQYNVLPQG 97 3 2 1 <1 <1 ......... 97 ......... 97
# 300-308 20116 0.3 QYNVLPQGW 97 3 2 1 <1 <1 ......... 97 ......... 97
# 301-309 20187 0.3 YNVLPQGWK 97 3 2 1 <1 <1 ......... 97 ......... 97
# 302-310 20220 0.3 NVLPQGWKG 97 3 2 <1 <1 <1 ......... 97 ......... 97
# 303-311 20275 0.3 VLPQGWKGS 97 3 2 <1 <1 <1 ......... 97 ......... 97
# 304-312 20299 0.3 LPQGWKGSP 97 3 2 1 <1 <1 ......... 97 ......... 97
# 305-313 20222 0.5 PQGWKGSPA 95 5 2 3 <1 <1 ......... 95 ......... 95
# 306-314 20254 0.5 QGWKGSPAI 94 6 2 3 <1 <1 ......... 94 ......... 94
# 307-315 20287 0.3 GWKGSPAIF 96 4 2 1 <1 <1 ......... 96 ......... 96
# 308-316 20314 0.3 WKGSPAIFQ 96 4 2 1 <1 <1 ......... 96 ......... 96
& 309-317 19890 1.6 KGSPAIFQS 72 28 15 13 <1 1 ......... 72 ......... 72
& 310-318 19907 1.6 GSPAIFQSS 72 28 15 13 <1 1 ......... 72 ......... 72
& 311-319 19912 1.6 SPAIFQSSM 72 28 15 13 <1 1 ......... 72 ......... 72
& 312-320 19797 1.8 PAIFQSSMT 70 30 14 15 <1 1 ......... 70 ......... 70
& 313-321 19576 2.2 AIFQSSMTK 63 37 14 22 <1 1 ......... 63 ......... 63
& 314-322 19607 2.0 IFQSSMTKI 64 36 15 20 <1 1 ......... 64 ......... 64
& 315-323 19605 2.0 FQSSMTKIL 65 35 15 20 <1 1 ......... 65 ......... 65
& 316-324 19548 2.3 QSSMTKILE 62 38 13 25 <1 1 ......... 62 ......... 62
& 317-325 19535 2.3 SSMTKILEP 62 38 13 25 <1 1 ......... 62 ......... 62
& 318-326 19881 1.2 SMTKILEPF 83 17 6 11 <1 1 ......... 83 ......... 83
& 319-327 19823 1.2 MTKILEPFR 82 18 6 11 <1 1 ......... 82 ......... 82
& 320-328 19591 1.9 TKILEPFRK 75 25 6 19 <1 1 ......... 75 ......... 75
& 321-329 19485 2.1 KILEPFRKQ 73 27 6 20 <1 1 ......... 73 ......... 73
& 322-330 19759 1.8 ILEPFRKQN 79 21 4 16 <1 1 ......... 79 ......... 79
& 323-331 19788 1.8 LEPFRKQNP 79 21 4 16 <1 1 ......... 79 ......... 79
& 324-332 19401 2.6 EPFRKQNPD 62 38 16 22 <1 2 ......... 62 ......... 62
& 325-333 19069 3.0 PFRKQNPDI 58 42 12 29 1 2 ......... 58 ......... 58
& 326-334 18845 3.5 FRKQNPDIV 54 46 11 33 1 3 ......... 54 ......... 54
& 327-335 18864 3.5 RKQNPDIVI 54 46 11 33 1 3 ......... 54 ......... 54
& 328-336 18694 3.7 KQNPDIVIY 51 49 10 37 2 3 ......... 51 ......... 51
& 329-337 18873 3.2 QNPDIVIYQ 54 46 12 33 1 2 ......... 54 ......... 54
& 330-338 19089 2.7 NPDIVIYQY 58 42 13 28 <1 1 ......... 58 ......... 58
& 331-339 18671 3.5 PDIVIYQYM 43 57 15 41 <1 2 ......... 43 ......... 43
& 332-340 18658 3.5 DIVIYQYMD 43 57 15 41 <1 2 ......... 43 ......... 43
& 333-341 18913 2.6 IVIYQYMDD 54 46 19 27 <1 1 ......... 54 ......... 54
& 334-342 19399 1.8 VIYQYMDDL 65 35 21 13 <1 1 ......... 65 ......... 65
& 335-343 19681 1.6 IYQYMDDLY 67 33 23 10 <1 1 ......... 67 ......... 67
& 336-344 19668 1.6 YQYMDDLYV 66 34 22 11 <1 1 ......... 66 ......... 66
& 337-345 19670 1.6 QYMDDLYVG 67 33 23 10 <1 1 ......... 67 ......... 67
& 338-346 19627 1.6 YMDDLYVGS 67 33 23 10 <1 1 ......... 67 ......... 67
& 339-347 19551 1.7 MDDLYVGSD 67 33 23 10 <1 1 ......... 67 ......... 67
& 340-348 20029 0.8 DDLYVGSDL 90 10 4 5 <1 1 ......... 90 ......... 90
& 341-349 19982 0.9 DLYVGSDLE 89 11 4 6 <1 1 ......... 89 ......... 89
& 342-350 19955 1.0 LYVGSDLEI 88 12 4 7 <1 1 ......... 88 ......... 88
& 343-351 19703 1.6 YVGSDLEIG 74 26 13 12 <1 1 ......... 74 ......... 74
& 344-352 19640 1.8 VGSDLEIGQ 74 26 13 13 <1 1 ......... 74 ......... 74
& 345-353 19719 1.7 GSDLEIGQH 74 26 13 12 <1 1 ......... 74 ......... 74
& 346-354 19948 1.3 SDLEIGQHR 79 21 14 7 <1 1 ......... 79 ......... 79
& 347-355 19074 2.6 DLEIGQHRT 54 46 17 28 <1 2 ......... 54 ......... 54
& 348-356 19045 2.6 LEIGQHRTK 55 45 16 28 <1 2 ......... 55 ......... 55
& 349-357 18824 3.0 EIGQHRTKI 50 50 15 33 <1 2 ......... 50 ......... 50
& 350-358 18663 3.3 IGQHRTKIE 49 51 14 36 1 2 ......... 49 ......... 49
& 351-359 18628 3.4 GQHRTKIEE 48 52 14 37 1 2 ......... 48 ......... 48
& 352-360 18840 2.7 QHRTKIEEL 57 43 15 26 <1 2 ......... 57 ......... 57
& 353-361 18875 2.5 HRTKIEELR 59 41 16 24 <1 1 ......... 59 ......... 59
& 354-362 18466 3.7 RTKIEELRQ 46 54 9 43 1 3 ......... 46 ......... 46
& 355-363 18261 4.0 TKIEELRQH 45 55 9 45 2 3 ......... 45 ......... 45
& 356-364 18724 2.7 KIEELRQHL 59 41 16 25 <1 2 ......... 59 ......... 59
& 357-365 18523 3.3 IEELRQHLL 51 49 14 34 1 2 ......... 51 ......... 51
& 358-366 17904 4.2 EELRQHLLR 31 69 20 48 2 3 ......... 31 ........K 20
& 359-367 18035 4.0 ELRQHLLRW 31 69 20 47 1 3 ......... 31 .......K. 20
& 360-368 18101 3.8 LRQHLLRWG 32 68 21 46 1 2 ......... 32 ......K.. 21
& 361-369 17861 4.4 RQHLLRWGF 26 74 17 56 1 3 ........L 6 .....K... 17
& 362-370 17476 5.3 QHLLRWGFT 20 80 14 64 2 4 .......L. 5 ....K...Y 2
& 363-371 17743 4.1 HLLRWGFTT 26 74 23 50 1 2 ......L.. 5 ...K...Y. 3
& 364-372 17912 3.9 LLRWGFTTP 26 74 23 50 1 2 .....L... 5 ..K...Y.. 4
& 365-373 17637 4.0 LRWGFTTPD 26 74 23 50 1 3 ....L.... 5 .K...Y... 3
& 366-374 17445 4.3 RWGFTTPDK 25 75 22 51 2 3 ...L..... 5 K...Y.... 11
& 367-375 17608 2.9 WGFTTPDKK 52 48 18 30 <1 2 ..L...... 9 ...Y..... 18
& 368-376 17151 3.0 GFTTPDKKH 51 49 17 31 <1 2 .L....... 9 ..Y...... 17
& 369-377 16986 3.0 FTTPDKKHQ 51 49 17 30 1 2 L........ 9 .Y....... 17
& 370-378 17045 2.7 TTPDKKHQK 60 40 16 22 1 2 ......... 60 Y........ 16
& 371-379 17352 1.7 TPDKKHQKE 79 21 6 14 <1 1 ......... 79 ......... 79
& 372-380 17260 1.7 PDKKHQKEP 79 21 6 15 <1 1 ......... 79 ......... 79
& 373-381 16472 1.7 DKKHQKEPP 79 21 6 15 <1 1 ......... 79 ......... 79
& 374-382 16289 1.6 KKHQKEPPF 78 22 8 13 <1 1 ......... 78 ......... 78
& 375-383 16175 1.1 KHQKEPPFL 86 14 4 9 <1 1 ......... 86 ......... 86
& 376-384 15871 1.2 HQKEPPFLW 86 14 4 9 <1 1 ......... 86 ......... 86
& 377-385 15330 1.1 QKEPPFLWM 87 13 5 8 <1 1 ......... 87 ......... 87
& 378-386 14910 1.1 KEPPFLWMG 87 13 5 8 <1 1 ......... 87 ......... 87
& 379-387 14938 0.9 EPPFLWMGY 88 12 5 6 <1 1 ......... 88 ......... 88
& 380-388 13335 0.9 PPFLWMGYE 88 12 6 5 <1 1 ......... 88 ......... 88
& 381-389 13201 0.8 PFLWMGYEL 89 11 6 5 <1 1 ......... 89 ......... 89
& 382-390 12954 0.8 FLWMGYELH 89 11 6 5 <1 1 ......... 89 ......... 89
& 383-391 12885 0.8 LWMGYELHP 89 11 6 5 <1 1 ......... 89 ......... 89
# 384-392 12536 0.3 WMGYELHPD 97 3 <1 1 <1 1 ......... 97 ......... 97
# 385-393 12412 0.4 MGYELHPDK 96 4 <1 3 <1 1 ......... 96 ......... 96
# 386-394 12290 0.4 GYELHPDKW 96 4 <1 3 <1 1 ......... 96 ......... 96
# 387-395 12105 0.4 YELHPDKWT 96 4 <1 3 <1 1 ......... 96 ......... 96
# 388-396 11518 0.4 ELHPDKWTV 96 4 <1 3 <1 1 ......... 96 ......... 96
# 389-397 11426 0.5 LHPDKWTVQ 95 5 <1 4 <1 1 ......... 95 ......... 95
# 390-398 11226 0.7 HPDKWTVQP 93 7 <1 5 <1 1 ......... 93 ......... 93
# 391-399 10726 0.7 PDKWTVQPI 92 8 <1 6 <1 1 ......... 92 ......... 92
& 392-400 9830 2.6 DKWTVQPIV 59 41 9 31 <1 2 ......... 59 ......... 59
& 393-401 9662 2.6 KWTVQPIVL 59 41 9 31 <1 2 ......... 59 ......... 59
& 394-402 9559 2.5 WTVQPIVLP 60 40 9 30 <1 2 ......... 60 ......... 60
& 395-403 5063 3.0 TVQPIVLPE 55 45 10 34 2 3 ......... 55 ......... 55
& 396-404 4986 3.0 VQPIVLPEK 55 45 10 34 2 3 ......... 55 ......... 55
& 397-405 4775 3.3 QPIVLPEKD 54 46 9 35 3 5 ......... 54 ......... 54
& 398-406 4501 3.3 PIVLPEKDS 54 46 9 34 3 5 ......... 54 ......... 54
& 399-407 4456 3.2 IVLPEKDSW 54 46 9 34 3 5 ......... 54 ......... 54
& 400-408 4298 3.2 VLPEKDSWT 54 46 9 33 3 5 ......... 54 ......... 54
& 401-409 4253 1.4 LPEKDSWTV 81 19 5 12 1 2 ......... 81 ......... 81
& 402-410 4111 1.4 PEKDSWTVN 82 18 5 12 1 2 ......... 82 ......... 82
& 403-411 3881 1.4 EKDSWTVND 82 18 5 12 1 2 ......... 82 ......... 82
& 404-412 3637 1.0 KDSWTVNDI 87 13 7 5 <1 1 ......... 87 ........L <1
& 405-413 3614 0.9 DSWTVNDIQ 88 12 7 4 <1 1 ......... 88 .......L. <1
# 406-414 3601 0.5 SWTVNDIQK 95 5 1 3 <1 1 ......... 95 ......L.. <1
# 407-415 3505 0.2 WTVNDIQKL 98 2 <1 <1 <1 1 ......... 98 .....L... <1
# 408-416 3483 0.2 TVNDIQKLV 98 2 <1 <1 <1 1 ......... 98 ....L.... <1
# 409-417 3474 0.2 VNDIQKLVG 98 2 <1 <1 <1 1 ......... 98 ...L..... <1
# 410-418 3458 0.2 NDIQKLVGK 98 2 <1 <1 <1 1 ......... 98 ..L...... <1
# 411-419 3448 0.2 DIQKLVGKL 98 2 <1 <1 <1 1 ......... 98 .L....... <1
# 412-420 3419 0.2 IQKLVGKLN 98 2 <1 <1 <1 1 ......... 98 L........ <1
# 413-421 3428 0.1 QKLVGKLNW 99 1 <1 <1 <1 1 ......... 99 ......... 99
# 414-422 3387 0.2 KLVGKLNWA 99 1 <1 <1 <1 1 ......... 99 ......... 99
# 415-423 3389 0.2 LVGKLNWAS 99 1 <1 <1 <1 1 ......... 99 ......... 99
# 416-424 3372 0.2 VGKLNWASQ 99 1 <1 <1 <1 1 ......... 99 ......... 99
# 417-425 3364 0.1 GKLNWASQI 99 1 <1 <1 <1 1 ......... 99 ......... 99
# 418-426 3357 0.1 KLNWASQIY 99 1 <1 <1 <1 1 ......... 99 ......... 99
& 419-427 3273 1.4 LNWASQIYP 52 48 42 6 <1 1 ......... 52 ......... 52
& 420-428 3264 1.4 NWASQIYPG 52 48 42 6 <1 1 ......... 52 ......... 52
& 421-429 3272 1.4 WASQIYPGI 52 48 42 6 <1 1 ......... 52 ......... 52
& 422-430 3242 1.6 ASQIYPGIK 50 50 41 8 <1 1 ......... 50 ......... 50
& 423-431 3215 1.8 SQIYPGIKV 48 52 41 10 <1 1 ......... 48 ......... 48
& 424-432 3075 2.7 QIYAGIKVK 30 70 28 41 <1 2 ...P....R 19 ...P..... 28
& 425-433 3046 3.0 IYAGIKVKQ 28 72 27 43 1 3 ..P....R. 18 ..P...... 27
& 426-434 3040 3.0 YAGIKVKQL 28 72 27 43 1 3 .P....R.. 18 .P....... 27
& 427-435 3012 3.0 AGIKVKQLC 28 72 27 43 1 3 P....R... 18 P........ 27
& 428-436 2973 2.0 GIKVKQLCK 55 45 29 14 1 2 ....R.... 29 ......... 55
& 429-437 2962 2.2 IKVKQLCKL 55 45 28 15 1 3 ...R..... 28 ......... 55
& 430-438 2972 2.4 KVKQLCKLL 52 48 27 20 1 3 ..R...... 27 ......... 52
& 431-439 2959 2.5 VKQLCKLLR 50 50 27 22 1 3 .R....... 27 ......... 50
& 432-440 2969 2.4 KQLCKLLRG 50 50 27 22 <1 2 R........ 27 ......... 50
& 433-441 2914 2.5 QLCKLLRGT 52 48 25 23 1 3 ......... 52 ......... 52
& 434-442 2914 2.2 LCKLLRGTK 54 46 27 19 <1 2 ......... 54 ......... 54
& 435-443 2865 2.7 CKLLRGTKA 48 52 25 27 1 2 ......... 48 ......... 48
& 436-444 2847 2.7 KLLRGTKAL 47 53 25 27 1 2 ......... 47 ......... 47
& 437-445 2889 2.5 LLRGTKALT 51 49 26 22 1 2 ......... 51 ......... 51
& 438-446 2869 2.8 LRGTKALTE 46 54 22 32 1 2 ......... 46 ......... 46
& 439-447 2843 2.8 RGTKALTEV 48 52 21 30 1 3 ......... 48 ......... 48
& 440-448 2762 3.5 GTKALTEVV 26 74 24 48 1 3 ........I 24 ......... 26
& 441-449 2734 3.9 TKALTEVVP 25 75 23 51 2 4 .......I. 23 ......... 25
& 442-450 2807 3.0 KALTEVIPL 35 65 33 31 1 3 ......... 35 ......V.. 33
& 443-451 2809 3.1 ALTEVIPLT 34 66 32 32 1 3 ......... 34 .....V... 32
& 444-452 2542 4.2 LTEVVPLTE 23 77 19 56 2 5 ....I.... 19 ........A 5
& 445-453 2503 4.3 TEVVPLTEE 24 76 18 57 2 5 ...I..... 18 .......A. 6
& 446-454 2365 4.3 EVVPLTEEA 23 77 18 57 2 5 ..I...... 18 ......A.. 6
& 447-455 2160 4.0 VVPLTEEAE 25 75 19 53 2 5 .I....... 19 .....A... 6
& 448-456 1407 3.7 VPLTEEAEL 30 70 18 49 3 6 I........ 18 ....A.... 8
& 449-457 1083 3.1 PLTEEAELE 45 55 16 36 3 6 ......... 45 ...A..... 12
& 450-458 898 2.4 LTEEAELEL 51 49 17 30 2 4 ......... 51 ..A...... 17
& 451-459 669 2.8 TEEAELELA 49 51 18 31 3 7 ......... 49 .A....... 18
& 452-460 592 2.4 EEAELELAE 52 48 19 27 2 5 ......... 52 A........ 19
# 453-461 431 0.7 EAELELAEN 91 9 6 1 2 3 ......... 91 ......... 91
# 454-462 411 0.7 AELELAENR 91 9 6 <1 2 3 ......... 91 ......... 91
# 455-463 401 0.6 ELELAENRE 91 9 6 <1 2 3 ......... 91 ......... 91
# 456-464 400 0.7 LELAENREI 90 10 6 1 3 4 ......... 90 ......... 90
# 457-465 396 0.7 ELAENREIL 90 10 6 1 3 4 ......... 90 ......... 90
& 458-466 390 1.1 LAENREILK 84 16 6 7 3 4 ......... 84 ......... 84
& 459-467 342 1.4 AENREILKE 81 19 6 10 4 6 ......... 81 ......... 81
& 460-468 337 1.2 ENREILKEP 84 16 5 6 5 7 ......... 84 ......... 84
& 461-469 331 1.2 NREILKEPV 84 16 5 5 5 8 ......... 84 ......... 84
& 462-470 312 1.3 REILKEPVH 84 16 5 6 6 8 ......... 84 ......... 84
& 463-471 310 1.3 EILKEPVHG 84 16 5 5 5 8 ......... 84 ......... 84
& 464-472 304 1.8 ILKEPVHGV 74 26 9 11 6 10 ......... 74 ......... 74
& 465-473 280 1.7 LKEPVHGVY 74 26 10 9 7 10 ......... 74 ......... 74
& 466-474 276 1.8 KEPVHGVYY 73 27 10 10 7 10 ......... 73 ......... 73
& 467-475 265 1.5 EPVHGVYYD 77 23 11 6 6 9 ......... 77 ......... 77
& 468-476 259 1.3 PVHGVYYDP 80 20 12 3 5 7 ......... 80 ......... 80
& 469-477 245 1.5 VHGVYYDPS 77 23 11 7 5 8 ......... 77 ......... 77
& 470-478 238 1.5 HGVYYDPSK 76 24 11 7 5 8 ......... 76 ......... 76
& 471-479 231 1.8 GVYYDPSKD 71 29 8 14 7 10 ......... 71 ........E 6
& 472-480 203 1.8 VYYDPSKDL 71 29 9 13 7 10 ......... 71 .......E. 5
& 473-481 201 1.8 YYDPSKDLI 71 29 9 15 5 8 ......... 71 ......E.. 8
& 474-482 199 1.7 YDPSKDLIA 71 29 9 14 6 8 ......... 71 .....E... 8
& 475-483 198 1.7 DPSKDLIAE 71 29 9 14 6 8 ......... 71 ....E.... 8
& 476-484 195 2.3 PSKDLIAEI 62 38 8 27 4 10 ......... 62 ...E..... 7
& 477-485 192 2.4 SKDLIAEIQ 60 40 8 27 5 10 ......... 60 ..E...... 7
& 478-486 189 2.2 KDLIAEIQK 63 37 8 22 6 10 ......... 63 .E....... 7
& 479-487 188 2.2 DLIAEIQKQ 63 37 9 23 6 11 ......... 63 E........ 7
& 480-488 187 2.0 LIAEIQKQG 68 32 9 17 6 11 ......... 68 ......... 68
& 481-489 176 3.5 IAEIQKQGQ 42 58 10 38 10 19 ......... 42 ........L 1
& 482-490 168 3.3 AEIQKQGQG 45 55 10 34 11 19 ......... 45 .......L. 2
483-491 * 66 3.2 EIQKQGYGQ 26 74 23 41 11 23 ......Q.. 23 ......L.. 0
484-492 * 64 3.0 IQKQGYGQW 28 72 23 39 9 20 .....Q... 23 .....L... 0
485-493 * 64 2.8 QKQGYGQWT 28 72 25 39 8 17 ....Q.... 25 ....L.... 0
486-494 * 64 2.8 KQGYGQWTY 28 72 25 39 8 17 ...Q..... 25 ...L..... 0
487-495 * 64 2.8 QGYGQWTYQ 28 72 25 39 8 17 ..Q...... 25 ..L...... 0
488-496 * 64 2.8 GYGQWTYQI 28 72 25 39 8 17 .Q....... 25 .L....... 0
489-497 * 64 2.7 YGQWTYQIY 28 72 27 39 6 16 Q........ 27 L........ 0
490-498 * 64 0.9 GQWTYQIYQ 78 22 19 0 3 5 ......... 78 ......... 78
491-499 * 64 0.2 QWTYQIYQE 97 3 2 0 2 3 ......... 97 ......... 97
492-500 * 64 0.4 WTYQIYQEP 95 5 2 0 3 5 ......... 95 ......... 95
493-501 * 64 0.5 TYQIYQEPF 94 6 2 0 5 6 ......... 94 ......... 94
494-502 * 64 0.7 YQIYQEPFK 89 11 6 0 5 6 ......... 89 ......... 89
495-503 * 64 0.7 QIYQEPFKN 89 11 6 0 5 6 ......... 89 ......... 89
496-504 * 64 0.7 IYQEPFKNL 89 11 5 0 6 8 ......... 89 ......... 89
497-505 * 64 0.9 YQEPFKNLK 88 13 5 0 8 9 ......... 88 ......... 88
498-506 * 64 0.8 QEPFKNLKT 88 13 5 0 8 9 ......... 88 ......... 88
499-507 * 63 0.9 EPFKNLKTG 87 13 5 0 8 10 ......... 87 ......... 87
500-508 * 63 0.9 PFKNLKTGK 87 13 5 0 8 10 ......... 87 ......... 87
501-509 * 62 0.6 FKNLKTGKY 90 10 5 0 5 6 ......... 90 ......... 90
502-510 * 62 0.6 KNLKTGKYA 90 10 5 0 5 6 ......... 90 ......... 90
503-511 * 62 0.9 NLKTGKYAR 82 18 13 0 5 6 ......... 82 ......... 82
504-512 * 62 2.3 LKTGKYARM 53 47 13 27 6 15 ......... 53 ......... 53
505-513 * 62 2.2 KTGKYARMR 55 45 13 27 5 13 ......... 55 ......... 55
506-514 * 62 2.6 TGKYARMRG 37 63 19 39 5 15 ......... 37 ......... 37
507-515 * 62 3.2 GKYARMRGA 27 73 19 45 8 23 ......... 27 ......... 27
508-516 * 68 3.1 KYARMRGAH 34 66 18 41 7 21 ......... 34 ......... 34
509-517 * 68 3.2 YARMRGAHT 34 66 18 40 9 22 ......... 34 ......... 34
510-518 * 68 3.3 ARMRGAHTN 32 68 18 40 10 24 ......... 32 ......... 32
511-519 * 68 3.3 RMRGAHTND 32 68 18 38 12 25 ......... 32 ......... 32
512-520 * 68 3.4 MRGAHTNDV 31 69 16 40 13 25 ......... 31 ......... 31
513-521 * 68 2.9 RGAHTNDVK 38 62 16 32 13 22 ......... 38 ......... 38
514-522 * 68 2.9 GAHTNDVKQ 38 62 16 32 13 22 ......... 38 ......... 38
515-523 * 68 2.1 AHTNDVKQL 56 44 18 18 9 15 ......... 56 ......... 56
516-524 * 68 1.6 HTNDVKQLT 65 35 18 13 4 10 ......... 65 ......... 65
517-525 * 68 1.9 TNDVKQLTE 60 40 18 16 6 13 ......... 60 ......... 60
518-526 * 68 2.0 NDVKQLTEA 59 41 18 19 4 13 ......... 59 ......... 59
519-527 * 68 1.9 DVKQLTEAV 60 40 18 19 3 12 ......... 60 ......... 60
520-528 * 68 1.8 VKQLTEAVQ 62 38 18 16 4 12 ......... 62 ......... 62
521-529 * 68 1.3 KQLTEAVQK 78 22 7 9 6 12 ......... 78 ......... 78
522-530 * 68 1.3 QLTEAVQKI 79 21 7 9 4 10 ......... 79 ......... 79
523-531 * 68 2.0 LTEAVQKIA 60 40 19 16 4 13 ........T 19 ........S 0
524-532 * 68 2.3 TEAVQKIAT 56 44 19 18 7 18 .......T. 19 .......S. 0
525-533 * 68 2.1 EAVQKIATE 56 44 22 15 7 15 ......T.. 22 ......S.. 0
526-534 * 68 2.4 AVQKIATES 46 54 24 24 7 15 .....T... 24 .....S... 0
527-535 * 68 2.4 VQKIATESI 49 51 24 19 9 16 ....T.... 24 ....S.... 0
528-536 * 68 2.8 QKIATESIV 34 66 24 34 9 18 ...T..... 24 ...S..... 0
529-537 * 68 2.7 KIATESIVI 35 65 24 34 7 16 ..T...... 24 ..S...... 0
530-538 * 68 2.7 IATESIVIW 35 65 22 35 7 16 .T....... 22 .S....... 0
531-539 * 68 2.7 ATESIVIWG 37 63 22 32 9 16 T........ 22 S........ 0
532-540 * 68 2.3 TESIVIWGK 56 44 16 19 9 18 ......... 56 ........R 3
533-541 * 68 2.5 ESIVIWGKT 46 54 16 31 7 15 ......... 46 .......R. 1
534-542 * 67 2.4 SIVIWGKTP 46 54 16 31 6 13 ......... 46 ......R.. 1
535-543 * 67 2.0 IVIWGKTPK 55 45 16 24 4 10 ......... 55 .....R... 1
536-544 * 67 1.7 VIWGKTPKF 60 40 16 21 3 7 ......... 60 ....R.... 0
537-545 * 67 2.0 IWGKTPKFK 40 60 36 21 3 9 ......... 40 ...R....R 0
538-546 * 66 2.0 WGKTPKFKL 41 59 36 20 3 9 ......... 41 ..R....R. 0
539-547 * 66 1.9 GKTPKFKLP 41 59 38 20 2 8 ......... 41 .R....R.. 0
540-548 * 66 1.9 KTPKFKLPI 41 59 38 20 2 8 ......... 41 R....R... 0
541-549 * 66 1.7 TPKFKLPIQ 41 59 38 20 2 6 ......... 41 ....R.... 38
542-550 * 66 1.1 PKFRLPIQK 55 45 44 0 2 3 ...K..... 44 ......... 55
543-551 * 61 1.1 KFRLPIQKE 56 44 43 0 2 3 ..K...... 43 ......... 56
544-552 * 61 1.3 FRLPIQKET 54 46 41 0 5 7 .K....... 41 ......... 54
545-553 * 61 1.2 RLPIQKETW 56 44 41 0 3 5 K........ 41 ......... 56
546-554 * 61 0.5 LPIQKETWE 92 8 5 0 3 5 ......... 92 ......... 92
547-555 * 60 1.2 PIQKETWET 80 20 8 3 8 12 ......... 80 ......... 80
548-556 * 53 0.9 IQKETWETW 87 13 4 0 9 11 ......... 87 ......... 87
549-557 * 53 0.9 QKETWETWW 87 13 4 0 9 11 ......... 87 ......... 87
550-558 * 53 1.6 KETWETWWT 68 32 19 4 9 13 ......... 68 ......... 68
551-559 * 53 2.2 ETWETWWTE 49 51 19 21 11 17 ......... 49 ........D 17
552-560 * 53 2.2 TWETWWTEY 49 51 19 21 11 17 ......... 49 .......D. 17
553-561 * 51 2.1 WETWWTEYW 49 51 22 20 10 16 ......... 49 ......D.. 16
554-562 * 51 2.1 ETWWTEYWQ 49 51 22 20 10 16 ......... 49 .....D... 16
555-563 * 51 2.1 TWWTEYWQA 49 51 22 22 8 14 ......... 49 ....D.... 16
556-564 * 51 1.7 WWTEYWQAT 51 49 24 22 4 8 ......... 51 ...D..... 24
557-565 * 51 1.7 WTEYWQATW 51 49 24 22 4 8 ......... 51 ..D...... 24
558-566 * 51 1.7 TEYWQATWI 51 49 24 22 4 8 ......... 51 .D....... 24
559-567 * 51 1.0 EYWQATWIP 73 27 24 0 4 6 ......... 73 D........ 24
560-568 * 51 0.1 YWQATWIPE 98 2 2 0 0 2 ......... 98 ......... 98
561-569 * 51 0.3 WQATWIPEW 96 4 2 0 2 4 ......... 96 ......... 96
562-570 * 51 0.1 QATWIPEWE 98 2 2 0 0 2 ......... 98 ......... 98
563-571 * 51 0.3 ATWIPEWEF 96 4 2 0 2 4 ......... 96 ......... 96
564-572 * 51 0.3 TWIPEWEFV 96 4 2 0 2 4 ......... 96 ......... 96
565-573 * 51 0.4 WIPEWEFVN 94 6 2 0 4 6 ......... 94 ......... 94
566-574 * 51 0.7 IPEWEFVNT 90 10 2 0 8 10 ......... 90 ......... 90
567-575 * 51 0.7 PEWEFVNTP 90 10 2 0 8 10 ......... 90 ......... 90
568-576 * 51 0.7 EWEFVNTPP 90 10 2 0 8 10 ......... 90 ......... 90
569-577 * 51 0.7 WEFVNTPPL 90 10 2 0 8 10 ......... 90 ......... 90
570-578 * 51 0.6 EFVNTPPLV 92 8 2 0 6 8 ......... 92 ......... 92
571-579 * 51 0.6 FVNTPPLVK 92 8 2 0 6 8 ......... 92 ......... 92
572-580 * 51 0.4 VNTPPLVKL 94 6 2 0 4 6 ......... 94 ......... 94
573-581 * 51 0.4 NTPPLVKLW 94 6 2 0 4 6 ......... 94 ......... 94
574-582 * 51 0.4 TPPLVKLWY 94 6 2 0 4 6 ......... 94 ......... 94
575-583 * 51 0.1 PPLVKLWYQ 98 2 2 0 0 2 ......... 98 ......... 98
576-584 * 51 0.1 PLVKLWYQL 98 2 2 0 0 2 ......... 98 ......... 98
577-585 * 51 0.1 LVKLWYQLE 98 2 2 0 0 2 ......... 98 ......... 98
578-586 * 51 0.3 VKLWYQLEK 96 4 2 0 2 4 ......... 96 ......... 96
579-587 * 51 0.9 KLWYQLEKE 78 22 18 0 4 6 ......... 78 ......... 78
580-588 * 51 1.0 LWYQLEKEP 78 22 18 0 4 6 ......... 78 ......... 78
581-589 * 51 1.0 WYQLEKEPI 78 22 18 0 4 6 ......... 78 ......... 78
582-590 * 51 1.9 YQLEKEPIV 55 45 18 22 6 12 ......... 55 ........A 6
583-591 * 51 1.9 QLEKEPIVG 57 43 18 20 6 12 ......... 57 .......A. 4
584-592 * 51 2.0 LEKEPIVGA 55 45 18 20 8 14 ......... 55 ......A.. 4
585-593 * 51 2.0 EKEPIVGAE 55 45 18 20 8 14 ......... 55 .....A... 4
586-594 * 51 2.0 KEPIVGAET 55 45 18 20 8 14 ......... 55 ....A.... 4
587-595 * 51 2.0 EPIVGAETF 53 47 18 24 6 14 ......... 53 ...A..... 4
588-596 * 51 1.9 PIVGAETFY 53 47 20 24 4 12 ......... 53 ..A...... 4
589-597 * 51 1.9 IVGAETFYV 53 47 20 24 4 12 ......... 53 .A....... 4
590-598 * 51 1.9 VGAETFYVD 53 47 20 24 4 12 ......... 53 A........ 4
591-599 * 51 1.0 GAETFYVDG 75 25 20 4 2 6 ......... 75 ......... 75
592-600 * 51 1.0 AETFYVDGA 75 25 20 4 2 6 ......... 75 ......... 75
593-601 * 51 1.1 ETFYVDGAA 75 25 18 4 4 8 ......... 75 ......... 75
594-602 * 51 0.9 TFYVDGAAN 76 24 18 4 2 6 ......... 76 ......... 76
595-603 * 51 0.9 FYVDGAANR 76 24 18 4 2 6 ......... 76 ......... 76
596-604 * 89 1.0 YVDGAANRE 83 17 10 4 2 6 ......... 83 ......... 83
597-605 * 89 1.5 VDGAANRET 72 28 11 15 2 8 ......... 72 ......... 72
598-606 * 89 1.9 DGAANRETK 62 38 11 25 2 9 ......... 62 ......... 62
599-607 * 89 2.9 GAANRETKL 46 54 10 36 8 18 ......... 46 ......... 46
600-608 * 89 2.9 AANRETKLG 46 54 10 36 8 18 ......... 46 ......... 46
601-609 * 89 3.1 ANRETKLGK 43 57 10 39 8 19 ......... 43 ........R 3
602-610 * 89 2.7 NRETKLGKA 51 49 10 33 7 17 ......... 51 .......R. 3
603-611 * 89 2.6 RETKLGKAG 52 48 10 33 6 16 ......... 52 ......R.. 3
604-612 * 89 2.6 ETKLGKAGY 52 48 10 33 6 16 ......... 52 .....R... 3
605-613 * 89 2.8 TKLGKAGYV 48 52 10 35 7 17 ......... 48 ....R.... 3
606-614 * 89 2.4 KLGKAGYVT 51 49 19 25 6 13 ......... 51 ...R..... 3
607-615 * 89 2.8 LGKAGYVTD 36 64 19 37 8 16 ........N 19 ..R...... 2
608-616 * 89 2.3 GKAGYVTDR 46 54 19 29 6 11 .......N. 19 .R....... 2
609-617 * 89 2.3 KAGYVTDRG 46 54 19 29 6 11 ......N.. 19 R........ 2
610-618 * 89 2.2 AGYVTDRGR 47 53 19 27 7 11 .....N... 19 ......... 47
611-619 * 89 2.2 GYVTDRGRQ 47 53 19 27 7 11 ....N.... 19 ......... 47
612-620 * 89 2.2 YVTDRGRQK 47 53 19 27 7 11 ...N..... 19 ......... 47
613-621 * 89 2.6 VTDRGRQKV 42 58 19 28 11 16 ..N...... 19 ......... 42
614-622 * 88 2.5 TDRGRQKVV 45 55 19 24 11 16 .N....... 19 ........I 2
615-623 * 88 3.0 DRGRQKVVS 41 59 17 30 13 20 N.......T 2 .......I. 2
616-624 * 87 2.8 RGRQKVVSL 53 47 11 18 17 25 .......T. 2 ......I.. 1
617-625 * 87 2.7 GRQKVVSLT 56 44 9 17 17 24 ......T.. 2 .....I... 1
618-626 * 87 3.0 RQKVVSLTD 52 48 9 21 18 26 .....T... 2 ....I.... 1
619-627 * 87 3.0 QKVVSLTDT 51 49 9 23 17 26 ....T.... 2 ...I..... 2
620-628 * 87 3.0 KVVSLTDTT 51 49 9 23 17 26 ...T..... 2 ..I...... 2
621-629 * 87 3.0 VVSLTDTTN 51 49 9 24 16 25 ..T...... 2 .I....... 2
622-630 * 87 2.9 VSLTDTTNQ 51 49 9 25 15 24 .T....... 2 I........ 2
623-631 * 87 2.8 SLTDTTNQK 52 48 9 23 16 23 T........ 2 ......... 52
624-632 * 87 2.1 LTDTTNQKT 62 38 17 10 10 16 ......... 62 ......... 62
625-633 * 87 1.1 TDTTNQKTE 84 16 3 7 6 10 ......... 84 ......... 84
626-634 * 87 0.7 DTTNQKTEL 90 10 5 3 2 5 ......... 90 ......... 90
627-635 * 87 0.3 TTNQKTELQ 97 3 1 0 2 3 ......... 97 ......... 97
628-636 * 87 0.2 TNQKTELQA 98 2 1 0 1 2 ......... 98 ......... 98
629-637 * 87 0.2 NQKTELQAI 98 2 1 0 1 2 ......... 98 ......... 98
630-638 * 87 1.9 QKTELQAIY 48 52 32 15 5 8 ......... 48 ........H 32
631-639 * 87 1.9 KTELQAIYL 48 52 32 15 5 8 ......... 48 .......H. 32
632-640 * 87 1.9 TELQAIYLA 49 51 31 15 5 8 ......... 49 ......H.. 31
633-641 * 87 2.0 ELQAIYLAL 48 52 31 15 6 9 ......... 48 .....H... 31
634-642 * 86 2.0 LQAIYLALQ 49 51 30 15 6 9 ......... 49 ....H.... 30
635-643 * 86 2.1 QAIYLALQD 49 51 28 17 6 10 ......... 49 ...H..... 28
636-644 * 86 2.0 AIYLALQDS 49 51 29 17 5 9 ......... 49 ..H...... 29
637-645 * 85 2.1 IYLALQDSG 47 53 29 18 6 12 ......... 47 .H....... 29
638-646 * 85 2.7 YLALQDSGL 42 58 22 24 12 18 ......... 42 H.......S 7
639-647 * 85 1.3 LALQDSGLE 78 22 12 2 8 11 ......... 78 .......S. 12
640-648 * 85 1.5 ALQDSGLEV 74 26 12 6 8 12 ......... 74 ......S.. 12
641-649 * 85 1.5 LQDSGLEVN 74 26 12 7 7 11 ......... 74 .....S... 12
642-650 * 85 1.4 QDSGLEVNI 75 25 12 7 6 9 ......... 75 ....S.... 12
643-651 * 84 1.4 DSGLEVNIV 76 24 11 7 6 10 ......... 76 ...S..... 11
644-652 * 84 1.3 SGLEVNIVT 79 21 10 4 8 11 ......... 79 ..S...... 10
645-653 * 84 1.3 GLEVNIVTD 79 21 10 4 8 11 ......... 79 .S....... 10
646-654 * 84 1.2 LEVNIVTDS 80 20 11 4 6 8 ......... 80 S........ 11
647-655 * 84 0.6 EVNIVTDSQ 92 8 4 0 5 6 ......... 92 ......... 92
648-656 * 84 0.5 VNIVTDSQY 93 7 4 0 4 5 ......... 93 ......... 93
649-657 * 82 0.4 NIVTDSQYA 95 5 1 0 4 5 ......... 95 ......... 95
650-658 * 80 0.3 IVTDSQYAL 96 4 1 0 3 4 ......... 96 ......... 96
651-659 * 80 0.2 VTDSQYALG 98 3 1 0 1 3 ......... 98 ......... 98
652-660 * 80 0.2 TDSQYALGI 98 3 1 0 1 3 ......... 98 ......... 98
653-661 * 80 0.1 DSQYALGII 99 1 1 0 0 1 ......... 99 ......... 99
654-662 * 80 0.1 SQYALGIIQ 99 1 1 0 0 1 ......... 99 ......... 99
655-663 * 80 0.2 QYALGIIQA 98 3 1 0 1 3 ......... 98 ......... 98
656-664 * 80 0.3 YALGIIQAQ 96 4 1 0 3 4 ......... 96 ......... 96
657-665 * 79 0.3 ALGIIQAQP 96 4 1 0 3 4 ......... 96 ......... 96
658-666 * 79 0.4 LGIIQAQPD 95 5 3 0 3 4 ......... 95 ......... 95
659-667 * 39 1.0 GIIQAQPDK 82 18 8 5 5 10 ........Q 8 ......... 82
660-668 * 39 1.0 IIQAQPDKS 82 18 8 5 5 10 .......Q. 8 ......... 82
661-669 * 39 1.0 IQAQPDKSE 82 18 8 5 5 10 ......Q.. 8 ......... 82
662-670 * 39 1.0 QAQPDKSES 82 18 8 5 5 10 .....Q... 8 ......... 82
663-671 * 39 1.0 AQPDKSESE 82 18 8 5 5 10 ....Q.... 8 ......... 82
664-672 * 39 1.7 QPDKSESEL 67 33 13 18 3 13 ...Q..... 8 ......... 67
665-673 * 39 1.6 PDKSESELV 67 33 13 21 0 10 ..Q...... 10 ......... 67
666-674 * 39 2.2 DKSESELVS 51 49 15 28 5 15 .Q......N 10 ........N 15
667-675 * 39 2.3 KSESELVSQ 49 51 15 28 8 18 Q......N. 10 .......N. 15
668-676 * 39 1.9 SESELVSQI 49 51 28 23 0 10 ......N.. 28 ......N.. 28
669-677 * 39 1.9 ESELVSQII 49 51 28 23 0 10 .....N... 28 .....N... 28
670-678 * 39 1.9 SELVSQIIE 49 51 28 23 0 10 ....N.... 28 ....N.... 28
671-679 * 39 2.4 ELVSQIIEQ 41 59 28 23 8 21 ...N..... 28 ...N....L 0
672-680 * 39 2.4 LVSQIIEQL 41 59 28 23 8 21 ..N...... 28 ..N....L. 0
673-681 * 39 1.8 VSQIIEQLI 54 46 28 10 8 13 .N....... 28 .N....L.. 0
674-682 * 39 2.3 SQIIEQLIK 33 67 28 31 8 15 N........ 28 N....L..N 0
675-683 * 39 1.7 QIIEQLIKK 62 38 21 10 8 13 ......... 62 ....L..N. 0
676-684 * 39 1.8 IIEQLIKKE 59 41 21 10 10 15 ......... 59 ...L..N.. 0
677-685 * 39 2.1 IEQLIKKEK 54 46 21 15 10 18 ......... 54 ..L..N... 0
678-686 * 39 2.2 EQLIKKEKV 54 46 18 15 13 21 ......... 54 .L..N...I 0
679-687 * 39 2.2 QLIKKEKVY 54 46 18 15 13 21 ......... 54 L..N...I. 0
680-688 * 39 1.8 LIKKEKVYL 64 36 18 5 13 18 ......... 64 ..N...I.. 3
681-689 * 39 1.9 IKKEKVYLA 62 38 18 5 15 21 ......... 62 .N...I... 3
682-690 * 39 1.9 KKEKVYLAW 62 38 18 5 15 21 ......... 62 N...I.... 3
683-691 * 39 1.2 KEKVYLAWV 79 21 8 5 8 13 ......... 79 ...I..... 5
684-692 * 39 1.2 EKVYLAWVP 79 21 8 5 8 13 ......... 79 ..I...... 5
685-693 * 39 1.1 KVYLAWVPA 79 21 10 5 5 10 ......... 79 .I....... 5
686-694 * 39 0.6 VYLAWVPAH 90 10 5 0 5 8 ......... 90 I........ 5
687-695 * 39 0.3 YLAWVPAHK 95 5 3 0 3 5 ......... 95 ......... 95
688-696 * 39 0.3 LAWVPAHKG 95 5 3 0 3 5 ......... 95 ......... 95
689-697 * 46 0.3 AWVPAHKGI 96 4 2 0 2 4 ......... 96 ......... 96
690-698 * 46 0.2 WVPAHKGIG 98 2 2 0 0 2 ......... 98 ......... 98
691-699 * 46 0.2 VPAHKGIGG 98 2 2 0 0 2 ......... 98 ......... 98
692-700 * 46 0.2 PAHKGIGGN 98 2 2 0 0 2 ......... 98 ......... 98
693-701 * 48 0.4 AHKGIGGNE 92 8 4 0 4 6 ......... 92 ......... 92
694-702 * 48 0.7 HKGIGGNEQ 88 13 4 0 8 10 ......... 88 ......... 88
695-703 * 48 1.0 KGIGGNEQV 83 17 6 4 6 10 ......... 83 ......... 83
696-704 * 48 1.0 GIGGNEQVD 83 17 6 4 6 10 ......... 83 ......... 83
697-705 * 53 1.2 IGGNEQVDK 81 19 6 6 8 11 ......... 81 ......... 81
698-706 * 55 1.1 GGNEQVDKL 82 18 5 5 7 11 ......... 82 ......... 82
699-707 * 55 1.1 GNEQVDKLV 82 18 5 5 7 11 ......... 82 ......... 82
700-708 * 55 1.1 NEQVDKLVS 82 18 5 5 7 11 ......... 82 ......... 82
701-709 * 55 2.8 EQVDKLVSA 44 56 18 18 20 25 ......... 44 ......... 44
702-710 * 55 2.6 QVDKLVSAG 45 55 18 18 18 24 ......... 45 ......... 45
703-711 * 55 2.5 VDKLVSAGI 45 55 18 25 11 18 ......... 45 ......... 45
704-712 * 55 2.2 DKLVSAGIR 47 53 20 27 5 13 ......... 47 ......... 47
705-713 * 55 2.4 KLVSAGIRK 42 58 20 33 5 15 ......... 42 ......... 42
706-714 * 55 2.4 LVSAGIRKV 42 58 20 33 5 15 ......... 42 ......... 42
707-715 * 55 2.4 VSAGIRKVL 42 58 20 33 5 15 ......... 42 ......... 42
708-716 * 17 1.9 SAGIRKVLF 47 53 24 18 12 24 ......... 47 ......... 47
709-717 * 32 1.9 AGIRKVLFL 47 53 25 25 3 13 ......... 47 ......... 47
710-718 * 33 0.0 GIRKVLFLD 100 0 0 0 0 0 ......... 100 ......... 100
711-719 * 33 0.2 IRKVLFLDG 97 3 3 0 0 3 ......... 97 ......... 97
712-720 * 35 0.4 RKVLFLDGI 91 9 3 0 6 9 ......... 91 ......... 91
713-721 * 34 0.8 KVLFLDGID 85 15 3 0 12 15 ......... 85 ......... 85
714-722 * 33 0.6 VLFLDGIDK 88 12 3 0 9 12 ......... 88 ........R 0
715-723 * 34 0.6 LFLDGIDKA 91 9 3 0 6 9 ......... 91 .......R. 0
& 716-724 523 1.0 FLDGIDKAQ 86 14 4 9 2 3 ......... 86 ......R.. 1
& 717-725 517 1.8 LDGIDKAQE 70 30 13 16 2 4 ........D 13 .....R... 1
& 718-726 516 2.5 DGIDKAQEE 48 52 21 29 2 6 .......D. 12 ....R...D <1
& 719-727 516 2.5 GIDKAQEEH 48 52 21 28 2 5 ......D.. 12 ...R...D. <1
& 720-728 526 2.6 IDKAQEEHE 49 51 19 30 2 6 .....D... 12 ..R...D.. <1
& 721-729 525 2.8 DKAQEEHEK 47 53 18 31 3 7 ....D.... 12 .R...D... <1
& 722-730 529 2.5 KAQEEHEKY 49 51 18 31 2 5 ...D..... 15 R...D.... <1
& 723-731 532 2.1 AQEEHEKYH 52 48 23 24 1 4 ..D...... 15 ...D..... 23
& 724-732 529 2.8 QEEHEKYHS 38 62 21 40 2 5 .D....... 14 ..D...... 21
& 725-733 528 2.8 EEHEKYHSN 38 62 21 40 2 5 D........ 14 .D....... 21
& 726-734 528 2.1 EHEKYHSNW 54 46 22 22 2 4 ......... 54 D........ 22
& 727-735 535 1.6 HEKYHSNWR 73 27 13 13 2 3 ......... 73 ......... 73
& 728-736 533 1.8 EKYHSNWRA 69 31 13 15 2 4 ......... 69 ......... 69
& 729-737 535 1.9 KYHSNWRAM 66 34 13 19 2 4 ......... 66 ......... 66
& 730-738 532 1.8 YHSNWRAMA 69 31 13 16 3 5 ......... 69 ......... 69
& 731-739 522 2.4 HSNWRAMAS 62 38 12 23 3 7 ......... 62 ........N 4
& 732-740 525 2.6 SNWRAMASD 60 40 12 25 4 8 ......... 60 .......N. 3
& 733-741 532 1.9 NWRAMASDF 76 24 3 18 3 6 ......... 76 ......N.. 2
& 734-742 538 2.1 WRAMASDFN 71 29 4 22 3 7 ......... 71 .....N... 2
& 735-743 538 2.4 RAMASDFNL 67 33 4 25 4 7 ......... 67 ....N.... 2
& 736-744 543 2.2 AMASDFNLP 71 29 4 23 3 7 ......... 71 ...N..... 2
& 737-745 543 2.1 MASDFNLPP 71 29 4 22 3 6 ......... 71 ..N...... 2
& 738-746 534 2.7 ASDFNLPPV 57 43 14 25 3 8 ......... 57 .N......I 1
& 739-747 541 2.8 SDFNLPPVV 57 43 13 26 4 8 ......... 57 N......I. 1
& 740-748 550 2.4 DFNLPPVVA 59 41 15 24 2 5 ......... 59 ......I.. 15
& 741-749 550 2.2 FNLPPVVAK 61 39 17 21 2 4 ......... 61 .....I... 17
& 742-750 548 2.1 NLPPVVAKE 61 39 17 20 2 4 ......... 61 ....I.... 17
& 743-751 551 1.7 LPPVVAKEI 65 35 20 14 <1 3 ......... 65 ...I..... 20
& 744-752 548 1.7 PPVVAKEIV 65 35 19 14 <1 3 ......... 65 ..I...... 19
& 745-753 548 1.7 PVVAKEIVA 65 35 19 14 <1 3 ......... 65 .I....... 19
& 746-754 536 2.2 VVAKEIVAS 60 40 18 21 1 4 ......... 60 I........ 18
& 747-755 546 1.5 VAKEIVASC 78 22 5 16 <1 3 ......... 78 ......... 78
& 748-756 545 1.4 AKEIVASCD 79 21 6 14 1 3 ......... 79 ......... 79
& 749-757 545 1.4 KEIVASCDK 79 21 6 14 1 3 ......... 79 ......... 79
& 750-758 545 1.3 EIVASCDKC 80 20 6 13 1 3 ......... 80 ......... 80
& 751-759 548 1.3 IVASCDKCQ 80 20 6 13 1 3 ......... 80 ......... 80
& 752-760 547 1.8 VASCDKCQL 76 24 4 18 2 5 ......... 76 ........V 2
& 753-761 549 1.7 ASCDKCQLK 76 24 4 18 2 5 ......... 76 .......V. 2
& 754-762 547 1.8 SCDKCQLKG 76 24 4 17 2 5 ......... 76 ......V.. 2
& 755-763 553 1.4 CDKCQLKGE 81 19 4 13 2 4 ......... 81 .....V... 3
& 756-764 553 1.4 DKCQLKGEA 81 19 4 13 2 4 ......... 81 ....V.... 3
& 757-765 539 1.9 KCQLKGEAM 70 30 11 16 3 5 ......... 70 ...V..... 2
& 758-766 543 2.0 CQLKGEAMH 69 31 11 17 3 6 ......... 69 ..V...... 2
& 759-767 542 2.0 QLKGEAMHG 69 31 11 17 3 6 ......... 69 .V....... 2
& 760-768 543 1.9 LKGEAMHGQ 69 31 11 17 2 5 ......... 69 V........ 2
& 761-769 544 1.4 KGEAMHGQV 75 25 15 8 2 3 ......... 75 ......... 75
& 762-770 545 1.3 GEAMHGQVD 75 25 15 8 1 3 ......... 75 ......... 75
& 763-771 545 1.4 EAMHGQVDC 74 26 15 9 2 4 ......... 74 ......... 74
& 764-772 544 1.3 AMHGQVDCS 75 25 17 5 3 4 ......... 75 ......... 75
& 765-773 543 1.3 MHGQVDCSP 76 24 17 5 3 4 ......... 76 ......... 76
# 766-774 559 0.6 HGQVDCSPG 93 7 4 3 1 2 ......... 93 ......... 93
# 767-775 558 0.6 GQVDCSPGI 93 7 3 3 1 3 ......... 93 ......... 93
# 768-776 559 0.6 QVDCSPGIW 92 8 3 3 1 3 ......... 92 ......... 92
# 769-777 557 0.6 VDCSPGIWQ 92 8 3 3 1 3 ......... 92 ......... 92
# 770-778 557 0.7 DCSPGIWQL 93 7 2 4 2 3 ......... 93 ......... 93
# 771-779 557 0.6 CSPGIWQLD 93 7 2 4 1 3 ......... 93 ......... 93
# 772-780 557 0.6 SPGIWQLDC 93 7 2 4 1 3 ......... 93 ......... 93
# 773-781 559 0.5 PGIWQLDCT 94 6 2 3 1 2 ......... 94 ......... 94
# 774-782 559 0.5 GIWQLDCTH 94 6 2 3 1 2 ......... 94 ......... 94
# 775-783 558 0.6 IWQLDCTHL 94 6 1 3 2 3 ......... 94 ......... 94
# 776-784 557 0.5 WQLDCTHLE 94 6 3 2 1 2 ......... 94 ......... 94
# 777-785 557 0.6 QLDCTHLEG 94 6 3 2 2 3 ......... 94 ......... 94
# 778-786 558 0.6 LDCTHLEGK 93 7 3 3 2 3 ......... 93 ......... 93
& 779-787 545 1.4 DCTHLEGKV 50 50 45 3 1 2 ......... 50 ........I 45
& 780-788 545 1.4 CTHLEGKVI 50 50 45 3 1 3 ......... 50 .......I. 45
& 781-789 543 1.7 THLEGKVIL 48 52 42 9 2 4 ......... 48 ......I.. 42
& 782-790 543 1.7 HLEGKVILV 48 52 42 9 2 4 ......... 48 .....I... 42
& 783-791 544 1.8 LEGKVILVA 48 52 42 9 2 4 ......... 48 ....I.... 42
& 784-792 546 1.7 EGKVILVAV 48 52 41 9 2 3 ......... 48 ...I..... 41
& 785-793 548 1.7 GKVILVAVH 48 52 41 9 2 3 ......... 48 ..I...... 41
& 786-794 549 1.7 KVILVAVHV 48 52 41 9 2 3 ......... 48 .I....... 41
& 787-795 549 1.7 VILVAVHVA 48 52 41 9 2 3 ......... 48 I........ 41
& 788-796 564 0.7 ILVAVHVAS 90 10 7 2 1 2 ......... 90 ......... 90
& 789-797 560 0.7 LVAVHVASG 90 10 7 2 2 3 ......... 90 ......... 90
# 790-798 560 0.6 VAVHVASGY 92 8 5 1 1 2 ......... 92 ......... 92
& 791-799 556 0.9 AVHVASGYI 87 13 5 6 1 3 ......... 87 ......... 87
& 792-800 556 0.9 VHVASGYIE 87 13 5 6 1 3 ......... 87 ......... 87
& 793-801 557 0.9 HVASGYIEA 88 12 5 6 2 3 ......... 88 ......... 88
& 794-802 557 0.9 VASGYIEAE 87 13 5 6 2 3 ......... 87 ......... 87
& 795-803 554 0.9 ASGYIEAEV 88 12 5 6 2 3 ......... 88 ......... 88
& 796-804 554 0.9 SGYIEAEVI 88 12 5 5 2 3 ......... 88 ......... 88
& 797-805 554 0.9 GYIEAEVIP 87 13 5 6 2 3 ......... 87 ......... 87
& 798-806 557 1.0 YIEAEVIPA 86 14 4 8 2 4 ......... 86 ......... 86
# 799-807 560 0.8 IEAEVIPAE 90 10 2 6 2 4 ......... 90 ......... 90
# 800-808 564 0.5 EAEVIPAET 94 6 1 2 2 3 ......... 94 ......... 94
# 801-809 564 0.5 AEVIPAETG 94 6 1 3 2 3 ......... 94 ......... 94
# 802-810 564 0.5 EVIPAETGQ 94 6 1 2 2 3 ......... 94 ......... 94
# 803-811 563 0.5 VIPAETGQE 94 6 <1 2 2 3 ......... 94 ......... 94
# 804-812 584 0.7 IPAETGQET 93 7 <1 3 3 4 ......... 93 ......... 93
# 805-813 585 0.6 PAETGQETA 93 7 <1 3 3 4 ......... 93 ......... 93
# 806-814 584 0.5 AETGQETAY 94 6 <1 3 2 4 ......... 94 ......... 94
# 807-815 584 0.5 ETGQETAYF 94 6 2 2 2 3 ......... 94 ......... 94
& 808-816 571 1.4 TGQETAYFL 58 42 37 4 2 3 ......... 58 ........I 37
& 809-817 571 1.3 GQETAYFLL 58 42 37 3 2 3 ......... 58 .......I. 37
& 810-818 568 1.4 QETAYFLLK 58 42 37 4 2 3 ......... 58 ......I.. 37
& 811-819 567 1.3 ETAYFLLKL 58 42 37 4 1 2 ......... 58 .....I... 37
& 812-820 568 1.3 TAYFLLKLA 58 42 38 4 <1 2 ......... 58 ....I.... 38
& 813-821 569 1.5 AYFLLKLAG 51 49 38 10 <1 2 ......... 51 ...I..... 38
& 814-822 570 1.6 YFLLKLAGR 50 50 38 10 1 2 ......... 50 ..I...... 38
& 815-823 571 1.5 FLLKLAGRW 51 49 39 10 <1 2 ......... 51 .I....... 39
& 816-824 571 1.4 LLKLAGRWP 50 50 40 8 1 2 ......... 50 I........ 40
# 817-825 583 0.6 LKLAGRWPV 91 9 7 2 <1 2 ......... 91 ......... 91
& 818-826 575 1.1 KLAGRWPVK 83 17 7 10 1 2 ......... 83 ......... 83
& 819-827 572 1.9 LAGRWPVKT 70 30 7 20 2 5 ......... 70 ......... 70
& 820-828 569 2.4 AGRWPVKTI 64 36 5 26 4 7 ......... 64 ........V 5
& 821-829 568 2.4 GRWPVKTIH 64 36 5 26 4 7 ......... 64 .......V. 5
& 822-830 566 2.1 RWPVKTIHT 67 33 6 23 4 6 ......... 67 ......V.. 5
& 823-831 566 2.1 WPVKTIHTD 67 33 6 23 3 5 ......... 67 .....V... 5
& 824-832 566 2.1 PVKTIHTDN 67 33 6 23 3 5 ......... 67 ....V.... 5
& 825-833 566 2.1 VKTIHTDNG 68 32 6 23 3 5 ......... 68 ...V..... 5
& 826-834 562 3.3 KTIHTDNGS 49 51 7 38 6 9 ......... 49 ..V.....P <1
& 827-835 568 2.9 TIHTDNGSN 52 48 8 37 3 6 ......... 52 .V.....P. <1
& 828-836 572 2.0 IHTDNGSNF 61 39 12 25 2 3 ......... 61 V.....P.. <1
& 829-837 572 2.0 HTDNGSNFT 64 36 9 26 <1 3 ......... 64 .....P..I 6
& 830-838 570 2.0 TDNGSNFTS 64 36 9 27 <1 3 ........G <1 ....P..I. 6
& 831-839 565 3.5 DNGSNFTST 37 63 16 45 2 6 .......GA <1 ...P..I.. 4
& 832-840 560 4.4 NGSNFTSTT 30 70 12 54 4 12 ......GA. <1 ..P..I..A 1
& 833-841 558 4.5 GSNFTSTTV 30 70 12 53 6 14 .....GA.. <1 .P..I..A. 1
& 834-842 558 4.5 SNFTSTTVK 30 70 11 53 6 14 ....GA..R <1 P..I..A.. 1
& 835-843 564 3.8 NFTSTTVKA 35 65 12 49 4 9 ...GA..R. <1 ..I..A... 3
& 836-844 564 3.8 FTSTTVKAA 35 65 12 49 4 9 ..GA..R.. <1 .I..A.... 3
& 837-845 565 3.8 TSTTVKAAC 35 65 12 49 4 9 .GA..R... <1 I..A..... 3
& 838-846 571 3.3 STTVKAACW 39 61 14 43 3 7 GA..R.... <1 ..A...... 9
& 839-847 574 3.3 TTVKAACWW 39 61 14 44 3 7 A..R..... <1 .A....... 9
& 840-848 580 2.0 TVKAACWWA 63 37 20 14 2 4 ..R...... <1 A........ 20
& 841-849 587 1.0 VKAACWWAG 87 13 3 7 3 4 .R....... <1 ......... 87
& 842-850 588 1.1 KAACWWAGI 84 16 6 8 2 3 R........ <1 ......... 84
& 843-851 585 1.4 AACWWAGIK 79 21 6 12 3 5 ......... 79 ......... 79
& 844-852 585 1.3 ACWWAGIKQ 82 18 6 9 3 4 ......... 82 ......... 82
& 845-853 585 1.3 CWWAGIKQE 82 18 6 9 3 5 ......... 82 ......... 82
& 846-854 585 1.3 WWAGIKQEF 82 18 6 9 3 5 ......... 82 ......... 82
& 847-855 584 1.3 WAGIKQEFG 82 18 6 9 3 5 ......... 82 ......... 82
& 848-856 582 1.3 AGIKQEFGI 82 18 6 9 3 5 ......... 82 ......... 82
& 849-857 582 1.3 GIKQEFGIP 82 18 6 9 2 4 ......... 82 ......... 82
& 850-858 582 1.2 IKQEFGIPY 82 18 6 10 2 3 ......... 82 ......... 82
& 851-859 580 0.8 KQEFGIPYN 89 11 4 6 1 3 ......... 89 ......... 89
# 852-860 583 0.5 QEFGIPYNP 94 6 4 1 1 2 ......... 94 ......... 94
# 853-861 582 0.2 EFGIPYNPQ 98 2 <1 <1 1 2 ......... 98 ......... 98
# 854-862 582 0.2 FGIPYNPQS 98 2 <1 <1 1 1 ......... 98 ......... 98
# 855-863 582 0.2 GIPYNPQSQ 98 2 <1 0 2 2 ......... 98 ......... 98
# 856-864 583 0.2 IPYNPQSQG 98 2 <1 0 1 2 ......... 98 ......... 98
# 857-865 584 0.2 PYNPQSQGV 98 2 <1 0 1 1 ......... 98 ......... 98
# 858-866 578 0.4 YNPQSQGVV 94 6 4 <1 1 2 ......... 94 ......... 94
# 859-867 579 0.5 NPQSQGVVE 93 7 4 1 1 2 ......... 93 ......... 93
& 860-868 581 0.8 PQSQGVVES 89 11 4 5 1 2 ......... 89 ......... 89
& 861-869 579 1.2 QSQGVVESM 82 18 4 12 2 3 ......... 82 ......... 82
& 862-870 579 1.2 SQGVVESMN 82 18 4 12 2 3 ......... 82 ......... 82
& 863-871 579 1.5 QGVVESMNK 76 24 6 16 2 3 ......... 76 ......... 76
& 864-872 579 1.6 GVVESMNKE 75 25 6 17 2 4 ......... 75 ......... 75
& 865-873 580 1.6 VVESMNKEL 75 25 6 17 2 4 ......... 75 ......... 75
& 866-874 581 1.6 VESMNKELK 76 24 6 16 2 4 ......... 76 ......... 76
& 867-875 587 1.5 ESMNKELKK 78 22 6 13 3 5 ......... 78 ......... 78
& 868-876 585 1.5 SMNKELKKI 78 22 6 13 3 4 ......... 78 ......... 78
& 869-877 584 1.5 MNKELKKII 78 22 5 14 3 4 ......... 78 ......... 78
& 870-878 584 1.5 NKELKKIIG 80 20 5 11 3 5 ......... 80 ........E 3
& 871-879 584 1.5 KELKKIIGQ 80 20 5 11 3 5 ......... 80 .......E. 3
& 872-880 583 1.4 ELKKIIGQV 81 19 4 11 3 5 ......... 81 ......E.. 3
& 873-881 583 1.4 LKKIIGQVR 81 19 4 11 3 5 ......... 81 .....E... 3
& 874-882 582 1.5 KKIIGQVRD 79 21 4 12 4 6 ......... 79 ....E.... 3
& 875-883 582 1.5 KIIGQVRDQ 79 21 4 12 4 6 ......... 79 ...E..... 3
& 876-884 579 1.3 IIGQVRDQA 81 19 4 11 3 4 ......... 81 ..E...... 4
& 877-885 578 1.3 IGQVRDQAE 81 19 4 11 3 4 ......... 81 .E....... 4
& 878-886 578 1.3 GQVRDQAEH 81 19 4 11 3 4 ......... 81 E........ 4
# 879-887 578 0.7 QVRDQAEHL 90 10 5 3 2 3 ......... 90 ......... 90
& 880-888 577 0.9 VRDQAEHLK 87 13 5 6 2 3 ......... 87 ......... 87
# 881-889 577 0.6 RDQAEHLKT 92 8 4 3 2 3 ......... 92 ......... 92
# 882-890 577 0.7 DQAEHLKTA 92 8 4 3 2 3 ......... 92 ......... 92
# 883-891 578 0.6 QAEHLKTAV 93 7 3 2 2 3 ......... 93 ......... 93
# 884-892 577 0.6 AEHLKTAVQ 93 7 3 2 2 3 ......... 93 ......... 93
# 885-893 579 0.6 EHLKTAVQM 93 7 3 2 2 3 ......... 93 ......... 93
# 886-894 580 0.6 HLKTAVQMA 93 7 3 2 2 3 ......... 93 ......... 93
# 887-895 582 0.5 LKTAVQMAV 94 6 3 <1 2 2 ......... 94 ......... 94
# 888-896 582 0.7 KTAVQMAVF 91 9 4 4 2 2 ......... 91 ......... 91
# 889-897 582 0.7 TAVQMAVFI 90 10 4 4 2 2 ......... 90 ......... 90
& 890-898 585 0.7 AVQMAVFIH 90 10 4 5 2 2 ......... 90 ......... 90
# 891-899 566 0.7 VQMAVFIHN 90 10 4 4 1 2 ......... 90 ......... 90
# 892-900 565 0.6 QMAVFIHNF 91 9 4 5 <1 2 ......... 91 ......... 91
# 893-901 566 0.6 MAVFIHNFK 91 9 4 5 <1 2 ......... 91 ......... 91
& 894-902 566 0.7 AVFIHNFKR 90 10 4 5 1 2 ......... 90 ......... 90
& 895-903 561 0.9 VFIHNFKRK 88 12 4 8 <1 2 ......... 88 ......... 88
& 896-904 561 0.9 FIHNFKRKG 88 12 4 8 1 3 ......... 88 ......... 88
# 897-905 562 0.7 IHNFKRKGG 91 9 4 5 <1 2 ......... 91 ......... 91
# 898-906 559 0.4 HNFKRKGGI 95 5 2 3 <1 2 ......... 95 ......... 95
# 899-907 557 0.4 NFKRKGGIG 96 4 2 2 <1 1 ......... 96 ......... 96
& 900-908 557 0.9 FKRKGGIGG 88 12 4 7 <1 3 ......... 88 ......... 88
& 901-909 557 0.8 KRKGGIGGY 89 11 4 6 <1 2 ......... 89 ......... 89
& 902-910 557 1.2 RKGGIGGYS 83 17 6 10 1 3 ......... 83 ......... 83
& 903-911 558 1.1 KGGIGGYSA 84 16 6 10 <1 3 ......... 84 ......... 84
& 904-912 562 1.0 GGIGGYSAG 85 15 6 8 1 2 ......... 85 ......... 85
& 905-913 560 1.0 GIGGYSAGE 85 15 6 8 1 3 ......... 85 ......... 85
& 906-914 560 1.0 IGGYSAGER 85 15 6 8 1 3 ......... 85 ......... 85
& 907-915 559 1.1 GGYSAGERI 85 15 4 10 1 3 ......... 85 ......... 85
& 908-916 545 2.0 GYSAGERIV 51 49 33 15 1 4 ......... 51 ......... 51
& 909-917 542 1.6 YSAGERIVD 55 45 36 8 1 3 ......... 55 ......... 55
& 910-918 542 1.9 SAGERIVDI 52 48 32 15 1 3 ......... 52 ......... 52
& 911-919 541 1.8 AGERIVDII 54 46 32 13 1 3 ......... 54 ........V <1
& 912-920 540 1.9 GERIVDIIA 54 46 30 15 1 3 ......... 54 .......V. <1
& 913-921 537 2.5 ERIVDIIAT 46 54 26 26 2 4 ......... 46 ......V.. <1
& 914-922 539 2.5 RIVDIIATD 46 54 26 26 2 4 ......... 46 .....V... <1
& 915-923 535 2.8 IVDIIATDI 44 56 24 28 3 6 ......... 44 ....V.... 0
& 916-924 534 2.7 VDIIATDIQ 45 55 24 28 3 6 ......... 45 ...V..... 0
& 917-925 545 1.9 DIIATDIQT 70 30 10 18 3 5 ......... 70 ..V...... 0
& 918-926 545 2.3 IIATDIQTK 64 36 10 22 4 7 ......... 64 .V....... 0
& 919-927 543 2.0 IATDIQTKE 69 31 10 18 4 6 ......... 69 V........ 0
& 920-928 542 2.0 ATDIQTKEL 68 32 10 18 4 6 ......... 68 ......... 68
& 921-929 543 1.9 TDIQTKELQ 70 30 10 17 3 5 ......... 70 ......... 70
& 922-930 544 1.6 DIQTKELQK 77 23 6 15 3 4 ......... 77 ......... 77
& 923-931 544 1.6 IQTKELQKQ 75 25 6 17 2 4 ......... 75 ......... 75
& 924-932 549 1.4 QTKELQKQI 80 20 6 12 2 4 ......... 80 ......... 80
& 925-933 549 1.9 TKELQKQIT 73 27 5 20 2 5 ......... 73 ......... 73
& 926-934 548 2.1 KELQKQITK 71 29 5 22 3 6 ......... 71 ......... 71
& 927-935 540 2.1 ELQKQITKI 71 29 6 21 3 6 ......... 71 ......... 71
& 928-936 541 2.1 LQKQITKIQ 71 29 6 20 3 7 ......... 71 ......... 71
& 929-937 543 2.3 QKQITKIQN 69 31 6 21 4 8 ......... 69 ......... 69
& 930-938 544 2.3 KQITKIQNF 69 31 6 21 4 8 ......... 69 ......... 69
& 931-939 546 2.2 QITKIQNFR 70 30 6 20 5 8 ......... 70 ......... 70
& 932-940 546 2.1 ITKIQNFRV 72 28 6 18 5 8 ......... 72 ......... 72
& 933-941 546 2.0 TKIQNFRVY 72 28 6 17 5 8 ......... 72 ......... 72
& 934-942 545 1.4 KIQNFRVYY 83 17 2 11 4 6 ......... 83 ......... 83
& 935-943 546 1.3 IQNFRVYYR 84 16 3 10 3 5 ......... 84 ......... 84
& 936-944 549 0.9 QNFRVYYRD 88 12 3 6 2 3 ......... 88 ......... 88
& 937-945 548 1.4 NFRVYYRDS 78 22 7 14 1 3 ......... 78 ......... 78
& 938-946 547 1.2 FRVYYRDSR 80 20 9 10 1 2 ......... 80 ......... 80
& 939-947 545 1.5 RVYYRDSRD 75 25 9 15 2 3 ........N 1 ......... 75
& 940-948 543 1.4 VYYRDSRDP 76 24 9 13 2 3 .......N. 1 ......... 76
& 941-949 541 2.2 YYRDSRDPL 62 38 11 25 2 4 ......N.. 1 ........I 11
& 942-950 541 2.2 YRDSRDPLW 62 38 11 25 2 4 .....N... 1 .......I. 11
& 943-951 544 1.9 RDSRDPLWK 64 36 11 23 1 3 ....N.... 1 ......I.. 11
& 944-952 545 2.0 DSRDPLWKG 64 36 11 23 2 3 ...N..... 1 .....I... 11
& 945-953 545 1.9 SRDPLWKGP 65 35 11 23 2 3 ..N...... 1 ....I.... 11
& 946-954 546 1.3 RDPLWKGPA 77 23 11 10 1 2 .N....... 1 ...I..... 11
& 947-955 544 1.4 DPLWKGPAK 77 23 8 15 1 3 N........ 1 ..I...... 8
& 948-956 543 1.0 PLWKGPAKL 83 17 8 9 <1 2 ......... 83 .I....... 8
& 949-957 543 1.0 LWKGPAKLL 83 17 8 9 <1 2 ......... 83 I........ 8
# 950-958 542 0.4 WKGPAKLLW 95 5 4 <1 <1 1 ......... 95 ......... 95
# 951-959 542 0.4 KGPAKLLWK 95 5 4 <1 <1 1 ......... 95 ......... 95
# 952-960 543 0.3 GPAKLLWKG 95 5 4 <1 <1 1 ......... 95 ......... 95
# 953-961 541 0.3 PAKLLWKGE 96 4 4 <1 <1 1 ......... 96 ......... 96
# 954-962 542 0.3 AKLLWKGEG 96 4 4 <1 <1 1 ......... 96 ......... 96
# 955-963 542 0.3 KLLWKGEGA 96 4 4 <1 <1 1 ......... 96 ......... 96
# 956-964 541 0.0 LLWKGEGAV 100 0 0 0 0 0 ......... 100 ......... 100
# 957-965 544 0.0 LWKGEGAVV 100 0 0 0 0 0 ......... 100 ......... 100
# 958-966 539 0.1 WKGEGAVVI 99 1 1 <1 0 <1 ......... 99 ......... 99
# 959-967 538 0.2 KGEGAVVIQ 98 2 1 <1 <1 1 ......... 98 ......... 98
# 960-968 538 0.3 GEGAVVIQD 96 4 1 2 <1 1 ......... 96 ......... 96
# 961-969 532 0.7 EGAVVIQDN 90 10 5 4 <1 2 ......... 90 ......... 90
& 962-970 531 0.9 GAVVIQDNS 89 11 4 5 2 3 ......... 89 ......... 89
& 963-971 528 1.6 AVVIQDNSD 70 30 19 9 3 5 ......... 70 ......... 70
& 964-972 526 1.6 VVIQDNSDI 69 31 19 9 3 5 ......... 69 ......... 69
& 965-973 527 1.7 VIQDNSDIK 69 31 19 9 3 5 ......... 69 ......... 69
& 966-974 525 1.7 IQDNSDIKV 69 31 19 9 3 5 ......... 69 ......... 69
& 967-975 527 1.5 QDNSDIKVV 71 29 19 7 3 5 ......... 71 ......... 71
& 968-976 528 1.5 DNSDIKVVP 71 29 19 7 3 4 ......... 71 ......... 71
& 969-977 526 1.4 NSDIKVVPR 72 28 20 6 3 4 ......... 72 ......... 72
& 970-978 528 1.3 SDIKVVPRR 72 28 20 6 2 2 ......... 72 ......... 72
& 971-979 527 0.9 DIKVVPRRK 77 23 21 <1 <1 1 ......... 77 ......... 77
& 972-980 526 0.9 IKVVPRRKA 75 25 24 <1 <1 1 ......... 75 ......... 75
& 973-981 523 0.9 KVVPRRKAK 75 25 24 <1 <1 1 ......... 75 ......... 75
& 974-982 522 0.9 VVPRRKAKI 75 25 24 <1 <1 1 ......... 75 ......... 75
& 975-983 522 1.0 VPRRKAKII 74 26 23 2 <1 2 ......... 74 ......... 74
& 976-984 519 1.1 PRRKAKIIR 73 27 22 4 <1 2 ......... 73 ......... 73
& 977-985 518 1.3 RRKAKIIRD 72 28 22 5 1 3 ......... 72 ......... 72
& 978-986 518 1.2 RKAKIIRDY 72 28 22 5 <1 2 ......... 72 ......... 72
& 979-987 518 1.2 KAKIIRDYG 72 28 22 5 <1 2 ......... 72 ......... 72
& 980-988 518 1.3 AKIIRDYGK 71 29 22 4 2 3 ......... 71 ......... 71
# 981-989 516 0.5 KIIRDYGKQ 94 6 2 3 <1 2 ......... 94 ......... 94
# 982-990 515 0.6 IIRDYGKQM 93 7 2 4 <1 2 ......... 93 ......... 93
# 983-991 516 0.6 IRDYGKQMA 93 7 2 4 <1 2 ......... 93 ......... 93
# 984-992 514 0.4 RDYGKQMAG 95 5 2 2 <1 2 ......... 95 ......... 95
# 985-993 511 0.7 DYGKQMAGD 91 9 3 4 2 3 ......... 91 ......... 91
# 986-994 506 0.7 YGKQMAGDD 90 10 4 4 2 3 ......... 90 ......... 90
& 987-995 507 0.8 GKQMAGDDC 90 10 3 5 2 4 ......... 90 ......... 90
& 988-996 505 0.9 KQMAGDDCV 90 10 3 5 3 5 ......... 90 ......... 90
# 989-997 505 0.8 QMAGDDCVA 90 10 3 5 2 4 ......... 90 ......... 90
& 990-998 500 1.3 MAGDDCVAS 80 20 10 8 2 5 ......... 80 ......... 80
& 991-999 498 1.6 AGDDCVASR 75 25 10 12 3 5 ......... 75 ......... 75
& 992-1000 493 1.6 GDDCVASRQ 75 25 10 12 3 5 ......... 75 ......... 75
& 993-1001 478 1.8 DDCVASRQD 71 29 10 15 4 6 ......... 71 ......... 71
& 994-1002 480 1.6 DCVASRQDE 72 28 11 13 3 5 ......... 72 ......... 72
& 995-1003 468 1.7 CVASRQDED 72 28 12 13 4 6 ......... 72 ......... 72
Vif # 1-9 1140 0.6 MENRWQVMI 94 6 2 4 1 2 ......... 94 ......... 94
# 2-10 1140 0.6 ENRWQVMIV 94 6 2 4 1 2 ......... 94 ......... 94
# 3-11 1141 0.6 NRWQVMIVW 94 6 2 4 <1 2 ......... 94 ......... 94
# 4-12 1141 0.6 RWQVMIVWQ 94 6 2 4 <1 2 ......... 94 ......... 94
# 5-13 1141 0.6 WQVMIVWQV 94 6 2 4 <1 2 ......... 94 ......... 94
# 6-14 1141 0.7 QVMIVWQVD 93 7 2 5 <1 2 ......... 93 ......... 93
# 7-15 1141 0.7 VMIVWQVDR 93 7 2 5 1 2 ......... 93 ......... 93
# 8-16 1142 0.6 MIVWQVDRM 94 6 1 4 1 3 ......... 94 ......... 94
# 9-17 1143 0.6 IVWQVDRMR 94 6 1 4 1 3 ......... 94 ......... 94
# 10-18 1143 0.5 VWQVDRMRI 95 5 <1 3 1 3 ......... 95 ......... 95
& 11-19 1139 1.6 WQVDRMRIR 73 27 14 11 2 4 ......... 73 ......... 73
& 12-20 1136 2.0 QVDRMRIRT 65 35 13 19 3 4 ......... 65 ......... 65
& 13-21 1136 2.0 VDRMRIRTW 66 34 13 19 3 4 ......... 66 ......... 66
& 14-22 1137 2.9 DRMRIRTWK 49 51 15 33 3 5 ......... 49 ........I <1
& 15-23 1137 2.8 RMRIRTWKS 49 51 15 33 3 5 ......... 49 .......I. <1
& 16-24 1135 2.8 MRIRTWKSL 50 50 15 33 3 5 ......... 50 ......I.. <1
& 17-25 1135 2.8 RIRTWKSLV 50 50 15 32 3 4 ......... 50 .....I... <1
& 18-26 1135 2.8 IRTWKSLVK 50 50 16 32 3 5 ......... 50 ....I.... <1
& 19-27 1135 3.0 RTWKSLVKH 48 52 15 34 3 5 ......... 48 ...I..... <1
& 20-28 1138 2.2 TWKSLVKHH 60 40 16 22 2 4 ......... 60 ..I...... <1
& 21-29 1137 2.4 WKSLVKHHM 57 43 15 26 2 4 ......... 57 .I....... <1
& 22-30 1134 2.9 KSLVKHHMY 54 46 14 29 3 5 ......... 54 I........ <1
& 23-31 1130 3.5 SLVKHHMYI 39 61 20 38 3 7 ........V 20 ......... 39
& 24-32 1130 3.5 LVKHHMYIS 40 60 20 37 3 7 .......V. 20 ......... 40
+ 25-33 1131 4.7 VKHHMYISG 17 83 15 63 5 11 ......V.. 5 ........K 15
+ 26-34 1131 4.9 KHHMYISGK 17 83 14 63 6 12 .....V... 5 .......K. 14
+ 27-35 1129 5.1 HHMYISGKA 16 84 13 64 7 14 ....V.... 4 ......K.. 13
+ 28-36 1129 5.6 HMYVSKKAK 11 89 11 67 10 18 .....G..R 1 ...I..... 11
+ 29-37 1128 6.5 MYVSKKAKG 8 92 7 69 16 26 ....G..R. 1 ..I...... 7
+ 30-38 1130 6.1 YISKKAKGW 11 89 9 67 13 22 .V.G..R.. 1 ......... 11
+ 31-39 1119 7.2 ISGKAKGWF 4 96 4 74 19 31 V....R... 1 ..K.....V 4
+ 32-40 1126 6.4 SKKAKGWFY 8 92 6 73 13 22 .G..R.... 2 .......V. 6
+ 33-41 1125 6.8 KKAKGWFYR 7 93 6 73 14 25 G..R..... 2 ......V.. 4
+ 34-42 1126 5.9 KAKGWFYRH 16 84 8 66 10 18 ..R...... 2 .....V... 8
+ 35-43 1126 5.8 AKGWFYRHH 17 83 8 66 9 17 .R....... 2 ....V.... 8
+ 36-44 1128 5.7 KGWFYRHHY 17 83 8 67 8 16 R........ 3 ...V..... 8
& 37-45 1128 5.1 GWFYRHHYE 21 79 12 61 7 13 ......... 21 ..V...... 12
& 38-46 1127 4.2 WFYRHHYES 31 69 18 47 4 9 ......... 31 .V......N 3
& 39-47 1123 5.3 FYRHHYEST 22 78 13 56 8 16 ........P 5 V......NP 1
& 40-48 1133 4.2 YRHHYESTH 35 65 12 47 6 10 .......P. 8 ......NP. 1
& 41-49 1133 4.2 RHHYESTHP 35 65 12 46 6 10 ......P.. 8 .....NP.. 1
& 42-50 1133 4.2 HHYESTHPR 28 72 17 50 5 10 .....P... 7 ....NP... 2
& 43-51 1133 4.6 HYESTHPRI 26 74 14 53 6 12 ....P.... 7 ...NP...V <1
& 44-52 1132 4.7 YESTHPRIS 26 74 14 53 7 13 ...P..... 7 ..NP...VG <1
& 45-53 1132 4.6 ESTHPRISS 26 74 14 53 6 12 ..P...... 7 .NP...VG. <1
& 46-54 1132 4.5 STHPRISSE 26 74 14 55 6 11 .P....... 6 NP...VG.. <1
& 47-55 1135 4.2 THPRISSEV 28 72 14 54 4 9 P........ 7 P...VG... <1
& 48-56 1138 3.0 HPRISSEVH 38 62 19 40 3 5 ......... 38 ...VG.... <1
& 49-57 1139 2.3 PRISSEVHI 57 43 22 19 2 5 ......... 57 ..VG..... <1
& 50-58 1139 2.3 RISSEVHIP 57 43 22 18 3 5 ......... 57 .VG...... <1
& 51-59 1142 1.7 ISSEVHIPL 78 22 7 13 2 4 ......... 78 VG....... <1
& 52-60 1141 1.4 SSEVHIPLG 83 17 4 11 2 4 ......... 83 G.......E <1
& 53-61 1136 2.2 SEVHIPLGD 64 36 18 14 3 5 ......... 64 .......E. 2
& 54-62 1132 2.6 EVHIPLGDA 60 40 17 19 4 8 ......... 60 ......E.. 2
& 55-63 1131 3.9 VHIPLGDAK 35 65 21 37 7 12 ........R 21 .....E... 2
& 56-64 1131 4.1 HIPLGDAKL 34 66 19 40 8 12 .......R. 19 ....E.... 2
& 57-65 1124 4.1 IPLGDAKLV 34 66 19 40 8 13 ......R.. 19 ...E..... 2
& 58-66 1120 4.8 PLGDAKLVI 26 74 12 52 9 15 .....R... 12 ..E.....V <1
& 59-67 1119 5.6 LGDAKLVIT 21 79 11 57 11 19 ....R.... 11 .E.....V. 0
& 60-68 1119 5.5 GDAKLVITT 21 79 11 58 10 18 ...R..... 11 E.....V.. 0
& 61-69 1120 5.3 DAKLVITTY 23 77 11 57 8 16 ..R...... 11 .....V... 4
& 62-70 1125 4.6 AKLVITTYW 26 74 14 55 5 11 .R....... 14 ....V.... 5
& 63-71 1129 4.2 KLVITTYWG 28 72 16 53 4 8 R........ 16 ...V....V 0
& 64-72 1132 2.9 LVITTYWGL 50 50 17 31 2 4 ......... 50 ..V....V. 0
& 65-73 1130 3.0 VITTYWGLH 48 52 18 31 3 5 ......... 48 .V....V.. 0
& 66-74 1135 2.9 ITTYWGLHT 49 51 18 30 3 5 ......... 49 V....V... 0
& 67-75 1137 2.1 TTYWGLHTG 67 33 9 22 2 4 ......... 67 ....V.... 0
& 68-76 1138 0.9 TYWGLHTGE 89 11 4 6 1 3 ......... 89 ...V..... 0
& 69-77 1138 1.2 YWGLHTGER 85 15 4 10 1 3 ......... 85 ..V...... 0
& 70-78 1137 2.1 WGLHTGERD 63 37 20 16 1 4 ......... 63 .V....... 0
& 71-79 1137 2.1 GLHTGERDW 63 37 20 16 1 4 ......... 63 V........ 0
& 72-80 1136 2.1 LHTGERDWH 62 38 20 16 2 4 ......... 62 ......... 62
& 73-81 1135 2.2 HTGERDWHL 62 38 19 16 2 4 ......... 62 ......... 62
& 74-82 1139 1.8 TGERDWHLG 65 35 21 12 2 3 ......... 65 ......... 65
& 75-83 1140 1.8 GERDWHLGQ 66 34 21 11 2 4 ......... 66 ......... 66
& 76-84 1140 1.8 ERDWHLGQG 66 34 21 11 2 4 ......... 66 ......... 66
& 77-85 1139 2.0 RDWHLGQGV 65 35 20 13 2 4 ......... 65 ......... 65
& 78-86 1139 1.8 DWHLGQGVS 67 33 21 10 2 4 ......... 67 ......... 67
& 79-87 1140 1.1 WHLGQGVSI 87 13 3 9 <1 3 ......... 87 ......... 87
& 80-88 1140 1.1 HLGQGVSIE 87 13 3 10 <1 3 ......... 87 ......... 87
& 81-89 1141 1.1 LGQGVSIEW 87 13 3 9 <1 3 ......... 87 ......... 87
& 82-90 1142 1.2 GQGVSIEWR 85 15 3 11 1 3 ......... 85 ......... 85
& 83-91 1138 2.0 QGVSIEWRK 75 25 3 19 2 5 ......... 75 ......... 75
& 84-92 1133 3.5 GVSIEWRKK 33 67 27 37 4 7 ......... 33 ........G 5
& 85-93 1131 4.3 VSIEWRKKR 28 72 22 43 7 12 ......... 28 .......GN 0
& 86-94 1132 4.0 SIEWRKKRY 29 71 23 42 6 11 ......... 29 ......GN. 0
& 87-95 1129 4.9 IEWRKKRYS 22 78 19 51 8 15 ......... 22 .....GN.. 0
& 88-96 1130 4.8 EWRKKRYST 22 78 20 51 7 14 ......... 22 ....GN... 0
& 89-97 1130 4.8 WRKKRYSTQ 22 78 20 51 7 14 ......... 22 ...GN.... 0
+ 90-98 1129 5.0 RKKRYSTQV 20 80 19 53 8 15 ......... 20 ..GN..... 0
+ 91-99 1128 5.1 KKRYSTQVD 19 81 19 53 9 16 ......... 19 .GN...... 0
& 92-100 1130 4.7 RRYSTQVDP 21 79 21 52 6 12 K........ 21 GN....... 0
+ 93-101 1130 4.6 RYSTQVDPG 18 82 18 58 6 12 ........E 1 N........ 0
& 94-102 1129 4.1 YSTQVDPDL 20 80 19 56 4 9 .......E. 1 .......G. 19
+ 95-103 1129 4.2 STQVDPDLA 20 80 19 57 5 9 ......E.. 1 ......G.. 19
& 96-104 1133 3.2 TQVDPDLAD 35 65 22 39 3 6 .....E... 2 .....G... 22
& 97-105 1133 3.8 QVDPDLADQ 23 77 21 53 4 7 ....E.... 2 ....G...R 1
& 98-106 1133 3.8 VDPDLADQL 23 77 21 53 3 7 ...E..... 2 ...G...R. 1
& 99-107 1134 3.4 DPDLADQLI 25 75 23 49 3 6 ..E...... 2 ..G...R.. 2
& 100-108 1134 3.1 PDLADQLIH 29 71 24 45 3 5 .E....... 2 .G...R... 2
& 101-109 1132 3.9 DLADQLIHL 26 74 17 54 4 7 E........ 1 G...R.... 2
& 102-110 1136 3.3 LADQLIHLY 47 53 10 40 3 6 ......... 47 ...R..... 2
& 103-111 1142 3.1 ADQLIHLYY 48 52 11 39 2 5 ......... 48 ..R...... 2
& 104-112 1142 3.1 DQLIHLYYF 48 52 11 38 2 5 ......... 48 .R....... 3
& 105-113 1141 3.2 QLIHLYYFD 47 53 12 39 3 5 ......... 47 R........ 2
& 106-114 1141 2.6 LIHLYYFDC 50 50 23 25 2 4 ......... 50 ......... 50
& 107-115 1141 2.6 IHLYYFDCF 50 50 23 25 2 4 ......... 50 ......... 50
& 108-116 1141 2.9 HLYYFDCFS 49 51 22 26 3 5 ......... 49 ......... 49
& 109-117 1139 3.4 LYYFDCFSE 46 54 12 39 4 7 ........D 3 ......... 46
& 110-118 1140 2.8 YYFDCFSES 52 48 12 34 3 5 .......D. 4 ........T 2
& 111-119 1140 2.1 YFDCFSESA 64 36 17 18 2 3 ......D.. 17 .......T. 2
& 112-120 1141 2.0 FDCFSESAI 64 36 17 18 2 3 .....D... 17 ......T.. 2
& 113-121 1141 2.1 DCFSESAIR 63 37 17 18 2 4 ....D.... 17 .....T... 2
& 114-122 1139 3.4 CFSESAIRN 44 56 11 42 3 6 ...D....K 3 ....T.... 2
& 115-123 1138 3.7 FSESAIRNA 40 60 10 46 3 7 ..D....K. 2 ...T..... 2
& 116-124 1137 4.1 SESAIRNAI 36 64 8 52 4 8 .D....K.L 1 ..T...... 2
& 117-125 1135 4.0 ESAIRNAIL 37 63 10 48 4 8 D....K.L. 1 .T....... 2
& 118-126 1135 3.5 SAIRNAILG 40 60 12 44 4 7 ....K.L.. 3 T........ 2
& 119-127 1135 4.7 AIRNAILGH 25 75 13 56 6 11 ...K.L... 2 ......... 25
+ 120-128 1133 5.7 IRNAILGHI 15 85 8 67 9 16 ..K.L.... 2 ........R 8
+ 121-129 1131 5.7 RNAILGHIV 14 86 8 68 9 16 .K.L..... 2 .......R. 8
+ 122-130 1130 6.4 NAILGHIVS 10 90 7 72 12 21 K.L...... 1 ......R.. 7
+ 123-131 1133 5.5 AILGHIVSP 15 85 11 66 8 15 .L....... 2 .....R... 11
+ 124-132 1129 6.1 ILGHRVSPR 9 91 8 74 9 18 L...I.... 1 ........S 6
+ 125-133 1132 5.8 LGHRVSPRC 11 89 9 71 8 16 ...I..... 9 .......S. 6
+ 126-134 1133 5.9 GHRVSPRCE 11 89 9 70 9 18 ..I...... 9 ......S.. 7
+ 127-135 1133 6.0 HRVSPRCEY 11 89 9 70 10 19 .I....... 9 .....S... 7
+ 128-136 1134 5.4 RVSPRCEYQ 15 85 14 62 9 17 I........ 14 ....S.... 7
& 129-137 1136 4.4 VSPRCEYQA 32 68 17 44 7 13 ......... 32 ...S..... 17
& 130-138 1136 4.3 SPRCEYQAG 32 68 18 43 7 13 ......... 32 ..S...... 18
& 131-139 1137 3.7 PRCEYQAGH 37 63 21 38 4 9 ......... 37 .S....... 21
& 132-140 1135 3.9 RCEYQAGHN 36 64 19 41 5 9 ......... 36 S........ 19
& 133-141 1134 3.0 CEYQAGHNK 59 41 7 31 4 7 ......... 59 ......... 59
& 134-142 1132 3.0 EYQAGHNKV 59 41 7 31 4 8 ......... 59 ......... 59
& 135-143 1134 2.3 YQAGHNKVG 70 30 4 23 3 6 ......... 70 ......... 70
& 136-144 1133 2.2 QAGHNKVGS 73 27 3 21 3 6 ......... 73 ......... 73
& 137-145 1134 1.8 AGHNKVGSL 77 23 4 17 2 4 ......... 77 ......... 77
& 138-146 1134 1.5 GHNKVGSLQ 81 19 4 14 2 4 ......... 81 ......... 81
& 139-147 1133 1.6 HNKVGSLQY 80 20 4 14 2 4 ......... 80 ......... 80
& 140-148 1132 1.5 NKVGSLQYL 81 19 4 14 2 4 ......... 81 ......... 81
& 141-149 1134 1.1 KVGSLQYLA 86 14 4 9 <1 3 ......... 86 ......... 86
# 142-150 1137 0.7 VGSLQYLAL 93 7 2 4 1 2 ......... 93 ......... 93
& 143-151 1135 2.2 GSLQYLALA 45 55 36 17 1 3 ......... 45 ........T 36
& 144-152 1134 2.4 SLQYLALAA 41 59 37 20 2 3 ......... 41 .......T. 37
& 145-153 1135 2.3 LQYLALAAL 42 58 37 19 2 4 ......... 42 ......T.. 37
& 146-154 1130 3.5 QYLALTALI 32 68 25 41 3 6 .....A... 25 ......... 32
& 147-155 1129 4.4 YLALTALIT 25 75 20 49 6 10 ....A.... 20 ......... 25
& 148-156 1129 4.5 LALTALITP 25 75 19 49 7 12 ...A..... 19 ......... 25
& 149-157 1128 4.8 ALTALITPK 24 76 18 50 8 14 ..A...... 18 ......... 24
+ 150-158 1125 5.5 LTALITPKK 20 80 15 55 10 18 .A....... 15 ........R 4
+ 151-159 1121 6.4 TALITPKKI 14 86 11 60 15 25 A........ 11 .......R. 2
& 152-160 1124 5.5 ALITPKKIK 26 74 5 57 11 20 ......... 26 ......R.R <1
& 153-161 1124 5.4 LITPKKIKP 28 72 6 56 11 19 ......... 28 .....R.R. <1
& 154-162 1124 5.4 ITPKKIKPP 28 72 6 56 11 19 ......... 28 ....R.R.. <1
& 155-163 1127 4.4 TPKKIKPPL 39 61 7 46 8 13 ......... 39 ...R.R... <1
& 156-164 1128 3.6 PKKIKPPLP 47 53 8 40 5 9 ......... 47 ..R.R.... <1
& 157-165 1129 3.5 KKIKPPLPS 48 52 8 40 4 8 ......... 48 .R.R..... <1
& 158-166 1130 3.2 KIKPPLPSV 50 50 8 38 4 7 ......... 50 R.R...... <1
& 159-167 1132 4.4 IKPPLPSVR 21 79 14 60 5 9 ........T 14 .R....... <1
& 160-168 1136 3.1 KPPLPSVRK 25 75 22 50 3 5 .......T. 22 R........ 1
& 161-169 1136 2.8 PPLPSVRKL 26 74 23 48 3 4 ......T.. 23 ......... 26
& 162-170 1137 2.9 PLPSVRKLT 26 74 23 48 3 5 .....T... 23 ......... 26
& 163-171 1137 2.8 LPSVRKLTE 26 74 23 48 3 5 ....T.... 23 ......... 26
& 164-172 1136 2.8 PSVRKLTED 26 74 23 48 3 5 ...T..... 23 ......... 26
& 165-173 1136 2.9 SVRKLTEDR 26 74 23 49 3 5 ..T...... 23 ......... 26
& 166-174 1135 2.8 VRKLTEDRW 26 74 23 49 2 4 .T....... 23 ......... 26
& 167-175 1135 2.6 RKLTEDRWN 26 74 25 47 2 4 T........ 23 ......... 26
& 168-176 1135 0.8 KLTEDRWNK 90 10 6 3 1 2 ......... 90 ......... 90
& 169-177 1135 0.9 LTEDRWNKP 88 12 6 5 <1 2 ......... 88 ......... 88
& 170-178 1129 1.3 TEDRWNKPQ 81 19 6 11 1 3 ......... 81 ......... 81
& 171-179 1127 2.0 EDRWNKPQK 69 31 10 18 2 4 ......... 69 ......... 69
& 172-180 1126 2.2 DRWNKPQKT 66 34 10 21 3 5 ......... 66 ......... 66
& 173-181 1126 2.5 RWNKPQKTK 63 37 10 24 3 6 ......... 63 ......... 63
& 174-182 1126 2.7 WNKPQKTKG 60 40 9 28 3 6 ......... 60 ........D 4
& 175-183 1124 2.9 NKPQKTKGH 58 42 9 29 4 8 ......... 58 .......D. 4
& 176-184 1124 3.2 KPQKTKGHR 54 46 9 33 4 8 ......... 54 ......D.. 3
& 177-185 1123 3.4 PQKTKGHRG 50 50 7 38 5 8 ......... 50 .....D... 3
& 178-186 1116 3.6 QKTKGHRGS 48 52 7 39 6 10 ......... 48 ....D.... 3
& 179-187 1112 3.5 KTKGHRGSH 50 50 7 38 5 9 ......... 50 ...D..... 4
& 180-188 1113 3.1 TKGHRGSHT 56 44 8 32 4 8 ......... 56 ..D...... 5
& 181-189 1114 3.3 KGHRGSHTM 56 44 8 32 5 10 ......... 56 .D....... 5
& 182-190 1111 3.6 GHRGSHTMN 52 48 6 35 7 11 ......... 52 D........ 4
& 183-191 1111 3.4 HRGSHTMNG 56 44 7 32 6 11 ......... 56 ......... 56
& 184-192 1109 3.3 RGSHTMNGH 56 44 7 31 6 10 ......... 56 ......... 56
Vpr & 1-9 994 1.4 MEQAPEDQG 82 18 5 11 2 4 ......... 82 ......... 82
& 2-10 992 1.4 EQAPEDQGP 81 19 5 11 3 5 ......... 81 ......... 81
& 3-11 987 1.7 QAPEDQGPQ 79 21 5 13 3 5 ......... 79 ......... 79
& 4-12 993 1.4 APEDQGPQR 83 17 4 10 3 5 ......... 83 ......... 83
& 5-13 991 1.4 PEDQGPQRE 83 17 4 11 3 5 ......... 83 ......... 83
& 6-14 986 1.3 EDQGPQREP 83 17 4 10 3 4 ......... 83 ......... 83
& 7-15 984 2.0 DQGPQREPY 74 26 6 16 4 6 ........H 6 ......... 74
& 8-16 980 2.2 QGPQREPYN 72 28 6 18 4 7 .......H. 6 ......... 72
& 9-17 970 2.6 GPQREPYNE 67 33 6 21 6 9 ......H.. 6 ......... 67
& 10-18 971 2.6 PQREPYNEW 67 33 6 22 6 9 .....H... 6 ......... 67
& 11-19 968 3.0 QREPYNEWT 59 41 8 27 6 10 ....H.... 6 ......... 59
& 12-20 967 2.9 REPYNEWTL 60 40 8 27 6 9 ...H..... 7 ......... 60
& 13-21 960 2.9 EPYNEWTLE 59 41 8 28 5 9 ..H...... 7 ......... 59
& 14-22 958 2.9 PYNEWTLEL 60 40 8 28 5 9 .H....... 7 ......... 60
& 15-23 961 2.9 YNEWTLELL 60 40 8 28 5 9 H........ 7 ......... 60
& 16-24 973 2.1 NEWTLELLE 72 28 8 16 4 8 ......... 72 ......... 72
& 17-25 982 1.9 EWTLELLEE 75 25 8 14 3 6 ......... 75 ......... 75
& 18-26 1001 1.4 WTLELLEEL 81 19 9 8 2 4 ......... 81 ......... 81
& 19-27 1002 1.3 TLELLEELK 81 19 9 8 2 4 ......... 81 ......... 81
& 20-28 989 2.5 LELLEELKN 52 48 23 21 3 5 ......... 52 ......... 52
& 21-29 990 2.5 ELLEELKNE 52 48 23 21 3 6 ......... 52 ......... 52
& 22-30 995 2.5 LLEELKNEA 53 47 23 21 3 6 ......... 53 ......... 53
& 23-31 999 2.5 LEELKNEAV 53 47 22 21 3 6 ......... 53 ......... 53
& 24-32 991 2.8 EELKNEAVR 50 50 21 25 4 7 ......... 50 ......... 50
& 25-33 992 2.8 ELKNEAVRH 51 49 21 25 4 7 ......... 51 ......... 51
& 26-34 995 2.6 LKNEAVRHF 52 48 21 24 3 6 ......... 52 ......... 52
& 27-35 995 2.6 KNEAVRHFP 52 48 21 24 3 6 ......... 52 ......... 52
& 28-36 990 2.8 NEAVRHFPR 51 49 20 26 4 7 ......... 51 ......... 51
& 29-37 960 3.6 EAVRHFPRP 28 72 19 47 5 8 ........I 19 ........V 11
& 30-38 962 3.5 AVRHFPRPW 28 72 19 48 4 7 .......I. 19 .......V. 12
& 31-39 962 3.5 VRHFPRPWL 28 72 19 48 4 7 ......I.. 19 ......V.. 12
& 32-40 948 3.7 RHFPRPWLH 26 74 19 51 4 8 .....I... 19 .....V... 12
& 33-41 940 4.5 HFPRPWLHG 20 80 14 60 5 11 ....I.... 14 ....V.... 10
& 34-42 940 4.5 FPRPWLHGL 20 80 14 60 5 11 ...I..... 14 ...V..... 10
& 35-43 941 4.5 PRPWLHGLG 20 80 14 60 5 11 ..I...... 14 ..V...... 10
+ 36-44 938 4.6 RPWLHGLGQ 20 80 14 60 6 12 .I....... 14 .V....... 10
+ 37-45 915 5.2 PWLHGLGQY 14 86 11 66 8 15 I.......H 11 V.......H 7
& 38-46 954 3.0 WLHGLGQHI 35 65 26 36 3 6 ......... 35 ......... 35
& 39-47 953 3.0 LHGLGQHIY 35 65 26 36 3 6 ......... 35 ......... 35
& 40-48 945 3.8 HGLGQHIYE 33 67 16 46 5 10 ......... 33 ......... 33
& 41-49 961 3.7 GLGQHIYET 35 65 17 43 6 10 ......... 35 ......... 35
& 42-50 974 2.6 LGQHIYETY 43 57 35 19 3 7 ......... 43 ......... 43
& 43-51 974 2.7 GQHIYETYG 43 57 34 19 3 7 ......... 43 ......... 43
& 44-52 971 2.7 QHIYETYGD 43 57 34 20 3 7 ......... 43 ......... 43
& 45-53 975 2.6 HIYETYGDT 43 57 35 19 3 6 ......... 43 ......... 43
& 46-54 1009 1.6 IYETYGDTW 79 21 4 14 2 5 ......... 79 ......... 79
& 47-55 982 2.5 YETYGDTWA 63 37 10 23 4 7 ......... 63 ........E 5
& 48-56 983 2.6 ETYGDTWAG 63 37 10 24 4 7 ......... 63 .......E. 5
& 49-57 994 1.9 TYGDTWAGV 67 33 10 20 3 4 ......... 67 ......E.. 10
& 50-58 992 2.0 YGDTWAGVE 66 34 13 18 2 5 ......... 66 .....E... 13
& 51-59 987 2.1 GDTWAGVEA 66 34 13 19 3 6 ......... 66 ....E.... 13
& 52-60 969 2.6 DTWAGVEAI 55 45 12 30 3 6 ......... 55 ...E....M <1
& 53-61 965 3.1 TWAGVEAII 51 49 12 33 4 8 ......... 51 ..E....ML <1
& 54-62 963 3.3 WAGVEAIIR 50 50 11 33 5 10 ......... 50 .E....ML. <1
& 55-63 929 4.2 AGVEAIIRI 39 61 9 43 9 15 ......... 39 E....ML.. <1
& 56-64 950 3.2 GVEAIIRIL 55 45 7 33 5 10 ......... 55 ....ML... <1
& 57-65 948 3.3 VEAIIRILQ 55 45 6 32 6 10 ......... 55 ...ML.... <1
& 58-66 948 3.3 EAIIRILQQ 55 45 6 33 6 11 ......... 55 ..ML..... <1
& 59-67 946 3.0 AIIRILQQL 58 42 6 30 5 10 ......... 58 .ML...... <1
& 60-68 948 3.1 IIRILQQLL 58 42 6 31 5 9 ......... 58 ML....... <1
& 61-69 957 2.6 IRILQQLLF 63 37 8 25 3 7 ......... 63 L........ <1
& 62-70 955 2.8 RILQQLLFI 59 41 8 30 4 7 ......... 59 ......... 59
& 63-71 956 2.6 ILQQLLFIH 60 40 8 29 3 6 ......... 60 ......... 60
& 64-72 995 1.6 LQQLLFIHF 76 24 11 12 2 3 ......... 76 ......... 76
& 65-73 995 1.6 QQLLFIHFR 75 25 11 13 2 3 ........Q 1 ......... 75
& 66-74 995 1.7 QLLFIHFRI 74 26 11 14 2 4 .......QN 1 ......... 74
& 67-75 997 1.8 LLFIHFRIG 73 27 11 15 1 3 ......QNW 1 ......... 73
& 68-76 1004 1.6 LFIHFRIGC 75 25 11 13 1 3 .....QNWV 1 ......... 75
& 69-77 984 2.6 FIHFRIGCR 51 49 20 26 2 4 ....QNWV- 0 ......... 51
& 70-78 989 2.5 IHFRIGCRH 52 48 20 26 2 4 ...QNWV-- 0 ......... 52
& 71-79 1001 1.8 HFRIGCRHS 56 44 29 12 2 3 ..QNWV--. 0 ......... 56
& 72-80 1001 1.9 FRIGCRHSR 56 44 29 12 2 3 .QNWV--.T 0 ......... 56
& 73-81 1002 1.7 RIGCRHSRI 57 43 31 10 2 3 QNWV--.T- 0 ......... 57
& 74-82 1002 1.8 IGCRHSRIG 56 44 31 10 2 3 NWV--.T-- 0 ......... 56
& 75-83 999 1.7 GCRHSRIGI 57 43 31 9 3 4 WV--.T--- 0 ......... 57
& 76-84 943 3.5 CRHSRIGIT 30 70 17 49 4 7 V--.T---- 0 ........I 17
+ 77-85 924 5.2 RHSRIGITP 12 88 8 73 7 13 --.T----- 0 .......I. 5
+ 78-86 889 5.0 HSRIGITPQ 14 86 12 66 9 14 -.T------ 0 ......I.. 6
+ 79-87 886 5.3 SRIGITPQR 13 87 10 65 11 17 .T------- 0 .....I... 6
+ 80-88 883 5.4 RIGITPQRR 13 87 11 65 11 19 T-------- 0 ....I.... 5
+ 81-89 872 6.0 IGITPQRRA 10 90 9 64 16 25 --------- 0 ...I....T 1
+ 82-90 875 6.0 GITPQRRAR 10 90 9 64 16 25 --------- 0 ..I....T. 1
+ 83-91 873 6.2 ITPQRRARN 10 90 9 62 18 27 --------- 0 .I....T.. 1
+ 84-92 875 6.1 TPQRRARNG 10 90 9 63 17 26 --------- 0 I....T... 1
+ 85-93 905 5.4 RQRRARNGA 16 84 15 54 15 22 --------- 0 P...T...S <1
& 86-94 922 4.4 QRRARNGAS 41 59 8 39 12 18 --------- 0 ...T...S. 2
& 87-95 970 3.8 RRARNGASR 48 52 10 34 8 14 --------- 0 ..T...S.. 2
& 88-96 980 3.7 RARNGASRS 48 52 10 35 7 12 --------- 0 .T...S... 2
Tat & 1-9 1257 2.3 MEPVDPRLE 65 35 9 25 1 4 ......... 65 .D....... 6
& 2-10 1260 2.3 EPVDPRLEP 65 35 9 25 1 4 ......... 65 D........ 6
& 3-11 1261 1.9 PVDPRLEPW 71 29 10 18 1 3 ......... 71 ......... 71
& 4-12 1259 2.3 VDPRLEPWK 67 33 9 22 2 4 ......... 67 ......... 67
& 5-13 1258 2.2 DPRLEPWKH 68 32 9 21 2 4 ......... 68 ......... 68
& 6-14 1258 2.2 PRLEPWKHP 68 32 9 21 2 4 ......... 68 ......... 68
& 7-15 1258 2.0 RLEPWKHPG 70 30 9 19 2 4 ......... 70 ......... 70
& 8-16 1264 1.1 LEPWKHPGS 86 14 3 10 <1 2 ......... 86 ......... 86
& 9-17 1264 1.2 EPWKHPGSQ 85 15 2 11 1 3 ......... 85 ......... 85
& 10-18 1264 1.0 PWKHPGSQP 88 12 3 8 <1 2 ......... 88 ......... 88
& 11-19 1260 2.2 WKHPGSQPK 58 42 23 16 2 4 ......... 58 ......... 58
& 12-20 1261 2.3 KHPGSQPKT 58 42 24 16 2 4 ......... 58 ......... 58
& 13-21 1262 2.4 HPGSQPKTA 56 44 22 20 2 5 ......... 56 ......... 56
& 14-22 1264 2.5 PGSQPKTAC 56 44 22 20 2 5 ......... 56 ......... 56
& 15-23 1263 3.3 GSQPKTACT 43 57 15 38 4 7 ......... 43 ......... 43
& 16-24 1258 4.9 SQPKTACTN 24 76 9 61 6 12 ......... 24 ......... 24
& 17-25 1258 4.8 QPKTACTNC 24 76 9 61 6 12 ......... 24 ......... 24
& 18-26 1257 4.9 PKTACTNCY 23 77 9 61 7 12 ......... 23 ......... 23
& 19-27 1257 4.8 KTACTNCYC 23 77 9 61 7 12 ......... 23 ......... 23
& 20-28 1260 3.9 TACTNCYCK 31 69 15 50 4 8 ......... 31 ......... 31
& 21-29 1251 4.9 ACTNCYCKK 24 76 11 59 6 12 ......... 24 ......... 24
& 22-30 1254 4.3 CTNCYCKKC 29 71 12 54 5 9 ......... 29 ......... 29
& 23-31 1254 4.3 TNCYCKKCC 29 71 12 55 4 9 ......... 29 ......... 29
& 24-32 1252 4.5 NCYCKKCCF 30 70 10 55 5 11 ......... 30 ........L 8
& 25-33 1257 2.9 CYCKKCCFH 55 45 11 31 2 6 ......... 55 .......L. 11
& 26-34 1255 2.9 YCKKCCFHC 55 45 11 31 3 6 ......... 55 ......L.. 11
& 27-35 1255 2.9 CKKCCFHCQ 55 45 11 31 3 6 ......... 55 .....L... 11
& 28-36 1247 3.3 KKCCFHCQV 52 48 11 32 5 9 ......... 52 ....L.... 11
& 29-37 1246 3.3 KCCFHCQVC 52 48 11 32 5 9 ......... 52 ...L..... 11
& 30-38 1256 2.2 CCFHCQVCF 66 34 16 15 4 6 ......... 66 ..L...... 16
& 31-39 1251 3.8 CFHCQVCFI 32 68 24 38 6 9 ......... 32 .L....... 3
& 32-40 1249 5.0 FHCQVCFIT 21 79 12 59 8 13 ......... 21 L.......Q <1
& 33-41 1250 4.3 HCQVCFITK 25 75 12 56 6 10 ......... 25 .......Q. 2
& 34-42 1250 4.8 CQVCFITKG 22 78 10 60 7 11 ........A 3 ......Q.. 2
& 35-43 1250 4.8 QVCFITKGL 22 78 10 60 7 11 .......A. 3 .....Q... 2
& 36-44 1252 4.7 VCFITKGLG 23 77 10 61 6 11 ......A.. 3 ....Q.... 2
& 37-45 1220 4.2 CFITKGLGI 26 74 11 59 4 7 .....A... 3 ...Q..... 2
& 38-46 1218 4.5 FITKGLGIS 26 74 11 58 5 9 ....A.... 3 ..Q...... <1
& 39-47 1218 4.6 ITKGLGISY 25 75 11 59 5 10 ...A..... 3 .Q....... <1
& 40-48 1226 3.1 TKGLGISYG 47 53 13 37 3 6 ..A...... 6 Q........ 1
& 41-49 1230 1.7 KGLGISYGR 73 27 14 11 2 4 .A....... 14 ......... 73
& 42-50 1248 1.7 GLGISYGRK 72 28 14 13 1 3 A........ 14 ......... 72
& 43-51 1252 1.0 LGISYGRKK 87 13 3 8 2 3 ......... 87 ......... 87
& 44-52 1251 1.2 GISYGRKKR 85 15 3 11 2 3 ......... 85 ......... 85
& 45-53 1249 1.4 ISYGRKKRR 83 17 2 13 2 3 ......... 83 ......... 83
& 46-54 1245 1.5 SYGRKKRRQ 81 19 2 14 3 4 ......... 81 ......... 81
& 47-55 1246 1.2 YGRKKRRQR 86 14 2 9 2 4 ......... 86 ......... 86
& 48-56 1247 1.0 GRKKRRQRR 89 11 3 6 2 4 ......... 89 ......... 89
& 49-57 1245 1.5 RKKRRQRRR 82 18 3 12 3 4 ......... 82 ......... 82
& 50-58 1239 3.0 KKRRQRRRA 47 53 16 33 4 7 ......... 47 ........P 16
& 51-59 1230 3.8 KRRQRRRAP 36 64 15 44 5 9 ........H 5 .......PS <1
& 52-60 1243 4.6 RRQRRRAPQ 30 70 13 49 9 14 .......H. 5 ......PS. <1
& 53-61 1238 5.4 RQRRRAPQD 25 75 9 54 11 18 ......H.N 1 .....PS.. <1
& 54-62 1237 6.0 QRRRAPQDS 20 80 7 58 14 22 .....H.N. 1 ....PS..C 0
+ 55-63 1236 6.6 RRRAPQDSQ 14 86 5 66 16 25 ....H.N.. <1 ...PS..CK 0
+ 56-64 1229 7.2 RRAPQDSQT 10 90 4 63 22 33 ...H.N... <1 ..PS..CK. 0
+ 57-65 1226 7.4 RAPQDSQTH 10 90 4 61 25 37 ..H.N.... <1 .PS..CK.. 0
+ 58-66 1225 7.4 APQDSQTHQ 10 90 4 61 24 35 .H.N..... <1 PS..CK... 0
+ 59-67 1227 7.3 PQDSQTHQV 8 92 7 61 23 35 H.N.....A <1 S..CK...A 0
+ 60-68 1227 7.4 QDSQTHQVS 8 92 7 61 24 36 .N.....A. 1 ..CK...A. 0
+ 61-69 1224 7.1 DSQTHQVSL 9 91 7 62 21 32 N.....A.. 1 .CK...A.. 0
+ 62-70 1227 6.7 SQTHQVSLS 13 87 8 61 18 29 .....A... 8 CK...A... 0
+ 63-71 1224 6.4 QTHQVSLSK 16 84 8 59 16 26 ....A.... 8 K...A.... 1
& 64-72 1016 5.5 THQVSLSKQ 20 80 13 54 13 20 ...A..... 13 ...A..... 13
& 65-73 601 4.9 HQVSLSKQP 26 74 15 46 12 20 ..A...... 15 ..A...... 15
+ 66-74 600 5.4 QVSLSKQPA 14 86 12 58 16 24 .A......T 5 .A......T 5
+ 67-75 601 5.7 VSLSKQPAS 14 86 10 59 17 27 A......T. 5 A......T. 5
& 68-76 599 5.1 SLSKQPASQ 23 77 16 45 16 23 ......T.. 16 ......T.. 16
+ 69-77 593 5.5 LSKQPASQP 20 80 11 51 18 27 .....T... 11 .....T... 11
+ 70-78 594 5.7 SKQPASQPR 17 83 10 57 16 26 ....T.... 10 ....T...G <1
& 71-79 598 5.2 KQPASQPRG 24 76 14 47 15 24 ...T..... 14 ...T...G. 1
& 72-80 604 5.2 QPASQPRGD 25 75 14 46 15 24 ..T...... 14 ..T...G.. 1
+ 73-81 861 5.7 PASQPRGDP 19 81 13 55 13 22 .T....... 13 .T...G... 4
+ 74-82 861 5.8 ASQPRGDPT 18 82 12 55 14 24 T........ 12 T...G.... 4
& 75-83 860 4.8 SQPRGDPTG 35 65 6 48 11 18 ......... 35 ...G..... 5
& 76-84 859 4.7 QPRGDPTGP 37 63 6 45 11 18 ......... 37 ..G...... 5
& 77-85 860 5.1 PRGDPTGPK 31 69 5 51 13 20 ......... 31 .G....... 5
& 78-86 861 4.1 RGDPTGPKE 45 55 6 39 10 15 ......... 45 G........ 6
& 79-87 779 4.0 GDPTGPKES 42 58 7 42 8 13 ........- 0 ......... 42
& 80-88 779 4.4 DPTGPKESK 39 61 7 45 9 15 .......-- 0 ......... 39
& 81-89 779 4.4 PTGPKESKK 37 63 7 49 7 13 ......--- 0 ......... 37
& 82-90 782 4.3 TGPKESKKK 35 65 7 52 6 12 .....---- 0 ......... 35
& 83-91 782 4.1 GPKESKKKV 38 62 7 50 5 11 ....----- 0 ......... 38
& 84-92 783 4.1 PKESKKKVE 37 63 7 50 5 10 ...------ 0 ......... 37
& 85-93 785 4.8 KESKKKVER 28 72 6 59 7 14 ..------- 0 ......... 28
& 86-94 784 4.5 ESKKKVERE 35 65 8 50 7 14 .-------- 0 ......... 35
& 87-95 786 4.5 SKKKVERET 35 65 8 50 8 15 --------- 0 ......... 35
& 88-96 791 4.1 KKKVERETE 47 53 6 39 8 15 --------- 0 ......... 47
& 89-97 786 4.2 KKVERETET 46 54 6 39 9 17 --------- 0 ......... 46
& 90-98 785 4.5 KVERETETD 43 57 7 40 10 19 --------- 0 ......... 43
& 91-99 784 4.7 VERETETDP 41 59 6 40 13 22 --------- 0 ......... 41
+ 92-100 765 6.6 ERETETDPV 16 84 7 55 22 35 --------- 0 ......... 16
+ 93-101 758 7.5 RETETDPVH 6 94 4 60 30 45 --------- 0 ......... 6
94-102 * 66 5.3 ETETDSVHQ 6 94 6 39 48 67 --------- 0 .....P..- 0
Rev & 1-9 612 1.8 MAGRSGDSD 76 24 4 17 3 6 ......... 76 ......... 76
& 2-10 603 2.2 AGRSGDSDE 70 30 4 23 3 7 ......... 70 ........D 4
& 3-11 602 3.3 GRSGDSDEE 48 52 18 30 4 10 ......... 48 .......DD <1
& 4-12 605 3.5 RSGDSDEEL 46 54 18 31 5 11 ......... 46 ......DD. <1
& 5-13 605 3.8 SGDSDEELL 40 60 17 35 7 13 ........I 6 .....DD.. <1
& 6-14 627 4.6 GDSDEELLK 31 69 14 43 12 19 .......IR 3 ....DD... <1
& 7-15 624 5.1 DSDEELLKT 26 74 10 50 14 23 ......IR. 2 ...DD.... <1
& 8-16 625 5.2 SDEELLKTV 23 77 10 54 13 23 .....IR.. 2 ..DD..... <1
& 9-17 629 5.0 DEELLKTVR 24 76 11 53 11 20 ....IR... 2 .DD...... <1
& 10-18 629 5.4 EELLKTVRL 23 77 10 51 16 25 ...IR.... 2 DD....... <1
& 11-19 636 5.2 ELLKTVRLI 25 75 10 50 14 23 ..IR..... 2 D........ 10
& 12-20 636 4.6 LLKTVRLIK 36 64 9 43 12 20 .IR...... 2 ......... 36
+ 13-21 635 5.9 LKTVRLIKF 19 81 8 56 17 28 IR......L 1 ........L 8
& 14-22 635 5.8 KTVRLIKFL 20 80 8 55 16 27 R......L. 3 .......L. 8
& 15-23 633 5.1 TVRLIKFLY 21 79 13 54 12 20 ......L.. 13 ......L.. 13
& 16-24 639 4.5 VRLIKFLYQ 28 72 15 49 8 15 .....L... 15 .....L... 15
& 17-25 631 4.3 RLIKFLYQS 31 69 16 45 8 15 ....L.... 16 ....L.... 16
& 18-26 616 4.2 LIKFLYQSN 32 68 15 46 7 13 ...L..... 15 ...L..... 15
& 19-27 617 3.3 IKFLYQSNP 44 56 17 35 4 9 ..L...... 17 ..L...... 17
& 20-28 615 4.1 KFLYQSNPP 36 64 14 43 7 13 .L....... 14 .L....... 14
& 21-29 616 3.9 FLYQSNPPP 39 61 14 42 6 12 L........ 14 L........ 14
& 22-30 616 3.3 LYQSNPPPS 41 59 20 34 5 10 ........N 20 ......... 41
& 23-31 612 4.2 YQSNPPPNP 22 78 19 52 7 13 ......... 22 .......SQ 5
& 24-32 614 4.5 QSNPPPNPE 22 78 17 51 10 16 ......... 22 ......SQ. 5
& 25-33 615 4.5 SNPPPNPEG 22 78 17 51 10 16 ......... 22 .....SQ.. 5
+ 26-34 736 4.8 NPPPNPEGT 19 81 15 58 8 15 ......... 19 ....SQ... 4
+ 27-35 1384 4.2 PPPNPEGTR 20 80 18 58 5 9 ......... 20 ...SQ.... 14
+ 28-36 1384 4.3 PPNPEGTRQ 20 80 18 58 4 9 ......... 20 ..SQ..... 14
& 29-37 1388 3.8 PSPEGTRQA 24 76 20 53 4 7 .N....... 20 ..Q...... 14
& 30-38 1389 3.8 SPEGTRQAR 24 76 20 53 4 7 N........ 20 .Q....... 14
& 31-39 1391 2.9 PEGTRQARR 49 51 14 35 2 5 ......... 49 Q........ 14
& 32-40 1396 1.3 EGTRQARRN 83 17 5 11 2 3 ......... 83 ......... 83
# 33-41 1396 0.7 GTRQARRNR 93 7 2 4 1 2 ......... 93 ......... 93
# 34-42 1396 0.7 TRQARRNRR 92 8 2 5 1 2 ......... 92 ......... 92
# 35-43 1396 0.8 RQARRNRRR 91 9 2 6 1 2 ......... 91 ......... 91
# 36-44 1396 0.7 QARRNRRRR 92 8 2 5 1 2 ......... 92 ......... 92
# 37-45 1395 0.6 ARRNRRRRW 93 7 2 4 1 2 ......... 93 ......... 93
# 38-46 1396 0.5 RRNRRRRWR 95 5 1 3 1 2 ......... 95 ......... 95
& 39-47 1396 1.8 RNRRRRWRE 70 30 11 18 1 3 ......... 70 ......... 70
& 40-48 1395 1.8 NRRRRWRER 68 32 13 18 1 3 ......... 68 ......... 68
& 41-49 1395 1.9 RRRRWRERQ 68 32 13 18 2 3 ......... 68 ......... 68
& 42-50 1393 2.1 RRRWRERQR 66 34 12 20 2 4 ......... 66 ......... 66
& 43-51 1394 3.0 RRWRERQRQ 53 47 11 33 3 6 ......... 53 ......... 53
& 44-52 1395 3.0 RWRERQRQI 52 48 11 34 4 7 ......... 52 ......... 52
& 45-53 1394 4.7 WRERQRQIR 30 70 9 56 5 10 ........H 6 ......... 30
+ 46-54 1391 6.2 RERQRQIRS 12 88 8 70 9 18 .......H. 4 ......... 12
+ 47-55 1383 6.7 ERQRQIRSI 11 89 6 71 12 22 ......H.. 4 ......... 11
+ 48-56 1382 6.2 RQRQIRSIS 13 87 7 70 11 18 .....H... 6 ......... 13
+ 49-57 1382 7.1 QRQIRSISE 6 94 4 76 14 25 ....H.... 2 ......... 6
+ 50-58 1381 7.3 RQIRSISGW 4 96 3 78 15 27 ...H...ER 2 .......ER 3
+ 51-59 1382 7.4 QIRSISGWI 3 97 3 79 14 27 ..H...ER. 2 ......ER. 3
+ 52-60 1381 7.3 IRTISGWIL 4 96 4 78 14 26 .HS..ER.. 2 ..S..ER.. 4
+ 53-61 1374 7.7 QSISGWILS 3 97 3 76 18 31 H...ER..G 1 R...ER... 2
+ 54-62 1372 7.5 SISGWILSN 5 95 4 75 16 29 ...ER..GT <1 ...ER...T 4
+ 55-63 1372 7.2 ISGWILSTY 6 94 4 76 14 26 ..ER..G.. 1 ..ER..... 3
+ 56-64 1379 6.8 SGWILSTYL 8 92 4 76 12 22 .ER..G... 1 .ER...... 4
+ 57-65 1380 6.8 GWILSTYLG 8 92 4 77 11 22 ER..G.... 1 ER....... 4
+ 58-66 1382 6.1 WILSTHLGR 10 90 9 74 8 17 R..G.Y... 1 R....Y... 6
+ 59-67 1382 6.5 ILSTYLGRP 7 93 7 76 9 19 ..G.....S 1 ......... 7
+ 60-68 1379 7.0 LSTYLGRSA 6 94 5 77 12 23 .G....... 1 .......P. 4
+ 61-69 1379 6.9 STYLGRSAE 6 94 4 78 12 23 G........ 1 ......P.. 4
+ 62-70 1386 6.3 TYLGRSAEP 8 92 6 77 9 17 ......... 8 .....P... 5
+ 63-71 1386 5.5 YLGRPAEPV 11 89 10 73 6 13 ....S.... 9 ......... 11
& 64-72 1389 4.2 LGRPAEPVP 26 74 18 51 5 9 ...S..... 18 ......... 26
& 65-73 1388 4.4 GRPAEPVPL 25 75 18 53 4 10 ..S...... 18 ......... 25
& 66-74 1384 4.7 RPAEPVPLQ 23 77 19 52 6 12 .S....... 19 ......... 23
& 67-75 1385 4.5 PAEPVPLQL 23 77 19 52 5 11 S........ 19 ......... 23
& 68-76 1385 3.7 AEPVPLQLP 43 57 16 37 4 8 ......... 43 ......... 43
& 69-77 1387 2.5 EPVPLQLPP 68 32 4 25 3 6 ......... 68 ......... 68
& 70-78 1385 2.6 PVPLQLPPL 65 35 5 26 3 6 ......... 65 ......... 65
& 71-79 1385 2.7 VPLQLPPLE 64 36 5 27 3 6 ......... 64 ......... 64
& 72-80 1386 2.5 PLQLPPLER 66 34 5 26 3 5 ......... 66 ......... 66
& 73-81 1387 2.3 LQLPPLERL 68 32 5 25 2 4 ......... 68 ......... 68
& 74-82 1387 2.2 QLPPLERLT 69 31 6 23 2 4 ......... 69 ......... 69
& 75-83 1392 1.6 LPPLERLTL 76 24 7 15 1 3 ......... 76 ......... 76
& 76-84 1388 2.0 PPLERLTLD 72 28 7 19 2 3 ......... 72 ........A <1
& 77-85 1388 2.4 PLERLTLDC 67 33 7 24 2 5 ......... 67 .......A. <1
& 78-86 1386 3.4 LERLTLDCN 34 66 30 33 3 6 ......... 34 ......A.S <1
& 79-87 1386 3.5 ERLTLDCNE 35 65 28 33 3 6 ......... 35 .....A.S. <1
& 80-88 1386 3.8 RLTLDCNED 34 66 26 36 4 8 ......... 34 ....A.S.. <1
& 81-89 1384 4.0 LTLDCNEDC 32 68 25 39 5 9 ......... 32 ...A.S... <1
& 82-90 1384 4.1 TLDCNEDCG 32 68 24 40 5 9 ......... 32 ..A.S.... <1
& 83-91 1382 4.5 LDCNEDCGT 30 70 20 45 6 11 ......... 30 .A.S..... <1
& 84-92 1382 4.5 DCNEDCGTS 30 70 18 45 7 12 ......... 30 A.S...... <1
& 85-93 1379 4.4 CNEDCGTSG 32 68 19 44 6 11 ......... 32 .S....... 19
& 86-94 1379 4.1 NEDCGTSGT 32 68 21 41 6 10 ......... 32 S........ 21
& 87-95 1378 3.1 EDCGTSGTQ 59 41 8 29 4 8 ......... 59 ......... 59
& 88-96 1382 2.8 DCGTSGTQG 63 37 8 25 4 8 ......... 63 ......... 63
& 89-97 1380 2.5 CGTSGTQGV 68 32 9 19 4 7 ......... 68 ......... 68
& 90-98 1381 2.3 GTSGTQGVG 72 28 9 17 3 6 ......... 72 ......... 72
& 91-99 1380 3.6 TSGTQGVGS 45 55 13 38 4 8 ......... 45 ........N 13
& 92-100 1499 3.8 SGTQGVGSP 42 58 17 36 5 10 ......... 42 .......N. 17
& 93-101 1492 3.9 GTQGVGSPQ 41 59 17 37 5 10 ......... 41 ......N.. 17
& 94-102 1494 4.6 TQGVGSPQI 30 70 11 54 5 11 ......... 30 .....N... 11
& 95-103 1494 4.9 QGVGSPQIL 26 74 11 56 6 12 ......... 26 ....N.... 10
& 96-104 1496 5.2 GVGSPQILV 24 76 10 60 6 13 ......... 24 ...N....L <1
& 97-105 1497 5.0 VGSPQILVE 25 75 10 60 6 12 ......... 25 ..N....L. <1
& 98-106 1498 5.2 GSPQILVES 24 76 10 59 6 13 ......... 24 .N....L.. <1
& 99-107 1497 5.3 SPQILVESP 25 75 10 57 7 14 ......... 25 N....L... <1
& 100-108 1492 5.0 PQILVESPT 21 79 17 55 7 12 ......... 21 ....L.... 2
+ 101-109 1492 5.1 QILVESPTV 19 81 14 61 6 12 ......... 19 ...L....I <1
+ 102-110 1498 5.0 ILVESPTVL 19 81 14 61 6 11 ......... 19 ..L....I. <1
& 103-111 1499 4.8 LVESPAVLE 23 77 19 52 6 11 .....T... 19 .L...TI.. <1
+ 104-112 1496 5.2 VESPAVLES 20 80 18 56 7 13 ....T.... 18 L...TI... <1
& 105-113 1494 4.8 ESPAVLESG 22 78 20 52 6 11 ...T..... 20 ...TI.... 4
& 106-114 1493 5.2 SPAVLESGT 20 80 17 56 6 13 ..T...... 17 ..TI....A <1
& 107-115 1492 5.2 PAVLESGTK 20 80 17 56 7 13 .T....... 17 .TI....A. <1
& 108-116 1494 5.2 AVLESGTKE 20 80 18 54 7 13 T........ 18 TI....A.. <1
Vpu + 1-9 1037 7.8 MQSLQILAI 7 93 3 59 31 45 ..PIP.V.. <1 ..P.V.YS. 0
+ 2-10 1037 8.0 QSLQILAIV 7 93 3 57 34 48 .PIP.V... <1 .P.V.YS.. 0
+ 3-11 1049 7.6 SLQILAIVA 8 92 3 63 27 41 PIP.V.... <1 P.V.YS... 0
+ 4-12 1064 6.9 LQILAIVAL 11 89 5 64 20 31 IP.V..... <1 .V.YS.... 0
+ 5-13 1068 6.8 QILAIVALV 13 87 5 62 20 31 P.V...... <1 V.YS..... 0
& 6-14 1096 5.3 ILAIVALVV 30 70 8 49 12 20 .V....... 8 .YS...... <1
& 7-15 1093 5.7 LAIVALVVA 25 75 7 58 11 20 V........ 6 YS......V <1
+ 8-16 1118 5.6 AIVALVVAA 19 81 10 60 10 18 ........I 7 S......V. 2
& 9-17 1123 5.2 IVALVVAAI 22 78 12 58 8 16 .......I. 8 ......V.. 12
+ 10-18 1123 5.5 VALVVAAII 17 83 12 61 10 18 ......I.. 6 .....V... 12
+ 11-19 1125 5.2 ALVVAAIIA 18 82 13 61 8 15 .....I... 6 ....V.... 13
+ 12-20 1124 5.1 LVVAAIIAI 19 81 13 61 7 14 ....I.... 6 ...V..... 13
+ 13-21 1120 5.4 VVAAIIAIV 16 84 12 64 8 16 ...I..... 6 ..V...... 12
+ 14-22 1122 5.2 VAAIIAIVV 17 83 12 63 7 14 ..I...... 6 .V....... 12
+ 15-23 1125 4.9 AAIIAIVVW 19 81 13 62 6 12 .I....... 6 V........ 13
+ 16-24 1131 4.9 AIIAIVVWS 18 82 15 61 6 12 I........ 6 ......... 18
& 17-25 1146 3.3 IIAIVVWSI 40 60 20 37 3 7 ......... 40 ......... 40
& 18-26 1144 3.3 IAIVVWSIV 40 60 20 36 3 7 ......... 40 ......... 40
& 19-27 1140 4.1 AIVVWSIVF 24 76 21 50 5 9 ........I 3 ......... 24
& 20-28 1141 4.2 IVVWSIVFI 24 76 21 49 6 10 .......I. 3 ......... 24
& 21-29 1142 4.2 VVWSIVFIE 24 76 21 49 6 10 ......I.. 3 ......... 24
& 22-30 1147 3.7 VWSIVFIEY 28 72 23 44 5 8 .....I... 3 ......... 28
& 23-31 1146 4.0 WSIVFIEYR 27 73 22 45 5 9 ....I.... 4 ......... 27
& 24-32 1142 4.3 SIVFIEYRK 25 75 21 48 6 11 ...I..... 3 ......... 25
& 25-33 1141 3.7 IVFIEYRKI 33 67 28 33 6 10 ..I...... 5 ......... 33
& 26-34 1141 4.0 VFIEYRKIL 30 70 28 35 7 11 .I....... 5 ......... 30
& 27-35 1140 4.3 FIEYRKILR 29 71 24 38 9 13 I........ 5 ......... 29
& 28-36 1148 2.8 IEYRKILRQ 63 37 6 26 5 8 ......... 63 ......... 63
& 29-37 1145 2.9 EYRKILRQR 61 39 6 27 6 9 ......... 61 ......... 61
& 30-38 1143 3.3 YRKILRQRK 56 44 5 32 7 11 ......... 56 ......... 56
& 31-39 1144 3.4 RKILRQRKI 55 45 5 33 7 10 ......... 55 ......... 55
& 32-40 1140 3.2 KILRQRKID 56 44 6 32 6 10 ......... 56 ......... 56
& 33-41 1144 3.2 ILRQRKIDR 57 43 6 31 6 10 ......... 57 ........K 3
& 34-42 1142 3.3 LRQRKIDRL 55 45 6 33 6 10 ......... 55 .......K. 2
& 35-43 1142 3.3 RQRKIDRLI 53 47 6 36 5 9 ......... 53 ......K.. 2
& 36-44 1140 3.9 QRKIDRLID 45 55 8 38 8 12 ......... 45 .....K... 2
& 37-45 1141 3.9 RKIDRLIDR 45 55 8 38 9 13 ......... 45 ....K.... 2
& 38-46 1145 3.7 KIDRLIDRI 47 53 8 37 8 12 ........L 4 ...K..... 2
& 39-47 1140 4.6 IDRLIDRIR 39 61 5 46 9 15 .......LI 4 ..K...... 1
& 40-48 1139 4.9 DRLIDRIRE 36 64 5 48 11 17 ......LI. 4 .K....... 1
& 41-49 1140 4.7 RLIDRIRER 37 63 6 47 10 16 .....LI.. 4 K........ 1
& 42-50 1140 4.7 LIDRIRERA 37 63 5 48 9 15 ....LI... 4 ......... 37
& 43-51 1143 4.3 IDRIRERAE 40 60 7 46 8 13 ...LI.... 4 ......... 40
& 44-52 1147 4.0 DRIRERAED 43 57 8 44 6 10 ..LI..... 4 ......... 43
& 45-53 1151 3.1 RIRERAEDS 49 51 10 37 4 6 .LI...... 5 ......... 49
& 46-54 1153 2.9 IRERAEDSG 51 49 10 36 3 6 LI....... 4 ......... 51
& 47-55 1152 2.7 RERAEDSGN 51 49 15 31 3 5 I........ 15 ......... 51
& 48-56 1158 1.1 ERAEDSGNE 86 14 5 8 2 3 ......... 86 ........D 1
# 49-57 1161 0.7 RAEDSGNES 92 8 1 5 1 2 ......... 92 .......D. 1
& 50-58 1159 1.5 AEDSGNESE 72 28 20 6 2 3 ......... 72 ......D.. <1
& 51-59 1158 1.3 EDSGNESEG 73 27 21 3 2 3 ......... 73 .....D... <1
& 52-60 1132 1.4 DSGNESEGD 72 28 21 5 2 3 ........- 0 ....D.... <1
& 53-61 1130 2.6 SGNESEGDQ 52 48 18 27 3 5 .......-- 0 ...D..... <1
& 54-62 1131 2.7 GNESEGDQE 51 49 17 28 4 6 ......--- 0 ..D...... <1
& 55-63 1122 2.9 NESEGDQEE 49 51 17 30 5 7 .....---. 0 .D....... <1
& 56-64 1169 3.0 ESEGDQEEL 48 52 17 30 5 8 ....---.I 0 D........ <1
& 57-65 1149 3.5 SEGDQEELS 42 58 17 35 6 9 ...---.I. 0 ......... 42
& 58-66 1141 4.2 EGDQEELSA 37 63 15 40 8 13 ..---.I.. 0 ......... 37
& 59-67 1146 3.9 GDQEELSAL 50 50 7 36 7 13 .---.I... 0 ......... 50
& 60-68 1115 4.2 DQEELSALV 45 55 7 39 10 16 ---.I.... 0 ......... 45
& 61-69 1107 4.7 QEELSALVE 41 59 6 43 11 17 --.I..... 0 ......... 41
& 62-70 1107 4.9 EELSALVEM 35 65 9 46 11 17 -.I...... 0 ........R 9
& 63-71 1129 4.8 ELSALVEMG 35 65 9 46 10 17 .I....... 1 .......R. 9
64-72 * 63 3.8 VSALVEMGV 24 76 13 40 24 37 I........ 11 L.....R.- 0
65-73 * 63 3.4 SALVEMGVE 37 63 13 25 25 35 ......... 37 .....R.-- 0
66-74 * 63 3.3 ALVEMGVEM 38 62 13 25 24 33 ......... 38 ....R.--- 0
67-75 * 63 3.3 LVEMGVEMG 38 62 13 29 21 32 ......... 38 ...R.---- 0
68-76 * 63 3.4 VEMGVEMGH 37 63 13 29 22 33 ......... 37 ..R.----. 0
69-77 * 63 3.3 EMGVEMGHH 37 63 13 29 22 32 ......... 37 .R.----.L 0
70-78 * 63 3.3 MGVEMGHHA 37 63 13 29 22 32 ......... 37 R.----.L. 0
71-79 * 63 2.5 GVEMGHHAP 41 59 33 8 17 22 ......... 41 .----.L.. 0
72-80 * 64 2.4 VEMGHHAPW 42 58 34 8 16 20 ......... 42 ----.L... 0
73-81 * 68 2.1 EMGHHAPWD 57 43 21 10 12 18 ......... 57 ---.L.... 0
74-82 * 68 2.7 MGHHAPWDI 31 69 28 28 13 19 ........V 28 --.L..... 0
75-83 * 70 3.1 GHHAPWDID 29 71 23 33 16 24 .......V. 23 -.L...... 0
+ 76-84 1163 6.0 HHAPWDVDD 11 89 8 67 15 22 ......... 11 .L....I.. 5
+ 77-85 1169 6.1 HAPWDVDDL 11 89 7 69 14 21 ......... 11 L....I... 5
Env & 1-9 246 4.2 MKVMETRRN 41 59 6 35 19 28 .R.K.K--- 0 .T.KGI.K. 0
& 2-10 243 4.3 KVMETRRNY 41 59 6 33 21 30 R.K.K---. 0 T.KGI.K.. 0
& 3-11 253 4.3 VMETRRNYQ 40 60 6 32 22 31 .K.K---.. 0 .KGI.K... 5
& 4-12 255 4.4 METRRNYQH 41 59 5 28 25 33 K.K---... 0 KGI.K.... 4
& 5-13 243 4.2 ETRRNYQHL 43 57 6 30 21 29 .K---.... 0 GI.K..... 3
& 6-14 241 3.9 TRRNYQHLW 46 54 6 29 18 26 K---..... 0 I.K...... 4
& 7-15 239 3.8 RRNYQHLWR 49 51 5 28 18 26 ---...... 0 .K....... 3
& 8-16 237 3.5 RNYQHLWRW 52 48 5 26 16 24 --....... 0 K.......G 3
& 9-17 241 3.3 NYQHLWRWG 55 45 5 27 14 21 -........ 0 .......G. 2
& 10-18 258 3.5 YQHLWRWGT 53 47 5 28 15 22 ......... 53 ......G.I 0
& 11-19 258 3.3 QHLWRWGTM 55 45 5 27 14 21 ......... 55 .....G.IL 0
& 12-20 258 3.5 HLWRWGTML 53 47 5 29 13 22 ......... 53 ....G.IL. 0
& 13-21 266 3.5 LWRWGTMLL 51 49 5 33 11 20 ......... 51 ...G.IL.. 0
& 14-22 267 3.3 WRWGTMLLG 52 48 6 31 10 18 ......... 52 ..G.IL... <1
& 15-23 269 3.8 RWGTMLLGM 42 58 9 36 12 20 ......... 42 .G.IL...I <1
& 16-24 270 3.6 WGTMLLGML 41 59 10 40 9 16 ......... 41 G.IL...I. <1
& 17-25 275 3.7 GTMLLGMLM 40 60 9 42 9 17 ......... 40 .IL...I.. <1
& 18-26 274 3.8 TMLLGMLMI 41 59 8 41 11 19 ......... 41 IL...I... <1
& 19-27 285 3.4 MLLGMLMIC 47 53 11 31 11 17 ......... 47 L...I.... 2
& 20-28 285 3.6 LLGMLMICK 39 61 12 38 12 18 ........S 11 ...I....S 12
& 21-29 285 3.7 LGMLMICKA 40 60 10 38 12 19 .......S. 10 ..I....S. 10
& 22-30 284 4.4 GMLMICKAA 35 65 7 42 16 25 ......S.T 2 .I....S.T 7
& 23-31 283 4.8 MLMICKAAE 28 72 7 48 17 28 .....S.T. 2 I....S.T. 6
& 24-32 279 5.0 LMICKAAEN 23 77 9 49 19 29 ....S.T.K 9 ....S.T.Q <1
& 25-33 278 5.0 MICKAAENL 24 76 8 49 19 30 ...S.T.K. 8 ...S.T.Q. <1
& 26-34 278 4.9 ICKAAENLW 24 76 9 49 18 28 ..S.T.K.. 9 ..S.T.Q.. <1
& 27-35 279 4.8 CKAAENLWV 24 76 9 52 15 26 .S.T.K... 9 .S.T.Q... <1
& 28-36 279 4.8 KAAENLWVT 24 76 9 54 13 25 S.T.K.... 9 S.T.Q.... <1
& 29-37 279 4.4 AAENLWVTV 27 73 10 52 11 20 .T.K..... 10 .T.Q..... 1
& 30-38 279 4.4 AENLWVTVY 27 73 10 53 10 20 T.K...... 10 T.Q...... 1
& 31-39 278 3.5 ENLWVTVYY 31 69 17 43 9 13 .K....... 17 .Q....... 4
& 32-40 278 2.6 NLWVTVYYG 45 55 26 23 6 9 K........ 26 Q........ 6
& 33-41 282 1.1 LWVTVYYGV 84 16 8 3 4 6 ......... 84 ......... 84
# 34-42 284 0.5 WVTVYYGVP 94 6 1 3 2 4 ......... 94 ......... 94
# 35-43 284 0.5 VTVYYGVPV 95 5 <1 2 2 4 ......... 95 ......... 95
# 36-44 284 0.4 TVYYGVPVW 96 4 <1 <1 3 4 ......... 96 ......... 96
# 37-45 284 0.5 VYYGVPVWK 94 6 2 1 3 4 ......... 94 ......... 94
& 38-46 284 0.8 YYGVPVWKE 88 12 7 3 3 4 ......... 88 ......... 88
& 39-47 284 0.9 YGVPVWKEA 87 13 7 4 3 5 ......... 87 ......... 87
& 40-48 284 1.0 GVPVWKEAT 86 14 6 5 4 6 ......... 86 ......... 86
& 41-49 286 1.0 VPVWKEATT 86 14 6 5 4 6 ......... 86 ......... 86
& 42-50 286 1.0 PVWKEATTT 86 14 6 4 4 6 ......... 86 ......... 86
& 43-51 286 1.1 VWKEATTTL 86 14 6 4 5 6 ......... 86 ......... 86
& 44-52 286 1.1 WKEATTTLF 85 15 6 5 5 7 ......... 85 ......... 85
& 45-53 285 1.1 KEATTTLFC 85 15 6 5 4 6 ......... 85 ......... 85
& 46-54 241 1.0 EATTTLFCA 85 15 7 5 3 5 ......... 85 ......... 85
# 47-55 241 0.6 ATTTLFCAS 92 8 2 2 3 5 ......... 92 ......... 92
& 48-56 241 0.9 TTTLFCASD 87 13 6 4 3 5 ......... 87 ......... 87
# 49-57 242 0.6 TTLFCASDA 91 9 6 <1 2 3 ......... 91 ......... 91
# 50-58 242 0.7 TLFCASDAK 90 10 6 2 2 4 ......... 90 ........R <1
& 51-59 242 1.2 LFCASDAKA 80 20 8 10 2 5 ......... 80 .......R. <1
& 52-60 241 1.6 FCASDAKAY 75 25 8 13 4 7 ......... 75 ......R.. <1
& 53-61 238 2.9 CASDAKAYD 45 55 21 29 6 12 ......... 45 .....R..K 0
& 54-62 238 3.7 ASDAKAYDT 41 59 14 37 8 18 ......... 41 ....R..K. 0
& 55-63 237 3.7 SDAKAYDTE 41 59 14 37 8 18 ......... 41 ...R..K.. 0
& 56-64 237 4.4 DAKAYDTEA 22 78 19 48 12 22 ........V 19 ..R..K..V 0
& 57-65 235 4.4 AKAYDTEAH 22 78 18 47 13 23 .......V. 18 .R..K..V. 0
& 58-66 235 4.5 KAYDTEAHN 22 78 18 46 14 24 ......V.. 18 R..K..V.. 0
& 59-67 234 4.4 AYDTEAHNV 21 79 20 46 13 24 .....V... 20 ..K..V... 2
& 60-68 233 4.0 YDTEVHNVW 22 78 21 46 11 20 ......... 22 .K....... 2
& 61-69 232 3.9 DTEVHNVWA 23 77 22 47 9 18 ......... 23 K........ 2
& 62-70 234 2.7 TEVHNVWAT 41 59 28 24 6 10 ......... 41 ......... 41
& 63-71 235 1.8 EVHNVWATH 57 43 30 7 6 7 ......... 57 ......... 57
& 64-72 235 1.8 VHNVWATHA 57 43 29 7 6 7 ......... 57 ......... 57
& 65-73 235 0.8 HNVWATHAC 89 11 6 0 6 6 ......... 89 ......... 89
# 66-74 272 0.7 NVWATHACV 91 9 5 0 4 4 ......... 91 ......... 91
# 67-75 272 0.6 VWATHACVP 92 8 5 0 3 4 ......... 92 ......... 92
# 68-76 287 0.4 WATHACVPT 96 4 1 0 3 3 ......... 96 ......... 96
& 69-77 606 0.8 ATHACVPTD 86 14 12 1 1 2 ......... 86 ......... 86
& 70-78 607 0.8 THACVPTDP 85 15 12 2 1 2 ......... 85 ......... 85
& 71-79 607 2.1 HACVPTDPN 51 49 25 23 2 3 ......... 51 ........S 25
& 72-80 607 2.1 ACVPTDPNP 51 49 25 22 2 3 ......... 51 .......S. 25
& 73-81 606 2.4 CVPTDPNPQ 48 52 24 26 2 4 ......... 48 ......S.. 24
& 74-82 606 2.4 VPTDPNPQE 48 52 25 26 2 4 ......... 48 .....S... 25
& 75-83 604 2.8 PTDPNPQEV 41 59 24 32 3 6 ......... 41 ....S...I <1
& 76-84 601 3.4 TDPNPQEVV 39 61 17 39 6 10 ......... 39 ...S...IP <1
& 77-85 601 3.7 DPNPQEVVL 32 68 17 45 6 10 ......... 32 ..S...IP. <1
& 78-86 600 4.0 PNPQEVVLE 21 79 17 53 9 13 ........V 1 .S...IP.I 0
& 79-87 600 4.0 NPQEVVLEN 21 79 17 53 9 13 .......V. 1 S...IP.I. 0
& 80-88 600 3.5 PQEVVLENV 39 61 11 43 8 11 ......V.. 1 ...IP.I.. 0
& 81-89 624 3.6 QEVVLENVT 37 63 10 46 7 11 .....V... 1 ..IP.I... 0
& 82-90 625 3.5 EVVLENVTE 37 63 12 43 7 11 ....V.... 1 .IP.I.... 0
& 83-91 625 4.1 VVLENVTEN 27 73 12 52 9 14 ...V..... 1 IP.I..... 0
& 84-92 626 3.9 VLENVTENF 32 68 12 48 7 12 ..V...... 1 P.I...... 0
& 85-93 634 3.8 LENVTENFN 25 75 17 52 6 10 .V....... 2 .I....... 0
& 86-94 634 3.6 GNVTENFNM 25 75 25 44 6 10 V........ 2 I........ 0
& 87-95 635 2.5 NVTENFNMW 56 44 15 24 5 7 ......... 56 ......... 56
& 88-96 622 2.9 VTENFNMWK 54 46 9 33 5 8 ......... 54 ........E 1
& 89-97 622 3.0 TENFNMWKN 53 47 9 32 6 9 ......... 53 .......E. 1
& 90-98 623 3.5 ENFNMWKNN 46 54 9 38 8 12 ........D 5 ......E.K 0
& 91-99 699 3.7 NFNMWKNNM 41 59 8 43 8 11 .......D. 5 .....E.K. 0
& 92-100 695 3.1 FNMWKNNMV 44 56 13 37 6 8 ......D.. 13 ....E.K.. 0
& 93-101 695 3.3 NMWKNNMVE 43 57 10 41 6 9 .....D... 10 ...E.K..D 0
& 94-102 695 2.9 MWKNNMVEQ 53 47 10 33 4 8 ....D.... 10 ..E.K..D. 0
& 95-103 735 2.7 WKNNMVEQM 52 48 19 25 4 7 ...D..... 19 .E.K..D.. 0
& 96-104 769 3.0 KNNMVEQMH 45 55 18 32 4 8 ..D...... 18 E.K..D... 0
& 97-105 771 2.4 NNMVEQMHE 55 45 19 21 4 7 .D....... 19 .K..D.... 0
& 98-106 770 2.4 NMVEQMHED 55 45 20 21 4 7 D........ 20 K..D..... 0
& 99-107 768 1.7 MVEQMHEDI 76 24 10 11 3 5 ......... 76 ..D...... 2
& 100-108 768 1.7 VEQMHEDII 76 24 10 11 3 5 ......... 76 .D....... 2
& 101-109 767 1.8 EQMHEDIIS 74 26 10 12 3 5 ......... 74 D........ 2
& 102-110 758 1.4 QMHEDIISL 78 22 11 8 3 4 ......... 78 ......... 78
& 103-111 757 1.4 MHEDIISLW 78 22 11 8 3 4 ......... 78 ......... 78
& 104-112 754 1.5 HEDIISLWD 76 24 12 10 2 4 ......... 76 ......... 76
& 105-113 770 1.5 EDIISLWDQ 75 25 13 10 2 4 ......... 75 ......... 75
& 106-114 770 1.4 DIISLWDQS 77 23 13 8 2 3 ......... 77 ......... 77
& 107-115 768 1.3 IISLWDQSL 77 23 13 8 2 3 ......... 77 ......... 77
& 108-116 786 1.3 ISLWDQSLK 78 22 13 6 2 3 ......... 78 ......... 78
& 109-117 795 1.6 SLWDQSLKP 71 29 13 14 2 4 ......... 71 ......... 71
& 110-118 877 1.4 LWDQSLKPC 76 24 11 11 2 3 ......... 76 ......... 76
& 111-119 893 1.4 WDQSLKPCV 76 24 11 11 2 3 ......... 76 ......... 76
& 112-120 892 1.7 DQSLKPCVK 71 29 11 16 2 3 ......... 71 ......... 71
& 113-121 1029 1.5 QSLKPCVKL 74 26 11 13 2 3 ......... 74 ......... 74
& 114-122 1032 1.0 SLKPCVKLT 86 14 6 7 1 2 ......... 86 ......... 86
& 115-123 1034 1.0 LKPCVKLTP 86 14 6 7 1 2 ......... 86 ......... 86
& 116-124 1066 1.1 KPCVKLTPL 85 15 6 8 2 3 ......... 85 ......... 85
& 117-125 1517 0.8 PCVKLTPLC 89 11 4 6 1 2 ......... 89 ......... 89
& 118-126 1568 0.8 CVKLTPLCV 89 11 5 5 1 2 ......... 89 ......... 89
& 119-127 1594 1.1 VKLTPLCVT 86 14 5 7 1 2 ........S 1 ......... 86
& 120-128 2665 1.0 KLTPLCVTL 88 12 4 7 1 2 .......S. 1 ......... 88
& 121-129 2670 1.7 LTPLCVTLN 76 24 5 17 1 2 ......S.K <1 ......... 76
& 122-130 3112 1.9 TPLCVTLNC 74 26 5 20 1 2 .....S.K. 1 ......... 74
& 123-131 3326 2.6 PLCVTLNCT 66 34 4 28 2 4 ....S.K.. 1 ........I 2
& 124-132 3368 4.1 LCVTLNCTD 44 56 13 40 3 6 ...S.K... 1 .......I. 1
+ 125-133 3673 6.2 CVTLNCTDN 12 88 10 72 6 11 ..S.K...L 1 ......I.V <1
+ 126-134 3675 7.4 VTLNCTDNW 10 90 3 79 8 15 .S.K...LK 1 .....I.VN <1
+ 127-135 3677 7.8 TLNCTDNWN 9 91 3 78 9 19 S.K...LK. 1 ....I.VNI 0
+ 128-136 3719 8.3 LNCTDNWNN 6 94 2 81 11 22 .K...LK.D 1 ...I.VNIT 0
+ 129-137 3725 8.3 NCTDNWNNT 6 94 2 79 12 24 K...LK.D. <1 ..I.VNITN 0
+ 130-138 3912 8.6 CTDNWNNTG 6 94 2 79 13 25 ...LK.D.N 1 .I.VNITNT 0
+ 131-139 3917 8.7 TDNWNNTGN 5 95 2 79 14 27 ..LK.D.NT 1 I.VNITNT. 0
+ 132-140 3911 8.9 DNWNNTGNV 5 95 2 78 15 28 .LK.D.NTN <1 .VNITNT.S 0
+ 133-141 3863 8.8 NWNNTGNVS 5 95 2 77 16 29 LK.D.NTN. <1 VNITNT.ST 0
+ 134-142 3838 9.0 WNNTGNVSD 5 95 2 77 16 30 K.D.NTN.S <1 NITNT.STN 0
+ 135-143 3807 9.0 NNTGNVSDS 5 95 2 76 17 31 .D.NTN.S. 1 ITNT.STNP 0
+ 136-144 3747 9.0 NTGNVSDSS 5 95 2 76 18 32 D.NTN.S.G 1 TNT.STNPT 0
+ 137-145 3701 9.1 TGNVSDSSW 5 95 2 75 18 32 .NTN.S.GR 1 NT.STNPTS 0
+ 138-146 3473 8.9 GNVSDSSWK 4 96 1 76 19 34 NTN.S.GRM 1 T.STNPTSS 0
+ 139-147 3090 9.2 TSVNSNSSG 2 98 1 78 19 35 .NSS.GRMI 1 N.T.PT..W 0
+ 140-148 2699 9.0 SVNSNSSGG 2 98 1 77 20 36 NSS.GRMIM 1 .T.PT..WE 0
+ 141-149 2334 8.8 NSTGGTVGG 2 98 1 76 21 37 S.S.RMIM- 0 TNPTSSWET 0
+ 142-150 2015 8.7 SSGEEIEGK 2 98 1 75 22 38 ...RM.M-- 0 NPTSSW.TM 0
+ 143-151 1735 8.6 SGEEIEGKI 2 98 2 73 23 39 ..RM.M--- 0 PTSSW.TM- 0
+ 144-152 1566 8.5 TNVTNATSS 2 98 2 73 22 38 GRMIM---- 0 .SSWETM-- 0
+ 145-153 1322 8.3 EEIEGKINQ 2 98 2 73 23 39 RM.M----- 0 SSW.TM--- 0
+ 146-154 1122 8.1 DLLSTNSTT 2 98 2 73 22 39 MIM------ 0 SWETM---- 0
+ 147-155 936 7.8 LLSTNSTTN 3 97 2 72 23 38 IM------- 0 WETM----- 0
+ 148-156 811 7.5 LSTNSTTNS 3 97 3 73 21 37 M-------- 0 ETM------ 0
+ 149-157 657 7.2 STNSTTNSS 5 95 4 69 23 37 --------- 0 TM------- 0
+ 150-158 500 6.7 TNSTTNSSG 6 94 5 65 24 38 --------- 0 M-------- 0
+ 151-159 463 6.4 NSTTNSSGE 7 93 5 67 22 35 --------- 0 --------- 0
+ 152-160 405 6.2 STTNSSGEN 8 92 6 65 21 34 --------- 0 --------- 0
+ 153-161 317 5.7 TTNSSGENR 10 90 7 62 21 32 --------- 0 --------- 0
+ 154-162 269 5.3 TNSSGENRM 12 88 9 58 21 31 --------- 0 --------- 0
+ 155-163 196 4.3 NSSGENRME 17 83 13 54 16 24 --------. 0 --------. 0
+ 156-164 166 3.8 SSGENRMER 19 81 15 52 14 20 -------.K 0 -------.K 0
+ 157-165 161 3.5 SGENRMERG 20 80 16 52 12 18 ------.K. 0 ------.K. 0
+ 158-166 161 3.5 GENRMERGD 20 80 16 53 11 17 -----.K.E 0 -----.K.E 0
+ 159-167 161 3.5 ENRMERGDI 20 80 16 53 11 17 ----.K.E. 0 ----.K.E. 0
+ 160-168 161 3.5 NRMERGDIK 20 80 16 53 11 17 ---.K.E.. 0 ---.K.E.. 0
+ 161-169 161 3.5 RMERGDIKN 20 80 16 55 9 16 --.K.E... 0 --.K.E... 0
& 162-170 160 3.3 MERGDIKNC 20 80 16 58 6 13 -.K.E.... 0 -.K.E.... 0
& 163-171 1262 3.1 EKGEIKNCS 42 58 20 37 2 4 ......... 42 ......... 42
& 164-172 1530 3.1 KGEIKNCSF 41 59 20 37 2 4 ......... 41 ......... 41
& 165-173 2641 2.9 GEIKNCSFN 51 49 19 28 2 4 ......... 51 ......... 51
& 166-174 3721 4.2 EIKNCSFNI 31 69 13 54 2 5 ......... 31 ......... 31
& 167-175 3944 4.3 IKNCSFNIT 28 72 17 52 3 6 ........S 2 ......... 28
& 168-176 3939 3.6 KNCSFNITT 47 53 12 38 2 5 .......S. 2 ......... 47
& 169-177 3938 5.0 NCSFNITTS 23 77 15 59 3 7 ......S.. 1 ........N 15
+ 170-178 3959 5.8 CSFNITTSI 17 83 10 69 4 9 .....S... 1 .......N. 10
+ 171-179 3945 6.3 SFNITTSIR 14 86 8 72 5 11 ....S.... 1 ......N.. 8
+ 172-180 3943 6.7 FNITTSIRD 13 87 8 74 6 12 ...S....G 1 .....N... 8
+ 173-181 3942 6.8 NITTSIRDK 13 87 7 73 6 13 ..S....G. 1 ....N.... 7
+ 174-182 3933 7.3 ITTSIRDKV 10 90 7 75 8 16 .S....G.. 1 ...N....I <1
+ 175-183 3925 7.1 TTNIRDKVQ 12 88 8 72 8 16 S.S..G... 1 .......I. <1
+ 176-184 3905 7.1 TNIRDKVQK 12 88 8 72 9 17 .S..G.... 1 ......I.. <1
+ 177-185 3906 7.4 NIRDKVQKE 12 88 7 72 9 18 S..G..... 1 .....I... <1
+ 178-186 3904 6.8 IRDKVQKEY 20 80 4 68 8 15 ..G...... 1 ....I.... <1
& 179-187 3907 6.2 RDKVQKEYA 23 77 5 65 7 13 .G....... 1 ...I..... <1
+ 180-188 3922 6.4 DKVQKEYAL 20 80 5 69 6 12 G.......F 1 ..I...... <1
& 181-189 3924 6.2 KVQKEYALF 21 79 5 68 6 12 .......F. 3 .I....... <1
& 182-190 3926 6.1 VQKEYALFY 23 77 5 66 6 11 ......F.. 3 I.......N <1
+ 183-191 3935 6.0 QKEYALFYK 20 80 6 69 5 10 .....F... 2 .......NR <1
& 184-192 3942 5.9 KEYALFYKL 22 78 7 66 5 10 ....F.... 3 ......NR. <1
& 185-193 3958 5.4 EYALFYKLD 27 73 7 62 4 8 ...F..... 3 .....NR.. <1
& 186-194 3956 5.3 YALFYKLDV 25 75 8 63 4 8 ..F.....I 1 ....NR... <1
& 187-195 3954 5.4 ALFYKLDVV 22 78 8 67 4 8 .F.....II 1 ...NR.... <1
+ 188-196 3936 5.9 LFYKLDVVP 18 82 7 69 5 10 F.....II. 1 ..NR..... <1
+ 189-197 3935 5.8 FYKLDVVPI 18 82 7 70 5 9 .....II.. 1 .NR...... <1
+ 190-198 3934 6.5 YKLDVVPID 12 88 7 75 6 12 ....II... 1 NR......N 0
+ 191-199 3933 7.2 KLDVVPIDN 9 91 6 78 7 15 ...II.... 1 R......N. <1
+ 192-200 3901 7.4 LDVVPIDND 9 91 7 76 8 17 ..II..... 1 ......N.S 0
+ 193-201 3901 7.8 DVVPIDNDN 8 92 5 77 10 19 .II.....T 1 .....N.S. 0
+ 194-202 3659 8.2 VVPIGENEN 5 95 5 78 12 23 II..DNDTT 1 ....NNSNT 0
+ 195-203 3600 8.0 VPIDNDNTS 6 94 5 76 13 24 I.....T.. 1 ...N.S..Y 0
+ 196-204 2463 8.1 PIGENENNS 7 93 4 74 15 28 ..DNDTTS- 0 ..NNSNTY- 0
+ 197-205 1806 8.1 IDNEDNAGN 5 95 3 74 18 32 ...DTTS-- 0 .N.SNTY-- 0
+ 198-206 1412 7.8 DNEDNAGNN 6 94 2 73 18 32 ..DTTS--- 0 N.SNTY--- 0
+ 199-207 1138 7.3 NEDNAGNNT 8 92 3 72 18 31 .DTTS---- 0 .SNTY---- 0
+ 200-208 953 7.2 EDNAGNNTN 8 92 3 70 18 32 DTTS----- 0 SNTY----- 0
+ 201-209 716 6.7 DNAGNNTNN 14 86 5 60 22 34 TTS------ 0 NTY------ 0
& 202-210 490 6.0 NAGNNTNNT 21 79 5 52 22 35 TS------- 0 TY------- 0
& 203-211 369 5.3 AGNNTNNTS 29 71 4 47 20 32 S-------- 0 Y-------- 0
+ 204-212 192 5.7 AKNNNTNTT 7 93 6 62 25 41 --------- 0 --------- 0
+ 205-213 168 5.6 SYNSSYSNY 7 93 6 61 26 43 --------. 0 --------. 0
+ 206-214 168 5.6 YNSSYSNYR 7 93 6 60 27 44 -------.K 0 -------.. 0
+ 207-215 168 5.6 NSSYSNYRL 8 92 7 61 25 43 ------.K. 0 ------... 0
+ 208-216 168 5.6 SSYSNYRLI 8 92 7 58 27 44 -----.K.T 0 -----.... 0
+ 209-217 168 5.6 SYSNYRLIN 8 92 7 58 28 44 ----.K.TS 0 ----....S 0
+ 210-218 168 5.5 YSNYRLINC 8 92 7 55 30 43 ---.K.TS. 0 ---....S. 0
+ 211-219 167 5.3 SNYRLINCN 8 92 8 55 29 40 --.K.TS.. 0 --....S.. 0
+ 212-220 167 4.9 NYRLISCNT 16 84 8 53 23 34 -.K.T.... 0 -........ 0
& 213-221 3760 3.5 YRLISCNTS 41 59 24 31 3 5 .K.T..... 2 ......... 41
& 214-222 3894 4.3 RLISCNTSV 36 64 19 41 4 7 K.T...... <1 ......... 36
& 215-223 3880 4.2 LISCNTSVI 34 66 22 41 4 6 .T....... 2 ........L 2
& 216-224 3880 4.1 ISCNTSVIT 34 66 22 40 3 6 T........ 2 .......L. 2
& 217-225 3881 3.7 SCNTSVITQ 39 61 22 35 3 5 ......... 39 ......L.. 3
& 218-226 3882 2.8 CNTSVITQA 65 35 4 28 3 4 ......... 65 .....L... 3
& 219-227 3897 2.8 NTSVITQAC 66 34 3 29 2 4 ......... 66 ....L.... 3
& 220-228 3898 2.7 TSVITQACP 66 34 4 28 2 4 ......... 66 ...L..... 3
& 221-229 3897 2.3 SVITQACPK 71 29 3 24 2 3 ......... 71 ..L...... 3
& 222-230 3883 3.1 VITQACPKV 54 46 14 29 2 4 ......... 54 .L....... 2
& 223-231 3843 2.9 ITQACPKVS 52 48 17 29 2 4 ......... 52 L........ 2
& 224-232 3775 2.4 TQACPKVSF 58 42 18 22 2 3 ......... 58 ......... 58
& 225-233 3719 2.6 QACPKVSFE 56 44 16 26 2 4 ......... 56 ......... 56
& 226-234 3721 2.6 ACPKVSFEP 56 44 16 26 2 4 ......... 56 ......... 56
& 227-235 3721 2.6 CPKVSFEPI 56 44 17 25 2 4 ......... 56 ......... 56
& 228-236 3721 2.6 PKVSFEPIP 56 44 17 25 2 4 ......... 56 ......... 56
& 229-237 3720 2.6 KVSFEPIPI 55 45 17 25 3 4 ......... 55 ......... 55
& 230-238 3756 2.7 VSFEPIPIH 55 45 17 26 3 4 ......... 55 ......... 55
& 231-239 3757 2.2 SFEPIPIHY 67 33 11 20 2 4 ......... 67 ......... 67
& 232-240 3757 1.6 FEPIPIHYC 78 22 7 12 2 3 ......... 78 ......... 78
& 233-241 3759 2.2 EPIPIHYCA 65 35 13 20 2 3 ......... 65 ......... 65
& 234-242 3757 1.7 PIPIHYCAP 71 29 15 12 1 2 ......... 71 ......... 71
& 235-243 3756 1.7 IPIHYCAPA 71 29 15 12 1 3 ......... 71 ......... 71
& 236-244 3759 1.7 PIHYCAPAG 71 29 15 12 1 2 ......... 71 ......... 71
& 237-245 3770 1.8 IHYCAPAGF 71 29 13 14 1 2 ......... 71 ......... 71
& 238-246 3736 1.8 HYCAPAGFA 71 29 13 14 1 2 ......... 71 ......... 71
& 239-247 3735 2.0 YCAPAGFAI 71 29 10 18 2 3 ......... 71 ......... 71
& 240-248 3736 1.9 CAPAGFAIL 72 28 10 16 2 3 ......... 72 ......... 72
& 241-249 3789 2.1 APAGFAILK 69 31 9 20 2 3 ......... 69 ......... 69
& 242-250 3793 1.6 PAGFAILKC 78 22 6 14 2 3 ......... 78 ......... 78
& 243-251 3820 2.6 AGFAILKCN 59 41 13 26 2 3 ......... 59 ......... 59
& 244-252 3835 3.6 GFAILKCND 39 61 18 40 3 5 ........N 18 ........E 2
& 245-253 3836 4.3 FAILKCNDK 28 72 17 51 3 6 .......N. 17 .......ET <1
& 246-254 3839 5.0 AILKCNDKK 22 78 15 59 4 8 ......N.T 15 ......ET. <1
& 247-255 3849 5.0 ILKCNDKKF 22 78 15 59 4 8 .....N.T. 15 .....ET.. <1
& 248-256 3847 5.4 LKCNDKKFN 21 79 13 61 5 9 ....N.T.. 13 ....ET... <1
& 249-257 3851 5.2 KCNDKKFNG 21 79 14 60 5 8 ...N.T... 14 ...ET.... <1
+ 250-258 3854 5.8 CNDKKFNGT 17 83 9 68 6 10 ..N.T.... 8 ..ET....S 0
+ 251-259 3859 5.8 NDKKFNGTG 17 83 9 69 5 10 .N.T..... 8 .ET....S. 0
& 252-260 3871 5.7 DKKFNGTGP 24 76 10 61 5 10 N.T...... 10 ET....S.. 0
& 253-261 3878 5.3 KKFNGTGPC 26 74 11 58 4 8 .T....... 11 T....S... <1
+ 254-262 3886 5.8 KFNGTGPCT 18 82 11 66 5 10 T........ 10 ....S...K 2
& 255-263 3923 5.0 FNGTGPCTN 28 72 13 55 4 8 ......... 28 ...S...K. 2
& 256-264 3936 4.9 NGTGPCTNV 28 72 13 55 4 8 ......... 28 ..S...K.. 2
& 257-265 3689 4.3 GTGPCTNVS 32 68 16 49 3 6 ......... 32 .S...K..T 0
& 258-266 3667 4.3 TGPCTNVST 33 67 15 49 3 7 ......... 33 S...K..T. 0
& 259-267 3667 3.3 GPCTNVSTV 48 52 20 29 3 5 ......... 48 ...K..T.. 0
& 260-268 3684 3.3 PCTNVSTVQ 48 52 20 29 3 5 ......... 48 ..K..T... 0
& 261-269 3685 2.7 CTNVSTVQC 52 48 24 22 2 4 ......... 52 .K..T.... 0
& 262-270 3685 2.7 TNVSTVQCT 52 48 24 22 2 4 ......... 52 K..T..... 0
& 263-271 3685 1.1 NVSTVQCTH 88 12 1 9 1 3 ......... 88 ..T...... 0
# 264-272 3674 0.8 VSTVQCTHG 92 8 1 6 1 2 ......... 92 .T....... <1
# 265-273 3673 0.8 STVQCTHGI 92 8 1 5 1 2 ......... 92 T........ <1
& 266-274 3656 1.5 TVQCTHGIR 73 27 20 6 1 2 ......... 73 ......... 73
& 267-275 3608 1.4 VQCTHGIRP 73 27 21 5 1 2 ......... 73 ......... 73
& 268-276 3607 1.4 QCTHGIRPV 72 28 21 6 1 2 ......... 72 ......... 72
& 269-277 3607 1.5 CTHGIRPVV 72 28 20 7 <1 2 ......... 72 ......... 72
& 270-278 3608 1.5 THGIRPVVS 72 28 20 7 <1 2 ......... 72 ......... 72
& 271-279 3612 1.5 HGIRPVVST 72 28 20 7 <1 2 ......... 72 ......... 72
& 272-280 3620 1.5 GIRPVVSTQ 72 28 20 7 <1 2 ......... 72 ......... 72
& 273-281 3636 1.5 IRPVVSTQL 72 28 20 7 <1 2 ......... 72 ......... 72
& 274-282 3638 1.4 RPVVSTQLL 72 28 21 7 <1 2 ......... 72 ......... 72
# 275-283 3641 0.7 PVVSTQLLL 93 7 2 5 <1 1 ......... 93 ......... 93
# 276-284 3701 0.7 VVSTQLLLN 92 8 2 5 <1 1 ......... 92 ......... 92
# 277-285 3833 0.6 VSTQLLLNG 94 6 2 4 <1 1 ......... 94 ......... 94
# 278-286 3841 0.6 STQLLLNGS 95 5 <1 4 <1 2 ......... 95 ......... 95
# 279-287 3844 0.6 TQLLLNGSL 95 5 <1 4 <1 2 ......... 95 ......... 95
# 280-288 3857 0.8 QLLLNGSLA 91 9 3 5 <1 2 ......... 91 ......... 91
# 281-289 3882 0.9 LLLNGSLAE 90 10 4 6 <1 2 ......... 90 ........V <1
& 282-290 4040 2.0 LLNGSLAEE 64 36 19 16 1 2 ......... 64 .......V. <1
& 283-291 4237 2.8 LNGSLAEEE 54 46 17 27 2 3 ......... 54 ......V.. <1
& 284-292 4297 3.6 NGSLAEEEV 41 59 13 44 2 4 ......... 41 .....V... <1
& 285-293 4493 4.3 GSLAEEEVV 37 63 8 52 3 5 ......... 37 ....V.... 0
& 286-294 4483 4.2 SLAEEEVVI 39 61 9 48 3 6 ......... 39 ...V..... 0
& 287-295 4582 4.1 LAEEEVVIR 39 61 10 48 3 5 ......... 39 ..V...... 0
& 288-296 4623 4.2 AEEEVVIRS 39 61 10 48 3 5 ......... 39 .V....... 0
& 289-297 5130 5.4 EEEVVIRSE 23 77 8 65 4 7 ........V 1 V........ 0
& 290-298 5265 5.3 EEVVIRSEN 24 76 8 64 4 7 .......V. 1 ......... 24
& 291-299 5389 5.2 EVVIRSENF 26 74 8 61 4 7 ......V.. 1 ......... 26
& 292-300 5526 5.4 VVIRSENFT 24 76 7 65 4 7 .....V... 1 ........S 3
+ 293-301 5685 5.6 VIRSENFTN 19 81 9 68 4 7 ....V...D 1 .......SD 1
& 294-302 5692 5.0 IRSENFTNN 23 77 10 63 4 6 ...V...D. 1 ......SD. 2
& 295-303 5694 5.5 RSENFTNNA 21 79 8 67 4 7 ..V...D.. 1 .....SD.. 2
+ 296-304 5731 5.5 SENFTNNAK 20 80 8 68 4 7 .V...D... 1 ....SD... 2
+ 297-305 5732 6.2 ENFTNNAKT 15 85 7 72 6 10 V...D.... 1 ...SD.... 2
+ 298-306 5936 5.4 NFTNNAKTI 18 82 14 64 4 7 ...D..... 14 ..SD..... 6
+ 299-307 6068 5.4 FTNNAKTII 18 82 13 65 4 8 ..D...... 13 .SD...... 6
& 300-308 6084 4.8 TNNAKTIIV 25 75 17 55 4 6 .D....... 17 SD......I <1
& 301-309 6096 4.4 NNAKTIIVQ 25 75 23 49 3 5 D........ 23 D......I. <1
& 302-310 6150 3.6 NAKTIIVQL 49 51 6 43 2 4 ......... 49 ......I.. 1
& 303-311 6146 4.5 AKTIIVQLN 30 70 17 50 3 5 ......... 30 .....I... 1
& 304-312 6146 4.9 KTIIVQLNE 25 75 17 55 3 6 ........T 2 ....I...T 0
+ 305-313 6135 5.7 TIIVQLNES 14 86 10 72 4 7 .......T. 2 ...I...T. 0
& 306-314 6149 5.1 IIVQLNESV 21 79 10 66 3 6 ......T.. 2 ..I...T.. 0
+ 307-315 6140 6.4 IVQLNESVE 9 91 8 78 5 9 .....T... 1 .I...T... 0
+ 308-316 6139 6.4 VQLNESVEI 10 90 8 77 4 9 ....T.... 1 I...T.... 0
+ 309-317 6141 6.5 QLNESVEIN 10 90 9 76 5 10 ...T..... 1 ...T..... 1
+ 310-318 6145 6.3 LNESVEINC 12 88 9 74 5 10 ..T...... 1 ..T...... 1
+ 311-319 6136 6.6 NESVEINCT 11 89 9 74 6 11 .T....... 1 .T....... 1
+ 312-320 6143 6.2 ESVEINCTR 15 85 9 71 5 10 T........ 1 T........ 1
& 313-321 6156 5.4 SVEINCTRP 22 78 9 65 4 7 ......... 22 ......... 22
& 314-322 6151 5.0 VEINCTRPN 31 69 9 56 4 7 ......... 31 ......... 31
& 315-323 6156 5.0 EINCTRPNN 32 68 9 54 4 7 ......... 32 ......... 32
& 316-324 6167 3.4 INCTRPNNN 56 44 9 33 3 5 ......... 56 ......... 56
& 317-325 6166 3.5 NCTRPNNNT 56 44 8 33 3 5 ......... 56 ......... 56
& 318-326 6219 3.4 CTRPNNNTR 55 45 8 34 3 5 ......... 55 ......... 55
& 319-327 6209 4.1 TRPNNNTRK 46 54 7 43 3 6 ......... 46 ......... 46
& 320-328 6210 4.4 RPNNNTRKS 36 64 16 45 3 6 ........R 2 ........G 16
& 321-329 6210 4.5 PNNNTRKSI 35 65 16 45 4 7 .......R. 1 .......G. 16
+ 322-330 6195 5.8 NNNTRKSIH 17 83 13 64 5 10 ......R.R <1 ......G.. 13
+ 323-331 6199 6.0 NNTRKSIHI 16 84 13 65 6 10 .....R.R. <1 .....G... 13
+ 324-332 6310 6.1 NTRKSIHIG 15 85 13 67 6 10 ....R.R.. <1 ....G.... 13
+ 325-333 6312 6.1 TRKSIHIGP 14 86 12 67 6 10 ...R.R... <1 ...G..... 12
+ 326-334 6245 6.1 RKSIHIGPG 15 85 13 68 5 9 ..R.R.... <1 ..G...... 13
+ 327-335 6221 6.4 KSIHIGPGR 12 88 12 71 5 9 .R.R..... <1 .G....... 12
+ 328-336 6212 6.1 SIHIGPGRA 14 86 9 72 5 9 R.R...... <1 G........ 9
& 329-337 6210 5.9 IHIGPGRAF 25 75 6 65 5 9 .R....... <1 ......... 25
& 330-338 6209 6.2 HIGPGRAFY 22 78 5 68 5 10 R.......V <1 ......... 22
& 331-339 6158 5.7 IGPGRAFYA 23 77 16 57 4 9 .......VT <1 ......... 23
& 332-340 6152 5.3 GPGRAFYAT 25 75 18 54 4 7 ......VTI <1 ......... 25
& 333-341 5529 5.3 PGRAFYATG 27 73 17 51 4 8 .....VTI. <1 ......... 27
+ 334-342 5455 6.5 GRAFYATGE 12 88 11 71 6 12 ....VTI.- 0 ........D 11
+ 335-343 5510 6.7 RAFYATGEI 11 89 11 72 7 13 ...VTI.-K 0 .......D. 11
+ 336-344 5493 6.5 AFYATGDII 14 86 11 68 7 13 ..VTI.-K. 0 ......... 14
+ 337-345 5497 6.3 FYATGDIIG 14 86 11 69 6 11 .VTI.-K.. 0 ......... 14
+ 338-346 5492 6.1 YATGDIIGD 13 87 10 72 5 10 VTI.-K..N 0 ......... 13
+ 339-347 5495 5.7 ATGDIIGDI 17 83 10 68 5 9 TI.-K..NM 0 ......... 17
& 340-348 5548 5.0 TGDIIGDIR 24 76 19 54 4 7 I.-K..NM. 0 ......... 24
+ 341-349 5555 5.6 GDIIGDIRQ 16 84 14 66 4 8 .-K..NM.. 0 ......... 16
+ 342-350 6153 5.4 DIIGDIRQA 16 84 16 65 3 7 -K..NM... 0 ......... 16
& 343-351 6213 3.8 IIGDIRQAH 45 55 10 42 3 5 K..NM.... <1 ......... 45
& 344-352 6244 3.5 IGDIRQAHC 47 53 11 40 2 5 ..NM..... <1 ......... 47
& 345-353 6140 3.4 GDIRQAHCN 51 49 10 37 2 5 .NM...... <1 ......... 51
& 346-354 6152 4.3 DIRQAHCNI 28 72 22 46 3 6 NM....... <1 ......... 28
& 347-355 6105 4.0 IRQAHCNIS 33 67 26 38 3 6 M........ <1 ......... 33
& 348-356 6088 5.3 RQAHCNISR 20 80 15 60 4 8 ......... 20 ........T <1
+ 349-357 6086 6.7 QAHCNISRA 11 89 7 76 6 11 ......... 11 .......T. <1
+ 350-358 6078 7.3 AHCNISRAK 13 87 3 76 8 14 ......... 13 ......T.. <1
+ 351-359 6070 7.3 HCNISRAKW 13 87 3 76 8 14 ......... 13 .....T... <1
+ 352-360 6061 7.4 CNISRAKWN 13 87 3 75 9 15 ......... 13 ....T.... <1
+ 353-361 6054 8.1 NISRAKWNN 9 91 2 77 11 20 ......... 9 ...T....D 0
+ 354-362 6019 8.0 ISRAKWNNT 10 90 3 77 11 19 ......... 10 ..T....D. 0
+ 355-363 6018 7.8 SRAKWNNTL 10 90 4 76 10 17 ......... 10 .T....D.. 0
+ 356-364 6009 8.4 RAKWNNTLR 5 95 3 79 13 22 ........K 3 T....D..K 0
+ 357-365 6019 8.0 AKWNNTLRQ 7 93 5 76 12 20 .......K. 5 ....D..KH <1
+ 358-366 6008 7.5 KWNNTLKQI 10 90 7 73 10 17 ......... 10 ...D...H. <1
+ 359-367 5990 7.2 WNNTLKQIV 11 89 6 75 8 14 ........A 3 ..D...H.. <1
+ 360-368 5962 8.4 NNTLRQIVI 4 96 4 79 13 22 ....K..AS <1 .D..KH..G 0
+ 361-369 5961 8.3 NTLRQIVIK 4 96 4 81 11 19 ...K..AS. <1 D..KH..G. 0
+ 362-370 5951 7.6 TLKQIVTKL 7 93 4 81 8 15 .....AS.. <1 ...H..G.. 0
+ 363-371 5941 8.0 LKQIVTKLR 6 94 4 80 10 18 ....AS... <1 ..H..G..K 0
+ 364-372 5844 8.3 KQIVTKLRE 6 94 4 79 11 20 ...AS.... <1 .H..G..K. 0
+ 365-373 5852 7.6 QIVTKLREQ 7 93 5 79 9 16 ..AS..... 2 H..G..K.. 0
+ 366-374 5855 7.3 IVTKLREQF 7 93 6 79 8 14 .AS...... 2 ..G..K... <1
+ 367-375 792 6.2 VKKLREQFG 14 86 7 61 18 28 AS....... 3 .G..K...R 0
+ 368-376 790 6.6 KKLREQFGN 10 90 5 66 19 29 S........ 3 G..K...R. 0
& 369-377 791 5.6 KLREQFGNN 23 77 8 53 16 24 ......... 23 ..K...R.A 4
& 370-378 791 5.5 LREQFGNNK 23 77 9 54 14 23 ......... 23 .K...R.AT 4
& 371-379 791 5.6 REQFGNNKT 23 77 9 53 16 25 ......... 23 K...R.ATK 0
& 372-380 789 5.3 EQFGNNKTI 29 71 9 47 15 23 ......... 29 ...R.ATK. <1
+ 373-381 788 5.8 QFGNNKTIV 19 81 6 58 17 26 ........I 6 ..R.ATK.. <1
+ 374-382 784 5.8 FGNNKTIVF 20 80 6 57 17 25 .......I. 6 .R.ATK... <1
+ 375-383 784 6.2 GNNKTIVFN 13 87 5 63 18 27 ......I.K 3 R.ATK.... 0
+ 376-384 5065 7.2 GNKTIVFNQ 10 90 6 76 9 15 N....I.K. 1 NATK....H 0
+ 377-385 5257 6.0 NKTIVFNQS 19 81 14 59 7 12 ....I.K.. 1 ATK....H. 0
+ 378-386 5180 6.0 KTIVFNQSS 19 81 14 60 6 11 ...I.K... 1 TK....H.. <1
& 379-387 4961 5.5 TIVFNQSSG 21 79 15 59 5 9 ..I.K.... 1 K....H... <1
& 380-388 4929 5.4 IVFNQSSGG 22 78 15 58 5 8 .I.K..... 1 ....H.... 6
& 381-389 4909 5.4 VFNQSSGGD 22 78 15 58 5 8 I.K...... 1 ...H..... 6
& 382-390 4900 4.6 FNQSSGGDP 33 67 9 55 3 6 .K....... 5 ..H...... 9
& 383-391 4752 4.6 NQSSGGDPE 32 68 9 56 3 6 K........ 5 .H....... 9
& 384-392 4583 4.0 QSSGGDPEI 36 64 10 51 3 5 ......... 36 H........ 10
& 385-393 4538 3.1 SSGGDPEIV 56 44 10 31 3 4 ......... 56 ......... 56
& 386-394 4471 3.4 SGGDPEIVM 47 53 13 37 3 5 ........T 13 ......... 47
& 387-395 4454 3.3 GGDPEIVMH 50 50 13 35 3 5 .......T. 13 ......... 50
& 388-396 4441 3.8 GDPEIVMHS 42 58 12 42 4 6 ......T.. 12 ......... 42
& 389-397 4395 3.8 DPEIVMHSF 42 58 12 42 4 6 .....T... 12 ......... 42
& 390-398 4331 3.9 PEIVMHSFN 42 58 12 42 4 6 ....T.... 12 ......... 42
& 391-399 4327 3.3 EIVMHSFNC 53 47 13 31 3 5 ...T..... 13 ......... 53
& 392-400 4279 3.7 IVMHSFNCG 47 53 12 38 3 6 ..T...... 12 ......... 47
& 393-401 4277 3.6 VMHSFNCGG 48 52 12 37 3 5 .T....... 12 ......... 48
& 394-402 4290 3.1 MHSFNCGGE 51 49 14 32 2 4 T........ 14 ......... 51
& 395-403 4290 2.3 HSFNCGGEF 66 34 10 22 2 3 ......... 66 ......... 66
& 396-404 4287 2.2 SFNCGGEFF 68 32 10 21 2 3 ......... 68 ......... 68
& 397-405 3968 1.7 FNCGGEFFY 78 22 7 13 1 3 ......... 78 ......... 78
& 398-406 3960 1.6 NCGGEFFYC 79 21 7 13 1 3 ......... 79 ......... 79
& 399-407 3902 1.9 CGGEFFYCN 74 26 7 18 2 3 ......... 74 ......... 74
& 400-408 3902 2.7 GGEFFYCNT 47 53 26 24 2 3 ........S 26 ......... 47
& 401-409 3901 2.9 GEFFYCNTT 47 53 20 31 2 4 .......S. 20 ......... 47
& 402-410 3898 4.6 EFFYCNTTQ 21 79 12 64 3 6 ......S.. 10 ........R 2
& 403-411 3898 4.6 FFYCNTTQL 21 79 12 64 3 6 .....S... 10 .......R. 2
& 404-412 3898 4.6 FYCNTTQLF 21 79 12 64 3 6 ....S.... 9 ......R.. 2
& 405-413 3897 4.8 YCNTTQLFN 20 80 12 64 4 7 ...S..... 9 .....R... 2
+ 406-414 3726 5.0 CNTTQLFNS 19 81 12 65 4 7 ..S...... 10 ....R.... 2
+ 407-415 3737 5.4 NTTQLFNST 16 84 11 68 5 9 .S....... 9 ...R..... 2
+ 408-416 3732 5.1 TTQLFNSTW 18 82 11 67 4 8 S........ 11 ..R...... 2
+ 409-417 3727 6.3 TQLFNSTWN 14 86 8 72 6 11 ........F <1 .R....... 1
+ 410-418 3725 7.5 PLFNSTWGS 7 93 4 81 8 16 Q......FN <1 R......NV 0
+ 411-419 3701 7.1 LFNSTWGSN 7 93 7 80 7 14 ......FNS <1 ......NVS <1
+ 412-420 3635 7.9 FNSTWGSND 7 93 2 81 9 19 .....FNST <1 .....NVST <1
+ 413-421 3633 8.3 NSTWGSNDS 5 95 2 82 11 22 ....FNSTW <1 ....NVSTW <1
+ 414-422 3632 8.4 STWGSNDSR 4 96 2 81 13 24 ...FNSTWS <1 ...NVSTWN <1
+ 415-423 3630 8.4 TWGSNDSRP 4 96 2 79 14 26 ..FNSTWST <1 ..NVSTWNI 0
+ 416-424 3628 8.7 WGSNDSRPE 4 96 2 79 15 27 .FNSTWST. <1 .NVSTWNIS 0
+ 417-425 3613 8.5 GSNDSRPEN 4 96 2 78 16 28 FNSTWST.G <1 NVSTWNISQ 0
+ 418-426 3610 8.7 SNDSRPENN 5 95 2 78 15 28 NSTWST.GS <1 VSTWNISQT 0
+ 419-427 3595 8.6 NDSRPENNT 6 94 2 78 15 27 STWST.GSN <1 STWNISQTE 0
+ 420-428 3567 8.6 DSRPENNTG 6 94 2 77 15 28 TWST.GSNN <1 TWNISQTE. 0
+ 421-429 3346 8.4 SRPENNTGG 6 94 2 76 16 28 WST.GSNNT <1 WNISQTE.S 0
+ 422-430 3055 8.3 RPENNTGGN 8 92 2 74 15 27 ST.GSNNTE <1 NISQTE.SY 0
+ 423-431 2411 7.7 PENNTGGNE 13 87 2 70 14 26 T.GSNNTEG 1 ISQTE.SYN 0
+ 424-432 1945 7.3 ENNTGGNET 15 85 3 68 14 25 .GSNNTEGS 1 SQTE.SYN. 0
+ 425-433 1232 7.5 SENTTGNGT 5 95 3 76 16 29 GS.N.EGSD 1 QTEGSY.TE 0
+ 426-434 825 7.1 TEVKNNTEG 5 95 3 75 17 31 SNNTEGSDT 2 ..GSY...E 0
+ 427-435 515 6.4 EVKNNTEGT 7 93 5 71 17 31 NNTEGSDT- 0 .GSY...EN 0
+ 428-436 322 5.9 STENITHPE 8 92 7 66 19 33 N..GSDT-- 0 GSY.TEEN- 0
+ 429-437 319 5.8 TENITHPEI 8 92 8 66 17 31 ..GSDT--. 0 SY.TEEN-. 0
+ 430-438 319 5.9 TGQSDSPIT 8 92 7 68 17 32 E.SDT--.. 0 YNTEEN-.. 0
+ 431-439 319 5.6 NITHPEITL 11 89 8 65 16 30 GSDT--... 0 .TEEN-... 0
+ 432-440 319 5.7 ITHPEITLP 11 89 8 66 16 30 SDT--.... 0 TEEN-.... 0
+ 433-441 319 5.6 THPEITLPC 11 89 8 67 15 28 DT--..... 0 EEN-..... 0
+ 434-442 319 5.5 HPEITLPCR 11 89 8 68 13 27 T--...... 0 EN-...... 0
+ 435-443 319 5.3 PEITLPCRI 12 88 8 71 8 21 --....... 0 N-....... 0
+ 436-444 319 4.6 EITLPCRIK 16 84 12 66 6 15 -........ 0 -........ 0
& 437-445 3542 3.3 ITLPCRIKQ 48 52 9 41 2 4 ......... 48 ......... 48
& 438-446 3608 3.6 TLPCRIKQI 45 55 9 44 3 5 ......... 45 ......... 45
& 439-447 3607 3.5 LPCRIKQII 44 56 12 41 2 4 ......... 44 ........V 12
& 440-448 3608 3.7 PCRIKQIIN 42 58 12 43 2 4 ......... 42 .......V. 12
& 441-449 3606 3.7 CRIKQIINM 40 60 12 45 3 4 ......... 40 ......V.. 10
& 442-450 3603 3.7 RIKQIINMW 40 60 12 45 3 5 ......... 40 .....V... 10
& 443-451 3603 3.2 IKQIINMWQ 52 48 11 35 2 4 ......... 52 ....V.... 11
& 444-452 3603 3.9 KQIINMWQE 44 56 11 42 3 5 ........K 3 ...V..... 11
& 445-453 3604 3.6 QIINMWQEV 46 54 12 40 2 4 .......K. 2 ..V...... 12
& 446-454 3603 3.5 IINMWQEVG 47 53 12 39 2 4 ......K.. 2 .V....... 12
& 447-455 3430 3.3 INMWQEVGK 45 55 15 37 2 4 .....K... 3 V........ 15
& 448-456 3355 2.7 NMWQEVGKA 61 39 8 28 2 3 ....K.... 3 ......... 61
& 449-457 3307 2.8 MWQEVGKAM 60 40 8 30 2 4 ...K..... 3 ......... 60
& 450-458 3307 2.0 WQEVGKAMY 73 27 6 19 2 3 ..K...... 6 ......... 73
& 451-459 3310 2.1 QEVGKAMYA 72 28 6 20 2 3 .K....... 6 ......... 72
& 452-460 3310 2.1 EVGKAMYAP 72 28 6 19 2 3 K........ 6 ......... 72
& 453-461 3311 1.0 VGKAMYAPP 89 11 2 9 <1 2 ......... 89 ......... 89
& 454-462 3309 1.2 GKAMYAPPI 86 14 2 11 1 2 ......... 86 ......... 86
& 455-463 3308 3.1 KAMYAPPIR 46 54 14 38 3 4 ........S 14 ......... 46
& 456-464 3309 2.9 AMYAPPIRG 48 52 14 36 2 4 .......S. 14 ......... 48
& 457-465 3305 4.5 MYAPPIRGQ 34 66 9 54 3 6 ......S.. 8 ........I 2
& 458-466 3306 4.5 YAPPIRGQI 35 65 8 54 3 6 .....S... 7 .......I. 1
& 459-467 3306 5.4 APPIRGQIR 30 70 5 61 4 9 ....S.... 5 ......I.. 1
& 460-468 3306 5.3 PPIRGQIRC 31 69 5 60 4 8 ...S..... 5 .....I... 1
& 461-469 3306 5.8 PIRGQIRCS 28 72 5 62 5 11 ..S...... 4 ....I.... 1
& 462-470 3304 5.9 IRGQIRCSS 27 73 5 63 5 11 .S....... 4 ...I..... <1
& 463-471 3304 6.0 RGQIRCSSN 27 73 5 62 6 12 S........ 3 ..I...... <1
& 464-472 3305 4.9 GQIRCSSNI 38 62 4 54 4 8 ......... 38 .I....... 2
& 465-473 3305 4.9 QIRCSSNIT 39 61 4 53 4 8 ......... 39 I........ 2
& 466-474 3306 3.6 IRCSSNITG 51 49 9 38 3 5 ......... 51 ......... 51
& 467-475 3285 3.7 RCSSNITGL 50 50 9 38 3 5 ......... 50 ........I <1
& 468-476 3282 2.7 CSSNITGLL 62 38 8 28 2 4 ......... 62 .......IM 0
& 469-477 3279 2.9 SSNITGLLL 60 40 8 29 2 4 ......... 60 ......IM. 0
& 470-478 3278 2.5 SNITGLLLT 62 38 10 27 2 3 ......... 62 .....IM.. 0
& 471-479 3277 2.5 NITGLLLTR 62 38 9 27 2 3 ......... 62 ....IM... 0
& 472-480 3278 2.1 ITGLLLTRD 67 33 10 22 1 3 ......... 67 ...IM.... 0
& 473-481 3277 2.1 TGLLLTRDG 67 33 9 22 2 3 ......... 67 ..IM..... 0
& 474-482 3276 2.1 GLLLTRDGG 67 33 9 22 2 3 ......... 67 .IM...... 0
& 475-483 3262 4.3 LLLTRDGGN 36 64 7 54 3 6 ......... 36 IM......K 0
+ 476-484 3216 6.0 LLTRDGGNN 16 84 7 72 5 10 ........S 7 M......K. 0
+ 477-485 3063 7.2 LTRDGGNNN 5 95 4 84 7 14 .......S. 3 ......K.R <1
+ 478-486 3008 8.0 TRDGGNNNN 2 98 2 84 11 21 ......S.. 1 .....K.RT 0
+ 479-487 2898 8.3 RDGGNQNGS 3 97 2 81 15 26 .....S.NE <1 ....KNRTE 0
+ 480-488 2219 8.2 DGGNQNGSN 3 97 2 77 17 30 ....S.NE- 0 ...KNRTE. 0
+ 481-489 1400 7.8 GGNNTTTNG 4 96 2 74 19 33 ...SNNE-- 0 ..K.R.E.T 0
+ 482-490 971 7.4 GNNTTTNGT 5 95 3 74 18 32 ..SNNE--- 0 .K.R.E.T- 0
+ 483-491 448 6.4 NNTTTNGTQ 12 88 3 61 24 36 .SNNE---- 0 K.R.E.T-- 0
+ 484-492 184 5.7 RNISDGTNG 7 93 7 58 28 43 S.NE----- 0 NRTENT--- 0
+ 485-493 123 4.8 NISDGTNGN 11 89 10 59 20 35 .NE-----S 0 RTENT---T 0
+ 486-494 121 4.7 ISDGTNGNE 11 89 10 60 19 34 NE-----S. 0 TENT---T. 0
+ 487-495 121 4.7 SDGTNGNET 11 89 10 60 19 34 E-----S.I 0 ENT---T.. 0
+ 488-496 120 4.6 NENGTTETF 11 89 11 63 16 31 -----S.I. 0 .T---.... 0
+ 489-497 119 4.5 ENGTTETFR 11 89 11 64 14 29 ----S.I.. 0 T---..... 0
+ 490-498 119 4.4 TNGNETFRP 12 88 11 66 12 27 ---S.I... 0 ---T..... 0
+ 491-499 104 4.3 GTTETFRPG 13 88 13 63 12 28 --S.I.... 0 --....... 0
492-500 * 62 4.0 GNETFRPIG 16 84 11 63 10 31 -S.I...G. 0 -T.....G. 0
& 493-501 1627 3.1 TEIFRPGGG 34 66 20 43 3 4 S........ 2 ..T...... 14
& 494-502 1587 2.9 EIFRPGGGD 34 66 29 33 3 5 ......... 34 .T......N 5
& 495-503 1064 2.9 TFRPGGGDM 32 68 31 33 4 6 I........ 31 .......N. 4
& 496-504 1014 1.8 FRPGGGDMR 75 25 7 14 4 6 ......... 75 ......N.M 0
& 497-505 964 2.0 RPGGGDMRD 72 28 7 17 4 6 ......... 72 .....N.M. 0
& 498-506 955 2.0 PGGGDMRDN 72 28 8 16 4 6 ......... 72 ....N.M.. 0
& 499-507 899 2.6 GGGDMRDNW 57 43 16 22 5 7 ......... 57 ...N.M... 0
& 500-508 879 2.2 GGDMRDNWR 62 38 18 17 4 6 ......... 62 ..N.M.... <1
& 501-509 789 2.3 GDMRDNWRS 58 42 20 18 5 7 ......... 58 .N.M..... <1
& 502-510 549 2.0 DMRDNWRSE 71 29 8 15 5 8 ......... 71 N.M...... <1
& 503-511 535 1.5 MRDNWRSEL 79 21 10 6 6 7 ......... 79 .M....... <1
& 504-512 528 1.3 RDNWRSELY 80 20 11 4 5 6 ......... 80 M........ <1
# 505-513 527 0.8 DNWRSELYK 91 9 2 3 4 6 ......... 91 ........N 0
# 506-514 529 0.6 NWRSELYKY 94 6 1 1 4 5 ......... 94 .......N. 0
# 507-515 533 0.6 WRSELYKYK 93 7 1 2 4 5 ......... 93 ......N.. 0
# 508-516 537 0.6 RSELYKYKV 93 7 1 2 3 4 ......... 93 .....N... 0
# 509-517 541 0.7 SELYKYKVV 92 8 2 3 3 4 ......... 92 ....N.... 0
& 510-518 542 1.7 ELYKYKVVK 70 30 15 11 4 5 ......... 70 ...N..... 0
& 511-519 542 1.8 LYKYKVVKI 69 31 15 12 4 6 ......... 69 ..N...... 0
& 512-520 541 1.8 YKYKVVKIE 69 31 15 13 4 6 ......... 69 .N....... 0
& 513-521 541 1.8 KYKVVKIEP 69 31 15 13 4 6 ......... 69 N........ 0
& 514-522 540 2.5 YKVVKIEPL 52 48 16 27 4 6 ......... 52 ......... 52
& 515-523 540 2.5 KVVKIEPLG 52 48 17 27 4 6 ......... 52 ......... 52
& 516-524 543 3.3 VVKIEPLGV 39 61 13 44 4 8 ......... 39 ......... 39
& 517-525 544 3.4 VKIEPLGVA 39 61 13 44 4 9 ......... 39 ......... 39
& 518-526 544 3.3 KIEPLGVAP 39 61 13 44 4 8 ......... 39 ......... 39
& 519-527 546 2.7 IEPLGVAPT 42 58 19 34 4 6 ......... 42 ......... 42
& 520-528 547 3.5 EPLGVAPTR 22 78 20 53 5 8 ........K 20 ........K 20
& 521-529 548 3.4 PLGVAPTRA 22 78 20 53 5 8 .......K. 20 .......K. 20
& 522-530 546 3.6 LGVAPTRAK 22 78 19 53 5 9 ......K.. 19 ......K.. 19
& 523-531 548 2.9 GVAPTRAKR 33 67 22 40 5 8 .....K... 22 .....K... 22
& 524-532 549 3.0 VAPTRAKRR 33 67 22 40 5 8 ....K.... 22 ....K.... 22
& 525-533 548 1.9 APTKAKRRV 47 53 41 8 3 6 ......... 47 ......... 47
& 526-534 551 1.9 PTKAKRRVV 47 53 41 8 3 6 ......... 47 ......... 47
& 527-535 549 2.3 TRAKRRVVQ 40 60 40 15 5 7 .K....... 40 .K....... 40
& 528-536 557 2.3 KAKRRVVQR 40 60 40 16 4 7 ......... 40 ......... 40
& 529-537 557 1.3 AKRRVVQRE 82 18 7 7 4 6 ......... 82 ......... 82
& 530-538 557 1.5 KRRVVQREK 78 22 7 11 4 6 ......... 78 ......... 78
& 531-539 559 1.5 RRVVQREKR 80 20 7 10 3 6 ......... 80 ......... 80
& 532-540 560 1.7 RVVQREKRA 77 23 7 13 4 7 ......... 77 ......... 77
& 533-541 548 2.6 VVQREKRAV 54 46 16 26 5 8 ......... 54 ........A 16
& 534-542 395 2.4 VQREKRAVG 63 37 9 21 7 10 ......... 63 .......A. <1
& 535-543 152 3.2 RREKRAIGT 24 76 23 41 11 17 Q.....V.- 0 Q.....A.- 0
& 536-544 152 3.4 REKRAIGTI 24 76 23 39 13 18 .....V.-. 0 .....A.-L 0
& 537-545 153 3.4 EKRAIGTIG 24 76 23 39 14 19 ....V.-.. 0 ....A.-L. 0
& 538-546 134 3.3 KRAIGTIGA 28 72 26 31 15 20 ...V.-... 0 ...A.-L.. 0
& 539-547 133 3.3 RAIGTIGAM 28 72 26 30 16 22 ..V.-...L 0 ..A.-L..L 0
+ 540-548 293 4.2 AVGTIGAMF 18 82 13 61 8 16 ...-...L. 0 .A.-L..L. 0
+ 541-549 305 4.2 VGTIGAMFL 18 82 13 62 7 15 ..-...L.. 0 A.-L..L.. 0
& 542-550 307 3.6 GTIGAMFLG 31 69 24 39 7 14 .-...L... 0 .-L..L... 0
& 543-551 382 3.7 TLGAMFLGF 29 71 25 39 7 13 -I..L.... 0 -...L.... 0
+ 544-552 1275 3.7 LGAMFLGFL 18 82 18 61 3 6 I..L..... 18 ...L..... 11
& 545-553 1263 2.5 GAMFLGFLG 35 65 30 33 2 4 ..L...... 30 ..L...... 30
& 546-554 1253 2.8 AMFLGFLGA 30 70 30 38 2 4 .L....... 30 .L....... 30
& 547-555 1257 2.7 LFLGFLGAA 30 70 30 38 2 4 ......... 30 ......... 30
& 548-556 1315 1.2 FLGFLGAAG 84 16 6 9 1 3 ......... 84 ......... 84
& 549-557 1321 0.9 LGFLGAAGS 87 13 7 6 <1 2 ......... 87 ......... 87
& 550-558 1323 0.8 GFLGAAGST 89 11 6 4 <1 2 ......... 89 ......... 89
& 551-559 1310 0.8 FLGAAGSTM 89 11 6 4 <1 2 ......... 89 ......... 89
& 552-560 1310 0.7 LGAAGSTMG 90 10 6 3 <1 2 ......... 90 ......... 90
& 553-561 1305 0.7 GAAGSTMGA 90 10 6 3 1 2 ......... 90 ......... 90
& 554-562 1307 0.8 AAGSTMGAA 89 11 6 3 1 2 ......... 89 ......... 89
# 555-563 1307 0.6 AGSTMGAAS 92 8 3 4 1 2 ......... 92 ......... 92
& 556-564 1260 2.6 GSTMGAASI 24 76 24 50 2 3 ........M 23 ........L 24
& 557-565 1274 3.1 STMGAASLT 24 76 23 51 2 4 .......M. 19 ......... 24
& 558-566 1300 3.2 TMGAASLTL 24 76 23 51 2 5 ......M.. 18 ......... 24
& 559-567 1399 3.1 MGAASLTLT 24 76 23 51 2 4 .....M... 19 ......... 24
& 560-568 1427 3.2 GAASLTLTV 24 76 22 52 2 4 ....M.... 19 ......... 24
& 561-569 1462 3.3 AASLTLTVQ 24 76 22 52 2 4 ...M..... 19 ......... 24
& 562-570 1459 3.3 ASLTLTVQA 24 76 22 52 3 5 ..M...... 19 ......... 24
& 563-571 1463 3.1 SLTLTVQAR 24 76 22 52 2 4 .M....... 20 ......... 24
+ 564-572 1456 3.8 LTLTVQARQ 18 82 16 63 2 5 M........ 8 ......... 18
& 565-573 1502 2.2 TLTVQARQL 55 45 24 19 2 3 ......... 55 ......... 55
& 566-574 1509 1.8 LTVQARQLL 62 38 24 11 2 3 ......... 62 ......... 62
& 567-575 1515 1.8 TVQARQLLS 62 38 24 12 2 3 ......... 62 ......... 62
& 568-576 1478 2.1 VQARQLLSG 59 41 23 16 2 4 ......... 59 ......... 59
& 569-577 1513 1.9 QARQLLSGI 63 37 23 12 2 3 ......... 63 ......... 63
& 570-578 1464 2.3 ARQLLSGIV 57 43 23 18 2 4 ......... 57 ......... 57
& 571-579 1501 2.2 RQLLSGIVQ 59 41 22 16 2 4 ......... 59 ......... 59
& 572-580 1541 2.3 QLLSGIVQQ 59 41 21 18 2 4 ......... 59 ......... 59
& 573-581 1614 1.4 LLSGIVQQQ 82 18 5 11 2 3 ......... 82 ......... 82
& 574-582 1619 2.2 LSGIVQQQN 69 31 8 21 2 4 ......... 69 ......... 69
& 575-583 1613 2.4 SGIVQQQNN 63 37 8 26 3 5 ......... 63 ......... 63
& 576-584 1629 2.4 GIVQQQNNL 63 37 9 26 2 4 ......... 63 ......... 63
& 577-585 1634 2.3 IVQQQNNLL 65 35 9 24 2 4 ......... 65 ......... 65
& 578-586 1629 2.9 VQQQNNLLR 58 42 7 33 2 5 ......... 58 ......... 58
& 579-587 1665 2.5 QQQNNLLRA 62 38 7 29 2 4 ......... 62 ......... 62
& 580-588 1669 2.5 QQNNLLRAI 62 38 7 29 2 4 ......... 62 ......... 62
& 581-589 1690 2.6 QNNLLRAIE 61 39 7 30 2 4 ......... 61 ......... 61
& 582-590 1832 2.7 NNLLRAIEA 58 42 11 29 2 4 ......... 58 ......... 58
& 583-591 1890 1.8 NLLRAIEAQ 74 26 8 17 <1 3 ......... 74 ......... 74
& 584-592 1941 1.5 LLRAIEAQQ 79 21 9 12 <1 2 ......... 79 ......... 79
& 585-593 1944 1.5 LRAIEAQQH 79 21 8 12 1 3 ......... 79 ......... 79
& 586-594 1944 2.2 RAIEAQQHL 57 43 24 18 1 3 ......... 57 ......... 57
& 587-595 1930 1.6 AIEAQQHLL 65 35 25 8 1 2 ......... 65 ......... 65
& 588-596 1849 1.9 IEAQQHLLQ 64 36 23 12 1 3 ......... 64 ......... 64
& 589-597 1844 1.9 EAQQHLLQL 64 36 23 12 1 3 ......... 64 ......... 64
& 590-598 2008 1.8 AQQHLLQLT 64 36 24 10 1 3 ......... 64 ......... 64
& 591-599 1962 1.8 QQHLLQLTV 64 36 24 11 1 3 ......... 64 ......... 64
& 592-600 1966 1.7 QHLLQLTVW 65 35 24 10 1 2 ......... 65 ......... 65
& 593-601 1967 1.6 HLLQLTVWG 66 34 24 8 1 2 ......... 66 ......... 66
& 594-602 1976 1.4 LLQLTVWGI 67 33 26 6 <1 2 ......... 67 ......... 67
# 595-603 2014 0.6 LQLTVWGIK 93 7 2 4 <1 2 ......... 93 ......... 93
# 596-604 2011 0.6 QLTVWGIKQ 93 7 2 4 <1 1 ......... 93 ......... 93
# 597-605 2039 0.3 LTVWGIKQL 97 3 1 1 <1 1 ......... 97 ......... 97
# 598-606 2038 0.4 TVWGIKQLQ 96 4 1 2 <1 1 ......... 96 ......... 96
# 599-607 2038 0.4 VWGIKQLQA 96 4 1 2 <1 1 ......... 96 ......... 96
# 600-608 2042 0.4 WGIKQLQAR 96 4 1 3 <1 1 ......... 96 ......... 96
& 601-609 2012 0.9 GIKQLQARV 88 12 6 6 <1 1 ........I 6 ......... 88
& 602-610 2007 0.9 IKQLQARVL 88 12 6 5 <1 1 .......I. 6 ......... 88
& 603-611 1994 0.8 KQLQARVLA 89 11 6 4 <1 1 ......I.. 6 ......... 89
& 604-612 1985 1.4 QLQARVLAV 76 24 9 14 <1 2 .....I... 6 ......... 76
& 605-613 1981 1.5 LQARVLAVE 76 24 9 14 <1 2 ....I.... 6 ......... 76
& 606-614 1966 1.7 QARVLAVER 74 26 9 16 1 2 ...I..... 6 ......... 74
& 607-615 1964 1.7 ARVLAVERY 73 27 9 16 1 3 ..I...... 6 ......... 73
& 608-616 1964 1.8 RVLAVERYL 73 27 6 20 1 3 .I....... 6 ......... 73
& 609-617 1898 3.2 VLAVERYLK 42 58 20 36 2 5 I........ 3 ........R 20
& 610-618 1920 2.8 LAVERYLKD 47 53 20 30 2 4 ......... 47 .......R. 20
& 611-619 1919 2.8 AVERYLKDQ 47 53 20 31 2 4 ......... 47 ......R.. 20
& 612-620 1917 3.0 VERYLKDQQ 45 55 20 32 2 4 ......... 45 .....R... 20
& 613-621 1918 2.6 ERYLKDQQL 49 51 24 25 2 4 ......... 49 ....R.... 24
& 614-622 1914 2.8 RYLKDQQLL 47 53 23 28 2 4 ......... 47 ...R..... 23
& 615-623 1919 2.6 YLKDQQLLG 49 51 24 25 2 3 ......... 49 ..R...... 24
& 616-624 1918 2.8 LKDQQLLGI 46 54 25 27 2 4 ......... 46 .R....... 25
& 617-625 1918 2.7 KDQQLLGIW 49 51 25 24 2 4 ......... 49 R........ 25
& 618-626 1983 1.2 DQQLLGIWG 84 16 4 11 <1 2 ......... 84 ......... 84
& 619-627 1984 1.2 QQLLGIWGC 84 16 4 11 <1 2 ......... 84 ......... 84
& 620-628 1985 1.4 QLLGIWGCS 81 19 4 14 <1 2 ......... 81 ......... 81
& 621-629 1987 1.3 LLGIWGCSG 82 18 4 13 <1 2 ......... 82 ......... 82
& 622-630 1970 1.4 LGIWGCSGK 80 20 5 14 <1 2 ......... 80 ......... 80
& 623-631 1967 1.4 GIWGCSGKL 82 18 4 13 1 3 ......... 82 ......... 82
& 624-632 1962 1.4 IWGCSGKLI 81 19 4 13 1 3 ......... 81 ......... 81
& 625-633 1969 1.0 WGCSGKLIC 86 14 4 9 <1 2 ......... 86 ......... 86
& 626-634 1966 1.4 GCSGKLICT 81 19 4 14 1 2 ......... 81 ......... 81
& 627-635 1963 1.4 CSGKLICTT 81 19 4 14 1 2 ......... 81 ......... 81
& 628-636 1903 2.8 SGKLICTTA 49 51 19 30 2 4 ......... 49 ........T 19
& 629-637 1902 2.8 GKLICTTAV 49 51 19 30 2 4 ......... 49 .......T. 19
& 630-638 1901 2.8 KLICTTAVP 49 51 19 30 2 4 ......... 49 ......T.. 19
& 631-639 1924 2.6 LICTTAVPW 51 49 19 28 2 4 ......... 51 .....T... 19
& 632-640 1930 2.3 ICTTAVPWN 54 46 20 26 1 2 ......... 54 ....T.... 20
& 633-641 1858 4.2 CTTAVPWNA 21 79 20 56 3 5 ......... 21 ...T..... 7
& 634-642 1853 4.4 TTAVPWNAS 21 79 20 56 3 7 ......... 21 ..T...... 7
& 635-643 1857 4.1 TAVPWNASW 23 77 21 53 3 5 ......... 23 .T....... 7
& 636-644 1857 4.1 AVPWNASWS 23 77 21 53 3 5 ......... 23 T........ 7
& 637-645 1873 2.8 VPWNTSWSN 33 67 33 31 3 4 ....A.... 33 ....A.... 33
& 638-646 1850 3.3 PWNASWSNK 29 71 29 38 3 5 ......... 29 ......... 29
& 639-647 1825 3.9 WNTSWSNKS 25 75 24 48 4 6 ..A...... 24 ..A.....N <1
+ 640-648 1790 5.3 NASWSNKSL 18 82 17 57 7 13 ......... 18 .......N. <1
+ 641-649 1692 6.8 ASWSNKSLD 12 88 8 67 14 23 ........E 2 ......N.T <1
+ 642-650 1702 7.3 SWSNKSLDN 4 96 4 77 14 25 .......EQ 2 .....N.TT 0
+ 643-651 1702 7.2 WSNKSLDNI 4 96 4 78 13 24 ......EQ. 2 ....N.TT. 0
+ 644-652 1700 7.2 SNKSLDNIW 4 96 4 78 13 24 .....EQ.. 2 ...N.TT.. 0
+ 645-653 1643 8.0 NKSLDNIWG 4 96 3 71 22 36 ....EQ..N 1 ..N.TT..N 0
+ 646-654 1662 8.0 KSLDNIWGN 4 96 3 71 23 36 ...EQ..NH <1 .N.TT..N. 0
+ 647-655 1674 7.9 SLDNIWGNM 4 96 3 74 20 33 ..EQ..NHT <1 N.TT..N.. 0
+ 648-656 1692 7.6 LNEIWDNMT 4 96 4 77 15 27 .EQ..NHT. <1 .TT..N... 0
+ 649-657 1715 6.8 EEIWNNMTW 6 94 5 81 8 17 .Q...HT.. <1 TT....... 0
+ 650-658 1790 5.7 QIWDNMTWM 10 90 9 76 5 11 ...NHT... <1 T..N..... 2
+ 651-659 1828 4.2 IWDNMTWME 19 81 14 63 4 7 ..NHT.... <1 ..N.....Q 11
+ 652-660 1828 4.2 WDNMTWMEW 19 81 14 63 4 7 .NHT..... <1 .N.....Q. 11
+ 653-661 1828 4.5 DNMTWMEWE 18 82 12 66 4 8 NHT.....D <1 N.....Q.. 11
& 654-662 1887 3.4 NMTWMEWER 34 66 17 46 3 5 HT.....D. <1 .....Q..K 17
& 655-663 1895 3.3 MTWMEWERE 34 66 18 45 3 5 T.....D.. <1 ....Q..K. 18
& 656-664 1900 3.3 TWMEWEREI 34 66 19 45 2 5 .....D... 3 ...Q..K.. 19
& 657-665 1876 4.4 WMEWEREID 24 76 16 56 4 8 ....D...N 2 ..Q..K... 16
& 658-666 1863 4.5 MEWEREIDN 23 77 15 56 5 9 ...D...N. 2 .Q..K.... 15
& 659-667 1873 4.1 EWEREIDNY 24 76 16 56 4 7 ..D...N.. 2 Q..K..... 16
& 660-668 1893 3.3 WEREIDNYT 39 61 21 37 3 6 .D...N... 4 ..K...... 21
+ 661-669 1782 5.5 EREIDNYTG 18 82 9 66 7 13 D...N...S 1 .K......E 2
+ 662-670 1751 6.5 REIDNYTGL 15 85 7 66 12 21 ...N...S. 1 K......EI <1
& 663-671 1782 5.9 EIDNYTGLI 22 78 7 62 9 16 ..N...S.. 1 ......EI. <1
& 664-672 1783 5.9 IDNYTGLIY 22 78 7 62 8 16 .N...S..H <1 .....EI.. <1
+ 665-673 1724 7.0 DNYTGLIYT 10 90 6 69 14 25 N...S..HS <1 ....EI..D 0
+ 666-674 1741 6.2 NYTGLIYTL 13 87 9 68 10 18 ...S..HS. <1 ...EI..D. 0
+ 667-675 1724 6.8 YTGLIYTLI 7 93 6 76 12 20 ..S..HS.. <1 ..EI..D.. 0
+ 668-676 1718 6.8 TGLIYTLIE 7 93 5 75 13 22 .S..HS... <1 .EI..D... 0
+ 669-677 1681 7.6 GLIYTLIEE 5 95 5 70 20 31 S..HS.... <1 EI..D...Q 0
+ 670-678 1742 6.6 LIYTLIEES 11 89 5 72 12 20 ..HS..... <1 I..D...Q. 0
+ 671-679 1776 5.4 IYTLIEESQ 19 81 8 67 6 12 .HS...... <1 ..D...Q.. 0
+ 672-680 1749 6.0 YTLIEESQN 16 84 6 68 10 17 HS....... <1 .D...Q... 0
+ 673-681 1741 6.0 TLIEESQNQ 16 84 7 67 10 17 S........ 7 D...Q.... 0
& 674-682 1814 4.5 LIEESQNQQ 29 71 12 54 5 9 ......... 29 ...Q..... 7
& 675-683 1810 4.6 IEESQNQQE 28 72 12 55 5 10 ......... 28 ..Q...... 7
& 676-684 1819 4.2 EESQNQQEK 38 62 12 43 6 11 ......... 38 .Q....... 11
& 677-685 1831 4.0 ESQNQQEKN 40 60 12 44 4 9 ......... 40 Q........ 11
& 678-686 1887 2.4 SQNQQEKNE 67 33 6 24 3 5 ......... 67 ......... 67
& 679-687 1863 3.0 QNQQEKNEQ 59 41 8 29 4 6 ......... 59 ......... 59
& 680-688 1859 3.6 NQQEKNEQE 49 51 11 36 5 8 ......... 49 ......... 49
& 681-689 1895 2.8 QQEKNEQEL 54 46 14 29 3 4 ......... 54 ......... 54
& 682-690 1902 2.7 QEKNEQELL 55 45 14 29 2 4 ......... 55 ......... 55
& 683-691 1874 3.7 EKNEQELLE 41 59 11 43 4 7 ......... 41 ......... 41
& 684-692 1873 3.6 KNEQELLEL 42 58 12 42 4 7 ......... 42 ......... 42
& 685-693 1889 3.4 NEQELLELD 42 58 12 43 3 5 ......... 42 ......... 42
& 686-694 1847 4.0 EQELLELDK 39 61 11 45 4 8 ......... 39 ......... 39
& 687-695 1846 4.0 QELLELDKW 39 61 11 45 4 8 ......... 39 ......... 39
& 688-696 1872 3.7 ELLELDKWA 49 51 11 36 4 8 ......... 49 ......... 49
& 689-697 1808 3.8 LLELDKWAS 40 60 14 42 4 8 ......... 40 ......... 40
& 690-698 1803 3.8 LELDKWASL 40 60 14 42 4 8 ......... 40 ......... 40
& 691-699 1801 3.8 ELDKWASLW 40 60 14 41 4 8 ......... 40 ......... 40
& 692-700 1796 3.6 LDKWASLWN 46 54 13 36 4 8 ......... 46 ........S 8
& 693-701 1797 3.5 DKWASLWNW 47 53 13 36 4 7 ......... 47 .......S. 8
& 694-702 1768 3.4 KWASLWNWF 47 53 13 36 4 7 ......... 47 ......S.. 8
& 695-703 1632 3.8 WASLWNWFD 40 60 12 44 4 8 ........N 6 .....S... 7
& 696-704 1627 3.9 ASLWNWFDI 40 60 12 44 5 8 .......N. 6 ....S.... 7
& 697-705 1615 4.1 SLWNWFDIT 29 71 12 56 3 7 ......N.. 5 ...S..... 6
& 698-706 1637 4.6 LWNWFDITN 24 76 11 61 4 8 .....N... 5 ..S...... 5
& 699-707 1612 4.6 WNWFDITNW 24 76 11 61 4 8 ....N.... 5 .S....... 5
& 700-708 1608 4.6 NWFDITNWL 24 76 11 61 4 8 ...N..... 5 S........ 5
& 701-709 1627 3.9 WFDITNWLW 29 71 16 52 3 5 ..N...... 5 ......... 29
& 702-710 1539 3.9 FDITNWLWY 30 70 14 53 3 5 .N....... 6 ......... 30
& 703-711 1497 3.8 DITNWLWYI 31 69 14 52 3 5 N........ 6 ......... 31
& 704-712 1289 3.0 ITNWLWYIK 42 58 15 41 2 4 ......... 42 ......... 42
& 705-713 1168 3.3 TNWLWYIKI 37 63 16 44 2 5 ........L 1 ......... 37
& 706-714 1129 2.5 NWLWYIKIF 54 46 18 26 2 4 .......L. 1 ......... 54
& 707-715 1141 1.0 WLWYIKIFI 85 15 7 6 1 2 ......L.. 2 ......... 85
& 708-716 1125 1.5 LWYIKIFIM 76 24 8 14 2 3 .....L... 2 ......... 76
& 709-717 1111 1.8 WYIKIFIMI 73 27 7 18 2 3 ....L.... 2 ......... 73
& 710-718 1078 1.8 YIKIFIMIV 72 28 8 19 1 3 ...L..... 2 ......... 72
& 711-719 1053 2.1 IKIFIMIVG 68 32 7 24 1 3 ..L...... 2 ......... 68
& 712-720 1033 2.1 KIFIMIVGG 68 32 6 25 2 3 .L....... 2 ......... 68
& 713-721 1020 1.8 IFIMIVGGL 73 27 7 19 1 3 L........ 5 ......... 73
& 714-722 961 2.3 FIMIVGGLI 60 40 19 20 2 4 ........V 19 ......... 60
& 715-723 955 2.4 IMIVGGLIG 59 41 19 20 2 5 .......V. 19 ......... 59
& 716-724 941 2.5 MIVGGLIGL 59 41 18 20 3 6 ......V.. 18 ......... 59
& 717-725 925 2.2 IVGGLIGLR 61 39 20 16 3 5 .....V... 20 ......... 61
& 718-726 931 1.9 VGGLIGLRI 63 37 22 13 2 4 ....V.... 22 ......... 63
& 719-727 893 2.5 GGLIGLRIV 50 50 20 28 3 5 ...V..... 20 ........I 13
& 720-728 897 2.2 GLIGLRIVF 53 47 23 21 3 5 ..V...... 23 .......I. 12
& 721-729 852 3.5 LIGLRIVFT 25 75 23 48 4 7 .V......A 9 ......I.A 9
& 722-730 822 3.6 IGLRIVFTV 24 76 22 48 5 7 V......A. 9 .....I.A. 9
& 723-731 813 3.3 GLRIVFTVL 30 70 28 37 5 8 ......A.. 28 ....I.A.. 9
& 724-732 806 3.3 LRIVFTVLS 30 70 29 36 5 8 .....A... 29 ...I.A... 9
& 725-733 782 3.7 RIVFTVLSI 29 71 24 41 5 10 ....A.... 24 ..I.A.... 8
& 726-734 776 4.1 IVFTVLSIV 27 73 20 48 6 10 ...A..... 20 .I.A..... 8
& 727-735 768 4.3 VFTVLSIVN 26 74 19 49 6 12 ..A...... 19 I.A...... 8
& 728-736 781 3.8 FTVLSIVNR 28 72 26 40 5 10 .A....... 26 .A....... 26
& 729-737 743 3.8 TVLSIVNRV 29 71 25 41 5 10 A........ 25 A........ 25
& 730-738 734 2.6 VLSIVNRVR 62 38 6 29 3 6 ......... 62 ......... 62
& 731-739 730 3.0 LSIVNRVRQ 52 48 9 37 3 6 ......... 52 ......... 52
& 732-740 728 2.4 SIVNRVRQG 60 40 10 28 2 5 ......... 60 ......... 60
& 733-741 727 2.4 IVNRVRQGY 60 40 10 28 2 5 ......... 60 ......... 60
& 734-742 750 1.7 VNRVRQGYS 73 27 10 16 2 4 ......... 73 ......... 73
& 735-743 754 1.5 NRVRQGYSP 76 24 10 12 1 3 ......... 76 ......... 76
& 736-744 750 1.4 RVRQGYSPL 78 22 10 11 1 3 ......... 78 ......... 78
& 737-745 753 1.4 VRQGYSPLS 77 23 10 12 1 3 ......... 77 ......... 77
& 738-746 753 1.7 RQGYSPLSF 70 30 10 18 1 3 ......... 70 ......... 70
& 739-747 752 1.7 QGYSPLSFQ 70 30 10 18 1 3 ......... 70 ......... 70
& 740-748 748 1.4 GYSPLSFQT 78 22 10 11 1 2 ......... 78 ......... 78
& 741-749 729 2.8 YSPLSFQTH 34 66 33 31 2 4 ......... 34 ......... 34
& 742-750 710 3.9 SPLSFQTHL 25 75 23 47 5 9 ......... 25 ......... 25
& 743-751 706 4.0 PLSFQTHLP 24 76 23 47 6 10 ......... 24 ......... 24
+ 744-752 686 5.2 LSFQTHLPA 11 89 10 70 9 16 ........T 9 ......... 11
+ 745-753 670 6.0 SFQTRLPAQ 6 94 5 78 10 21 ....H..TP 4 ....H...R 3
+ 746-754 666 5.9 FQTRLPTPR 7 93 6 76 11 21 ...H..... 4 ...H..AR. 3
+ 747-755 650 5.7 QTRLPTPRG 7 93 7 75 11 20 ..H...... 5 ..H..AR.. 3
+ 748-756 679 5.8 TRLPTPRGP 7 93 7 75 11 20 .H....... 5 .H..AR... 4
+ 749-757 676 5.9 RLPAQRGPD 7 93 7 75 11 21 H..TP.... 5 H...R.... 4
+ 750-758 705 4.8 LPTPRGPDR 15 85 11 66 7 14 ......... 15 ..AR..... 8
& 751-759 719 4.0 PAPRGPDRP 20 80 17 59 4 9 .T....... 15 ..R...... 8
+ 752-760 692 4.5 APRGPDRPE 19 81 14 62 5 11 T........ 11 .R....... 5
& 753-761 704 3.3 PRGPDRPEG 37 63 23 37 3 7 ......... 37 R........ 5
& 754-762 707 2.4 RGPDRPEGI 59 41 15 23 3 6 ......... 59 ......... 59
& 755-763 702 2.8 GPDRPEGIE 54 46 12 31 3 6 ......... 54 ......... 54
& 756-764 708 3.0 PDRPEGIEE 50 50 12 35 3 6 ......... 50 ......... 50
& 757-765 706 3.1 DRPEGIEEE 49 51 10 39 2 6 ......... 49 ......... 49
& 758-766 694 3.1 RPEGIEEEG 49 51 9 40 2 6 ......... 49 ......... 49
& 759-767 697 3.1 PEGIEEEGG 48 52 9 40 2 6 ......... 48 ......... 48
& 760-768 689 3.6 EGIEEEGGE 42 58 8 47 3 8 ......... 42 ......... 42
& 761-769 715 3.7 GIEEEGGER 39 61 9 48 4 8 ......... 39 ......... 39
& 762-770 715 3.8 IEEEGGERD 39 61 9 48 5 9 ......... 39 ......... 39
& 763-771 724 3.6 EEEGGERDR 43 57 8 45 4 9 ......... 43 ......... 43
& 764-772 723 3.7 EEGGERDRD 45 55 6 45 4 9 ......... 45 ......... 45
& 765-773 731 4.2 EGGERDRDR 34 66 14 48 5 11 ......... 34 ......... 34
& 766-774 742 3.9 GGERDRDRS 38 62 15 43 4 10 ......... 38 ......... 38
+ 767-775 736 5.5 GERDRDRSG 16 84 12 64 8 18 ........I 2 ......... 16
+ 768-776 718 6.4 ERDRDRSGP 7 93 6 74 13 25 .......IR 3 ......... 7
+ 769-777 717 6.2 RDRDRSGPL 8 92 6 74 12 23 ......IR. 5 ......... 8
+ 770-778 716 6.2 DRDRSGPLV 9 91 6 74 10 22 .....IR.. 5 ......... 9
+ 771-779 714 6.7 RDRSGPLVD 6 94 4 76 14 28 ....IR..N <1 ........N 4
+ 772-780 714 6.6 DRSGPLVDG 7 93 4 76 13 27 ...IR..N. 1 .......N. 4
+ 773-781 716 6.6 RSGPLVDGF 7 93 5 74 14 27 ..IR..N.S <1 ......N.. 3
+ 774-782 716 6.1 SGPLVDGFL 9 91 7 73 11 22 .IR..N.S. <1 .....N... 5
+ 775-783 708 6.3 GPLVDGFLA 8 92 6 74 12 24 IR..N.S.. <1 ....N.... 5
+ 776-784 711 5.9 PLVDGFLAI 8 92 7 76 9 19 R..N.S..L <1 ...N....L 3
+ 777-785 725 5.4 LVDGFLAII 18 82 8 67 7 16 ..N.S..L. <1 ..N....L. 3
+ 778-786 726 5.2 VDGFLAIIW 18 82 8 68 7 15 .N.S..L.. <1 .N....L.. 8
+ 779-787 724 5.6 DGFLAIIWV 17 83 7 69 7 17 N.S..L..D <1 N....L... 5
& 780-788 736 4.6 GFLAIIWVD 24 76 9 62 4 10 .S..L..D. <1 ....L.... 9
& 781-789 735 4.5 FLAIIWVDL 24 76 10 62 4 10 S..L..D.. <1 ...L..... 10
& 782-790 736 4.2 LAIIWVDLR 26 74 13 57 4 9 ..L..D... 11 ..L...... 13
& 783-791 727 4.4 AIIWVDLRS 25 75 11 60 5 10 .L..D.... 11 .L....... 11
& 784-792 736 3.8 IIWVDLRSL 26 74 20 51 3 7 L..D..... 14 L........ 20
& 785-793 728 3.7 IWVDLRSLC 32 68 17 48 3 7 ..D...... 17 ......... 32
& 786-794 729 2.9 WVDLRSLCL 37 63 23 38 2 5 .D....... 23 ......... 37
& 787-795 730 3.0 VDLRSLCLF 36 64 22 40 2 5 D........ 22 ......... 36
& 788-796 727 2.4 DLRSLCLFS 56 44 18 24 2 5 ......... 56 ......... 56
& 789-797 725 2.4 LRSLCLFSY 56 44 18 24 2 5 ......... 56 ......... 56
& 790-798 720 2.6 RSLCLFSYH 55 45 18 25 2 6 ......... 55 ......... 55
& 791-799 716 2.8 SLCLFSYHR 54 46 17 25 4 7 ......... 54 ......... 54
& 792-800 723 2.5 LCLFSYHRL 56 44 17 24 3 6 ......... 56 ......... 56
& 793-801 718 2.7 CLFSYHRLR 54 46 17 27 3 7 ......... 54 ......... 54
& 794-802 729 2.0 LFSYHRLRD 71 29 8 18 2 5 ......... 71 ......... 71
& 795-803 733 2.1 FSYHRLRDL 70 30 8 20 2 5 ......... 70 ......... 70
& 796-804 733 2.3 SYHRLRDLL 68 32 8 22 2 5 ......... 68 ......... 68
& 797-805 745 1.6 YHRLRDLLL 79 21 2 17 2 4 ......... 79 ......... 79
& 798-806 743 1.8 HRLRDLLLI 77 23 3 18 2 5 ......... 77 ........L <1
& 799-807 732 2.2 RLRDLLLIV 70 30 8 20 2 6 ......... 70 .......LA 0
& 800-808 720 2.6 LRDLLLIVT 53 48 21 23 3 7 ......... 53 ......LAA 0
& 801-809 719 2.6 RDLLLIVTR 53 47 21 23 3 7 ......... 53 .....LAA. 0
& 802-810 713 3.1 DLLLIVTRI 47 53 19 31 3 8 ......... 47 ....LAA.. 0
& 803-811 707 3.3 LLLIVTRIV 43 57 18 35 4 8 ......... 43 ...LAA... 0
& 804-812 700 3.5 LLIVTRIVE 42 58 16 38 4 9 ......... 42 ..LAA.... 0
& 805-813 693 3.8 LIVTRIVEL 39 61 16 41 5 10 ......... 39 .LAA..... 0
& 806-814 696 3.7 IVTRIVELL 40 60 16 39 5 10 ......... 40 LAA...... 0
& 807-815 701 3.7 VTRIVELLG 39 61 17 40 4 9 ......... 39 AA....... 6
& 808-816 704 3.4 TRIVELLGR 41 59 24 30 5 9 ......... 41 A........ 24
& 809-817 720 2.6 RIVELLGRR 65 35 5 26 4 8 ......... 65 ......... 65
& 810-818 712 2.6 IVELLGRRG 64 36 5 27 4 8 ......... 64 ......... 64
& 811-819 723 2.1 VELLGRRGW 71 29 5 21 3 6 ......... 71 ......... 71
& 812-820 720 2.2 ELLGRRGWE 68 32 6 23 3 5 ......... 68 ......... 68
& 813-821 896 3.6 LLGRRGWEA 33 67 20 44 3 7 ......... 33 ........I 20
& 814-822 913 3.2 LGRRGWEAL 36 64 24 38 2 5 ......... 36 .......I. 24
& 815-823 910 3.2 GRRGWEALK 36 64 24 38 3 6 ......... 36 ......I.. 24
& 816-824 910 3.1 RRGWEALKY 36 64 24 38 3 6 ......... 36 .....I... 24
& 817-825 910 3.7 RGWEALKYW 27 73 22 49 2 6 ......... 27 ....I...C 2
& 818-826 910 3.8 GWEALKYWW 26 74 23 49 2 6 ......... 26 ...I...C. 2
& 819-827 911 4.1 WEALKYWWN 25 75 20 53 2 7 ......... 25 ..I...C.. 2
& 820-828 911 4.2 EALKYWWNL 25 75 19 53 3 7 ......... 25 .I...C... 2
& 821-829 911 4.0 ALKYWWNLL 26 74 20 51 3 7 ......... 26 I...C.... 2
& 822-830 920 2.4 LKYWWNLLQ 62 38 7 30 2 4 ......... 62 ...C..... 7
& 823-831 919 2.5 KYWWNLLQY 61 39 7 30 2 4 ......... 61 ..C...... 7
& 824-832 924 2.3 YWWNLLQYW 63 37 7 29 1 3 ......... 63 .C....... 7
& 825-833 907 3.1 WWNLLQYWS 50 50 7 40 2 5 ......... 50 C........ 5
& 826-834 915 2.4 WNLLQYWSQ 63 37 8 27 2 5 ......... 63 ......... 63
& 827-835 918 2.2 NLLQYWSQE 65 35 8 25 2 4 ......... 65 ......... 65
& 828-836 916 1.9 LLQYWSQEL 70 30 8 20 2 3 ......... 70 ......... 70
& 829-837 904 2.1 LQYWSQELK 66 34 8 24 2 4 ......... 66 ......... 66
& 830-838 896 2.9 QYWSQELKN 52 48 8 37 3 5 ......... 52 ......... 52
& 831-839 860 2.6 YWSQELKNS 56 44 9 33 2 4 ......... 56 ......... 56
& 832-840 858 2.6 WSQELKNSA 55 45 9 34 2 4 ......... 55 ......... 55
& 833-841 838 3.2 SQELKNSAV 45 55 11 42 2 6 ......... 45 ......... 45
& 834-842 837 2.6 QELKNSAVS 54 46 14 30 2 5 ......... 54 ......... 54
& 835-843 841 2.6 ELKNSAVSL 55 45 15 29 2 4 ......... 55 ......... 55
& 836-844 817 3.5 LKNSAVSLL 39 61 15 44 3 6 ......... 39 ......... 39
& 837-845 817 3.6 KNSAVSLLN 39 61 14 43 4 8 ......... 39 ........D 1
& 838-846 813 4.0 NSAVSLLNA 34 66 12 51 3 9 ......... 34 .......D. <1
& 839-847 805 3.9 SAVSLLNAT 38 62 11 47 4 10 ......... 38 ......D.. <1
& 840-848 808 3.9 AVSLLNATA 38 62 11 47 4 10 ......... 38 .....D... <1
& 841-849 804 3.9 VSLLNATAI 38 62 11 46 4 10 ......... 38 ....D...V 0
& 842-850 825 3.6 SLLNATAIA 47 53 8 41 4 10 ......... 47 ...D...VT 0
& 843-851 833 3.5 LLNATAIAV 49 51 8 40 3 8 ......... 49 ..D...VT. 0
& 844-852 830 3.7 LNATAIAVA 47 53 8 42 4 9 ......... 47 .D...VT.. 0
& 845-853 847 2.9 NATAIAVAE 56 44 12 29 3 7 ......... 56 D...VT..G 0
& 846-854 855 2.8 ATAIAVAEG 56 44 13 29 3 6 ......... 56 ...VT..G. 0
& 847-855 866 2.0 TAIAVAEGT 63 37 21 14 3 5 ......... 63 ..VT..G.. 0
& 848-856 886 1.1 AIAVAEGTD 85 15 4 9 2 3 ......... 85 .VT..G... 0
& 849-857 885 1.1 IAVAEGTDR 84 16 4 10 2 3 ......... 84 VT..G.... 0
& 850-858 849 2.2 AVAEGTDRI 45 55 38 15 2 5 ........V 38 T..G..... 0
& 851-859 850 2.1 VAEGTDRII 45 55 39 13 2 4 .......V. 39 ..G.....L 0
& 852-860 845 2.2 AEGTDRIIE 43 57 40 15 3 5 ......V.. 40 .G.....L. 0
& 853-861 810 3.4 EGTDRIIEV 28 72 24 44 3 7 .....V... 24 G.....L.. 0
+ 854-862 789 4.9 GTDRVIEVV 15 85 12 68 5 12 ......... 15 ....IL..L <1
+ 855-863 787 5.0 TDRVIEVVQ 14 86 12 67 6 13 ......... 14 ...IL..LR 0
+ 856-864 781 5.3 DRVIEVVQR 13 87 12 67 7 15 ........G 1 ..IL..LR. 0
+ 857-865 766 6.5 RIIEVLQRA 7 93 6 75 13 24 .V...V.G. <1 ..L...R.I 0
+ 858-866 763 7.3 IIEVLQRAG 4 96 3 74 18 34 V...V.G.C <1 .L...R.IW 0
+ 859-867 496 6.7 IEVLQRAGR 7 93 5 67 21 36 ...V.G.C. 1 L...R.IW. 0
+ 860-868 494 6.6 EVLQRAGRA 7 93 5 67 20 35 ..V.G.C.. 1 ...R.IW.. 0
+ 861-869 491 6.7 VLQRAGRAI 7 93 5 67 20 37 .V.G.C... 1 ..R.IW..F 0
+ 862-870 506 6.4 LQRAGRAIL 8 92 5 70 17 32 V.G.C...R 1 .R.IW..F. 0
+ 863-871 514 6.0 QRAGRAILH 8 92 8 70 14 26 .G.C...R. 1 R.IW..F.. 0
+ 864-872 512 6.0 RAGRAILHI 9 91 8 70 14 26 G.C...R.. 1 .IW..F... 0
+ 865-873 517 5.8 AGRAILHIP 9 91 8 72 11 23 .C...R... 1 IW..F.... 0
+ 866-874 526 5.8 CRAILHIPT 8 92 6 76 10 21 ....R...R 5 W..F....R 0
& 867-875 529 4.3 RAILHIPTR 26 74 13 57 5 11 ...R...R. 6 ..F....R. 2
& 868-876 529 4.3 AILHIPTRI 25 75 13 57 5 12 ..R...R.. 6 .F....R.. 2
& 869-877 534 4.2 ILHIPTRIR 26 74 13 56 5 11 .R...R... 6 F....R... 1
& 870-878 536 3.6 LHIPTRIRQ 28 72 19 50 3 7 R...R.... 6 ....R.... 19
& 871-879 544 2.5 HIPTRIRQG 36 64 35 28 1 4 ...R..... 35 ...R..... 35
& 872-880 552 2.5 IPTRIRQGL 39 61 30 30 2 4 ..R...... 30 ..R...... 30
& 873-881 556 2.5 PTRIRQGLE 40 60 29 29 2 4 .R....... 29 .R....... 29
& 874-882 554 2.5 TRIRQGLER 39 61 30 29 2 4 R........ 30 R........ 30
& 875-883 551 1.9 RIRQGLERA 68 32 12 17 3 5 ........I 2 ......... 68
& 876-884 551 2.0 IRQGLERAL 68 32 12 17 3 5 .......I. 2 ......... 68
& 877-885 547 2.2 RQGLERALL 65 35 11 21 3 6 ......I.. 2 ......... 65
Nef + 1-9 3651 6.0 MGGKWKRSV 11 89 11 72 5 11 ......S.. 11 ......... 11
+ 2-10 3605 7.1 GGKWKSSVV 8 92 6 76 10 18 ........I 3 .....R..P 6
+ 3-11 3590 7.1 GKWKSSVVG 8 92 6 75 11 19 .......I. 3 ....R..P. 6
+ 4-12 3603 7.1 KWKSSVVGW 9 91 6 75 10 18 ......I.. 3 ...R..P.. 6
+ 5-13 3592 7.5 WKSSVVGWP 9 91 6 72 13 22 .....I... 3 ..R..P... <1
+ 6-14 3572 8.1 KSSVVGWPA 8 92 4 70 17 27 ....I...T 1 .R..P.... <1
+ 7-15 3555 8.5 SSVVGWPAV 6 94 2 72 19 30 ...I...T. 1 R..P....I <1
+ 8-16 3589 8.0 SVVGWPAVR 8 92 3 74 15 25 ..I...T.. 1 ..P....I. <1
+ 9-17 4047 8.3 VVGWPAVRE 6 94 3 76 15 25 .I...T... 1 .P....I.. <1
+ 10-18 4236 7.3 VGWPAVRER 9 91 4 77 10 18 I...T.... 1 P....I... 1
+ 11-19 4443 6.0 GWPAVRERM 19 81 7 68 6 11 ...T..... 7 ....I...T 0
+ 12-20 4521 6.5 WPAVRERMR 12 88 7 74 7 13 ..T...... 7 ...I...T. 0
+ 13-21 4495 6.9 PAVRERMRR 11 89 6 74 8 15 .T....... 6 ..I...T.. 0
+ 14-22 4500 6.5 AVRERMRRA 11 89 9 72 8 13 T........ 9 .I...T... 0
& 15-23 1845 5.7 VRERMRRAE 21 79 8 62 9 15 ........- 0 I...T.... 0
& 16-24 1860 5.3 RERMRRAEP 29 71 12 50 8 15 .......-- 0 ...T..... <1
+ 17-25 1613 6.4 ERMRRAEPA 18 82 8 60 14 22 ......--- 0 ..T...... <1
+ 18-26 1283 7.0 RMRRAEPAA 12 88 9 59 20 31 .....---- 0 .T....... 0
+ 19-27 575 7.6 MRRAEPAAE 3 97 3 57 38 51 ....----- 0 T.......D 0
+ 20-28 418 7.6 RRAPAAEAA 3 97 3 48 46 61 ...------ 0 ...EP.ADG <1
+ 21-29 323 7.3 QTEPAAERT 4 96 2 42 52 66 RA------- 0 RA....DGR <1
+ 22-30 243 7.1 TDPAADVRR 3 97 2 42 53 68 A-------- 0 AE....G.A 0
+ 23-31 244 7.1 EPAAEERRE 2 98 2 43 52 67 --------. 0 ....DG.A. <1
+ 24-32 244 7.0 PAEEERREP 2 98 2 48 48 64 -------.. 0 ..ADG.A.. <1
+ 25-33 245 7.0 AAEERREPA 2 98 2 47 48 64 ------... 0 ..DG.A... <1
+ 26-34 247 6.8 EEERREPAA 5 95 4 47 45 60 -----.... 0 ADG.A.... <1
+ 27-35 250 6.9 EERREPAAV 6 94 4 44 47 62 ----....D 0 DG.A....A 0
+ 28-36 252 6.7 ERREPAAVG 6 94 4 50 40 56 ---....DR 0 G.A....A. 0
+ 29-37 256 5.9 RTEPAADGV 10 90 6 54 30 42 --.....R. 0 .A....A.. 3
+ 30-38 257 5.0 AEPAADGVG 13 87 10 59 18 28 -.....R.. 0 .....A... 3
& 31-39 4585 3.3 EPAADGVGA 40 60 27 30 3 6 .....R... <1 ....A.... 4
& 32-40 4576 3.7 PAADGVGAV 26 74 20 51 3 5 ....R...A <1 ...A..... 3
& 33-41 4582 3.4 AADGVGAVS 26 74 22 50 2 3 ...R...A. <1 ..A...... 4
& 34-42 4578 3.6 ADGVGAVSR 26 74 21 51 2 4 ..R...A.. <1 .A....... 4
& 35-43 4570 3.6 DGVGAVSRD 26 74 21 51 2 4 .R...A... <1 A........ 4
& 36-44 4628 2.0 GVGAVSRDL 54 46 31 14 1 2 R...A.... <1 ......... 54
& 37-45 4604 2.6 VGAVSRDLE 48 52 28 23 1 3 ...A..... 28 ......... 48
& 38-46 4555 4.0 GAVSRDLEK 33 67 18 47 2 4 ..A...... 18 ......... 33
& 39-47 4510 4.4 AVSRDLEKH 31 69 14 51 3 6 .A....... 14 ......... 31
& 40-48 4508 4.1 VSRDLEKHG 32 68 15 50 3 5 A........ 15 ......... 32
& 41-49 4555 3.3 SRDLEKHGA 48 52 16 34 2 4 ......... 48 ......... 48
& 42-50 4539 4.0 RDLEKHGAI 42 58 11 44 3 6 ......... 42 ......... 42
& 43-51 4553 3.8 DLEKHGAIT 43 57 11 43 3 5 ......... 43 ......... 43
& 44-52 4495 4.4 LEKHGAITS 40 60 11 46 3 6 ......... 40 ......... 40
& 45-53 4485 4.7 EKHGAITSS 39 61 10 47 4 8 ......... 39 ......... 39
& 46-54 4499 4.1 KHGAITSSN 42 58 12 43 3 6 ......... 42 ......... 42
& 47-55 4466 3.4 HGAITSSNT 53 47 8 37 2 4 ......... 53 ......... 53
& 48-56 4265 3.4 GAITSSNTA 51 49 8 38 2 4 ......... 51 ......... 51
& 49-57 4189 4.5 AITSSNTAA 40 60 7 49 4 7 ......... 40 ......... 40
& 50-58 4170 5.3 ITSSNTAAT 28 72 11 56 5 9 ......... 28 ........N 11
& 51-59 4185 4.6 TSSNTAATN 30 70 14 52 3 7 ......... 30 .......N. 14
& 52-60 4177 4.9 SSNTAATNA 29 71 13 54 5 8 ......... 29 ......N.P 1
& 53-61 4182 5.2 SNTAATNAD 26 74 9 60 5 8 ........A 4 .....N.P. 2
& 54-62 4212 5.1 NTAATNADC 27 73 9 59 5 9 .......A. 4 ....N.P.. 2
& 55-63 4212 5.1 TAATNADCA 27 73 9 59 5 9 ......A.. 4 ...N.P... 2
& 56-64 4214 5.2 AATNADCAW 27 73 9 59 5 9 .....A... 4 ..N.P.... 2
& 57-65 4277 4.8 ATNADCAWL 28 72 11 57 4 8 ....A.... 4 .N.P..... 1
& 58-66 4519 4.0 TNADCAWLE 30 70 17 50 3 6 ...A..... 6 N.P...... 2
& 59-67 4574 3.2 NADCAWLEA 49 51 23 25 3 5 ..A...... 23 .P....... 4
& 60-68 4561 3.2 ADCAWLEAQ 48 52 24 26 2 5 .A....... 24 P........ 4
& 61-69 4558 3.1 DCAWLEAQE 49 51 23 25 2 4 A........ 23 ......... 49
& 62-70 4527 3.0 CAWLEAQEE 57 43 15 25 2 4 ......... 57 ......... 57
& 63-71 1150 4.6 AWLEAQEEE 24 76 13 58 4 10 ........- 0 ........G 6
& 64-72 1145 5.0 WLEAQEEEE 23 77 7 64 6 12 .......-. 0 .......GD 2
& 65-73 1144 5.1 LEAQEEEEE 24 76 7 62 7 14 ......-.. 0 ......GD. 2
& 66-74 1154 4.7 EAQEEEEEV 28 72 8 58 6 12 .....-... 0 .....GD.. 2
& 67-75 1159 4.3 AQEEEEEVG 34 66 8 53 6 10 ....-.... 0 ....GD... 2
& 68-76 1159 4.3 QEEEEEVGF 34 66 8 52 6 10 ...-..... 0 ...GD.... 2
& 69-77 1160 4.2 EEEEEVGFP 34 66 8 53 5 10 ..-...... 0 ..GD..... 2
& 70-78 1165 3.6 EEEEVGFPV 43 57 9 43 4 8 .-....... 0 .GD...... 2
& 71-79 1153 3.9 EEEVGFPVR 39 61 10 47 5 8 -.......T 0 GD....... 3
& 72-80 4547 1.9 EEVGFPVRP 71 29 12 17 1 2 .......T. 4 D........ 1
& 73-81 4572 1.6 EVGFPVRPQ 74 26 12 13 <1 2 ......T.. 4 ......... 74
& 74-82 4582 1.2 VGFPVRPQV 80 20 12 8 <1 2 .....T... 4 ......... 80
& 75-83 4581 1.2 GFPVRPQVP 80 20 12 7 <1 1 ....T.... 4 ......... 80
& 76-84 4562 1.3 FPVRPQVPL 78 22 12 9 <1 1 ...T..... 4 ......... 78
& 77-85 4513 1.4 PVRPQVPLR 78 22 12 9 <1 2 ..T...... 4 ......... 78
& 78-86 4511 1.4 VRPQVPLRP 78 22 12 9 <1 2 .T....... 4 ......... 78
& 79-87 4510 1.3 RPQVPLRPM 79 21 12 9 <1 2 T........ 4 ......... 79
# 80-88 4570 0.7 PQVPLRPMT 93 7 1 5 <1 1 ......... 93 ......... 93
& 81-89 4530 1.4 QVPLRPMTY 80 20 9 11 <1 2 ......... 80 ......... 80
& 82-90 4513 1.6 VPLRPMTYK 78 22 9 12 1 2 ......... 78 ......... 78
& 83-91 4467 2.6 PLRPMTYKG 42 58 35 21 1 3 ........A 35 ......... 42
& 84-92 4472 2.7 LRPMTYKGA 42 58 34 22 1 3 .......A. 34 ......... 42
& 85-93 4419 3.8 RPMTYKGAL 30 70 22 46 2 4 ......A.V 22 ......... 30
& 86-94 4422 3.8 PMTYKGALD 30 70 22 46 2 5 .....A.V. 22 ......... 30
& 87-95 4405 4.1 MTYKGALDL 30 70 19 48 3 5 ....A.V.. 19 ......... 30
& 88-96 4401 4.2 TYKGALDLS 30 70 19 48 3 6 ...A.V... 19 ......... 30
& 89-97 4405 4.1 YKGALDLSH 30 70 19 48 3 6 ..A.V.... 19 ......... 30
& 90-98 4429 3.8 KGALDLSHF 34 66 20 43 2 5 .A.V..... 20 ......... 34
& 91-99 4412 3.7 GALDLSHFL 34 66 20 44 2 4 A.V...... 20 ......... 34
& 92-100 4420 3.3 ALDLSHFLK 36 64 27 34 2 4 .V....... 27 ......... 36
& 93-101 4414 3.5 LDLSHFLKE 36 64 27 35 2 4 V........ 27 ......... 36
& 94-102 4488 2.3 DLSHFLKEK 67 33 9 23 1 3 ......... 67 ......... 67
& 95-103 4491 2.3 LSHFLKEKG 68 32 9 22 1 2 ......... 68 ......... 68
& 96-104 4519 2.0 SHFLKEKGG 72 28 9 18 <1 2 ......... 72 ......... 72
& 97-105 4521 1.9 HFLKEKGGL 72 28 9 17 <1 2 ......... 72 ......... 72
& 98-106 4511 2.0 FLKEKGGLE 69 31 9 21 <1 2 ......... 69 ......... 69
& 99-107 4511 2.0 LKEKGGLEG 70 30 9 20 <1 2 ......... 70 ......... 70
& 100-108 4506 2.2 KEKGGLEGL 68 32 9 22 1 2 ......... 68 ......... 68
& 101-109 4482 2.6 EKGGLEGLI 51 49 25 23 1 3 ......... 51 ........V 25
& 102-110 4449 3.8 KGGLEGLIY 31 69 17 51 2 4 ........H 17 .......VH 7
& 103-111 4474 3.3 GGLEGLIYS 32 68 18 48 2 3 .......H. 18 ......VH. 8
& 104-112 4470 3.8 GLEGLIYSQ 28 72 17 53 2 4 ......H.. 17 .....VH.. 8
+ 105-113 4403 4.9 LEGLIYSQK 18 82 11 68 3 6 .....H..R 6 ....VH..Q <1
+ 106-114 4404 4.9 EGLIYSQKR 17 83 11 68 3 6 ....H..R. 6 ...VH..Q. <1
+ 107-115 4408 4.8 GLIYSQKRQ 19 81 11 66 3 6 ...H..R.. 6 ..VH..Q.. <1
+ 108-116 4384 5.3 LIYSQKRQD 17 83 9 70 4 7 ..H..R... 5 .VH..Q... <1
+ 109-117 4391 5.1 IYSQKRQDI 18 82 10 69 3 6 .H..R.... 5 VH..Q.... <1
& 110-118 4431 4.2 YSQKRQDIL 27 73 13 58 2 4 H..R..... 8 H..Q..... 2
& 111-119 4470 2.9 SQKRQDILD 48 52 17 34 2 3 ..R...... 17 ..Q...... 8
& 112-120 4470 2.9 QKRQDILDL 48 52 17 34 2 3 .R....... 17 .Q....... 8
& 113-121 4470 2.5 KRQDILDLW 48 52 17 34 1 2 R........ 17 Q........ 9
& 114-122 4456 2.2 RQDILDLWV 55 45 18 26 1 2 ........I 18 ........I 18
& 115-123 4456 2.4 QDILDLWVY 53 47 17 28 1 2 .......I. 17 .......I. 17
& 116-124 4450 2.7 DILDLWVYH 45 55 17 37 1 2 ......I.. 17 ......I.. 17
& 117-125 4476 2.0 ILDLWVYHT 58 42 20 21 <1 2 .....I... 20 .....I... 20
& 118-126 4477 2.0 LDLWVYHTQ 58 42 20 21 <1 2 ....I.... 20 ....I.... 20
& 119-127 4477 2.0 DLWVYHTQG 58 42 20 21 <1 2 ...I..... 20 ...I..... 20
& 120-128 4458 2.6 LWVYHTQGY 46 54 18 35 1 2 ..I...... 18 ..I...... 18
& 121-129 4449 2.6 WVYHTQGYF 46 54 18 35 1 2 .I....... 18 .I....... 18
& 122-130 4452 2.6 VYHTQGYFP 46 54 18 35 1 2 I........ 18 I........ 18
& 123-131 4540 1.8 YHTQGYFPD 65 35 14 20 <1 2 ......... 65 ......... 65
& 124-132 4552 1.7 HTQGYFPDW 66 34 14 18 <1 1 ......... 66 ......... 66
& 125-133 4552 1.5 TQGYFPDWQ 75 25 13 11 <1 1 ......... 75 ......... 75
& 126-134 4550 1.8 QGYFPDWQN 73 27 12 14 <1 2 ......... 73 ......... 73
& 127-135 4551 1.7 GYFPDWQNY 74 26 12 14 <1 2 ......... 74 ......... 74
& 128-136 4551 1.7 YFPDWQNYT 74 26 12 14 <1 2 ......... 74 ......... 74
& 129-137 4557 1.4 FPDWQNYTP 82 18 5 13 <1 2 ......... 82 ......... 82
& 130-138 4557 1.4 PDWQNYTPG 82 18 5 13 <1 2 ......... 82 ......... 82
& 131-139 4555 1.4 DWQNYTPGP 82 18 5 12 <1 2 ......... 82 ......... 82
& 132-140 4544 1.4 WQNYTPGPG 82 18 5 13 <1 2 ......... 82 ......... 82
& 133-141 4435 3.0 QNYTPGPGI 33 67 30 36 1 3 ........V 17 ......... 33
& 134-142 4451 2.6 NYTPGPGIR 38 62 31 30 1 2 .......V. 19 ......... 38
& 135-143 4427 3.0 YTPGPGIRY 37 63 17 44 1 3 ......V.. 17 ........F 1
& 136-144 4427 3.0 TPGPGIRYP 37 63 18 44 1 3 .....V... 18 .......F. 1
& 137-145 4418 3.0 PGPGIRYPL 37 63 17 44 1 3 ....V.... 17 ......F.. 1
& 138-146 4423 3.0 GPGIRYPLT 36 64 18 45 1 2 ...V..... 17 .....F..C <1
& 139-147 4419 3.3 PGIRYPLTF 34 66 18 46 1 3 ..V...... 16 ....F..C. <1
& 140-148 4419 3.3 GIRYPLTFG 34 66 18 46 2 3 .V....... 16 ...F..C.. <1
& 141-149 4416 3.3 IRYPLTFGW 34 66 18 46 1 3 V........ 16 ..F..C... <1
& 142-150 4522 2.0 RYPLTFGWC 62 38 23 15 <1 2 ......... 62 .F..C.... <1
& 143-151 4520 2.2 YPLTFGWCF 58 42 22 19 <1 2 ........Y 4 F..C..... <1
& 144-152 4549 1.5 PLTFGWCFK 79 21 6 14 <1 2 .......Y. 4 ..C...... 6
& 145-153 4549 1.5 LTFGWCFKL 79 21 6 14 <1 2 ......Y.. 4 .C....... 6
& 146-154 4556 1.5 TFGWCFKLV 79 21 6 14 <1 2 .....Y... 4 C........ 6
& 147-155 4623 1.2 FGWCFKLVP 85 15 4 10 <1 1 ....Y.... 4 ......... 85
& 148-156 4606 1.5 GWCFKLVPV 78 22 8 13 <1 2 ...Y..... 5 ........M 1
& 149-157 4567 2.5 WCFKLVPVE 52 48 24 22 1 2 ..Y...... 3 .......M. <1
& 150-158 4532 3.0 CFKLVPVEP 47 53 23 28 2 3 .Y....... 3 ......M.. <1
& 151-159 4494 4.0 FKLVPVEPE 38 62 12 47 3 5 Y.......D 1 .....M... <1
& 152-160 4455 4.9 KLVPVEPEK 26 74 9 61 4 8 .......D. 7 ....M.... <1
+ 153-161 4334 5.4 LVPVEPEKV 18 82 10 68 4 8 ......D.I 1 ...M..... <1
+ 154-162 4329 5.4 VPVEPEKVE 18 82 9 68 5 9 .....D.I. 1 ..M...... <1
+ 155-163 4266 5.8 PVEPEKVEE 17 83 10 67 6 11 ....D.I.. 1 .M....... <1
+ 156-164 4249 6.0 VEPEKVEEA 16 84 9 67 8 13 ...D.I... <1 M........ <1
+ 157-165 4232 6.4 EPEKVEEAN 12 88 7 73 8 13 ..D.I.... <1 ......... 12
+ 158-166 4207 6.5 PEKVEEANE 12 88 10 70 8 14 .D.I....K <1 ......... 12
+ 159-167 4210 6.2 EKVEEANEG 14 86 10 69 8 13 D.I....K. <1 ......... 14
& 160-168 4229 5.5 KVEEANEGE 24 76 7 63 6 10 .I....K.. 1 ......... 24
& 161-169 4228 4.9 VEEANEGEN 30 70 10 56 5 8 I....K... 3 ......... 30
& 162-170 4276 4.7 EEANEGENN 33 67 11 51 5 9 ....K...T 1 ......... 33
& 163-171 4242 5.8 EANEGENNS 20 80 9 64 7 12 ...K...T. 1 ......... 20
& 164-172 4297 5.2 ANEGENNSL 27 73 14 53 6 10 ..K...T.. 1 ......... 27
& 165-173 4331 4.9 NEGENNSLL 27 73 15 53 5 9 .K...T... 1 ......... 27
& 166-174 4366 4.4 EGENNSLLH 30 70 22 44 4 7 K...T.... 1 ......... 30
& 167-175 4483 3.3 GENNSLLHP 36 64 34 27 3 5 ...T..... 2 ......... 36
& 168-176 4438 4.3 ENNSLLHPM 26 74 24 47 3 6 ..T.....V 1 ........L 1
& 169-177 4428 5.1 NNSLLHPMS 24 76 16 56 4 8 .T.....V. 1 .......L. 1
+ 170-178 4427 5.4 NCLLHPMSQ 16 84 15 65 4 8 TS....V.L 1 .S....L.. <1
+ 171-179 4440 5.0 SLLHPMSLH 17 83 17 63 3 6 .....V... 2 .....L.Q. <1
& 172-180 4500 3.7 LLHPMSQHG 28 72 25 46 1 3 ....V.L.. 3 ....L.... 1
& 173-181 4468 4.3 LHPMSQHGM 23 77 23 53 2 5 ...V.L... 3 ...L..... 1
+ 174-182 4450 5.0 HPMSQHGMD 20 80 12 65 3 6 ..V.L.... 2 ..L...... <1
+ 175-183 4454 5.0 PMSQHGMDD 20 80 12 65 3 6 .V.L..... 2 .L....... 1
+ 176-184 4413 5.5 MSQHGMDDP 19 81 9 68 4 8 V.L...... 2 L........ <1
& 177-185 4490 4.5 SQHGMDDPE 23 77 14 59 3 6 .L....... 14 ......... 23
& 178-186 4456 4.9 QHGMDDPEK 21 79 9 66 4 7 L.......R 8 ......... 21
& 179-187 4485 4.3 HGMDDPEKE 28 72 17 51 3 6 .......R. 17 ......... 28
& 180-188 4486 4.3 GMDDPEKEV 28 72 17 51 3 6 ......R.. 17 ......... 28
& 181-189 4484 4.2 MDDPEKEVL 28 72 17 51 3 6 .....R... 17 ......... 28
+ 182-190 4467 5.5 DDPEKEVLV 14 86 8 74 5 9 ....R...E 5 ......... 14
+ 183-191 4484 4.8 DPEKEVLVW 19 81 12 65 4 7 ...R...E. 6 ......... 19
+ 184-192 4457 5.3 PEKEVLVWK 14 86 10 71 5 9 ..R...E.R 5 ......... 14
+ 185-193 4502 4.9 EKEVLVWKF 15 85 10 71 3 6 .R...E.R. 5 ......... 15
+ 186-194 4504 4.8 KEVLVWKFD 15 85 10 71 3 5 R...E.R.. 5 ......... 15
& 187-195 4563 3.6 EVLVWKFDS 26 74 20 52 3 4 ...E.R... 12 ......... 26
+ 188-196 4480 4.8 VLVWKFDSR 17 83 15 64 4 7 ..E.R.... 11 ......... 17
+ 189-197 4479 4.7 LVWKFDSRL 17 83 15 64 3 6 .E.R..... 11 ......... 17
+ 190-198 4476 4.8 VWKFDSRLA 17 83 15 64 4 7 E.R...... 11 ......... 17
& 191-199 4470 3.7 WKFDSRLAF 39 61 22 36 3 5 .R....... 22 ......... 39
& 192-200 4439 4.3 KFDSRLAFH 35 65 20 41 4 7 R........ 20 ......... 35
& 193-201 4466 3.5 FDSRLAFHH 55 45 5 37 3 6 ......... 55 ......... 55
& 194-202 4389 4.7 DSRLAFHHM 33 67 17 44 5 9 ........V 17 ........V 17
& 195-203 4389 4.7 SRLAFHHMA 33 67 17 44 5 9 .......V. 17 .......V. 17
& 196-204 4379 4.9 RLAFHHMAR 32 68 17 46 5 9 ......V.. 17 ......V.. 17
& 197-205 4427 4.2 LAFHHMARE 34 66 20 42 4 7 .....V... 20 .....V... 20
+ 198-206 4381 5.4 AFHHMAREL 19 81 12 63 6 10 ....V.... 12 ....V...K 4
+ 199-207 4372 5.5 FHHMARELH 19 81 12 63 6 10 ...V..... 12 ...V...K. 4
& 200-208 4397 5.1 HHMARELHP 20 80 13 62 4 8 ..V...... 12 ..V...K.. 5
& 201-209 4416 4.4 HMARELHPE 26 74 15 56 4 6 .V....... 15 .V...K... 6
& 202-210 4405 4.9 MARELHPEY 24 76 14 58 5 8 V........ 14 V...K.... 5
& 203-211 4477 3.8 ARELHPEYY 40 60 14 42 3 6 ........F 5 ...K....F 5
& 204-212 4462 3.9 RELHPEYYK 39 61 14 43 4 6 .......F. 5 ..K....F. 5
& 205-213 4422 4.6 ELHPEYYKD 23 77 18 55 4 7 ......F.N 3 .K....F.N 3
& 206-214 3814 4.2 LHPEYYKDC 25 75 15 56 3 5 .....F.N. 3 K....F.N. 3
^All percentages are shown to the nearest whole number. a Amino acid number at the start and end of the nonamer position in the protein 
alignment. The symbols #, & and + denote the highly conserved, mixed-variable and highly diverse nonamer positions, respectively (see Figure 3
 for definitions). Positions with less than 100 sequences are denoted with *. b Total number of protein sequences analysed at the respective 
nonamer position; the differences between nonamer positions was due to the inclusion of both partial and full-length sequences in the 
alignments. c Shannon nonamer entropy (see Figure 2 for details). d The index nonamer is the most prevalent sequence at the given aligned 
nonamer position. e Variants differ by one or more amino acids from the index sequence. f The major variant is the most common variant 
sequence at the position. g Minor variants are multiple different sequences, each occurring more than once and with an incidence less than or 
occasionally  equal to the major. h Unique variants are those that occur only once in the alignment. i Nonatypes are the distinct sequences 
among the variants. j HXB2 nonamer sequence and its incidence at the given nonamer position; amino acids identical to the index are denoted
as ".". k C1P nonamer sequence and its incidence at the given nonamer position; amino acids identical to the index are denoted as ".". HXB2 
and C1P nonamers not found at the aligned nonamer position are indicated with 0% incidence. 





Protein # HXB2 & Index 
aa identical 
# C1P & Index 
aa Identical 
# HXB2 & C1P 
aa Identical 
# HXB2, C1P & 
Index aa Identical 
[%] 
Gag 91 88 91 87 
Pol 98 94 72 92 
Vif 93 89 72 85 
Vpr 73 91 75 70 
Tat 80 89 86 77 
Rev 89 84 71 73 
Vpu 84 86 87 81 
Env 82 79 80 74 
Nef 82 85 81 77 














Protein # HXB2 & Index 
Nonamers 
identical 
# C1P & Index 
Nonamers 
Identical 
# HXB2 & C1P 
Nonamers 
Identical 




Gag 77 62 58 55 
Pol 85 60 56 56 
Vif 58 34 25 25 
Vpr 52 58 35 35 
Tat 48 48 37 30 
Rev 56 36 31 24 
Vpu 28 43 11 11 
Env 47 37 31 27 
Nef 17 42 21 15 
Proteome 61 49 41 38 
^ All comparisons in these analyses contained more than 100 sequences. # denotes “number of”. 
 
 Figure S1| Sample alignments showing the anchor regions of relatively 
conserved amino acids (boxed in red) that facilitated reliable alignment. The 




Figure S2 | The effect of mutation on overlapping nonamer sequences. A. The 
numbers represent amino acids of overlapping nonamer sequences. B. A change 
in one amino acid, for example from C to P at position 9, will affect nine 




























Figure S3| Comparison of concatenated index sequence of each HIV-1 clade 
B protein with the corresponding proteins of HXB2 (green) and C1P (blue) 
sequences. The numbers before and after the concatenated index sequence 
represent amino acid positions of the comparison; the comparison is shown in 
blocks of 60 amino acids. Identical amino acids between the comparisons are 
represented by “.”; those that differ are shown by the respective amino acids. 
Amino acid mutations of the aligned viruses that did not follow the concatenation 
of the index are shown in red. The corresponding amino acids of HXB2 and C1P 
sequences are also shown at these positions, but without representing identical 
amino acids by “.”. The green and blue dashes represent amino acid deletions in 
HXB2 and C1P, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
